Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJMN1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:36:14 ON 06 MAR 2009

=> FIL REG
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.44 0.44

FILE 'REGISTRY' ENTERED AT 16:37:38 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 MAR 2009 HIGHEST RN 1116197-74-0
DICTIONARY FILE UPDATES: 5 MAR 2009 HIGHEST RN 1116197-74-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10541429\1.str



```
chain nodes :
1  2  3  4  5  6  7  8
ring/chain nodes :
9
chain bonds :
1-2  1-3  1-4  4-5  5-6  5-7  7-8  8-9
exact/norm bonds :
1-2  1-3  1-4  5-6  5-7  7-8
exact bonds :
4-5  8-9


Match level :
1:Atom  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
Generic attributes :
1:
Saturation             : Unsaturated




L1      STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> S L1
SAMPLE SEARCH INITIATED 16:37:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     4931 TO ITERATE

 40.6% PROCESSED     2000 ITERATIONS                                 8 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        94409 TO   102831
PROJECTED ANSWERS:             128 TO      660

L2            8 SEA SSS SAM L1

=> D SCAN
```

L2 8 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4H-1,4-Benzoxazine-4-acetamide, 6-chloro-2,3-dihydro-2-methyl-N-[(4-methylphenyl)sulfonyl]-3-oxo-
MF C18 H17 Cl N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> S L1 FULL
FULL SEARCH INITIATED 16:38:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    99548 TO ITERATE

100.0% PROCESSED    99548 ITERATIONS                          514 ANSWERS
SEARCH TIME: 00.00.08

L3          514 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             186.36     186.80

FILE 'CAPLUS' ENTERED AT 16:38:57 ON 06 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Mar 2009  VOL 150 ISS 11
FILE LAST UPDATED: 5 Mar 2009  (20090305/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> S L3
L4          162 L3

=> S L4 AND INTERLEUKIN
        190936 INTERLEUKIN
L5            5 L4 AND INTERLEUKIN

=> D IBIB ABS HITSTR L5 TOT
```

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:675710 CAPLUS
DOCUMENT NUMBER: 141:190512
TITLE: A preparation of 2-arylacetic acid derivatives, useful for the treatment of IL-8 mediated diseases
INVENTOR(S): Morisseau, Alessandro; Allegretti, Marcello; Bertini, Riccardo; Cesta, Maria Candida; Bizzarri, Cinzia; Colotta, Francesco
PATENT ASSIGNEE(S): Dompe' S.p.A., Italy
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069792	A2	20040819	WO 2004-EP1021	20040204
WO 2004069792	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210082	A1	20040819	AU 2004-210082	20040204
CA 2511582	A1	20040819	CA 2004-2511582	20040204
EP 1593314	A2	20051102	EP 2004-707926	20040204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1768026	A	20060503	CN 2004-80008741	20040204
JP 2006516592	T	20060706	JP 2006-501733	20040204
US 20060223843	A1	20061005	US 2005-541829	20050705
NO 20050004037	A	20050830	NO 2005-4037	20050830
			A	20030206
PRIORITY APPLN. INFO.:			EP 2003-2716	
			WO 2004-EP1021	W 20040204

OTHER SOURCE(S): MARPAT 141:190512
GI



I

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 740839-47-8 CAPLUS
CN Benzeneacetamide, 2-methyl-N-[methylsulfonyl)-4-[(trifluoromethyl)sulfonyl]amino]- (CA INDEX NAME)



RN 740839-48-9 CAPLUS
CN 1H-Pyrrole-2-acetamide, 1-methyl-5-(4-methylbenzoyl)-N-(methylsulfonyl)- (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
AB The invention relates to a preparation of 2-arylacetic acid derivs. of formula

[X = CHRC(O)-Y (wherein: A is a 5 to 6 membered (hetero)aromatic ring where heterocom is selected from N, O, S, etc.; the 5-6 membered (hetero)aromatic ring is optionally fused with a second ring; Y is NH1, NH-(cyclo)alkyl, or NH-cycloalkenyl, etc.), useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compds. are used for the prevention and treatment of pathologies deriving from oxid.activation. In particular, o-substituted arylacetic acid derivs., such as amides and sulfonamides, lack cyclo-oxygenase inhibition activity and are particularly useful in the treatment of neutrophil-dependent pathologies such as psoriasis, ulcerative colitis, or melanoma, etc. For instance, prepared in the example 2 acetic acid derivative I (10-9M) showed 62% (IL-8) and 54% (GRO-.alpha.) inhibitory activity on CXCR1 and CXCR2 receptors.

IT 740839-45-6P 740839-46-7P 740839-47-8P
740839-48-9P
RL: PAC (Pharmacological activity); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylacetic acids useful for the treatment of IL-8 mediated diseases)

RN 740839-45-6 CAPLUS
CN 1H-Pyrrole-2-acetamide, 5-acetyl-1-methyl-N-(methylsulfonyl)- (CA INDEX NAME)



RN 740839-46-7 CAPLUS
CN Benzeneacetamide, 2-methyl-4-(2-methylpropyl)-N-(methylsulfonyl)- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:410159 CAPLUS
DOCUMENT NUMBER: 141:174068
TITLE: Vesicant treatment with (phenylalkyl)thiophenes as vitamin D receptor modulators
INVENTOR(S): Nagpal, Sunil
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Yee, Ying Kwong
SOURCE: PCT Int. Appl., 496 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004063348	A2	20040729	WO 2004-US6	20040107
WO 2004063348	A8	20040930		
WO 2004063348	A3	20051027		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
EP 1587905	A2	20051026	EP 2004-700549	20040107
EP 1587905	A3	20051214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060135484	A1	20060622	US 2003-549687	20050624
PRIORITY APPLN. INFO.:			US 2003-439575P	P 20030110
			WO 2004-US6	W 20040107

OTHER SOURCE(S): MARPAT 141:174068
GI

AB The present invention relates to a method of treating or preventing human

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
to human skin cells by chem. vesicants, such as mustard, by administering non-secosteroidal, title compds. I [wherein R1 and R2 = independently (fluoro)alkyl; or CR1R2 = (un)substituted carbocycle; Q1 and Q2 = C, S, with the proviso that one atom = S and the other atom = C; R3 and R4 = independently H, halo, (fluoro)alkyl, (fluoro)alkoxy, (fluoro)alkylthio, CN, NO2, acetyl, (cyclo)alkenyl, cycloalkyl; L1 and L2 = independently a bond, (CH2)mCX1, (CH2)mCHOH, (CH2)mO, (CH2)mS, (CH2)mSO, (CH2)mSO2, (CH2)mNR5, (CH2)mC(R5)2, (CH2)mC.tplbond.C, (CH2)mCH=CH, CHOHCX1, SO2NH, SO2O, SO2CX1, NHCCX1, NHSO, CH2SO, OSO; m = 0-2; X1 = O, S; R5 = H, (fluoro)alkyl; Z1 and Z2 = independently H, OH, halo, formyl, NO2, CN, (fluoro)phenyl, benzyl, (un)substituted (cyclo)alkyl, (cyclo)alkenyl, acyl, carboxy, carbamoyl, alkoxy, alkylthio, sulfamoyl, (thio)ureido, amino, etc.; with provisos; and pharmaceutically acceptable salts or prodrugs thereof] with vitamin D receptor (VDR) modulating activity. Examples include prepns. and bioassays for efficacy and toxicity of representative I. For instance, reaction of 3-[4-(benzyloxy)-3-methylphenyl]-3-[4-methyl-5-(hydroxymethyl)thiophen-2-yl]pentane with PBr3 and LiHMDS, followed by addn. of pinacolone gave the 5-(3-oxo-4,4-dimethylpentyl)-4-methylthiophene deriv. (82%).
Deprotection
using Pd/C in EtOH/EtOAc provided the phenol (97%), which was alkylated with methylmercaptomethyl chloride (73%) and oxidized using m-CPBA to afford the 4-(methylsulfonylmethoxy)-3-methylphenyl deriv. (33%). Redn. of the ketone using NaBH2 in MeOH yielded the alc. II (quant.). The preferred enantiomer of latter exhibited VDR activity in the RXR-VDR heterodimer assay (EC50 = 40.57 nM) and showed osteoporosis inhibition activity in the osteocalcin (OCN) promoter assay (EC50 = 46.82 nM), while demonstrating low toxicity in the mouse hypercalcemia assay (EC50 = >1000 nM). In addn., results from the keratinocyte proliferation assay (IC50 = 76 nM) and the IL-10 induction assay (IC50 = 26 nM) indicated that the preferred enantiomer of II may also be useful for the treatment of psoriasis, abscesses, and adhesions.

IT 633341-19-2P 633341-20-5P 633341-21-6P
633341-22-7P 633341-23-8P 633341-24-9P
633341-25-0P 633341-26-1P 633341-27-2P
633341-28-3P 633341-29-4P 633341-30-7P
633341-31-8P 633341-32-9P 633341-33-0P
633341-34-1P 633341-35-2P 633341-36-3P
633344-85-1P 633344-86-2P 633344-87-3P
633344-88-4P 633344-89-5P 633344-90-8P
633344-91-9P 633344-92-0P 633344-93-1P
633344-94-2P 633344-95-3P 633344-96-4P
633344-97-5P 633344-98-6P 633344-99-7P
633345-00-3P 633345-01-4P 633345-02-5P
633350-14-8P 633350-15-9P 633350-16-0P
633350-17-1P 633350-18-2P 633350-19-3P
633350-20-6P 633350-21-7P 633350-22-8P
633350-23-9P 633350-24-0P 633350-25-1P
633350-26-2P 633350-27-3P 633350-28-4P
633350-29-5P 633350-30-8P 633350-31-9P
633353-96-5P 633353-97-6P 633353-98-7P
633353-99-8P 633354-00-4P 633354-01-5P
633354-02-6P 633354-03-7P 633354-04-8P
633354-05-9P 633354-06-0P 633354-07-1P

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
633354-08-2P 633354-09-3P 633354-10-6P
633354-11-7P 633354-12-8P 633354-13-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(VDR modulator; prepn. of (phenylalkyl)thiophenes as VDR modulators for preventing or treating damage to human skin cells by chem. vesicants)

RN 633341-19-2 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-[4-(4,4-dimethyl-3-oxopentyl)-3-methylphenyl]-1-ethylpropyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-20-5 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-21-6 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3,4,4-trimethylpentyl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 633341-22-7 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[3-methyl-4-(2,4,4-trimethyl-3-oxopentyl)phenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-23-8 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-2,4,4-trimethylpentyl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-24-9 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-2,3,4,4-tetramethylpentyl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-25-0 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-[4-(4,4-dimethyl-3-oxopentyl)-3-methylphenyl]-1-ethylpropyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633341-26-1 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633341-27-2 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3,4,4-trimethylpentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633341-28-3 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[3-methyl-4-(2,4,4-trimethyl-3-oxopentyl)phenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633341-29-4 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-2,4,4-trimethylpentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633341-30-7 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-2,3,4,4-tetramethylpentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633341-31-8 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-[4-[4,4-dimethyl-3-oxopentyl)-3-methylphenyl]-1-ethylpropyl]-3-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633341-35-2 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-2,4,4-trimethylpentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633341-36-3 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-2,3,4,4-tetramethylpentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633344-85-1 CAPLUS
CN Benzeneacetamide, 4-[1-[5-(4,4-dimethyl-3-oxopentyl)-4-methyl-2-thienyl]-1-ethylpropyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633341-32-9 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633341-33-0 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-3,4,4-trimethylpentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633341-34-1 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[3-methyl-4-[2,4,4-trimethyl-3-oxopentyl)phenyl]propyl]-3-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633344-86-2 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-thienyl]propyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)



RN 633344-87-3 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-(3-hydroxy-3,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)



RN 633344-88-4 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-methyl-5-[2,4,4-trimethyl-3-oxopentyl)-2-thienyl]propyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 633344-89-5 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-[3-hydroxy-2,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-N-(ethylsulfonyl)-2-methyl- (CA INDEX NAME)



RN 633344-90-8 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-[3-hydroxy-2,3,4,4-tetramethylpentyl)-4-methyl-2-thienyl]propyl]-N-(ethylsulfonyl)-2-methyl- (CA INDEX NAME)



RN 633344-91-9 CAPLUS
CN Benzeneacetamide, 4-[1-[5-[4,4-dimethyl-3-oxopentyl)-4-methyl-2-thienyl]-1-ethylpropyl]-2-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633344-92-0 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-[3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633344-96-4 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-[3-hydroxy-2,3,4,4-tetramethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633344-97-5 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-[5-[4,4-dimethyl-3-oxopentyl)-4-methyl-2-thienyl]-1-ethylpropyl]-2-methyl- (CA INDEX NAME)



RN 633344-98-6 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-1-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633344-93-1 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-(3-hydroxy-3,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633344-94-2 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[4-methyl-5-[2,4,4-trimethyl-3-oxopentyl)-2-thienyl]propyl]-2-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633344-95-3 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-(3-hydroxy-2,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633344-99-7 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-1-[5-(3-hydroxy-3,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)



RN 633345-00-3 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-1-[4-methyl-5-(2,4,4-trimethyl-3-oxopentyl)-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)



RN 633345-01-4 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-1-[5-(3-hydroxy-2,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633345-02-5 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-1-[5-(3-hydroxy-2,3,4,4-tetramethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)

RN 633350-14-8 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methylpentyl)-3-methylphenyl]propyl]-N-[ethylsulfonyl]-3-methyl- (CA INDEX NAME)



RN 633350-15-9 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-penten-1-yl)-3-methylphenyl]propyl]-N-[ethylsulfonyl]-3-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-19-3 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-pentyn-1-yl)-3-methylphenyl]propyl]-N-[ethylsulfonyl]-3-methyl- (CA INDEX NAME)



RN 633350-20-6 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methylpentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633350-21-7 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-penten-1-yl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-16-0 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-pentyn-1-yl)-3-methylphenyl]propyl]-N-[ethylsulfonyl]-3-methyl- (CA INDEX NAME)

RN 633350-17-1 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxypentyl)-3-methylphenyl]propyl]-N-[ethylsulfonyl]-3-methyl- (CA INDEX NAME)



RN 633350-18-2 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-penten-1-yl)-3-methylphenyl]propyl]-N-[ethylsulfonyl]-3-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-22-8 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-pentyn-1-yl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633350-23-9 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxypentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633350-24-0 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-penten-1-yl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-25-1 CAPLUS
CN 2-Thiophenesacetamide, 5-[1-ethyl-1-[4-[3-ethyl-3-hydroxy-1-pentyn-1-yl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633350-26-2 CAPLUS
CN 2-Thiophenesacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[3-hydroxy-3-methylpentyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633350-27-3 CAPLUS
CN 2-Thiophenesacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[3-hydroxy-3-methyl-2-(3-penten-1-yl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)

RN 633350-31-9 CAPLUS
CN 2-Thiophenesacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[3-ethyl-3-hydroxy-1-pentyn-1-yl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)

RN 633353-96-5 CAPLUS
CN 2-Thiophenesacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethyl]-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633353-97-6 CAPLUS
CN 2-Thiophenesacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethynyl]-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633353-98-7 CAPLUS

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-28-4 CAPLUS
CN 2-Thiophenesacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[3-hydroxy-3-methyl-1-pentyn-1-yl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633350-29-5 CAPLUS
CN 2-Thiophenesacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[3-ethyl-3-hydroxypentyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633350-30-8 CAPLUS
CN 2-Thiophenesacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[3-ethyl-3-hydroxy-1-penten-1-yl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 633353-99-8 CAPLUS
CN 2-Thiophenesacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethyl]-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633354-00-4 CAPLUS
CN 2-Thiophenesacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethynyl]-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633354-01-5 CAPLUS
CN 2-Thiophenesacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethenyl]-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 633354-02-6 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633354-02-7 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethynyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633354-04-9 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethenyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633354-05-0 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633354-09-3 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethynyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633354-10-6 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethenyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633354-11-7 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633354-06-0 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethynyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633354-07-1 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethenyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633354-08-2 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 633354-12-8 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethynyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633354-13-9 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethenyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:805685 CAPLUS
DOCUMENT NUMBER: 141:146031
TITLE: Preparation of bicyclic piperidine derivatives as antagonists of the CCR1 chemokine receptor
INVENTOR(S): Blomberg, Lena Cook; Brown, Matthew Frank; Hayward, Matthew Merrill; Pena, Christopher Stanley
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089888	A1	20041029	WO 2003-IB3155	20030707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492116	A1	20040129	CA 2003-2492116	20030707
AU 2003281527	A1	20040209	AU 2003-281527	20030707
BR 0312639	A	20050426	BR 2003-12639	20030707
EP 1525201	A1	20050427	EP 2003-741007	20030707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1668614	A	20050914	CN 2003-817920	20030707
JP 2005533849	T	20051110	JP 2004-520238	20030707
US 20040063693	A1	20040401	US 2003-614843	20030708
IN 2004DN04155	A	20050401	IN 2004-DN4155	20041228
MX 2005000757	A	20050419	MX 2005-757	20050118

PRIORITY APPLN. INFO.: US 2002-397263P P 20020718
WO 2003-IB3155 W 20030707

OTHER SOURCE(S): MARPAT 141:146031
GI

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I

AB The title compds. [I; a = 1-5; b = 0-4; c = 0-1; Q = alkyl; W = aryl, heteroaryl; T = O, NH, N(alkyl); Z = O, NH, N(alkyl), N(acetyl); R1 = H, halo, CN, NO2, et.c, E2, R3 = H, alkyl, haloalkyl; R4 = alkylene, (CR2)xO(CR2)y (wherein x, y = 1-2); R5 = H, halo, alkyl, etc.; R6 = H, halo, alkyl, etc.], useful as potent and selective inhibitors of MIP-1α(CCL2) binding to its receptor (CCR) found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes), were prepared E.g., a multi-step synthesis of

(trans)-5-chloro-2-[2-[3-(4-fluorophenoxy)-8-aza-bicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]benzamide was given. All exemplified compds. I had IC50 of <10 nM in the chemotaxis assay. Pharmaceutical composition comprising the compound I is claimed.

IT 652146-44-0P 652147-08-5P 652147-89-2P
653589-92-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic piperidine derivs. as antagonists of the CCR1 chemokine receptor)

RN 652146-44-0 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(3-endo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 652147-08-5 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
NAME)

Relative stereochemistry.



RN 652147-89-2 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(7-endo)-7-(4-fluorophenoxy)-3-oxa-9-azabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 653589-92-9 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(3-exo)-3-(4-fluorophenoxy)-8-azabicyclo[3.2.1]oct-8-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:90563 CAPLUS
DOCUMENT NUMBER: 140:146007
TITLE: Preparation of piperidinylketones as selective inhibitors of macrophage inflammatory protein 1α (MIP-1α) binding to CCR1 chemokine receptors
INVENTOR(S): Blumberg, Laura Cook; Brown, Matthew Frank; Hayward, Matthew Merrill; Poss, Christopher Stanley
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009550	A1	20040129	WO 2003-IB2876	20030707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2492651	A1	20040129	CA 2003-2492651	20030707
AU 2003242961	A1	20040209	AU 2003-242961	20030707
EP 1534677	A1	20050601	EP 2003-765230	20030707
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003251984	A	20050712	BR 2003-11984	20030707
CN 1668592	A	20050914	CN 2003-817092	20030707
JP 2005537279	T	20051208	JP 2004-523601	20030707
US 20040167179	A1	20040401	US 2003-616844	20030708
IN 2004MN04166	A	20070511	IN 2004-MN4166	20040129
ZA 2005000067	A	20051102	ZA 2005-67	20050104
MX 2005000890	A	20050331	MX 2005-890	20050106
PRIORITY APPLN. INFO.:			US 2002-397108P	P 20020718
			WO 2003-IB2876	W 20030707

OTHER SOURCE(S): MARPAT 140:146007
GI



RN 651301-27-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[4-(4-fluorophenoxy)-1-piperidinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB Title compds. [I; n = 1-7; n = 0-4; p = 0-1; Q = alkyl; W = aryl, heteroaryl; T = O, NR9; R8 = H, alkyl; Z = O, NR9; R9 = H, alkyl; Ar; R1 = H, halo, cyano, NO2, CF3, OCF3, alkyl, OR, alkylcarbonyloxy, alkoxy; R2-R5 = H, halo(alkyl; R6 = H, halo, (halo)alkyl, cyano, alkoxy, aminocarbonyl, carboxy, alkylcarbonyl, (halo)alkoxy; R7 = H, halo, (halo)alkyl, dialkylaminosulfonylaminocarbonyl, alkoxy, aminocarbonyl, ureido, aminosulfonyl, alkylsulfonylaminoalkylamine, aminosulfonylamine, heterocyclyl, ureidoalkylaminocarbonyl, etc.; z1 or R2-R5 = alkyl, were prepared Thus, 2-[2-amino-4-chlorophenoxy]-1-[4-(4-fluorophenoxy)piperidin-1-yl]ethanone (preparation given) in CH2Cl2 was treated with Et3N and Ph chloroformate, The reaction was stirred at ambient temperature for 4 h, concentrated in vacuo, and the resulting residue dissolved in methanol followed by bubbling in ammonia gas for 10 min and stirred overnight at ambient temperature to give 5-chloro-2-[2-[4-(4-fluorophenoxy)piperidin-1-yl]-2-oxoethoxy]phenylurea. I inhibited chemotaxis with IC50 <10 μM.

IT 651301-03-0P 651301-07-4P, N-[[5-chloro-2-[2-[4-(4-fluorophenoxy)piperidin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidinylketones as selective inhibitors of macrophage inflammatory protein 1α (MIP-1α) binding to CCR1 chemokine (receptors))

RN 651301-03-0 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,4S,5R)-4-(4-fluorophenoxy)-2,5-dimethyl-1-piperidinyl]-2-oxoethoxy]-N-(methylsulfonyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:174640 CAPLUS
DOCUMENT NUMBER: 136:340711
TITLE: Bridged piperazine derivatives, specifically 3,8-diazabicyclo[3.2.1]octane, 8-oxa-3-azabicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, and 3,8-diazabicyclo[3.2.1]octane derivatives, useful as inhibitors of chemokines binding to CCR1 receptors, for treating inflammation and other immune disorders.
INVENTOR(S): Blumberg, Laura Cook; Brown, Matthew Frank; Glaude, Ronald Paul; Poss, Christopher Stanley
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002037901	A2	20020425	WO 2001-IB1844	20011004
WO 2002037901	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2427859	A1	20020425	CA 2001-2427859	20011004
AU 2001092160	A	20020429	AU 2001-92160	20011004
EP 1326867	A2	20030716	EP 2001-982389	20011004
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
EE 200300189	A	20031015	EE 2003-189	20011004
BR 2001014697	A	20031118	BR 2001-14697	20011004
NO 2003001442	A2	20030529	NO 2003-1442	20011004
NO 2003001442	A3	20070726		
JP 2004511558	T	20040415	JP 2002-536283	20011004
NZ 524742	A	20041224	NZ 2001-524742	20011004
US 20020119961	A1	20020829	US 2001-972377	20011005
IN 2003MN00309	A	20050211	IN 2003-MN309	20030317
ZA 2003003157	A	20040422	ZA 2003-3157	20030418
BG 107655	A	20040130	BG 2003-107655	20030320
NO 2003001572	A	20030610	NO 2003-1572	20030404
MX 2003003475	A	20030714	MX 2003-3475	20030416
PRIORITY APPLN. INFO.:			US 2000-241904P	P 20001019
			WO 2001-IB1844	W 20011004

OTHER SOURCE(S): MARPAT 136:340711
GI

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I

II

AB Compds. I and their pharmaceutically acceptable salts, useful for treatment of inflammation and other immune disorders, are disclosed [wherein n = 1-3; m = 1-5; q = 0-1; a, b, c = (CR2)0-4 (independently); a, b, and c cannot all be null; if a and/or c is not null, then b must be null; W = CH or N; X = CO, CHR, or CH2; Y = CH2; Z = O, (un)substituted NR or (un)substituted CH2; R = certain (un)substituted [hetero]aryl or [hetero]cycloalkyl; R1 = [independently] H, OH, NO2N, halo, alkyl, RN, CF3, wide variety of other substituents]. The compds. are useful for treatment of a wide variety of diseases and disorders, which are cited specifically in claims. Approx. 100 specific examples of I are given, many with synthetic details. For example, 3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]octan-2-one (preparation given) underwent a sequence of: (1) reduction of the amide carbonyl using LiAlH4 (94%); (2) N-N-acylation with chloroacetyl chloride (69%); and (3) etherification with 2-nitro-4-trifluoromethylphenol (50%); to give title compound II. In a bioassay for the ability to inhibit chemotaxis of various cells (THP-1 cells, primary human monocytes, or primary lymphocytes) in vitro, all example compds. had IC50 values of less than 10 μM.

IT 417727-33-4P, N-[[5-Chloro-2-[2-[3-[4-fluorobenzyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; preparation of bridged piperazine derivs. as inhibitors of cytokines binding to CCR1 receptors)

RN 417727-33-4 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[2-[3-[(4-fluorophenyl)methyl]-3,9-diazabicyclo[3.3.1]non-9-yl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> S L3 AND PSORIASIS
           162 L3
         18533 PSORIASIS
L6          10 L3 AND PSORIASIS

=> S L4 AND PSORIASIS
         18533 PSORIASIS
L7          10 L4 AND PSORIASIS

=> S L4 AND ARTHRITIS
         56545 ARTHRITIS
L8          11 L4 AND ARTHRITIS

=> S L4 AND MELANOMA
         41696 MELANOMA
L9           1 L4 AND MELANOMA

=> S L4 AND COLITIS
         15133 COLITIS
L10          3 L4 AND COLITIS

=> S L4 AND PULMONARY
        107332 PULMONARY
L11         16 L4 AND PULMONARY

=> S L4 AND BULLOUS
          1837 BULLOUS
L12          1 L4 AND BULLOUS

=> S L4 AND FIBROSIS
         46849 FIBROSIS
L13          8 L4 AND FIBROSIS

=> S L4 AND REPERFUSION
         38509 REPERFUSION
L14          5 L4 AND REPERFUSION

=> S L4 AND ISCHEMIA
         88120 ISCHEMIA
L15          7 L4 AND ISCHEMIA

=> S L4 AND GLOMERULONEPHRITIS
         10320 GLOMERULONEPHRITIS
L16          4 L4 AND GLOMERULONEPHRITIS

=> S L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L15 OR L16
L17         24 L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14
               OR L15 OR L16

=> S L17 NOT L5
L18         19 L17 NOT L5

=> D IBIB ABS HITSTR L18 TOT
```

L18 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:894289 CAPLUS
DOCUMENT NUMBER: 145:292869
TITLE: Preparation of indole derivatives as leukotriene receptor antagonists
INVENTOR(S): Takeuchi, Juny Nakagawa, Yoshiakee Fujita, Masabu
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 359pp.
CODEN: PIXD2D
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094317	A1	20041031	WO 2004-JP02374	20040224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2004216170	A1	20041031	AU 2004-216170	20040224
CA 2599348	A1	20040831	CA 2004-2599348	20040224
EP 1852420	A1	20071107	EP 2004-714513	20040224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
NZ 2007102112	A	20071026	NZ 2007-102112	20070820
CN 101128424	A	20080220	CN 2004-80005791	20070822
KR 2007114140	A	20071129	KR 2007-7019758	20070824
US 20080188532	A1	20080807	US 2007-885018	20070824
IN 200700003516	A	20080118	IN 2007-KN03516	20070907
NO 2007004679	A	20071119	NO 2007-4679	20070913
PRIORITY APPLN. INFO.:			JP 2003-51392	A 20030225
			JP 2003-352787	A 20051207
			WO 2004-JP02374	W 20040224
			WO 2004-JP3374	W 20040224
OTHER SOURCE(S):	MARPAT 145:292869			
GI				

L18 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB Indole compds. represented by the general formula (I) or salts or solvates thereof or prodrugs thereof [R11, R12 = substituents; two of R51, R52, and R53 are independently groups having a (un)protected acidic group and the remaining one group is R or a substituent; R3 = a substituent; n = an integer of 0-4; n = an integer of 0-3; p = 0, 1] are prepared. These compds. have a leukotriene receptor antagonistic effect and are expected to be more effective than those of the leukotriene receptor antagonists currently used in clin. medicine. They are therefore useful as agents for prevention and/or treatment of a leukotriene-mediated disease such as a respiratory disease, e.g., bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g., interstitial pneumonia), severe acute respiratory syndromes (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g., acute sinusitis, chronic sinusitis), and pulmonary fibrosis, and as supportomants or antitussives. Thus, Me 6-bromo-1-(4-methoxy-4-oxobutyl)-1H-indole-3-carboxylate was coupled with 4-vinylphenyl acetate in the presence of palladium acetate and tris(2-methylphenyl)phosphine in a solution of Et3N in MeCN at 85° for 2 h to give Me 6-[(E)-2-[4-(4-acetyloxyphenyl)ethenyl]-1-(4-methoxy-4-oxobutyl)-1H-indole-3-carboxylate. The latter compound was deacetylated by treatment with K2CO3 in a mixture of methanol and THF at room temperature for 2 h and etherified with 1-chloro-4-phenylbutane in the presence of NaI and K2CO3 in DMF at 95° for 2 h to give Me 1-(4-methoxy-4-oxobutyl)-6-[(E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-1H-indole-3-carboxylate which was stirred with a mixture of 1 M aqueous NaOH solution, THF, and MeOH and acidified with 1.2 M aqueous HCl solution to give 1-(3-carboxypropyl)-6-[(E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-1H-indole-3-carboxylic acid. 4-[1-[(3-Carboxymethyl)-7-[(E)-2-[4-(4-phenoxybutoxy)phenyl]ethenyl]-1H-indol-3-yl]butanoic acid at 10 mg/kg p.o. in vivo inhibited the ovalbumin-induced constriction of airway in guinea pigs. A tablet and an ampule formulation containing 4-[3-(carboxymethyl)-6-[(E)-2-[4-(4-phenylbutoxy)phenyl]ethenyl]-1H-indol-1-yl]butanoic acid were described.

L18 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT 928137-47-39
RL: PAC (Pharmacological activity); SFM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. as leukotriene receptor antagonists for prevention and/or treatment of respiratory diseases)
RN 928137-47-3 CAPLUS
CN 1H-Indole-3-butanoic acid, 7-[(1E)-2-[4-[4-[2,2-difluoroghenoxy)butoxy]phenyl]ethenyl]-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]- (CA INDEX NAMES)

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:499970 CAPLUS
DOCUMENT NUMBER: 145:167236
TITLE: Preparation of pyrazolyl acylsulfonamide derivatives as endothelin converting enzyme inhibitors useful in the treatment of chronic obstructive pulmonary disease
INVENTOR(S): Baxter, Andrew; Furber, Mark; Ping, Sarah; Luckhurst, Christopher; Pinns, Austen; Seuberson, Janes
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078855	A1	20040916	WO 2004-SE242	20040211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NO, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			SE 2003-105	A 20030113
OTHER SOURCE(S):	MARPAT 145:167236			
GI				

AB The title compds. I [R1 = (un)substituted (hetero)aryl; R2, R4 = H, halo, alkyl, etc.; R3 = (un)substituted (hetero)aryl; cycloalkyl; useful in the treatment of chronic obstructive pulmonary disease, were prepared E.g., a 3-step synthesis of II, starting from 2,2-dimethyl-1,3-dioxane-4,6-dione with dibutene, was given. Exemplified compds. I were tested to determine inhibition od endothelin-converting enzyme-1

L18 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
[ECA-1]. For example, II showed pIC50 of 7.52. The invention also provides processes for prepg. compds. I, pharmaceutical compns. comprising such compds. and to the use of the compds. I as active therapeutic agents.
IT 902813-68-5P
RL: PAC (Pharmacological activity); PCT (Reactant); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolylacylsulfonamides as endothelin converting enzyme inhibitors useful in the treatment of chronic obstructive pulmonary disease)
RN 902813-68-5 CAPLUS
CN 1H-Pyrazole-5-acetamide, 4-bromo-N-[(4-chlorophenyl)sulfonyl]-3-methyl-1-phenyl- (CA INDEX NAME)



IT 902813-69-6P 902813-70-9P
RL: PAC (Pharmacological activity); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolylacylsulfonamides as endothelin converting enzyme inhibitors useful in the treatment of chronic obstructive pulmonary disease)
RN 902813-69-6 CAPLUS
CN 1H-Pyrazole-5-acetamide, N-[(4-chlorophenyl)sulfonyl]-4-iodo-3-methyl-1-phenyl- (CA INDEX NAME)



RN 902813-70-9 CAPLUS
CN 1H-Pyrazole-5-acetamide, N-[(4-chlorophenyl)sulfonyl]-3,4-dimethyl-1-phenyl- (CA INDEX NAME)

L18 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:435742 CAPLUS
DOCUMENT NUMBER: 145:103563
TITLE: Preparation of piperidine derivatives as antagonists of the CC chemokine receptor CCR1 and their use as anti-inflammatory agents
INVENTOR(S): Arnaiz, Damian O.; Choo, You-Ling; Kochanny, Monica J.; Lee, Wheesoong; Li, Shou-Pu; Mengel, Anne; Phillips, Gary; Wei, Guo Ping; Yu, Hongyi
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006064949	A1	20060622	WO 2005-EP13938	20051220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060167044	A1	20060727	US 2005-305322	20051219
EP 1928829	A1	20080611	EP 2005-824154	20051220
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008524214	T	20080703	JP 2007-546985	20051220
PRIORITY APPLN. INFO.:			US 2004-638033P	P 20041220
			WO 2005-EP13938	W 20051220
OTHER SOURCE(S):	MARPAT 145:103563			
GI				

L18 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB Title compds. represented by the formula I [wherein Ar = Ph, pyridinyl, (iso)quinolinyl; R1 = H, halo, (cyclo)alkyl, etc.; R2 = a bond, O, S, N(R8); N(R8)C(O) or C(R8)2; R3 = (un)substituted alkylene or alkenylene; R4 = CO, OCO, CS, CR8 or a bond; R5 = independently H, oxo, (halo)alkyl, etc.; R6 = CO, CS, C(R8)2, etc.; R8 = independently H, halo, (cyclo)alkyl, etc.; R9 = independently H, (halo)alkyl, aryl, etc.; R = (un)substituted Ph or 2-thienyl; and enantiomers, diastereomers, tautomers, salts, solvates and radiolabeled analogs thereof] were prepared as CC chemokine receptor CCR1 antagonists. For example, II was provided in a multi-step synthesis starting from 1-(5-chloro-2-hydroxyphenyl)ethanone. I and their pharmaceutical compns. are useful for the treatment of inflammatory disorders, such as multiple sclerosis, leukoencephalopathy, and etc.
IT 894772-51-1P, N-[2-[5-Bromo-2-[2-[4-cyano-4-[(4-fluorophenyl)methyl]-1-piperidinyl]-2-oxoethoxy]phenyl]ethanesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted piperidine derivs. as antagonists of CC chemokine receptor CCR1 and their use as anti-inflammatory agents)
RN 894772-51-1 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[4-cyano-4-[(4-fluorophenyl)methyl]-1-piperidinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS

L18 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L18 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:979623 CAPLUS
DOCUMENT NUMBER: 143:286441
TITLE: Preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors
INVENTOR(S): Zoelen-Baertwig, Heike; Albrecht, Barbara; Neldenich, Joerg; Li, Volkhart; Perner-storfer, Josef; Schlemmer, Karl-Heinz; Telan, Lelia
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082864	A1	20050909	WO 2005-EP1486	20050215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2557271	A1	20050909	CA 2005-2557271	20050215
EP 1723121	A1	20061122	EP 2005-707396	20050215
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007514696	T	20070606	JP 2006-553009	20050215
US 20090064704	A1	20090313	US 2007-590770	20070818
PRIORITY APPLN. INFO.:			EP 2004-4714	A 20040226
			WO 2005-EP1486	W 20050215

OTHER SOURCE(S): CASREACT 143:286441; MARPAT 143:286441
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = aryl or heteroaryl ring; R1, R2 and R3 independently = H, halo, nitro, etc.; R4 = (un)substituted alkyl, cycloalkylcarbonyl, alkylcarbonyl, etc.; R5 = (un)substituted alkyl; R6 = H, formyl, aminocarbonyl, etc.; R7 = cyano, OH, nitro, etc.; W, W', X, Y and Z independently = CH or N wherein the ring contains either 0, 1 or 2

L18 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
nitrogen atoms] and their pharmaceutically adequate salts, are prepd. and disclosed as human neutrophil elastase (HNE) inhibitors. Thus, e.g., II was prepd. by cyclization of N-[3-(trifluoromethyl)phenyl]urea and 4-cyanobenzaldehyde with ethyl-3-oxobutanoate and subsequent redn. using LAH. The activity of I against HNE was evaluated in an in vitro enzyme assay utilizing a fluorgenic peptide substrate and it was revealed that selected compds. of the invention possessed IC50 values in the range of 5 up to 1000 nM. I as inhibitors of human neutrophil elastase should prove useful in the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development. Pharmaceutical compns. comprising I are disclosed.

IT 864250-84-0P 864250-85-1P 864250-89-5P
864250-90-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl-dihydropyrimidin-2-ones as human neutrophil elastase inhibitors)

RN 864250-84-0 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-5-[cyclopropylcarbonyl]-3,6-dihydro-4-methyl-2-oxo-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864250-85-1 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 6-[4-(cyanophenyl)-5-[cyclopropylcarbonyl]-3,6-dihydro-4-methyl-2-oxo-N-[3,2,2-trifluoroethyl]sulfonyl]-3-[3-(trifluoromethyl]phenyl]- (CA INDEX NAME)

L18 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864250-89-5 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 6-[4-(cyanophenyl)sulfonyl]-5-[cyclohexylcarbonyl]-3,6-dihydro-4-methyl-2-oxo-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

RN 864250-90-8 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 6-[4-(cyanophenyl)-5-[cyclohexylcarbonyl]-3,6-dihydro-4-methyl-2-oxo-N-[2,2,2-trifluoroethyl]sulfonyl]-3-[3-(trifluoromethyl]phenyl]- (CA INDEX NAME)

L18 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:979622 CAPLUS
DOCUMENT NUMBER: 143:286440
TITLE: Preparation of tetrasubstituted pyrimidin-2-ones as human neutrophil elastase inhibitors
INVENTOR(S): Gielen-Haertwig, Heike; Albrecht, Barbara; Keldenich, Joerg; Li, Volkhart; Pernerstorfer, Josef; Schlemmer, Karl-Heinz; Telan, Leila
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005082863	A2	20050909	WO 2005-EP1487		20050215
WO 2005082863	A3	20051222			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2557272	A1	20050909	CA 2005-2557272		20050215
EP 1730121	A2	20061213	EP 2005-707387		20050215
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
JP 2007523931	T	20070823	JP 2007-500100		20050215
US 20080021053	A1	20080124	US 2007-590786		20070720
PRIORITY APPLN. INFO.:			EP 2004-4315	A	20040226
			WO 2005-EP1487	W	20050215

OTHER SOURCE(S): MARPAT 143:286440
GI

L18 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB Title compds. I [A = heteroaryl ring; R1-3 = H, halo, NO2, etc.; R4 = CF3CO, alkylcarbonyl, etc.; R5 = alkyl, alkoxy, etc.; R6 = T-U; T = alkanediyl, akenediyl; U = aryl, heteroaryl, etc.; R7 = halo, NO2, CN, etc.; Y1-5 = independently CH, N wherein the ring contains 0-2 N atoms] and analogs are prepared For instance, II is prepared in 6 steps from 2-bromo-5-methylpyridine, allyl 3-oxobutanoate and N-[3-(trifluoromethyl)phenyl]urea. II has an IC50 = 70 nM for human neutrophil elastase (HNE). I are useful for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

IT 864151-12-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetrasubstituted pyrimdin-2-ones as human neutrophil elastase inhibitors)

RN 864151-12-2 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[2-oxo-2-[[(2,2,2-trifluoroethyl)sulfonyl]amino]ethyl]-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)



IT 864150-91-4P 864150-92-5P 864151-01-9P
864151-02-0P 864151-13-3P 864151-14-4P

L18 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

864151-15-5P 864151-17-7P 864151-18-8P
864151-19-9P 864151-20-2P 864151-21-3P
864151-22-4P 864151-30-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrasubstituted pyrimdin-2-ones as human neutrophil elastase inhibitors)

RN 864150-91-4 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-N-[(4-cyanophenyl)sulfonyl]-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864150-92-5 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-5-(2-furanylcarbonyl)-3,6-dihydro-4-methyl-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-01-9 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 6-(4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-5-(3-pyridinylcarbonyl)-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-

L18 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-92-9 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 6-[4-cyanophenyl)-N-[[4-cyanophenyl]sulfonyl]-3,6-dihydro-4-methyl-2-oxo-5-[3-pyridinylcarbonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-13-3 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-[4-cyanophenyl]-3,6-dihydro-6-methyl-2-oxo-3-[2-oxo-2-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]ethyl]-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)

L18 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864151-17-7 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 5-acetyl-6-[4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 864151-38-8 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 5-acetyl-6-[4-cyanophenyl)-N-[[4-cyanophenyl]sulfonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L18 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864151-14-4 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-[4-cyanophenyl)-1,2,3,6-tetrahydro-6-methyl-3-[2-[[(4-nitrophenyl)sulfonyl]amino]-2-oxoethyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)



RN 864151-15-5 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-[4-cyanophenyl)-3-[2-[[(4-cyanophenyl)sulfonyl]amino]-2-oxoethyl]-1,2,3,6-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-, 2-propen-1-yl ester (CA INDEX NAME)

L18 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864151-19-9 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 5-acetyl-6-[4-cyanophenyl)-3,6-dihydro-4-methyl-2-oxo-N-[(2,2,2-trifluoroethyl)sulfonyl]-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.

RN 864151-20-2 CAPLUS
CN 1(2H)-Pyrimidineacetamide, 5-acetyl-6-(4-cyanophenyl)-N-[(4-cyanophenyl)sulfonyl]-3,6-dihydro-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 864151-21-3 CAPLUS
CN 5-Pyrimidinecarboxylac acid, 4-[4-cyanophenyl)-1,2,3,6-tetrahydro-6-methyl-2-oxo-3-[2-oxo-2-[[(2,2,2-trifluoroethyl)sulfonyl]amino]ethyl]-1-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L18 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864151-22-4 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 4-[4-cyanophenyl]-1,4,7,8-tetrahydro-6-methyl-2-oxo-3-[2-oxo-2-[[2,2,2-trifluoroethyl]sulfonyl]amino]ethyl]-1-[3-[trifluoromethyl]phenyl]-, 2-hydroxyethyl ester (CA INDEX NAME)



RN 864131-36-4 CAPLUS
CN 1[2H]-Pyrimidineacetamide, 6-[4-cyanophenyl]-3,4-dihydro-4-methyl-5-[2-methyl-1-oxopropyl]-2-oxo-N-[[2,2,2-trifluoroethyl]sulfonyl]-3-[7-[trifluoromethyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L18 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:685497 CAPLUS
DOCUMENT NUMBER: 141:174329
TITLE: Synthesis and anti-inflammatory effects of novel pimarane diterpenoid analogs
AUTHOR(S): Suh, Young-Ger; Lee, Kwang-Ok; Moon, Sung-Hyun; Seo, Seung-Yong; Lee, Yong-Sil; Kim, Seok-No; Paek, Seung-Wan; Kim, Young-Ae; Lee, Yun-Sang; Jeong, Jae Min; Lee, Seung Jin; Kim, Sang Geon
CORPORATE SOURCE: College of Pharmacy, Pharmaceutical Chemistry, Seoul National University, San 56-1 Shinrim-Dong, Kwanak-Gu, Seoul, 151-742, S. Korea
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3487-3490
CODEN: BMCLE8, ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:174329
GI

AB Syntheses and excellent anti-inflammatory effects of a series of novel acanthoic acid analogs (e.g. I) are reported. In particular, the mechanistic basis for their anti-inflammatory effects is also described.
IT 233750-12-4P
RL: BAC (Biological activity or effector, except adverse); BAM (Biological activity, miscellaneous); BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and anti-inflammatory activity of acanthoic acid analogs)
RN 233750-12-4 CAPLUS
CN 1-Phenanthrenecarboxylic acid, 7-ethenyldecahydro-1,2,5,5,6a,6b,7,8,8a,9,10,10a-dodecahydro-8-[[4-iodophenyl]sulfonyl]-1,4a,7-trimethyl-, [1S,4aS,7S,8aS,10aR]- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 864131-36-4 CAPLUS
CN 1[2H]-Pyrimidineacetamide, 6-[4-cyanophenyl]-3,4-dihydro-4-methyl-5-[2-methyl-1-oxopropyl]-2-oxo-N-[[2,2,2-trifluoroethyl]sulfonyl]-3-[7-[trifluoromethyl]phenyl]- (CA INDEX NAME)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L18 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 2004:392321 CAPLUS
DOCUMENT NUMBER: 140:406826
TITLE: Preparation of N-benzylpiperazine derivatives as chemokine receptor CCR1 antagonists useful as immunomodulatory agents
INVENTOR(S): Blumberg, Laura C.; Brown, Matthew F.; Gaweco, Anderson S.; Gladue, Ronald P.; Hayward, Matthew M.; Lundquist, Gregory D.; Poss, Christopher S.; Shavnya, Andrei
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 58 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20040092529	A1	20040513	US 2003-686993		20031016
PRIORITY APPLN. INFO.:			US 2002-422590P	P	20021030

OTHER SOURCE(S): MARPAT 140:406826
GI



I

AB The present invention relates to compds. of the formula (I) and the pharmaceutically acceptable forms thereof [m = 0-5; n, p = 0-2; q = 0-4; X = O, S, CH2, (un)substituted NH; Y = C6-10 aryl, C2-9 heteroaryl; R1 = H, HO, halo, C1-8 alkyl, C1-8 alkoxy, HO-C1-8 alkyl, cyano, NH2, H2N-C1-8 alkyl, CO2H, C1-8 alkyl-CO, C1-8 alkyl-CO-C1-8 alkyl, CONH2, or H2NCO-C1-8 alkyl; R2, R3 = H, oxo, C1-8 alkyl, C3-8 cycloalkyl-C1-8 alkyl, C6-10 aryl, C6-10 aryl-C1-8 alkyl, HO-C1-8 alkyl, C1-8 alkyl-O-C1-8 alkyl, H2N-C1-8 alkyl, C1-8 alkyl-NH-C1-8 alkyl, (C1-8 alkyl)2N-C1-8 alkyl, C2-9 heterocyclyl-C1-8 alkyl, C3-8 cycloalkyl-NH-C1-8 alkyl, C1-8 alkyl-CO-NH-C1-8 alkyl-O-CO-NH-C1-8 alkyl, H2NCO-NH-C1-8 alkyl, C1-8 alkyl-SO2NH-C1-8 alkyl, C2-9 heteroaryl-C1-8 alkyl, H2NCO, H2NCO-C1-8 alkyl; R4 = (HO2C)(H2N)-C1-8 alkyl, (HO2C)[(C1-8 alkyl)NH]-C1-8 alkyl, (HO2C)[(C1-8 alkyl)2N]-C1-8 alkyl, (HO2C-C1-8 alkyl)(C1-8 alkyl)N, (HO2C-C1-8 alkyl)(C1-8 alkyl)N-C1-8 alkyl, (HO2C-C1-8 alkyl)(C1-8 alkyl-SO2)N, (HO2C-C1-8 alkyl)(C1-8 alkyl-SO2)N-C1-8 alkyl, (HO2C-C1-8

alkyl)(C1-8 alkyl-CO)N, etc.; R5 = H, HO, halo, cyano, CO2H, H2N, C1-8 alkyl-NH, (C1-8 alkyl)2N, C1-8 alkyl, C1-8 alkyl-O, HO-C1-8 alkyl, C1-8 alkyl-NH-C1-8 alkyl, (C1-8 alkyl)2N-C1-8 alkyl, etc.]. Moreover, the present invention is also directed at pharmaceutical compns. comprising the compd. I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compds. and compns. for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal. Particularly, disclosed is a method of treating or preventing a disorder or condition selected from the group consisting of fibrosis, Alzheimer's disease, conditions assocd. with leptin prodn., sequelae assocd. with cancer, cancer metastasis, diseases or conditions related to prodn. of cytokines at inflammatory sites, and tissue damage caused by inflammation induced by infectious agents, wherein the method comprises administering to a mammal in need of such treatment or prevention a pharmaceutically effective amt. of the compd. I or a pharmaceutically acceptable form thereof. The compds. I are potent and selective inhibitors of MIP-1α (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). [2-[3-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-3-oxopropyl]-5-methylphenoxy]acetic acid was condensed with methanesulfonamide in CH2Cl2 at room temp. for 18 h using 4-dimethylaminopyridine and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride to give N-[[2-[3-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-3-oxo-propyl]-5-methylphenoxy]acetyl]methanesulfonamide. All the compds. I inhibited MIP-1α (and the related chemokines shown to interact with CCR1) induced chemotaxis of THP-1 cells and human leukocytes with IC50 of <10 μM.

IT 519172-07-7P, N-[[5-Chloro-2-[2-[4-(4-Fluoro-Benzyl)-(2R,5S)-2,5-Dimethyl-Piperazin-1-yl]-2-Oxo-Ethoxy]-Phenyl]-Acetyl]-Methanesulfonamide 519172-37-3P, N-[[5-Chloro-2-[2-[4-(4-Fluoro-Benzyl)-(2R,5S)-2,5-Dimethyl-Piperazin-1-yl]-2-Oxo-Ethoxy]-Pyridin-3-yl]-Acetyl]-Methanesulfonamide 519173-91-2P,

N-[[5-Bromo-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519173-92-3P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519173-93-4P,

N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-trifluoromethanesulfonamide 519173-94-5P 519173-95-6P, N-[[2-[2-[4-(4-Fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]-4-methoxyphenyl]acetyl]methanesulfonamide 519173-96-7P 519173-97-8P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-2-methylbenzenesulfonamide 519173-98-9P, Ethanesulfonic acid

N-[[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]amide 519173-99-0P, 3,5-Dimethylisoxazole-4-sulfonic acid

N-[[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]amide 519174-00-6P, N-[[5-Bromo-2-[2-[4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-01-7P, (R)-N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-02-8P, (R)-N-[[5-Bromo-2-[2-[4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-03-9P,

N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-4-methoxybenzenesulfonamide 519174-04-0P, 2-Chloro-N-[[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]benzenesulfonamide 519174-05-1P,

N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-2-fluorobenzenesulfonamide 519174-06-2P , N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-4-methylbenzenesulfonamide 519174-07-3P, Propane-2-sulfonic acid

[[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]amide 519174-08-4P, Propane-1-sulfonic acid [[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]amide 519174-11-9P,

N-[[4-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-12-0P, (R)-N-[[4-Chloro-2-[2-[4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-13-1P,

N-[[5-Chloro-2-[2-[4-(3,4-difluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-14-2P,

N-[[5-Chloro-2-[2-[4-(4-chlorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-16-4P,

N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]phenylmethanesulfonamide 519174-18-6P, (R)-N-[[5-Chloro-2-[2-[4-(4-chlorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-19-7P, (R)-N-[[5-Chloro-2-[2-[4-(3,4-difluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-20-0P, (R)-N-[[5-Chloro-2-[2-[2-ethyl-4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-21-1P, (R)-N-[[5-Bromo-2-[2-[2-ethyl-4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-22-2P, (R)-N-[[2-[2-[2-Ethyl-4-(4-fluorobenzyl)piperazin-1-yl]-2-oxo-ethoxy]-5-methylphenyl]acetyl]methanesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-benzylpiperazine derivs. as chemokine receptor CCR1 antagonists useful as immunomodulatory agents)

RN 519172-07-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519172-37-3 CAPLUS
CN 3-Pyridineacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-91-2 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-92-3 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519173-93-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-94-5 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(4-fluorophenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-95-6 CAPLUS
CN Benzeneacetamide,
2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-4-methoxy-N-(methylsulfonyl)- (CA INDEX NAME)

L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 519173-98-9 CAPLUS
CN Benzeneacetamide, 5-chloro-N-(ethylsulfonyl)-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-99-0 CAPLUS
CN Benzeneacetamide, 5-chloro-N-(3,5-dimethyl-4-isoxazolyl)sulfonyl]-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-00-6 CAPLUS
CN Benzeneacetamide,
5-bromo-2-[2-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Absolute stereochemistry.



RN 519173-96-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[phenylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-97-8 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(2-methylphenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519174-01-7 CAPLUS
CN Benzeneacetamide,
5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-02-8 CAPLUS
CN Benzeneacetamide,
5-bromo-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-03-9 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(4-methoxyphenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519174-84-0 CAPLUS
CN Benzeneacetamide, 5-chloro-N-[[2-chlorophenyl]sulfonyl]-2-[2-[[2R,5S]-4-[[4-fluorophenyl]methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-85-1 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[[2R,5S]-4-[[4-fluorophenyl]methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[[2-fluorophenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 519174-88-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[[2R,5S]-4-[[4-fluorophenyl]methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[propylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-11-9 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[[2R,5S]-4-[[4-fluorophenyl]methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[methylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-12-0 CAPLUS
CN Benzeneacetamide, 4-chloro-2-[2-[[2R,5S]-4-[[4-fluorophenyl]methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-[methylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519174-86-2 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[[2R,5S]-4-[[4-fluorophenyl]methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-87-3 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[[2R,5S]-4-[[4-fluorophenyl]methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 519174-13-1 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[[2R,5S]-4-[[2,4-difluorophenyl]methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[methylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-14-2 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[[2R,5S]-4-[[4-chlorophenyl]methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[methylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-16-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[[2R,5S]-4-[[4-fluorophenyl]methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(phenylmethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-18-6 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[[2R,5S]-4-[[4-chlorophenyl]methyl]-2-methyl-

L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-19-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R)-4-[(3,4-difluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-20-0 CAPLUS
CN Benzeneacetamide,
5-chloro-2-[2-[(2R)-2-ethyl-4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-21-1 CAPLUS

L18 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Benzeneacetamide,
5-bromo-2-[2-[(2R)-2-ethyl-4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-22-2 CAPLUS
CN Benzeneacetamide, 2-[2-[(2R)-2-ethyl-4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-5-methyl-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:387265 CAPLUS
DOCUMENT NUMBER: 140:391297
TITLE: Preparation of piperazine derivatives as CCR1 antagonists
INVENTOR(S): Blumberg, Laura Cook; Brown, Matthew Frank; Gaweco, Anderson See; Gladue, Ronald Paul; Hayward, Matthew Merrill; Lundquist, Gregory Dean; Poss, Christopher Stanley; Shavnya, Andre
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004039376	A1	20040513	WO 2003-IB4612		20031020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2498261	A1	20040513	CA 2003-2498261		20031020
AU 2003269364	A1	20040525	AU 2003-269364		20031020
BR 2003015777	A	20050913	BR 2003-15777		20031020
EP 1583533	A1	20051012	EP 2003-751145		20031020
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006506391	T	20060223	JP 2004-547876		20031020
MX 2005004650	A	20050608	MX 2005-4650		20050429
PRIORITY APPLN. INFO.:			US 2002-422590P	P	20021030
			WO 2003-IB4612	W	20031020

OTHER SOURCE(S): MARPAT 140:391297
GI

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB Title compds. I [a = 0-5; b,c = 0-2; p = 0-4; X = O, S, CH2, (un)substituted amino; Y = (hetero)aryl; R1 = H, OH, halo, alkyl, alkoxy, etc.; R2-3 = H, oxo, (cyclo)alkyl, aryl, etc.; R4 = alkyl, etc.; R5 = H, OH, halo, CN, etc.] are prepared. For instance, (2R,5S)-1-(4-fluorobenzyl)-2,5-dimethylpiperazine (preparation given) is reacted with 7-methylchroman-2-one (PhMe, reflux 48 h), the resulting propanone treated with bromoacetic acid Me ester (THF, NaH) and the ester saponified to give II. All example compds. have IC50 < 10 μM in the chemotaxis assay. I are useful for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.

IT 519172-07-7P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519172-37-3P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]pyridin-3-yl]acetyl]methanesulfonamide 519173-91-2P 519173-92-3P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519173-93-4P 519173-94-5P 519173-95-6P 519173-96-7P 519173-97-8P 519173-98-9P 519173-99-0P 519174-00-6P, N-[[5-Bromo-2-[2-[4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-01-7P, (R)-N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-02-8P, (R)-N-[[5-Bromo-2-[2-[4-(4-fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-03-9P 519174-04-0P 519174-05-1P 519174-06-2P 519174-07-3P, Propane-2-sulfonic acid

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

1[5-chloro-2-[2-[4-[4-fluorobenzyl]-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-
oxoethoxy]phenyl]acetyl]amide 519174-08-8P 519174-11-9P
519174-12-0P, (R)-N-[4-Chloro-2-[2-[4-(4-fluorobenzyl)-2-
methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide
519174-13-1P 519174-14-2P 519174-16-4P
519174-18-6P, (R)-N-[5-Chloro-2-[2-[4-(4-chlorobenzyl)-2-
methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide
519174-19-7P, (R)-N-[5-Chloro-2-[2-[4-(3,4-difluorobenzyl)-2-
methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide
519174-20-0P, (R)-N-[5-Chloro-2-[2-[2-methyl-4-(4-
fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide
519174-23-3P, (R)-N-[5-Bromo-2-[2-[2-ethyl-4-(4-
fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide
519174-22-2P, (R)-N-[5-[2-[2-Ethyl-4-(4-fluorobenzyl)piperazin-1-
yl]-2-oxoethoxy]-4-methylphenyl]acetyl]methanesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(prepn. of substituted N-acylpiperazine derivs. as CCR1 antagonists)

RN 519172-07-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-
dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[methylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 519172-37-3 CAPLUS
CN 3-Pyridineacetamide,
5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-
dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[methylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 519173-94-5 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-
dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(4-fluorophenyl)sulfonyl]- (CA
INDEX NAME)

Absolute stereochemistry.

RN 519173-95-6 CAPLUS
CN Benzeneacetamide,
2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-
piperazinyl]-2-oxoethoxy]-4-methoxy-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-96-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-
dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[phenylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519173-91-2 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-
dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

RN 519173-92-3 CAPLUS
CN Benzeneacetamide,
5-chloro-2-[2-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-
2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

RN 519173-93-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-
dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(trifluoromethyl)sulfonyl]- (CA
INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519173-97-8 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-
dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(2-methylphenyl)sulfonyl]- (CA
INDEX NAME)

Absolute stereochemistry.



RN 519173-98-9 CAPLUS
CN Benzeneacetamide, 5-chloro-N-[ethylsulfonyl]-2-[2-[(2R,5S)-4-[(4-
fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]- (CA INDEX
NAME)

Absolute stereochemistry.

RN 519173-99-0 CAPLUS
CN Benzeneacetamide, 5-chloro-N-[(5,5-dimethyl-4-isoxazolyl)sulfonyl]-2-[2-
[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-
oxoethoxy]- (CA INDEX NAME)

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Absolute stereochemistry.



RN 519174-00-6 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-[methylsulfonyl]- (CA INDEX NAME)



RN 519174-01-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[(2S)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519174-02-8 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-03-9 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(4-methoxyphenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-04-0 CAPLUS

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Benzeneacetamide, 5-chloro-N-[(2-chlorophenyl)sulfonyl]-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-00-1 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(2-fluorophenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-06-2 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519174-07-3 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-08-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(propylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-11-9 CAPLUS
CN Benzeneacetamide, 4-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519174-12-9 CAPLUS
CN Benzeneacetamide, 4-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-13-1 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(3,4-difluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-14-2 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2S,5R)-4-[(4-chlorophenyl)methyl]-2,5-

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 519174-15-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R)-4-[(3,4-difluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-20-0 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R)-2-ethyl-4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-21-1 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[(2R)-2-ethyl-4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-22-2 CAPLUS
CN Benzeneacetamide, 2-[2-[(2R)-2-ethyl-4-[(4-fluorophenyl)methyl]-1-

L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-16-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(phenylmethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-18-6 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R)-4-[(4-chlorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
piperazinyl]-2-oxoethoxy]-5-methyl-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:972066 CAPLUS
DOCUMENT NUMBER: 140:27753
TITLE: Preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders
INVENTOR(S): Dahnke, Karl Robert; Gajewski, Robert Peter; Jones, Charles David; Linebarger, Jared Harris; Lu, Jianliang; Ma, Tianwei; Nagpal, Sunil; Simard, Todd Parker; Yee, Ying Kwong; Bunel, Emilio Enrique; Stites, Ryan Edward
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 504 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003101978	A1	20031211	WO 2003-US14539		20030522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2485503	A1	20031211	CA 2003-2485503		20030522
AU 2003233505	A1	20031219	AU 2003-233505		20030522
BR 2003009983	A	20050222	BR 2003-9983		20030522
EP 1511740	A1	20050309	EP 2003-728782		20030522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1656089	A	20050817	CN 2003-812198		20030522
JP 2005532348	T	20051027	JP 2004-509669		20030522
MX 2004011903	A	20050331	MX 2004-11903		20041129
IN 2004KN01967	A	20061103	IN 2004-KN1967		20041221
US 20060287536	A1	20061221	US 2006-515403		20060125
PRIORITY APPLN. INFO.:			US 2002-384151P	P	20020529
			WO 2003-US14539	W	20030522

OTHER SOURCE(S): MARPAT 140:27753
GI

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB The present invention relates to novel, nonsecosteroidal, phenylalkyl thiophene compds. (shown as I; variables defined below; e.g.

3'-[4-(2-oxo-3,3-dimethylbutoxy)-3-methylphenyl]-3'-[5-(methoxycarbonyl)-4-(methyl)thiophen-2-yl]pentane (II)) with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compds. are useful for treating bone disease and psoriasis. For I: R and R' = C1-C5 alkyl, C1-C5 fluoroalkyl, or together R and R' form a (un)substituted, (un)saturated carbocyclic ring having 3-8 C atoms; ring atoms Q1 and Q2 = C or S, with the proviso that one atom is S and the other atom is C; RP and RT = H, halo, C1-C5 alkyl, C1-C5 fluoroalkyl, -O-C1-C5 alkyl, -S-C1-C5 alkyl, -O-C1-C5 fluoroalkyl, -CN, -NO2, acetyl, -S-C1-C5 fluoroalkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, and C3-C5 cycloalkenyl; LP and LT are divalent linking bond,
-(CH2)mC(X1)-
(X1 = O, S; m = 0-2), -(CH2)mCH(OH)-, etc.; ZP and ZT = H, Ph, benzyl, fluorophenyl, C1-C5 alkyl, etc.; addnl. details including provisos are given in the claims. Although the methods of preparation are not
claimed,
.apprx.180 example prepns. are included. For example, II was prepared
in 7
steps starting from 2-hydroxy-5-bromotoluene and tert-butyldimethylsilyl chloride and involving intermediates
2-(tert-Butyldimethylsilyloxy)-5-bromotoluene,
3'-[4-(tert-Butyldimethylsilyloxy)-3-methylphenyl]pentan-3-ol,
3'-[4-(Hydroxy)-3-methylphenyl]-3'-[4-(methyl)thiophen-2-yl]pentane,
3'-[4-(Benzyloxy)-3-methylphenyl]-3'-[4-(methyl)thiophen-2-yl]pentane,
3'-[4-(Benzyloxy)-3-methylphenyl]-3'-[5-(methoxycarbonyl)-4-(methyl)thiophen-2-yl]pentane, and

3'-[4-(Hydroxy)-3-methylphenyl]-3'-[5-(methoxycarbonyl)-4-(methyl)thiophen-

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
2-yl]pentane with yields of 97, 72, 95, 92, 54, 100 and 85, resp.
Results
are tabulated for many of the example I for the following assays: RXR-VDR heterodimerization (SaOS-2 cells), VDR co-transfection (Caco-2 cells), osteocalcin promotor, mouse hypercalcemia, keratinocyte proliferation,
and
IL-10 induction; e.g. one enantiomer of
1-[4-[1-ethyl-1-(5-hydroxymethyl-4-methylthiophen-2-yl)propyl]-2-methylphenoxy]-3,3-dimethylbutan-2-ol exhibits an EC50 = 2.8 nM in the RXR-VDR assay compared to 3 nM for the control calcipotriol.

IT 633341-19-2P 633341-20-5P 633341-21-6P
633341-22-7P 633341-23-8P 633341-24-9P
633341-25-0P 633341-26-1P 633341-27-2P
633341-28-3P 633341-29-4P 633341-30-7P
633341-31-8P 633341-32-9P 633341-33-0P
633341-34-1P 633341-35-2P 633341-36-3P
633344-85-1P 633344-86-2P 633344-87-3P
633344-88-4P 633344-89-5P 633344-90-8P
633344-91-9P 633344-92-0P 633344-93-1P
633344-94-2P 633344-95-3P 633344-96-4P
633344-97-5P 633344-98-6P 633344-99-7P
633345-00-3P 633345-01-4P 633345-02-5P
633350-14-8P 633350-15-9P 633350-16-0P
633350-17-1P 633350-18-2P 633350-19-3P
633350-20-6P 633350-21-7P 633350-22-8P
633350-23-9P 633350-24-0P 633350-25-1P
633350-26-2P 633350-27-3P 633350-28-4P
633350-29-5P 633350-30-8P 633350-31-9P
633353-96-5P 633353-97-6P 633353-98-7P
633353-99-8P 633354-00-4P 633354-01-5P
633354-02-6P 633354-03-7P 633354-04-8P
633354-05-9P 633354-06-0P 633354-07-1P
633354-08-2P 633354-09-3P 633354-10-6P
633354-11-7P 633354-12-8P 633354-13-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenylalkyl thiophene-type vitamin D receptor modulators for treating bone disease, psoriasis and other disorders)

RN 633341-19-2 CAPLUS
CN 2-Thiopheneacetamide,
5-[1-[4-(4,4-dimethyl-3-oxopentyl)-3-methylphenyl]-1-ethylpropyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-20-5 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-21-6 CAPLUS
CN 2-Thiopheneacetamide,
5-[1-ethyl-1-[4-(3-hydroxy-3,4,4-trimethylpentyl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-22-7 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[3-methyl-4-(2,4,4-trimethyl-3-oxopentyl)phenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-23-8 CAPLUS
CN 2-Thiopheneacetamide,
5-[1-ethyl-1-[4-(3-hydroxy-2,4,4-trimethylpentyl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633341-24-9 CAPLUS
CN 2-Thiophenesulfonamide, 5-[1-ethyl-1-[4-(3-hydroxy-2,3,4,4-tetramethylpentyl)-3-methylphenyl]propyl]-N-[ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633341-25-0 CAPLUS
CN 2-Thiophenesulfonamide, 5-[1-[4-(4,4-dimethyl-3-oxopentyl)-3-methylphenyl]-1-ethylpropyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633341-26-1 CAPLUS
CN 2-Thiophenesulfonamide, 5-[1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633341-30-7 CAPLUS
CN 2-Thiophenesulfonamide, 5-[1-ethyl-1-[4-(3-hydroxy-2,3,4,4-tetramethylpentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633341-31-8 CAPLUS
CN 2-Thiophenesulfonamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-[4-(4,4-dimethyl-3-oxopentyl)-3-methylphenyl]-1-ethylpropyl]-3-methyl- (CA INDEX NAME)

RN 633341-32-9 CAPLUS
CN 2-Thiophenesulfonamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-4,4-dimethylpentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633341-27-2 CAPLUS
CN 2-Thiophenesulfonamide, 5-[1-ethyl-1-[4-(3-hydroxy-3,4,4-trimethylpentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633341-28-3 CAPLUS
CN 2-Thiophenesulfonamide, 5-[1-ethyl-1-[3-methyl-4-(2,4,4-trimethyl-3-oxopentyl)phenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633341-29-4 CAPLUS
CN 2-Thiophenesulfonamide, 5-[1-ethyl-1-[4-(3-hydroxy-2,4,4-trimethylpentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633341-33-0 CAPLUS
CN 2-Thiophenesulfonamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-3,4,4-trimethylpentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633341-34-1 CAPLUS
CN 2-Thiophenesulfonamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[3-methyl-4-(2,4,4-trimethyl-3-oxopentyl)phenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633341-35-2 CAPLUS
CN 2-Thiophenesulfonamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-2,4,4-trimethylpentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633341-36-3 CAPLUS
CN 2-Thiophenesulfonamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-2,3,4,4-tetramethylpentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633344-85-5 CAPLUS
CN Benzeneacetamide,
4-[5-[3-[4,4-dimethyl-3-oxopentyl]-4-methyl-2-thienyl]-1-
ethylpropyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)



RN 633344-86-2 CAPLUS
CN Benzeneacetamide,
4-[1-ethyl-1-[5-[3-hydroxy-4,4-dimethylpentyl]-4-methyl-
2-thienyl]propyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)



RN 633344-87-3 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-(3-hydroxy-3,4,4-trimethylpentyl)-4-
methyl-2-thienyl]propyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633344-91-9 CAPLUS
CN Benzeneacetamide,
4-[1-[5-[4,4-dimethyl-3-oxopentyl]-4-methyl-2-thienyl]-1-
ethylpropyl]-2-methyl-N-[[1-methylethyl]sulfonyl]- (CA INDEX NAME)



RN 633344-92-0 CAPLUS
CN Benzeneacetamide,
4-[1-ethyl-1-[5-[3-hydroxy-4,4-dimethylpentyl]-4-methyl-
2-thienyl]propyl]-2-methyl-N-[[1-methylethyl]sulfonyl]- (CA INDEX NAME)



RN 633344-93-1 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-(3-hydroxy-3,4,4-trimethylpentyl)-4-
methyl-2-thienyl]propyl]-2-methyl-N-[[1-methylethyl]sulfonyl]- (CA INDEX NAME)



L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633344-88-4 CAPLUS
CN Benzeneacetamide,
4-[1-ethyl-1-[4-methyl-5-(2,4,4-trimethyl-3-oxopentyl)-2-
thienyl]propyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)



RN 633344-89-5 CAPLUS
CN Benzeneacetamide, 4-[1-ethyl-1-[5-(3-hydroxy-2,4,4-trimethylpentyl)-4-
methyl-2-thienyl]propyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)

RN 633344-90-8 CAPLUS
CN Benzeneacetamide,
4-[1-ethyl-1-[5-(3-hydroxy-2,3,4,4-tetramethylpentyl)-4-
methyl-2-thienyl]propyl]-N-[ethylsulfonyl]-2-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633344-94-2 CAPLUS
CN Benzeneacetamide,
4-[1-ethyl-1-[4-methyl-5-(2,4,4-trimethyl-3-oxopentyl)-2-
thienyl]propyl]-2-methyl-N-[[1-methylethyl]sulfonyl]- (CA INDEX NAME)



RN 633344-95-3 CAPLUS
CN Benzeneacetamide, 4-[3-ethyl-1-[5-(3-hydroxy-2,4,4-trimethylpentyl)-4-
methyl-2-thienyl]propyl]-2-methyl-N-[[1-methylethyl]sulfonyl]- (CA INDEX NAME)



RN 633344-96-4 CAPLUS
CN Benzeneacetamide,
4-[1-ethyl-1-[5-(3-hydroxy-2,3,4,4-tetramethylpentyl)-4-
methyl-2-thienyl]propyl]-2-methyl-N-[[1-methylethyl]sulfonyl]- (CA INDEX NAME)

RN 633344-97-5 CAPLUS
CN Benzeneacetamide,
N-[[1,1-dimethylethyl]sulfonyl]-4-[3-[5-(4,4-dimethyl-3-
oxopentyl)-4-methyl-2-thienyl]-1-ethylpropyl]-2-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633344-96-6 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-3-[5-(3-hydroxy-4,4-dimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)



RN 633344-99-7 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-1-[5-(3-hydroxy-3,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)



RN 633345-00-3 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-1-[4-methyl-5-[2,4,4-trimethyl-3-oxopentyl]-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-15-9 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-pentyn-1-yl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633350-16-0 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-pentyn-1-yl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633350-17-1 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[3-ethyl-3-hydroxypentyl]-2-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633345-01-4 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-1-[5-(2-hydroxy-2,4,4-trimethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)



RN 633345-02-5 CAPLUS
CN Benzeneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-4-[1-ethyl-1-[5-(2-hydroxy-2,3,4,4-tetramethylpentyl)-4-methyl-2-thienyl]propyl]-2-methyl- (CA INDEX NAME)



RN 633350-14-8 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methylpentyl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 633350-18-2 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-penten-1-yl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633350-19-3 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-pentyn-1-yl)-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)



RN 633350-20-6 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methylpentyl)-2-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

RN 633350-21-7 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-penten-1-yl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-20-8 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-pentyn-1-yl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633350-23-9 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxypentyl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633350-24-0 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-pentenyl-3-yl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-28-4 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-pentyn-1-yl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633350-29-5 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-ethyl-3-hydroxypentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633350-30-8 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-pentyn-1-yl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-25-1 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-pentyn-1-yl)-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633350-26-2 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-3-methylpentyl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633350-27-3 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-hydroxy-3-methyl-1-pentene-1-yl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633350-31-9 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-(3-ethyl-3-hydroxy-1-pentyn-1-yl)-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633353-96-5 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethyl]-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)

RN 633352-97-6 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethynyl]-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)

RN 633353-98-7 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethenyl]-3-methylphenyl]propyl]-N-(ethylsulfonyl)-3-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 677253-99-9 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethyl]-3-methylphenyl]propyl]-N-[ethylsulfonyl]-3-methyl- (CA INDEX NAME)



RN 633354-00-4 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethynyl]-3-methylphenyl]propyl]-N-[ethylsulfonyl]-3-methyl- (CA INDEX NAME)



RN 633354-01-5 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethenyl]-3-methylphenyl]propyl]-N-[ethylsulfonyl]-3-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 633354-06-0 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethynyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633354-07-1 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethenyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633354-09-2 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,3-dimethylethyl)sulfonyl]-5-[3-ethyl-3-[4-[2-(1-hydroxycyclopentyl)ethyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633354-09-3 CAPLUS

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 633354-02-6 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633354-03-7 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethynyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

RN 633354-04-8 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethenyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



RN 633354-05-9 CAPLUS
CN 2-Thiopheneacetamide, 5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethyl]-3-methylphenyl]propyl]-3-methyl-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 633354-08-1 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethynyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)

RN 633354-10-4 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclopentyl)ethenyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633354-11-7 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



RN 633354-12-8 CAPLUS
CN 2-Thiopheneacetamide, N-[(1,1-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethynyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)

L18 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 633354-33-9 CAPLUS
CN 2-Thiophenecarboxamide, N-[(1,2-dimethylethyl)sulfonyl]-5-[1-ethyl-1-[4-[2-(1-hydroxycyclohexyl)ethenyl]-3-methylphenyl]propyl]-3-methyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



II

AB The title indole compds., substituted by either dihydrobenzoxazinyl or benzodioxanyl, with general formula of I [wherein R = COR1, CR2OR5, or CO2R2; R0 = H or acyl; R1 = alkoxy or (un)substituted amino; R20 = allyl or PhCH2; R2 = H, (alkoxy)alkyl, alkoxy, halo, NH2, trihalomethyl, CH, PhCH2, or 4-MeO-PhCH2; R3 = H, alkyl, alkoxy, halo, trihalomethyl, CH, or CH; R4 and R5 = independently H, (alkoxy)alkyl, alkoxy, halo, NO2, NH2, trihalomethyl, trihalomethoxy, CH, or CH; T = a single bond, alkylene, alkenylene, or oxyalkylene; G = CONR6, NHCO, SO2NR6, NHSO2, diazo, (un)substituted alkylene, or alkenylene; R6 = 3-15 membered cyclyl or (un)substituted 4-15 membered heterocyclyl; or G and R6 together form (un)substituted alkyl, alkenyl, or alkynyl; n = 1-3; m = 1-3; p = 1-4] and pharmaceutically acceptable salts thereof are prepared as prostaglandin D2 (PGD2) receptor antagonists. For example, the indole II was prepared in a multi-step synthesis. II showed K1 of 0.031 nM against DP receptor in rat. Compds. I are useful in preventing/treating allergic diseases, diseases associated with itch, diseases secondarily caused by behaviors associating itch, inflamation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular diseases, rheumatoid arthritis-complicated pleuritis, ulcerative colitis, etc (no data). Formulations containing I as an active ingredient were also described.

IT 502434-28-8P 502434-30-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(DP receptor antagonist; preparation of indole derivs. as DP receptor antagonists)

RN 502434-28-8 CAPLUS
CN 1H-Indole-4-acetamide, 1-[4-[[(2R)-2,4-dihydro-4-methyl-2H-1,4-benzoxazin-

L18 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
2-yl]methoxy]benzoyl]-2-methyl-N-[methylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 502434-30-2 CAPLUS
CN 1H-Indole-4-acetamide, 1-[4-[[(2R)-2,4-dihydro-4-methyl-2H-1,4-benzoxazin-2-yl]methoxy]benzoyl]-2-methyl-N-[phenylsulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:223458 CAPLUS
DOCUMENT NUMBER: 138:255237
TITLE: Preparation of indole derivatives as DP receptor antagonists
INVENTOR(S): Torisu, Kazuhiko; Hasegawa, Tomoyuki; Kobayashi, Kaoru; Nambu, Fumio
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032843	A1	20020425	WO 2002-JP9977	20020926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002335354	A1	20030324	AU 2002-335354	20020926
EP 1424325	A1	20040602	EP 2002-798037	20020926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20050004096	A1	20050106	US 2004-488874	20040308
US 7153852	B2	20061226		
PRIORITY APPLN. INFO.:			JP 2001-271281	A 20010907
			WO 2002-JP9977	W 20020926

OTHER SOURCE(S): MARPAT 138:255237
GI

I

AB The title indole compds., substituted by either dihydrobenzoxazinyl or benzodioxanyl, with general formula of I [wherein R = COR1, CR2OR5, or CO2R2; R0 = H or acyl; R1 = alkoxy or (un)substituted amino; R20 = allyl or PhCH2; R2 = H, (alkoxy)alkyl, alkoxy, halo, NH2, trihalomethyl, CH, PhCH2, or 4-MeO-PhCH2; R3 = H, alkyl, alkoxy, halo, trihalomethyl, CH, or CH; R4 and R5 = independently H, (alkoxy)alkyl, alkoxy, halo, NO2, NH2, trihalomethyl, trihalomethoxy, CH, or CH; T = a single bond, alkylene, alkenylene, or oxyalkylene; G = CONR6, NHCO, SO2NR6, NHSO2, diazo, (un)substituted alkylene, or alkenylene; R6 = 3-15 membered cyclyl or (un)substituted 4-15 membered heterocyclyl; or G and R6 together form (un)substituted alkyl, alkenyl, or alkynyl; n = 1-3; m = 1-3; p = 1-4] and pharmaceutically acceptable salts thereof are prepared as prostaglandin D2 (PGD2) receptor antagonists. For example, the indole II was prepared in a multi-step synthesis. II showed K1 of 0.031 nM against DP receptor in rat. Compds. I are useful in preventing/treating allergic diseases, diseases associated with itch, diseases secondarily caused by behaviors associating itch, inflamation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular diseases, rheumatoid arthritis-complicated pleuritis, ulcerative colitis, etc (no data). Formulations containing I as an active ingredient were also described.

IT 502434-28-8P 502434-30-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(DP receptor antagonist; preparation of indole derivs. as DP receptor antagonists)

RN 502434-28-8 CAPLUS
CN 1H-Indole-4-acetamide, 1-[4-[[(2R)-2,4-dihydro-4-methyl-2H-1,4-benzoxazin-

L18 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:154382 CAPLUS
DOCUMENT NUMBER: 138:187795
TITLE: Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
INVENTOR(S): Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1009 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016254	A1	20030227	WO 2002-JP8120	20020808
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457468	A1	20030227	CA 2002-2457468	20020808
AU 2002323916	A1	20030303	AU 2002-323916	20020808
EP 1431267	A1	20040623	EP 2002-755874	20020808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011810	A	20040824	BR 2002-11810	20020808
CN 1551866	A	20041201	CN 2002-817376	20020808
HU 2004001963	A2	20050128	HU 2004-1963	20020808
HU 2004001963	A3	20060130		
NZ 531153	A	20051028	NZ 2002-531153	20020808
NZ 541950	A	20070223	NZ 2002-541950	20020808
RU 2315746	C2	20080127	RU 2004-106623	20020808
CN 101284773	A	20081015	CN 2008-10002260	20020808
ZA 2004000973	A	20050104	ZA 2004-973	20040205
NO 2004000564	A	20040510	NO 2004-564	20040206
MX 2004001253	A	20040603	MX 2004-1253	20040209
US 20060258728	A1	20061116	US 2004-486220	20040909
US 7491748	B2	20090217		
PRIORITY APPLN. INFO.:			JP 2001-241867 A	20010809
			CN 2002-817376 A3	20020808
			WO 2002-JP8120 W	20020808

OTHER SOURCE(S): MARPAT 138:187795

GI

L18 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I

AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepared These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisoindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide, (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching),

L18 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reprodn. disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers assocd. therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, redn. of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation contg. (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT 499152-81-7P 499153-88-7P 499154-07-3P
499154-08-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499152-81-7 CAPLUS
CN Benzeneacetamide, 2-[2-(2-naphthalenyl)ethoxy]-N-(phenylsulfonyl)-4-(1H-pyrazol-1-ylmethyl)- (CA INDEX NAME)

L18 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 499153-88-7 CAPLUS
CN 1H-Indole-3-acetamide, N-[(3,4-difluorophenyl)sulfonyl]-2-methyl-1-[2-(1-naphthalenyl)-1-oxopropyl]- (CA INDEX NAME)



RN 499154-07-3 CAPLUS
CN 1H-Isoindole-1-acetamide, N-[(3,4-difluorophenyl)sulfonyl]-2,3-dihydro-2-(1-naphthalenylmethyl)-3-oxo-5-(1H-pyrazol-1-ylmethyl)- (CA INDEX NAME)

L18 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 439154-08-4 CAPLUS
CN 1H-Imidazole-1-acetamide, N-[(3,4-difluorophenyl)sulfonyl]-2,3-dihydro-2-[3-methyl-1-phenylbutyl]-3-oxo-5-[phenoxymethyl]- (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L18 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:22713 CAPLUS
DOCUMENT NUMBER: 138:83384
TITLE: Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase
INVENTOR(S): Sugiyama, Yasuo; Nishimoto, Tomoyuki; Kiyota, Yoshihiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003002147	A1	20030109	WO 2002-JP6495	20020627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2451363	A1	20030109	CA 2002-2451363	20020627
AU 2002313277	A1	20030303	AU 2002-313277	20020627
JP 2003081973	A	20030319	JP 2002-188173	20020627
EP 1407782	A1	20040414	EP 2002-738833	20020627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040204500	A1	20041014	US 2003-480797	20031211
US 20060214096	A1	20060926	US 2006-473560	20060623
US 20080132483	A1	20080605	US 2008-9277	20080111
PRIORITY APPLN. INFO.:			JP 2001-197419 A	20010628
			WO 2002-JP6495 W	20020627
			US 2003-480797 A3	20031211
			US 2006-473560 B1	20060623

OTHER SOURCE(S): MARPAT 138:83384
AB Preventives/remedies for organ functional disorders, preventives/remedies for organ dysfunction and preventives/remedies for obesity and sequels thereof which contain a compound having an effect of increasing ubiquinone, its salt or prodrugs of the same; and ubiquinone increasing agents containing a compound having a squalene synthase inhibitory effect, its salt or prodrugs of the same.
IT 189059-84-5 189059-85-6 189060-07-9

L18 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
189240-45-5 383452-05-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Preventives/remedies for organ functional disorders with increasing ubiquinone and inhibiting squalene synthase)
RN 189059-84-5 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2,2-dimethylpropyl]-N-(methylsulfonyl)-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 189059-85-6 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-N-(methylsulfonyl)-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 189060-07-9 CAPLUS

L18 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.

RN 189060-65-5 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383452-05-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2,2-dimethylpropyl]-2-oxo-N-(propylsulfonyl)-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L18 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:252935 CAPLUS
DOCUMENT NUMBER: 134:280607
TITLE: Preparation of acyl sulfonamide derivatives as selective inhibitors of human chymase
INVENTOR(S): Aoyama, Yukio; Seki, Maki; Masuda, Hirokazu; Usui, Yoshihiro; Abe, Yuji; Shimada, Mayumi; Yamamoto, Mitsuya
PATENT ASSIGNEE(S): Mitsubishi Chemical Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXGAP
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001097946	A	20010410	JP 1999-278076	19990930
PRIORITY APPLN. INFO.:			JP 1999-278076	19990930

OTHER SOURCE(S): MARPAT 134:280607
AB The title compds. represented by formula R1CH(X2)CONHSO2R2 [R1 = (un)substituted Ph, naphthyl, H; R2 = halo, alkoxy, NH2, acyl, cyano, CO2H, WC2; (un)substituted Ph, H; provided that R1 and R2 are not simultaneously H; X2 = (un)substituted aryl; X = O, S(O)n; wherein n = 0-2], pharmacol. acceptable salts thereof or hydrates or solvates thereof are prepared. These compds. are useful for the prevention and/or treatment of hypertension, ischemic heart failure, myocardial diseases, arteriosclerosis, coronary arterial diseases, myocardial infarction, vascular restenosis after angioplasty or thrombolytic therapy, peripheral circulation disorders, angiitis, diabetic or non-diabetic nephropathy, pulmonary hypertension, bronchial asthma, chronic obtrusive lung diseases, chronic bronchitis, pulmonary emphysema, allergic rhinitis, atopic dermatitis, rheumatism, arthritis, or cancer (no data). Thus, a solution of diphenylacetic acid in THF was added dropwise to a solution of 1,1'-carbonyldiimidazole in THF, stirred at 25° for 0.5 h, refluxed fro 0.5 h, and cooled to 25°, followed by adding dropwise a solution of 2-naphthalenesulfonamide and 1,8-diazabicyclo[5.4.0]-7-undecene in THF, and the resulting mixture was stirred at 25° overnight to give 95% N-(2-naphthalenesulfonyl)diphenylacetamide, i.e. N-(diphenylacetyl)-2-naphthalenesulfonamide.
IT 333335-12-9P, N-(2-Naphthalenesulfonyl)-2-(3,4-dichlorophenyl)acetamide 333335-13-0P, N-(2-Naphthalenesulfonyl)-2-(2,4-dichlorophenyl)acetamide
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acyl sulfonamide deriva. as selective inhibitors of human chymase and preventives or therapeutics for chymase-related diseases)
RN 333335-12-9 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-(2-naphthalenylsulfonyl)- (CA INDEX

L18 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 333335-13-0 CAPLUS
CN Benzeneacetamide, 2,4-dichloro-N-(2-naphthalenylsulfonyl)- (CA INDEX NAME)

L18 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:247709 CAPLUS
DOCUMENT NUMBER: 134:280845
TITLE: Preparation of acylsulfonamide derivatives as chymase inhibitors
INVENTOR(S): Aoyama, Yukio; Seki, Maki; Masuda, Hirokazu; Usui, Yoshihiro; Abe, Yuji; Shimada, Mayumi; Yamamoto, Mitsuya
PATENT ASSIGNEE(S): Mitsubishi Chemical Corporation, Japan
SOURCE: PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023349	A1	20010405	WO 2000-JP6695	20000928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 1999-278074	A 19990930
			JP 1999-278375	A 19990930
			JP 1999-278377	A 19990930
			JP 1999-278378	A 19990930
			JP 1999-278379	A 19990930

OTHER SOURCE(S): MARPAT 134:280845
GI

L18 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I

AB The title compds. RICH[(CH2R2)n](NR)nCONHSO2R3 [R1 = (un)substituted heterocyclyl, etc.; n = 1-4; m = 0 or 1; R2 = (un)substituted heterocyclyl, etc.; when R2 is (un)substituted aryl, R3 is (un)substituted naphthyl, heterocyclyl; when R2 is (un)substituted heterocyclyl, R3 is (un)substituted Ph, naphthyl, heterocyclyl] are prepared The title compds. are useful as remedies for hypertension. The title compound I in vitro showed IC50 of 0.66 nM against chymase.

IT 76812-31-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylsulfonamide deriva. as chymase inhibitors)

RN 76812-31-2 CAPLUS

CN 1H-Indole-3-acetamide, 1-[4-chlorobenzoyl]-5-methoxy-2-methyl-N-[[4-methylphenyl]sulfonyl]- (CA INDEX NAME)

L18 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:78227 CAPLUS

DOCUMENT NUMBER: 134:231078

TITLE: Preparation of bicyclic antagonists selective for the $\alpha v\beta 3$ integrin

INVENTOR(S): Earl, Arlo; Hasse, Diane Barbara; Kess, Kenneth Lewis;

Coghlan, Richard Dale; Yardley, John

PATENT ASSIGNEE(S): American Home Products Corporation, USA

SOURCE: PCT Int. Appl., 256 pp.

CODEN: PIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007036	A1	20010201	WO 2000-US19985	20000720
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2378868	A1	20010201	CA 2000-2378868	20000720
BR 2000012683	A	20020416	BR 2000-12683	20000720
EP 1198233	A2	20020424	EP 2000-950509	20000720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6429214	B1	20020806	US 2000-620581	20000720
JP 2003504416	T	20030212	JP 2001-511922	20000720
MX 2002000722	A	20020702	MX 2002-722	20020121
US 2003109523	A1	20030612	US 2002-163844	20020606
PRIORITY APPLN. INFO.:			US 1999-358035 P	19990721
			US 2000-620581 A3	20000720
			WO 2000-US19985 W	20000720

OTHER SOURCE(S): MARPAT 134:231078

GI

L18 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

I

II

III IV

AB This invention provides novel bicyclic compds. I and II (tetrahydro- and dihydroquinolines, tetrahydronaphthalenes and tetrahydro-fd-benzocycloheptenes) or pharmaceutically acceptable salts thereof that exhibit activity as inhibitors of bone resorption with minimal inhibition of platelet aggregation mediated by $\alpha IIb\beta 3$ integrin. An example is [6-(3-guanidinopropoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]acetic acid-trifluoroacetate. Results are reported for some of the claimed compds. for vitronectin receptor ($\alpha v\beta 3$) binding, effect on integrin ($\alpha v\beta 3$)-mediated attachment of cells to osteopontin, osteoclast bone pitting, effects on PTH-induced hypercalcemia of thyro-parathyroidectomized rats, effects on serum calcium in TPTX male rats treated with rPTH(1-34), and effect on ADP-induced platelet aggregation. In I and II, the dotted line represents the presence of an optional double bond. M = 2-5. V = O, 1. A-B = diradical -CR2(CR2)m- or -NRSC(O)-. M = 3, 4. Y = -O-, -CH2CH2-, -CR:CR-, -C.tplbond.C-, -NRlaC(O)-. R1 = H or straight chain alkyl of 1-6 C atoms; phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with one or more substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms; heterocycloalkyl, wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the heterocyclo moiety is selected from a 5- or 6-membered heterocyclic ring which contains 1-2 heteroatoms which may be the same or different, selected from N, O and S optionally substituted with 1-3 substituents which may be the same or different, and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, cyano and nitro. R1a = H or straight chain alkyl of 1-6 C atoms; phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with R1 substituents which may be the same or different and are

L18 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms. R2 = H, -NHR1, or -OR1, aryl of 6-12 C atoms optionally substituted with ≥1 substituents selected from straight chain alkyl of 1-6 C atoms, alkoxy of 1-6 C atoms, -S-alkyl of 1-6 C atoms, cyano, nitro, halogen and phenyl; the heterocyclic moiety is selected from a 5- or 6-membered heterocyclic ring which contains 1-3 heteroatoms which may be the same or different, selected from N, O and S optionally substituted with ≥1 substituents which may be the same or different, and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, cyano and nitro; phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms; heterocycloalkyl, wherein the alkyl moiety
is
a straight chain alkyl of 1-6 C atoms and the heterocyclic moiety is selected from a 5- or 6-membered heterocyclic ring which contains 1-3 heteroatoms which may be the same or different, selected from N, O and S optionally substituted with ≥1 substituents which may be the same or different, and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, cyano and nitro. G is a N-contg. moiety selected from H2NC(:NH)-, R4C(O)NHC(:NC(O)R4)-, R1NHC(O)-, 2-pyrimidinyl, 1,4,5,6-tetrahydropyrimidin-2-yl, 6-amino-2-pyridinyl, 2-pyridinyl, 2-imidazolin-2-yl, 3-amino-1,2,4-triazol-5-yl, III and IV. U = 0, 1. R4 = straight chain alkyl of 1-6 C atoms, alkoxy or phenylalkyloxy wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight chain alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms. R5 = H, straight chain alkyl of 1-6 C atoms, or phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety
is
optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight
chain
alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms and dialkylamino of 1-6 C atoms. R5a = H, straight chain alkyl of 1-6 C atoms, or phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight
chain
alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro, alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms. R5b = H, straight chain alkyl of 1-6 C atoms, or phenylalkyl wherein the alkyl moiety is a straight chain alkyl of 1-6 C atoms and the Ph moiety is optionally substituted with ≥1 substituents which may be the same or different and are selected from hydroxy, amino, halogen, straight
chain
alkyl of 1-6 C atoms, branched chain alkyl of 3-7 C atoms, cyano, nitro,

L18 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
alkylamino of 1-6 C atoms, and dialkylamino of 1-6 C atoms. The optional double bond is a single bond when A-B is the diradical -CH2(CH2)m-. In II, D = OR3, NHSO2C6H3R5aR5b; R3 = H, straight chain alkyl of 1-6 C atoms optionally substituted with a group selected from amino, hydroxyl and carboxyl or branched chain alkyl of 3-7 C atoms optionally substituted with a group selected from amino, hydroxyl and carboxyl; certain combinations of values of variables are excluded as described in the claims. Pharmaceutical compns. contg. the above compds. are claimed to
be
useful against mammalian bone resorption diseases selected from osteoporosis, hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilization-induced osteopenia and the result of glucocorticoid treatment. Although the methods of prepn. of the compds. are not
claimed,
>200 example prepns. of products and intermediates are given.

IT 321886-97-9P, 4-Methyl-N-[[7-(3-guanidinopropoxy)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]acetyl]benzenesulfonamide
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic antagonists selective for αvβ3 integrin)

RN 321886-97-9 CAPLUS

CN 3-Quinolineacetamide, 7-[3-[(aminoiminomethyl)amino]propoxy]-1,2,3,4-tetrahydro-N-[(4-methylphenyl)sulfonyl]-2-oxo- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L18 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:476314 CAPLUS
DOCUMENT NUMBER: 127:135799
ORIGINAL REFERENCE NO.: 127:26201a
TITLE: Preparation of benzimidazole derivatives as drugs
INVENTOR(S): Yamasaki, Noritsugu; Imoto, Takafumi; Murai, Yoshiyuki; Hiramura, Takahiro; Oku, Teruo; Sawada, Kouzou
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 380 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724334	A1	19970710	WO 1996-JP3858	19961227
W: AU, BR, CA, CN, HU, IL, JP, KR, MX, NZ, RU, SG, TR, US, AM, AZ, BY, KG, KZ, MD, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2241186	A1	19970628	CA 1996-2241186	19961227
CA 2241186	C	20060214		
AU 9712095	A	19970728	AU 1997-12095	19961227
AU 722514	B2	20000803		
EP 882718	A1	19981209	EP 1996-943331	19961227
EP 882718	B1	20050831		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1211238	A	19990317	CN 1996-180137	19961227
HU 9900625	A2	19990628	HU 1999-625	19961227
HU 9900625	A3	20030428		
BR 9612434	A	19991228	BR 1996-12434	19961227
JP 2000159749	A	20000613	JP 2000-8395	19961227
JP 3063162	B2	20000712	JP 1997-524201	19961227
NZ 324834	A	20011130	NZ 1996-324834	19961227
IL 124969	A	20020912	IL 1996-124969	19961227
AT 303365	T	20050915	AT 1996-943331	19961227
ES 2244979	T3	20051216	ES 1996-943331	19961227
ZA 9610918	A	19970708	ZA 1996-10918	19961230
TW 548272	B	20030821	TW 1997-86100149	19970108
ZA 9708998	A	19980420	ZA 1997-8998	19971008
US 6166219	A	20001226	US 1998-91997	19981102
US 6352985	B1	20020305	US 2000-492955	20000128

PRIORITY APPLN. INFO.:

JP 1995-343425	A	19951228
JP 1996-287676	A	19961008
JP 1997-524201	A	19961227
WO 1996-JP3858	W	19961227
US 1998-91997	A1	19981102

OTHER SOURCE(S): MARPAT 127:135799
GI

L18 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB The title compds. [I; R1 = H, arylsulfonyl, (un)substituted lower alkyl, etc.; R2 = H, lower cycloalkyl, alkylthio, or alkoxy, OH, SH, NH2, aryl, etc.; R3 = CO2H, NH2, CONH, etc.; R = substituting group or H; m = 1-3] are prepared I, possessing hypoglycemic or PDE5 inhibitory effects, are useful as remedies for impaired glucose tolerance, diabetes,
complications
of diabetes, insulin resistant syndrome, hyperlipidemia, atherosclerosis, cardiovascular diseases, hyperglycemia, hypertension, angina pectoris, pulmonary hypertension, congestive heart failure, glomerular diseases, tubular interstitial diseases, renal failure, angiostenosis, peripheral vascular disease, apoplexy, chronic reversible obstructive diseases, allergic rhinitis, urticaria, glaucoma, diseases characterized by abnormality in intestinal motility, sexual impotence, nephritis, cancerous cachexia, and post-PCTA reconstriction. Thus, benzimidazole derivative (II; X = OH) was reacted with C6H5SO2NH2 in the presence of N,N'-carbonyldiimidazole and diazabicycloundecene in DMF at 100° for 70 h to give the title compound II (X = PhSO2NH), which showed 72%
blood
sugar lowering activity when tested with mouse

IT 193010-87-6P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole derivs. as drugs)

RN 193010-87-6 CAPLUS

CN 1H-Benzimidazole-6-acetamide, 1-[(2-chlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (CA INDEX NAME)

L18 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L18 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:318279 CAPLUS
DOCUMENT NUMBER: 127:50498
ORIGINAL REFERENCE NO.: 127:9433a,9434a
TITLE: Dual Inhibition of Human Leukocyte Elastase and Lipid Peroxidation: In Vitro and in Vivo Activities of Azabicyclo[2.2.2]octane and Perhydroindole Derivatives
AUTHOR(S): Portevin, Bernard; Lonchampt, Michel; Canet, Emmanuel; De Nanteuil, Guillaume
CORPORATE SOURCE: Division D of Medicinal Chemistry and Division of Respiratory Pharmacology, Institut de Recherche Servier, Suresnes, 92150, Fr.
SOURCE: Journal of Medicinal Chemistry (1997), 40(12), 1906-1918
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of potent and selective human leukocyte elastase (HLE) inhibitors of the Val-Pro-Val type has been developed. Initially, the central proline residue was replaced by non-natural amino acids Phi [(2S,7aS,7aS)-perhydroindole-2-carboxylic acid] and Abc [(3S)-2-azabicyclo[2.2.2]octane-3-carboxylic acid], and secondly several groups able to confer antioxidant properties onto the mol. were introduced at the lipophilic N-terminal side chain. When compared to reference inhibitors, in vitro HLE inhibitory potency was maintained (10-100 nM) both with compds. containing the antioxidant moiety at the end of the N-terminal side chain and with compds. in which the N-terminal valine of the tripeptidic sequence had been replaced by a ε-substituted lysine. The lipidic peroxidn. inhibitory potency of this series of inhibitors was found to be similar to that of the reference antioxidant compds. (around 1 μM). Moreover, HLE-induced hemorrhage in the hamster lung was effectively prevented (40-60% at 15 μg/kg) by most of the inhibitors tested when administered intratracheally 3 h before instillation of elastase. Three compds. were still active when administered 18 h before elastase. Interestingly, one compound was able to prevent HLE-mediated lung damage when administered 72 h prior to enzymic challenge, indicating exceptional stability and retention in the lung. In a 14-day chronic model of emphysema in the hamster, this compound significantly conserved alveolar spaces, a marker of lung tissue destruction, and was more potent than reference inhibitor ICI 200 880. This indicates that addition of peroxidn. inhibitory properties to an HLE inhibitor can provide a powerful in vivo inhibitor of pulmonary tissue destruction.
IT 190833-42-0P 190833-43-3P 190833-67-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L18 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(dual inhibition of human leukocyte elastase and lipid peroxidn. by azabicyclo[2.2.2]octanes and perhydroindoles)
RN 190833-42-0 CAPLUS
CN 1H-Indole-2-carboxamide, 1-[(2S)-2-[[4-[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]acetyl]amino]-sulfonyl]benzoyl]amino]-3-methyl-1-oxobutyl]octahydro-N-[3,3,3-trifluoro-1-[1-methylethyl]-2-oxopropyl]-, (2S,3aS,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 190833-43-3 CAPLUS
CN 2-Azabicyclo[2.2.2]octane-3-carboxamide, 2-[(2S)-2-[[4-[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]acetyl]amino]-sulfonyl]benzoyl]amino]-3-methyl-1-oxobutyl]-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.

L18 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 190833-67-1 CAPLUS
CN 1H-Indole-2-carboxamide, 1-[(2S)-2-[[4-[[[3-[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]acetyl]amino]sulfonyl]-4-chlorobenzoyl]amino]sulfonyl]benzoyl]amino]-3-methyl-1-oxobutyl]octahydro-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, (2S,3aS,7aS)- (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 161787-49-1P 161787-52-4P 190833-84-2P
190833-89-7P 190833-93-3P 190833-96-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(dual inhibition of human leukocyte elastase and lipid peroxidn. by azabicyclo[2.2.2]octanes and perhydroindoles)

RN 161787-49-1 CAPLUS
CN Benzoic acid, 4-[[[2-[3,5-bis[1,1-dimethylethyl]-4-hydroxyphenyl]acetyl]amino]sulfonyl]- (CA INDEX NAME)

RN 161787-52-4 CAPLUS
CN Benzoic acid, 4-[[[3-[[2-[3,5-bis[1,1-dimethylethyl]-4-hydroxyphenyl]acetyl]amino]sulfonyl]-4-chlorobenzoyl]amino]sulfonyl]- (CA INDEX NAME)

L18 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 190833-96-6 CAPLUS
CN Benzoic acid, 4-[[[3-[[2-[3,5-bis[1,1-dimethylethyl]-4-hydroxyphenyl]acetyl]amino]sulfonyl]-4-chlorobenzoyl]amino]sulfonyl]-, ethyl ester (CA INDEX NAME)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS 7838 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 190833-84-2 CAPLUS
CN Benzoic acid, 4-[[[2-[3,5-bis[1,1-dimethylethyl]-4-hydroxyphenyl]acetyl]amino]sulfonyl]-, ethyl ester (CA INDEX NAME)

RN 190833-89-7 CAPLUS
CN Benzoic acid, 3-[[[2-[3,5-bis[1,1-dimethylethyl]-4-hydroxyphenyl]acetyl]amino]sulfonyl]-4-chloro-, ethyl ester (CA INDEX NAME)

RN 190833-93-3 CAPLUS
CN Benzoic acid, 3-[[[2-[3,5-bis[1,1-dimethylethyl]-4-hydroxyphenyl]acetyl]amino]sulfonyl]-4-chloro- (CA INDEX NAME)

L18 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:646024 CAPLUS
DOCUMENT NUMBER: 122:214528
ORIGINAL REFERENCE NO.: 122:39239a,39242a
TITLE: Preparation of peptide derivatives from trifluoromethyl ketones and pharmaceutical compositions containing them
INVENTOR(S): Vinsent, Michel; de Nanteuil, Guillaume; Remond, Georges; Portevin, Bernard; Herve, Yolande; Canet, Emmanuel; Londenget, Michel
PATENT ASSIGNEE(S): Adir et Cie., Fr.
SOURCE: Can. Pat. Appl., 51 pp.
DOCUMENT TYPE: CODEN: CPXXEB
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: French
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2101350	A1	19940129	CA 1993-2101350	19930727
FR 2694295	A1	19940204	FR 1992-9254	19920728
FR 2694295	B1	19940902		
AU 9342180	A	19940203	AU 1993-42180	19930727
AU 662232	B2	19950824		
EP 585155	A1	19940302	EP 1993-401837	19930727
EP 585155	B1	19961211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 06184192	A	19940705	JP 1993-185221	19930727
JP 08026966	B	19960313		
AT 146186	T	19961215	AT 1993-401837	19930727
ES 2098004	T3	19970416	ES 1993-401837	19930727
ZA 9305434	A	19940222	ZA 1993-5434	19930729
US 5565429	A	19961015	US 1995-439233	19950511
PRIORITY APPLN. INFO.:			FR 1992-9254 A	19920728
			US 1993-99915 B1	19930730

OTHER SOURCE(S): MARPAT 122:214528

GI

AB Title compds. I [R1 = C1-6 alkyl, C3-7 cycloalkyl, Ph,

(benzyloxycarbonyl)amino, etc.; R2 = C1-6 alkyl, C3-7 cycloalkyl, phenyl; A with the N and C it is attached to = 2-azabicyclo[2.2.2]octane ring, 2-azabicyclo[2.2.1]heptane ring, perhydroindole, perhydroisoindole, indoline, isoindoline, perhydroquinoline, etc.; B = Q, Z-Y-NR3-X-, R4R5N-CO-NH-SO2-, etc.; R3 = H, C1-6 alkyl; X, Y = CO, SO2; Z = C1-6 alkyl, C3-7 cycloalkyl, trihalo-C1-4 alkyl, adamant-1-yl, (un)substituted Ph, etc.; R4, R5 = (un)substituted C1-6 alkyl, (un)substituted Ph, etc.], inhibitors of human leukocyte elastase and therefore useful for treatment of many degenerative diseases of conjunctive tissue, are prepd. Thus, 4-(4-chlorobenzoylaminosulfonyl)benzoyl-(S)Val-(S)Abo-(R,S)Val-CF3 [II; Abo = 2-azabicyclo[2.2.2]octane-3-carboxylic acid residue] was prepd. in many steps via reaction of BOC-(S)Val-OH with 3-(S)-(ethoxycarbonyl)-2-azabicyclo[2.2.2]octane, sapon., condensation with 1-isopropyl-2-hydroxy-3,3,3-trifluoropropylamine, oxidn., and treatment of the hydrochloride salt of the resulting H-(S)Val-(S)Abo-(R,S)Val-CF3 with 4-(4-chlorobenzoylaminosulfonyl)benzoic acid (prepn. given). In a study using methoxysuccinyl-L-alanyl-L-alanyl-prolylvaline p-nitroanilide as the substrate, II had an IC50 of 24 nM against human sputum elastase. Pharmaceutical compns. contg. I are described.

IT 161787-03-7P 161787-18-4P 161787-22-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as human leukocyte elastase inhibitor)

RN 161787-03-7 CAPLUS

CN 2-Azabicyclo[2.2.2]octane-3-carboxamide, 2-[2-[[4-[[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]acetyl]amino]sulfonyl]benzoyl]amino]-3-methyl-1-oxobutyl]-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (CA INDEX NAME)



RN 161787-18-4 CAPLUS

CN 1H-Indole-2-carboxamide, 1-[2-[[4-[[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]acetyl]amino]sulfonyl]benzoyl]amino]-3-methyl-1-oxobutyl]octahydro-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 161787-22-0 CAPLUS

CN 1H-Indole-2-carboxamide, 1-[2-[[4-[[[3-[[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]acetyl]amino]sulfonyl]-4-chlorobenzoyl]amino]sulfonyl]benzoyl]amino]-3-methyl-1-oxobutyl]octahydro-N-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 161787-49-1P 161787-52-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation as intermediate for human leukocyte elastase inhibitors)

RN 161787-49-1 CAPLUS

CN Benzoic acid, 4-[[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]acetyl]amino]sulfonyl]- (CA INDEX NAME)



RN 161787-52-6 CAPLUS

CN Benzoic acid, 4-[[[3-[[[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]acetyl]amino]sulfonyl]-4-chlorobenzoyl]amino]sulfonyl]- (CA INDEX NAME)



L18 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:108550 CAPLUS
DOCUMENT NUMBER: 121:108550
ORIGINAL REFERENCE NO.: 121:19581a,19584a
TITLE: Preparation of 2-substituted quinolines, and their use
in medicaments
INVENTOR(S): Reddatz, Siegfried; Mohrs, Klaus Helmut; Matzke, Michael; Frischmann, Romanis; Ratzelmann, Armin; Kahlsdorfer, Christian; Moeller-Peddinghaus, Reiner; Theisen-Popp, Pia
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: U.S., 26 pp. Cont.-in-part of U.S. Ser. No. 934,734.
CODEN: USXAAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5294563	A	19940419	US 1992-967881	19921028
DE 4105551	A1	19920827	DE 1991-4105551	19910222
DE 4226649	A1	19940217	DE 1992-4226649	19920812
PRIORITY APPLN. INFO.:			DE 1991-4105551	A 19910222
			US 1992-934734	A2 19920212
			DE 1992-4226649	A 19920812

OTHER SOURCE(S): MARPAT 121:108550
GI



AB Title compds. I [A, B, D, E, G, L = H, HO, halo, NC, HO2C, O2N, F3C, F3CO,
C1-8 alkyl, C1-8 alkoxy, (substituted) C6-8 aryl; R1 = halo, NC, O2N, N3, F3C, F3CO, F3CS, C1-8 alkoxy, C1-8 aryl, (substituted) C1-8 alkyl, (substituted) amino, hydroxyl, etc.; R2 = C3-12 cycloalky or -alkenyl;
R3 = (substituted) HO, PhO, R8R02R7N wherein R7 = H, C1-6 alkyl, R8 = (substituted) C6-10 aryl, (substituted) C1-8 alkyl) and a salt thereof useful in particularly as lipoxygenase inhibitors. I are dialked for

L18 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 145043-10-3 CAPLUS
CN Benzeneacetamide, N-(methylsulfonyl)-4-[2-quinolinylmethoxy)-3-[(trifluoromethyl)thio]- (CA INDEX NAME)



RN 145043-19-2 CAPLUS
CN Benzeneacetamide, N-(methylsulfonyl)-3-propyl-4-(2-quinolinylmethoxy)- (CA INDEX NAME)



RN 145043-26-1 CAPLUS
CN Benzeneacetamide, 3-ethyl-N-(methylsulfonyl)-4-(2-quinolinylmethoxy)- (CA
INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS

L18 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
treatment of allergies/asthma, bronchitis, emphysema, shock lung, pulmonary hypertension, inflammations/rheumatism, edema, thromboses, ischemias, cardiac and cerebral infarcts, angina pectoris, arteriosclerosis, in tissue transplantation, psoriasis, and cytoprotection in the gastrointestinal tract (no data) Me
3-fluoro-5-hydroxyphenylacetate (prepn. given) in DMF was added to NaOH in
MeOH followed by 3-(chloromethyl)quinoline in DMF to give I (A, B, D, E, G, L = H, R1 = F, CH2CO2R3 = p-MeOAc). A similar prepd. compd. I (A, B, D, E, L = H = H, R1 = vinyl, CH2CO2R3 = p-(-cyclopentylacetic acid) (II) inhibited 5-lipoxygenase with IC50 at 0.56 μmol/L.
IT 145043-99-1P 145043-00-1P 145043-05-6P
145043-10-3P 145043-19-2P 145043-26-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of lipoxygenase inhibitors)
RN 145042-99-5 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-(methylsulfonyl)-4-(2-quinolinylmethoxy)- (CA INDEX NAME)

RN 145043-00-1 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[(phenylmethyl)sulfonyl]-4-(2-quinolinylmethoxy)- (CA INDEX NAME)



RN 145043-05-6 CAPLUS
CN Benzeneacetamide, 3-bromo-N-(methylsulfonyl)-4-(2-quinolinylmethoxy)- (CA
INDEX NAME)

L18 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=>
=> D HIS

     (FILE 'HOME' ENTERED AT 16:36:14 ON 06 MAR 2009)

     FILE 'REGISTRY' ENTERED AT 16:37:38 ON 06 MAR 2009
L1             STRUCTURE UPLOADED
L2               8 S L1
L3             514 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 16:38:57 ON 06 MAR 2009
L4             162 S L3
L5               5 S L4 AND INTERLEUKIN
L6              10 S L3 AND PSORIASIS
L7              10 S L4 AND PSORIASIS
L8              11 S L4 AND ARTHRITIS
L9               1 S L4 AND MELANOMA
L10              3 S L4 AND COLITIS
L11             16 S L4 AND PULMONARY
L12              1 S L4 AND BULLOUS
L13              8 S L4 AND FIBROSIS
L14              5 S L4 AND REPERFUSION
L15              7 S L4 AND ISCHEMIA
L16              4 S L4 AND GLOMERULONEPHRITIS
L17             24 S L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14
L18             19 S L17 NOT L5

=> S L4 NOT L17
L19            138 L4 NOT L17

=> D IBIB L19 1-10
```

```
L19  ANSWER 1 OF 138  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2009:1279  CAPLUS
DOCUMENT NUMBER:         150:98047
TITLE:                   Preparation of purine nucleobases via coupling
                         reaction for treating disorders related to TRPA1
INVENTOR(S):             Ng, Howard; Weigele, Manfred; Moran, Magdalene;
Chong,
                         Jayhong; Fanger, Christopher; Larsen, Gleen R.; Del
                         Camino, Donato; Hayward, Neil; Adams, Steve; Ripka,
                         Amy
PATENT ASSIGNEE(S):      Hydra Biosciences, Inc., USA
SOURCE:                  PCT Int. Appl., 275pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE       APPLICATION NO.        DATE
     ---------------     ----  --------   --------------------   --------
     WO 2009002933        A1   20081231   WO 2008-US67901        20080623
         W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                    US 2007-945840P     P  20070622

                                          US 2007-945866P     P  20070622

OTHER SOURCE(S):         MARPAT 150:98047
REFERENCE COUNT:         4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT
```

```
L19  ANSWER 2 OF 138  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2008:1338708  CAPLUS
DOCUMENT NUMBER:         149:534238
TITLE:                   Preparation of bicyclic heterocyclic compounds as
                         inhibitors of P2Y12
INVENTOR(S):             Koga, Yuji; Okuda, Takao; Kamikubo, Takashi;
Kageyama,
                         Michihito; Moritomo, Hiroyuki
PATENT ASSIGNEE(S):      Astellas Pharma Inc., Japan
SOURCE:                  PCT Int. Appl., 132pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                Japanese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE       APPLICATION NO.        DATE
     ---------------     ----  --------   --------------------   --------
     WO 2008133155        A1   20081106   WO 2008-JP57465        20080417
         W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                    JP 2007-109958      A  20070419

OTHER SOURCE(S):         MARPAT 149:534238
REFERENCE COUNT:         22    THERE ARE 22 CITED REFERENCES AVAILABLE FOR
THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT
```

```
L19  ANSWER 3 OF 138  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2008:1006368  CAPLUS
DOCUMENT NUMBER:         149:307661
TITLE:                   Novel indole derivatives as inhibitors hepatitis C
                         virus replication and their preparation and use in
the
                         treatment of hepatitis C infection
INVENTOR(S):             Beigelman, Leonid; Buckman, Brad; Wang, Guangyi;
                         Matulic-Adamic, Jasenka; Stoycheva, Antitsa
Dimitrova;
                         Andrews, Steven W.; Misialek, Shawn Maurice;
                         Rajagopalan, P. T. Ravi; Fryer, Andrew M.;
                         Gunawardana, Indrani; Haas, Julia; Huang, Lily;
                         Madduru, Machender R.; Zhang, Gan; Kossen, Karl;
                         Serebryany, Vladimir
PATENT ASSIGNEE(S):      Intermune, Inc., USA
SOURCE:                  PCT Int. Appl., 397pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE       APPLICATION NO.        DATE
     ---------------     ----  --------   --------------------   --------
     WO 2008100867        A2   20080821   WO 2008-US53617        20080211
     WO 2008100867        A3   20090108
         W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     US 20090047246       A1   20090219   US 2008-29399          20080211
PRIORITY APPLN. INFO.:                    US 2007-889433P     P  20070212

OTHER SOURCE(S):         MARPAT 149:307661
```

```
L19  ANSWER 4 OF 138  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2008:975253  CAPLUS
DOCUMENT NUMBER:         149:268044
TITLE:                   Preparation of fused ring compounds for treatment of
                         diabetes
INVENTOR(S):             Tawaraishi, Taisuke; Imoto, Hiroshi; Cho, Nobuo
PATENT ASSIGNEE(S):      Japan
SOURCE:                  U.S. Pat. Appl. Publ., 145pp.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE       APPLICATION NO.        DATE
     ---------------     ----  --------   --------------------   --------
     US 20080194617       A1   20080814   US 2008-68442          20080206
     WO 2008099794        A1   20080821   WO 2008-JP52217        20080205
         W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                    JP 2007-31221       A  20070209

OTHER SOURCE(S):         MARPAT 149:268044
```

```
L19  ANSWER 5 OF 138  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2008:940576  CAPLUS
DOCUMENT NUMBER:         149:224247
TITLE:                   Preparation of pyrazole compounds for lowering blood
                         sugar
INVENTOR(S):             Imoto, Hiroshi
PATENT ASSIGNEE(S):      Takeda Pharmaceutical Co., Ltd., Japan
SOURCE:                  PCT Int. Appl., 404pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                Japanese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE      APPLICATION NO.       DATE
     ---------------     ----  --------  --------------------  --------
     WO 2008093639        A1   20080807  WO 2008-JP51210       20080128
         W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
            CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
            FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
            KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
            ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
            PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
            IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
            TR, BF, BJ, CF, CG, CI, GM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
            TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
            AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                   JP 2007-17656      A  20070129

                                         JP 2007-207273     A  20070808

OTHER SOURCE(S):         MARPAT 149:224247
REFERENCE COUNT:         22    THERE ARE 22 CITED REFERENCES AVAILABLE FOR
THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT
```

```
L19  ANSWER 6 OF 138  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2008:338556  CAPLUS
DOCUMENT NUMBER:         148:552726
TITLE:                   Structure-activity relationships and pharmacokinetic
                         parameters of quinoline acylsulfonamides as potent
and
                         selective antagonists of the EP4 receptor
AUTHOR(S):               Burch, Jason D.; Belley, Michel; Fortin, Rejean;
                         Deschenes, Denis; Girard, Mario; Colucci, John;
                         Farand, Julie; Therien, Alex G.; Mathieu,
                         Marie-Claude; Denis, Danielle; Vigneault, Erika;
                         Levesque, Jean-Francois; Gagne, Sebastien; Wrona,
                         Mark; Xu, Daigen; Clark, Patsy; Rowland, Steve; Han,
                         Yongxin
CORPORATE SOURCE:        Merck Frosst Centre for Therapeutic Research,
                         Kirkland, QC, H9H 3L1, Can.
SOURCE:                  Bioorganic & Medicinal Chemistry Letters (2008),
                         18(6), 2048-2054
                         CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER:               Elsevier Ltd.
DOCUMENT TYPE:           Journal
LANGUAGE:                English
OTHER SOURCE(S):         CASREACT 148:552726
REFERENCE COUNT:         28    THERE ARE 28 CITED REFERENCES AVAILABLE FOR
THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT
```

```
L19  ANSWER 7 OF 138  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2008:256101  CAPLUS
DOCUMENT NUMBER:         148:308196
TITLE:                   Azaspirocyclic compounds as inhibitors of
                         11β-hydroxysteroid dehydrogenase type 1 and their
                         preparation, pharmaceutical compositions and use in
                         the treatment of diseases
INVENTOR(S):             Claremon, David A.; Singh, Suresh B.; Tice, Colin M.;
                         Ye, Yuanjie; Cacatian, Salvacion; He, Wei; Simpson,
                         Robert; Xu, Zhenrong; Zhao, Wei
PATENT ASSIGNEE(S):      Vitae Pharmaceuticals, Inc., USA
SOURCE:                  PCT Int. Appl., 225pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE      APPLICATION NO.       DATE
     ---------------     ----  --------  --------------------  --------
     WO 2008024497        A2   20080228  WO 2007-US18789       20070824
     WO 2008024497        A3   20080724
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
            GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
            KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
            MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
            PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:                   US 2006-840203P    P  20060825

OTHER SOURCE(S):         MARPAT 148:308196
```

```
L19  ANSWER 8 OF 138  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2008:43631  CAPLUS
DOCUMENT NUMBER:         148:121602
TITLE:                   Preparation of aminosulfonylpiperidinylnicotinates as
                         P2Y12 G-protein coupled receptor inhibitors for
                         treatment of platelet aggregation disorders.
INVENTOR(S):             Johansson, Johan
PATENT ASSIGNEE(S):      Astrazeneca AB, Swed.
SOURCE:                  PCT Int. Appl., 87pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE      APPLICATION NO.       DATE
     ---------------     ----  --------  --------------------  --------
     WO 2008004941        A1   20080110  WO 2007-SE641         20070702
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
            CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
            GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
            KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG,
            MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
            RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
            TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
        RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
            IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
            BJ, CF, CG, CI, GM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
            GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM
     AU 2007270081        A1   20080110  AU 2007-270081        20070702
     US 20080009523       A1   20080110  US 2007-772257        20070702
PRIORITY APPLN. INFO.:                   SE 2006-1465       A  20060704

                                         WO 2007-SE641      W  20070702

OTHER SOURCE(S):         MARPAT 148:121602
```

L19 ANSWER 9 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1075862 CAPLUS
DOCUMENT NUMBER: 147:541555
TITLE: A new and efficient method for the facile synthesis of
TITLE: N-acyl sulfonamides under Lewis acid catalysis
AUTHOR(S): Reddy, Chada Raji; Mahipal, Bodugam; Yaragorla, Srihvasa Rao
CORPORATE SOURCE: Organic Division-I, Indian Institute of Chemical Technology, Hyderabad, 500 007, India
SOURCE: Tetrahedron Letters (2007), 48(40), 7528-7532
CODEN: TELAEY; ISSN: 0040-4039
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:541555
REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 10 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:673293 CAPLUS
DOCUMENT NUMBER: 147:95480
TITLE: Preparation of tetrazole containing benzenesulfone derivatives as prostaglandin D2 ligands
INVENTOR(S): Bennett, Roger Victor; Lukey, Timothy Jon; Mohammed, Rukhsana Tasneem; Thom, Stephen; Cook, Andrew
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 119pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007060894	A2	20070531	WO 2006-GB4497	20061212
WO 2007060894	A3	20071206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NG, NA, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
US 20080287775	A1	20081127	US 2008-96557	20080606
IN 2008MN01278	A	20081010	IN 2008-MN1278	20080616
CN 101174804	A	20080507	CN 2006-80053967	20080915
PRIORITY APPLN. INFO.:			GB 2005-25477	A 20051215
			GB 2006-7409	A 20060413
			GB 2006-14787	A 20060726
			WO 2006-GB4497	W 20061212

OTHER SOURCE(S): MARPAT 147:95480

L19 ANSWER 11 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:526097 CAPLUS
DOCUMENT NUMBER: 147:45201
TITLE: Piperazinyl CCR1 antagonists-optimization of human liver microsome stability
AUTHOR(S): Brown, Matthew F.; Bahnck, Kevin B.; Blumberg, Laura C.; Brissette, William H.; Burrell, Sara A.; Driscoll, James P.; Fedeles, Flavia; Fisher, Michael B.; Foti, Robert S.; Gladue, Ronald P.; Guzman-Martinez, Aikomari; Hayward, Matthew M.; Lira, Paul D.; Lillie, Brett M.; Lu, Yi; Lundquist, Greg D.; McElroy, Eric B.; McGlynn, Molly A.; Paradis, Timothy J.; Poss, Christopher S.; Roache, James H.; Shavnya, Andrei; Shepard, Richard M.; Trevena, Kristen A.; Tylaska, Laurie A.
CORPORATE SOURCE: Pfizer Global Research and Development, Groton, CT, 06340, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(11), 3109-3112
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:45201
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 12 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:512074 CAPLUS
DOCUMENT NUMBER: 146:501086
TITLE: Preparation of benzyl piperazine derivatives as prostaglandin D2 ligand
INVENTOR(S): Luker, Timothy
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2007052023	A2	20070510	WO 2006-GB4075		20061101
WO 2007052023	A3	20071108			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
EP 1948630	A2	20080730	EP 2006-808382		20061101
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
US 20080255150	A1	20081016	US 2008-92431		20080502
CN 101356164	A	20090128	CN 2006-80050571		20080707
PRIORITY APPLN. INFO.:			GB 2005-22619	A	20051105
			GB 2006-7353	A	20060412
			WO 2006-GB4075	W	20061101

OTHER SOURCE(S): MARPAT 146:501086

L19 ANSWER 13 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:356176 CAPLUS
DOCUMENT NUMBER: 146:368627
TITLE: Silver halide color reversal photographic film
INVENTOR(S): Maeno, Hiroshi; Hosokawa, Junichiro
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 135pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007078852	A	20070329	JP 2005-264105	20050912
PRIORITY APPLN. INFO.:			JP 2005-264105	20050912

OTHER SOURCE(S): MARPAT 146:368627

L19 ANSWER 14 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:330181 CAPLUS
DOCUMENT NUMBER: 146:358833
TITLE: Preparation of thiazolinone and oxazolinone derivatives as PTP-1B inhibitors
INVENTOR(S): Banerjee, Rakesh Kumar; Gupta, Ramesh Chandra; Tuli, Davinder; Rode, Milind; Shuthar, Bharat; Umrani, Dhananjay; Pathak, Padmaja; Choksi, Tejal; Chaudhary, Anita
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Ltd., India
SOURCE: PCT Int. Appl., 110pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2007032028	A1	20070322	WO 2006-IN368		20060915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2006290250	A1	20070322	AU 2006-290250		20060915
CA 2622518	A1	20070322	CA 2006-2622518		20060915
EP 1934192	A1	20080625	EP 2006-796203		20060915
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS					
JP 2009508848	T	20090305	JP 2008-530756		20060915
CN 101268060	A	20080917	CN 2006-80034134		20080317
MX 2008003783	A	20080507	MX 2008-3783		20080318
KR 2008056730	A	20080623	KR 2008-709160		20080416
PRIORITY APPLN. INFO.:			IN 2005-KO860	A	20050916
			WO 2006-IN368	W	20060915

OTHER SOURCE(S): MARPAT 146:358833
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 15 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:174303 CAPLUS
DOCUMENT NUMBER: 146:251838
TITLE: Preparation of therapeutic agents for diabetes
INVENTOR(S): Abe, Hidenori; Wakabayashi, Takeshi; Rikimaru, Kentarou
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 509pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007018314	A2	20070215	WO 2006-JP316068	20060809
WO 2007018314	A3	20070705		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 2006277231	A1	20070215	AU 2006-277231	20060809
CA 2617969	A1	20070215	CA 2006-2617969	20060809
EP 1912645	A2	20080423	EP 2006-782747	20060809

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 4094660	B1	20080604	JP 2007-531530	20060809
JP 2008526685	T	20080724		
JP 2008044943	A	20080228	JP 2007-212457	20070706
US 20080009530	A1	20080110	US 2007-666812	20070713
MX 2008001386	A	20080407	MX 2008-1386	20080129
NO 2008001196	A	20080507	NO 2008-1196	20080306
KR 2008033524	A	20080416	KR 2008-705621	20080307
IN 2008KN01028	A	20080822	IN 2008-KN1028	20080310
CN 101282725	A	20081008	CN 2006-80037552	20080409

PRIORITY APPLN. INFO.:
JP 2005-232646 A 20050810
JP 2007-531530 A3 20060809
WO 2006-JP16068 W 20060809
WO 2006-JP316068 W 20060809

OTHER SOURCE(S): MARPAT 146:251838

L19 ANSWER 15 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L19 ANSWER 16 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1225142 CAPLUS
DOCUMENT NUMBER: 145:505342
TITLE: Preparation of pyrrolo[3,4-g]quinoline derivatives as EP4 receptor antagonists for the treatment of pain
INVENTOR(S): Belley, Michel; Burch, Jason; Colucci, John; Farand, Julie; Girard, Mario; Han, Yongxin
PATENT ASSIGNEE(S): Merck Frosst Canada Ltd., Can.
SOURCE: PCT Int. Appl., 67pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006122403	A1	20061123	WO 2006-CA789	20060515

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 2006246930	A1	20061123	AU 2006-246930	20060515
CA 2608214	A1	20061123	CA 2006-2608214	20060515
EP 1885722	A1	20080213	EP 2006-741503	20060515

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2008540584	T	20081120	JP 2008-511515	20060515

PRIORITY APPLN. INFO.:
US 2005-682589P P 20050519
WO 2006-CA789 W 20060515

OTHER SOURCE(S): MARPAT 145:505342
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 17 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1034892 CAPLUS
DOCUMENT NUMBER: 145:386333
TITLE: Silver halide emulsion containing specific sensitizing dye and color photographic material
INVENTOR(S): Tanabe, Junichi
PATENT ASSIGNEE(S): Konica Minolta Medical & Graphic, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 52pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006267208	A	20061005	JP 2005-81880	20050322

PRIORITY APPLN. INFO.: JP 2005-81880 20050322

OTHER SOURCE(S): MARPAT 145:386333

L19 ANSWER 19 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:494447 CAPLUS
DOCUMENT NUMBER: 145:27683
TITLE: Practical synthesis of amides from in situ generated copper(I) acetylides and sulfonyl azides
AUTHOR(S): Cassidy, Michael P.; Raushel, Jessica; Fokin, Valery V.
CORPORATE SOURCE: Department of Chemistry, The Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Angewandte Chemie, International Edition (2006), 45(19), 3154-3157
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:27683
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 20 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1024914 CAPLUS
DOCUMENT NUMBER: 143:460312
TITLE: Dichlorokeketene-Induced Cyclizations of Vinyl Sulfilimines: Application of the Method in the Synthesis of (±)-Deoxypreussoline
AUTHOR(S): Padwa, Albert; Nara, Shinji; Wang, Qiu
CORPORATE SOURCE: Department of Chemistry, Emory University, Atlanta, GA, 30322, USA
SOURCE: Journal of Organic Chemistry (2005), 70(21), 8538-8549
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:460312
REFERENCE COUNT: 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 19 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:139642 CAPLUS
DOCUMENT NUMBER: 144:298833
TITLE: Hair dye composition comprising a substituted derivative of carboxyamine
INVENTOR(S): Lagrange, Alain
PATENT ASSIGNEE(S): L'Oreal, Fr.
SOURCE: Fr. Demande, 35 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2875392	A1	20060317	FR 2004-9693	20040913
FR 2875392	B1	20061215		
EP 1652564	A1	20060503	EP 2005-291879	20050912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 20060195990	A1	20060907	US 2005-223149	20050912
US 7425211	B2	20080916		
WO 2006030127	A1	20060323	WO 2005-FR2267	20050913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
JP 2006512432	T	20080424	JP 2007-530745	20050913
PRIORITY APPLN. INFO.:			FR 2004-9693	A 20040913
			US 2004-616352P	P 20041007
			WO 2005-FR2267	W 20050913

OTHER SOURCE(S): MARPAT 144:298833
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 21 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1003617 CAPLUS
DOCUMENT NUMBER: 143:295655
TITLE: Lithographic printing plate material containing infrared absorbing agent
INVENTOR(S): Nakamura, Ippei
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005249878	A	20050915	JP 2004-56565	20040301
PRIORITY APPLN. INFO.:			JP 2004-56565	20040301

L19 ANSWER 22 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1003615 CAPLUS
DOCUMENT NUMBER: 143:295654
TITLE: Lithographic printing plate material containing infrared absorbing dye
INVENTOR(S): Nakamura, Ippei
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 56 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005249875	A	20050915	JP 2004-56531	20040301
JP 4202949	B2	20081224		
PRIORITY APPLN. INFO.:			JP 2004-56531	20040301

L19 ANSWER 23 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:962024 CAPLUS
DOCUMENT NUMBER: 143:248412
TITLE: Preparation of piperazine derivatives as CCR1 antagonists for the treatment of endometriosis
INVENTOR(S): Kaufmann, Ulrike
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany; Horuk, Richard
SOURCE: PCT Int. Appl., 291 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079769	A2	20050901	WO 2005-EP2036	20050223
WO 2005079769	A3	20070104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,
SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 2005215156	A1	20050901	AU 2005-215156	20050223
CA 2556423	A1	20050901	CA 2005-2556423	20050223
EP 1727526	A2	20061206	EP 2005-715567	20050223

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BR 2005007985	A	20070508	BR 2005-7985	20050223
JP 2007523126	T	20070816	JP 2006-553572	20050223
CN 101090723	A	20071219	CN 2005-80012936	20050223
US 20080119471	A1	20080522	US 2005-64116	20050223
MX 2006009687	A	20061030	MX 2006-9687	20060824
IN 2006DN04855	A	20070817	IN 2006-DN4855	20060824
NO 2006004298	A	20061124	NO 2006-4298	20060922
KR 2007033961	A	20070327	KR 2006-719708	20060922
PRIORITY APPLN. INFO.:			EP 2004-90065 A	20040224
			US 2004-548950P P	20040302
			WO 2005-EP2036 W	20050223

OTHER SOURCE(S): MARPAT 143:248412
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 24 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:567156 CAPLUS
DOCUMENT NUMBER: 143:97350
TITLE: Preparation of aromatic compounds having carboxylic acid moiety as lysophosphatidic acid (LPA) receptor antagonists
INVENTOR(S): Tanaka, Motoyuki; Nakade, Shinji; Takaoka, Yoshikazu
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058790	A1	20050630	WO 2004-JP19456	20041217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1695955	A1	20060830	EP 2004-807811	20041217

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070149595	A1	20070628	US 2006-583469	20060619
PRIORITY APPLN. INFO.:			JP 2003-422431 A	20031219
			JP 2004-101378 A	20040330
			WO 2004-JP19456 W	20041217

OTHER SOURCE(S): MARPAT 143:97350
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 25 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:423738 CAPLUS
DOCUMENT NUMBER: 142:457104
TITLE: Use of sulfonamide compounds for the treatment of diabetes and/or obesity
INVENTOR(S): Budd Haeberlein, Samantha Louise; Buckett, Linda Karen
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC NUM COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005044250	A1	20050519	WO 2004-GB4582		20041028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1682112	A1	20060726	EP 2004-791619		20041028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1901893	A	20070124	CN 2004-80039410		20041028
JP 2007509919	T	20070419	JP 2006-537427		20041028
IN 2006DN02342	A	20070803	IN 2006-DN2342		20060427
US 20070155832	A1	20070705	US 2006-577357		20060428
PRIORITY APPLN. INFO.:			GB 2003-25192	A	20031029
			WO 2004-GB4582	W	20041028

OTHER SOURCE(S): MARPAT 142:457104
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 26 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:857325 CAPLUS
DOCUMENT NUMBER: 141:350033
TITLE: Preparation of 5-methoxy-2-methylindole-3-acetamide derivs. as potassium channel blockers for treating ocular hypertension
INVENTOR(S): Fisher, Michael H.; Garcia, Maria L.; Kaczorowski, Gregory J.; Meinke, Peter T.; Parsons, William H.; Boyd, Edward Andrew; Price, Stephen; Stibbard, John
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Evotec Oai
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004087051	A2	20041014	WO 2004-US9028		20040324
WO 2004087051	A3	20050721			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004226479	A1	20041014	AU 2004-226479		20040324
CA 2519899	A1	20041014	CA 2004-2519899		20040324
EP 1610776	A2	20060104	EP 2004-758273		20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK					
CN 1791402	A	20060621	CN 2004-80013916		20040324
JP 2006524239	T	20061026	JP 2006-509260		20040324
US 20060069256	A1	20060330	US 2005-542169		20050713
US 7414067	B2	20080819			
IN 2005DN04100	A	20070831	IN 2005-DN4100		20050912
PRIORITY APPLN. INFO.:			US 2003-458103P	P	20030327
			WO 2004-US9028	W	20040324

OTHER SOURCE(S): CASREACT 141:350033; MARPAT 141:350033
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 27 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:470991 CAPLUS
DOCUMENT NUMBER: 139:44172
TITLE: Silver halide photographic material containing methine dye and coupler
INVENTOR(S): Nakamura, Akio
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 70 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 2003172994	A	20030620	JP 2002-236352		20020814
JP 4166529	B2	20081015			
US 20040038159	A1	20040226	US 2002-251841		20020923
US 6828087	B2	20041207			
US 20050037296	A1	20050217	US 2004-927469		20040827
US 7052827	B2	20060530			
PRIORITY APPLN. INFO.:			JP 2001-293949	A	20010926
			US 2002-251841	A1	20020923

OTHER SOURCE(S): MARPAT 139:44172

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:335088 CAPLUS
DOCUMENT NUMBER: 138:354006
TITLE: Preparation of piperazine derivatives with CCR1 receptor antagonist activity
INVENTOR(S): Blumberg, Laura Cook; Brown, Matthew Frank; Hayward, Matthew Merrill; Poss, Christopher Stanley; Lundquist, Gregory Dean, Jr.; Shavnya, Andrei
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003035627	A1	20030501	WO 2002-IB3989		20020926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2463272	A1	20030501	CA 2002-2463272		20020926
AU 2002337408	A1	20030506	AU 2002-337408		20020926
EP 1438298	A1	20040721	EP 2002-772651		20020926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
EE 200400088	A	20041015	EE 2004-88		20020926
BR 2002013452	A	20041109	BR 2002-13452		20020926
HU 2004001735	A2	20050128	HU 2004-1735		20020926
HU 2004001735	A3	20050628			
CN 1575283	A	20050202	CN 2002-820888		20020926
JP 2005507923	T	20050324	JP 2003-538143		20020926
US 20040034034	A1	20040219	US 2002-273658		20021018
US 7098212	B2	20060829			
MX 2004002423	A	20040531	MX 2004-2423		20040312
ZA 2004002090	A	20050523	ZA 2004-2090		20040316
BG 108674	A	20050430	BG 2004-108674		20040408
NO 2004001631	A	20040526	NO 2004-1631		20040421
PRIORITY APPLN. INFO.:			US 2001-338601P	P	20011022
			WO 2002-IB3989	W	20020926

OTHER SOURCE(S): MARPAT 138:354006
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 29 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:96169 CAPLUS
DOCUMENT NUMBER: 138:131174
TITLE: Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
INVENTOR(S): Hamm, Reynold
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: Eur. Pat. Appl., 41 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1281399	A2	20030205	EP 2002-255156	20020723
EP 1281399	A3	20040211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2395066	A1	20030201	CA 2002-2395066	20020725
SA 2002230702	A	20040210	SA 2002-4932	20020729
AU 2002300119	A1	20030612	AU 2002-300119	20020730
NO 2002002548	A2	20030228	NO 2002-2548	20020731
CN 1404829	A	20030326	CN 2002-127401	20020731
JP 2003104878	A	20030409	JP 2002-222616	20020731
US 2020274895	A1	20030717	US 2002-209236	20020731
NZ 520487	A	20040226	NZ 2002-520487	20020731
PRIORITY APPLN. INFO.:			US 2001-309736P P	20010801

OTHER SOURCE(S): MARPAT 138:131174
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 30 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:407895 CAPLUS
DOCUMENT NUMBER: 137:177047
TITLE: Silver halide photographic material containing more than two kinds of sensitizing dyes
INVENTOR(S): Nakamura, Akiou Morimura, Kimiyasu; Hioki, Takarori
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002229145	A	20020814	JP 2001-21719	20010130
US 20020168599	A1	20021114	US 2002-58285	20020130
US 6759186	B2	20040706		
PRIORITY APPLN. INFO.:			JP 2001-21719 A	20010130

OTHER SOURCE(S): MARPAT 137:177047

=>
=> D IBIB ABS HITSTR L19 27-138

L19 ANSWER 27 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:470991 CAPLUS
DOCUMENT NUMBER: 139:44172
TITLE: Silver halide photographic material containing methine dye and coupler
INVENTOR(S): Nakamura, Akio
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 70 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 2003172994	A	20030620	JP 2002-236352		20020814
JP 4166529	B2	20081015			
US 20040038159	A1	20040226	US 2002-251841		20020923
US 6828087	B2	20041207			
US 20050037296	A1	20050217	US 2004-927469		20040827
US 7052827	B2	20060530			
PRIORITY APPLN. INFO.:			JP 2001-293949	A	20010926
			US 2002-251841	A1	20020923

OTHER SOURCE(S): MARPAT 139:44172
GI



I



II



III

AB The material, comprising a support coated with ≥1 Ag halide emulsion layer, contains ≥1 methine dye I [X1-2 = O, S, Se, Te, N, C,; Y1 = furan, pyrrole, or thiophene ring which may be condensed and/or substituted; Y2 = atoms to form benzene ring or 5-6 membered unsatd. heterocycle which may be condensed and/or substituted; R1-2 = (un)substituted alkyl, aryl, heterocycle; L1-3 = methine group; n1 = 0-1; M1 = counter ion; m1 ≥0] and ≥1 coupler selected from II [Z1-2 = CQ3, N; Q1, Q3 = H, monovalent group; Q2 = H, coupling releasing group; II may form dimer or polymer] and III [Q5 = (un)substituted aryl; Q6 = (un)substituted alkyl; Q7 = H, halo, alkoxy,alkyl; X = H, releasing group by the reaction with developer oxide]. The material shows high sensitivity and less residual color after processing.

L19 ANSWER 27 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 540753-72-8 540753-74-0
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. emulsion containing methine dye sensitizer and pyrazolotriazole or phenol coupler)

RN 540753-72-8 CAPLUS
CN Benzothiazolium, 5-chloro-2-[[5-chloro-3,4-dihydro-3-(3-sulfopropyl)-2H-pyrrolo[2,3-d]thiazol-2-ylidene]methyl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 540753-74-0 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-chloro-3-(3-sulfopropyl)thieno[2,3-d]oxazol-2(3H)-ylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:335088 CAPLUS
DOCUMENT NUMBER: 138:354006
TITLE: Preparation of piperazine derivatives with CCR1 receptor antagonist activity
INVENTOR(S): Blumberg, Laura Cook; Brown, Matthew Frank; Hayward, Matthew Merrill; Poss, Christopher Stanley; Lundquist, Gregory Dean, Jr.; Shavnya, Andrei
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003035627	A1	20030501	WO 2002-IB3989		20020926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2463272	A1	20030501	CA 2002-2463272		20020926
AU 2002337408	A1	20030506	AU 2002-337408		20020926
EP 1438298	A1	20040721	EP 2002-772651		20020926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
EE 200400088	A	20041015	EE 2004-88		20020926
BR 2002013452	A	20041109	BR 2002-13452		20020926
HU 2004001735	A2	20050128	HU 2004-1735		20020926
HU 2004001735	A3	20050628			
CN 1575283	A	20050202	CN 2002-820888		20020926
JP 2005507923	T	20050324	JP 2003-538143		20020926
US 20040034034	A1	20040219	US 2002-273658		20021018
US 7098212	B2	20060829			
MX 2004002423	A	20040531	MX 2004-2423		20040312
ZA 2004002090	A	20050523	ZA 2004-2090		20040316
BG 108674	A	20050430	BG 2004-108674		20040408
NO 2004001631	A	20040526	NO 2004-1631		20040421
PRIORITY APPLN. INFO.:			US 2001-338601P	P	20011022
			WO 2002-IB3989	W	20020926

OTHER SOURCE(S): MARPAT 138:354006
GI

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB The present invention relates to piperazine derivs. (shown as I; variables defined below; e.g. N-[[2-[3-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-3-oxopropyl]-5-methylphenoxy]acetyl]methanesulfonamide (shown as II)) and the pharmaceutically acceptable forms thereof. Moreover, the present invention is also directed at pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compds. and compns. for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the 15 CCR1 receptor in a mammal. For I: a = 0-5; b = 0-2; c = 0-2; d = 0-4; X = O, S, CH2, or NR6; Y = (C6-C10)aryl or (C2-C9)heteroaryl; each R1 = H, HO, halo, (C1-C8)alkyl, (C1-C8)alkylO, HO(C1-C8)alkyl, NC, H2N, H2N(C1-C8)alkyl, HO2C, (C1-C8)alkylC(O), (C1-C8)alkylC(O)(C1-C8)alkyl, H2NC(O), or H2NC(O)(C1-C8)alkyl. Each R2 and R3 = H, oxo, (C1-C8)alkyl, (C3-C8)cycloalkyl(C1-C8)alkyl, (C6-C10)aryl, etc. R4 = (HO2C)(H2N)(C1-C8)alkyl, (HO2C)[[(C1-C8)alkyl]NH](C1-C8)alkyl, (HO2C)[[(C1-C8)alkyl]2N](C1-C8)alkyl, etc.; R5 = H, HO, halo, NC, HO2C, H2N, (C1-C8)alkylNH, [(C1-C8)alkyl]2N, etc.; R6 = H, (C1-C8)alkyl, (C1-C8)alkylC(O), (C6-C10)arylC(O), (C2-C9)heteroarylC(O), H2NC(O), (C1-C8)alkylNHC(O), [(C1-C8)alkyl]2NC(O), (C1-C8)alkylOC(O), or (C1-C8)alkylSO2; addnl. details are given in the claims. Although the methods of preparation are not claimed, 47 example prepns. and characterization data (mass spectral parent ion mass) for 259 examples of I are included. I are potent and selective inhibitors of MIP-1α (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). These compds. also inhibit MIP-1α (and the related chemokines shown to interact with CCR1)-induced chemotaxis of THP-1 cells and human leukocytes. All I in the examples had IC50 of <10 μM in the MIP-1α-induced chemotaxis assay.

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT 519172-07-7, N-[5-Chloro-2-[2-[4-(4-fluorobenzyl)-1-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519172-13-3P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-1-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519172-82-2P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519173-93-6P,

N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-C,C,C-trifluoromethanesulfonamide 519173-94-7P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-4-fluorobenzenesulfonamide 519173-95-8P, N-[[5-[2-[4-(4-Fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]-4-methoxyphenyl]acetyl]methanesulfonamide 519173-96-9P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,3S)-2,3-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]benzenesulfonamide 519173-97-0P,

N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-2-methylbenzenesulfonamide 519173-98-1P , Ethanesulfonic acid [[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]amide 519173-99-2P, 3,5-Dimethylisoxazole-4-sulfonic acid

[[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]amide 519174-00-6P, N-[[5-Bromo-2-[2-[4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-01-7P, N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-02-8P, N-[[5-Bromo-2-[2-[4-(4-fluorobenzyl)-(2R)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-03-9P,

N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-4-fluorobenzenesulfonamide 519174-04-0P, 2-Chloro-N-[[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]benzenesulfonamide 519174-05-1P,

N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-2-fluorobenzenesulfonamide 519174-06-2P , N-[[5-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]-4-methylbenzenesulfonamide 519174-07-3P, Propane-2-sulfonic acid

[[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]amide 519174-09-4P, Propane-1-sulfonic acid [[5-chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]amide 519174-11-9P,

N-[[4-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-12-0P,

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT N-[[4-Chloro-2-[2-[4-(4-fluorobenzyl)-(2R)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-13-1P,

N-[[5-Chloro-2-[2-[4-[3,4-difluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-14-2P,

N-[[5-Chloro-2-[2-[4-(4-chlorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-15-3P,

N-[[5-Chloro-2-[2-[4-(4-chlorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]phenylmethanesulfonamide 519174-16-4P, N-[[5-Chloro-2-[2-[4-(4-chlorobenzyl)-(2R)-2-methylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-17-5P, N-[[5-Chloro-2-[2-[4-(3,4-difluorobenzyl)-(2R,5S)-2,5-dimethylpiperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-20-0P, N-[[5-Chloro-2-[2-[(2R)-2-ethyl-4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-21-1P, N-[[5-Bromo-2-[2-[(2R)-2-methyl-4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]phenyl]acetyl]methanesulfonamide 519174-22-2P, N-[[2-[2-[(2R)-2-Ethyl-4-(4-fluorobenzyl)piperazin-1-yl]-2-oxoethoxy]-5-methylphenyl]acetyl]methanesulfonamide

RLs PAC (Pharmacological activity) SPN (Synthetic preparation); TEU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of piperazine derivs. with CCR1 receptor antagonist activity)

RN 519172-07-7 CAPLUS
CN Benzeneacetamide, 5-chloro-N-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519172-37-3 CAPLUS
CN 3-Pyridinesacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519173-91-2 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-92-3 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)



RN 519173-93-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519173-94-5 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(4-fluorophenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-95-6 CAPLUS
CN Benzeneacetamide, 2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-4-methoxy-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-96-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(phenylsulfonyl)- (CA INDEX NAME)

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Absolute stereochemistry.



RN 519173-97-0 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(2-methylphenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519173-98-1 CAPLUS
CN Benzeneacetamide, 5-chloro-N-(ethylsulfonyl)-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519174-02-8 CAPLUS
CN Benzeneacetamide,
5-bromo-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-03-9 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(4-methoxyphenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-04-0 CAPLUS
CN Benzeneacetamide, 5-chloro-N-[(2-chlorophenyl)sulfonyl]-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]- (CA INDEX NAME)

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 519173-99-2 CAPLUS
CN Benzeneacetamide, 5-chloro-N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-00-6 CAPLUS
CN Benzeneacetamide,
5-bromo-2-[2-[4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)



RN 519174-01-7 CAPLUS
CN Benzeneacetamide,
5-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Absolute stereochemistry.



RN 519174-05-1 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(2-fluorophenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-06-2 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 519174-07-3 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-08-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2S,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(propylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-11-9 CAPLUS
CN Benzeneacetamide, 4-chloro-2-[2-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Benzeneacetamide, 5-chloro-2-[2-[(2S,5S)-4-[(4-chlorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-16-4 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2S,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-[(phenylmethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-18-6 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R)-4-[(4-chlorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-19-7 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(3R)-4-[(3,4-difluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 519174-12-0 CAPLUS
CN Benzeneacetamide, 4-chloro-2-[2-[(2R)-4-[(4-fluorophenyl)methyl]-2-methyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-13-1 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2S,5S)-4-[(3,4-difluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-14-2 CAPLUS

L19 ANSWER 28 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Absolute stereochemistry.



RN 519174-20-0 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[2-[(2R)-2-ethyl-4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-21-1 CAPLUS
CN Benzeneacetamide, 5-bromo-2-[2-[(2R)-2-ethyl-4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 519174-22-2 CAPLUS
CN Benzeneacetamide, 2-[2-[(2R)-2-ethyl-4-[(4-fluorophenyl)methyl]-1-piperazinyl]-2-oxoethoxy]-5-methyl-N-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 29 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 29 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2003:96149 CAPLUS			
DOCUMENT NUMBER:	138:133174			
TITLE:	Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production			
INVENTOR(S):	Nenan, Reynold			
PATENT ASSIGNEE(S):	Warner-Lambert Company, USA			
SOURCE:	Eur. Pat. Appl., 41 pp.			
	CODEN: EPXLDW			
DOCUMENT TYPE:	Patent			
LANGUAGE:	English			
FAMILY ACC. NUM. COUNT:	1			
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1281399	A2	20030205	EP 2002-255156	20020723
EP 1281399	A3	20040211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2395066	A1	20030201	CA 2002-2395066	20020725
AU 2002300232	A	20040210	AU 2002-300232	20020729
AU 2002300319	A1	20030612	AU 2002-300319	20020730
HU 2002002548	A2	20030228	HU 2002-2548	20020731
CN 1404829	A	20030326	CN 2002-127403	20020731
JP 2003104878	A	20030409	JP 2002-222616	20020731
US 2003034498	A1	20030717	US 2002-209276	20020731
NZ 520457	A	20040326	NZ 2002-520457	20020731
PRIORITY APPLN. INFO.:			US 2001-3933749 P	20010801

OTHER SOURCE(S): MARPAT 138:133174

AB The invention provides a method for inhibiting sebum production and treating sebaceous gland disorders comprising administering to a patient in need of said treatment an effective amount of a compound that inhibits both acyl-CoA:cholesteryl acyltransferase (ACAT), and acyl-CoA:fatty acid acyltransferase (AFAT), provided that the compound is not [(2,4,6-trilsopropylphenyl)acetyl]sulfamic acid 2,6-diisopropylphenyl ester or a pharmaceutically acceptable salt or solvate thereof. The method of the invention is useful for the treatment of sebaceous gland disorders caused or exacerbated by the overprodn. of sebum, including oily skin, acne, seborrhea, perioral dermatitis, rosacea, and corticosteroid-induced acneiform lesions.

IT 166518-64-5 176433-68-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wax ester-cholesteryl ester synthesis dual inhibitors for inhibiting sebum production)

RN 166518-64-5 CAPLUS

CN Benzeneacetamide, 2,6-bis[1-methylethyl)-N-[[2,4,6-tris[1-methylethyl]phenyl]methyl]sulfonyl]- (CA INDEX NAME)

L19 ANSWER 29 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 176433-68-4 CAPLUS

CN Benzeneacetamide, 2,6-bis[1-methylethyl)-N-[[2,4,6-tris[1-methylethyl]phenyl]methyl]sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 30 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2002:607988 CAPLUS			
DOCUMENT NUMBER:	137:177047			
TITLE:	Silver halide photographic material containing more than two kinds of sensitizing dyes			
INVENTOR(S):	Nakamura, Akio; Morimura, Yimiyasu; Hioki, Takanori			
PATENT ASSIGNEE(S):	Fuji Photo Film Co., Ltd., Japan			
SOURCE:	Jpn. Kokai Tokkyo Koho, 36 pp.			
	CODEN: JKXXAF			
DOCUMENT TYPE:	Patent			
LANGUAGE:	Japanese			
FAMILY ACC. NUM. COUNT:	1			
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002229145	A	20020814	JP 2001-21719	20010130
US 2002108599	A1	20020114	US 2002-58285	20020130
US 6759186	B2	20040706		
PRIORITY APPLN. INFO.:			JP 2001-21719 A	20010130

OTHER SOURCE(S): MARPAT 137:177047

GI

I

AB The invention relates to a photog. material comprised of at least one Ag halide photosensitive emulsion layer on a support, wherein the Ag halide emulsion contains at least two kinds of sensitizing dyes represented by I (X = O, S, Se, NR'; R, R' = alkyl, aryl, heterocycle; D = group for forming methine dye; M = counter ion; m = 0 -). The Ag halide emulsion comprises ≥50 % Ag halide tabular grains with an aspect ratio of ≥2. The photog. material shows high sensitivity, excellent granularity, and reduced residual color upon fast processing.

IT 331229-77-7 364367-01-1
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(sensitizer; Ag halide photog. material containing more than two kinds of sensitizing dyes to improve photog. properties)

RN 331229-77-7 CAPLUS

CN Benzothiazolium, 5-chloro-2-[2-[[5-fluoro-2-[4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-1-butenyl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 36 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 364767-01-1 CAPLUS
CN Benzotriazolium, 5-chloro-2-[2-[[5-fluoro-3-(2-sulfopropyl)-2(3H)-benzothiazolylidene]methyl]-3-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 31 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:467528 CAPLUS
DOCUMENT NUMBER: 137:63173
TITLE: Preparation of benzo[f]isoindoles which bind to the EP4 receptor
INVENTOR(S): Giblin, Gerard Martin Paul; Jones, Haydn Terrence; Mason, Andrew McMurtrie; Miller, Neil Derek; Rowman, Susan; Shanahan, Stephen Edward; Walker, Ann Louise
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059633	A1	20020627	WO 2001-GB5676	20011220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002206135	A	20020701	AU 2002-16135	20011220
EP 1351934	A1	20031015	EP 2001-271355	20011220
EP 1351934	B1	20070829		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517099	T	20040610	JP 2002-551529	20011220
AT 371645	T	20070915	AT 2001-271355	20011220
US 20040102508	A1	20040527	US 2004-458891	20040130
US 6924297	B2	20050802		
PRIORITY APPLN. INFO.:			GB 2000-31382	A 20001221
			WO 2001-GB5676	W 20011220

OTHER SOURCE(S): MARPAT 137:63173
GI

L19 ANSWER 31 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB The title compds. [I; a = 0-1; b = 0-2; R1 = H, halo, alkyl, etc.; R2 = alkyl; R3 = H, O; R4 = H, alkyl; R5, R6 = H, halo, alkyl; or R5 and R6 are taken together to form a cyclopropyl ring; R7-R10 = H, alkyl, alkoxy, etc.; R11 = H, OH, halo, etc.; R12 = H, alkyl, R9, etc.] which bind with high affinity to the EP4 receptor and are of use in the treatment of prevention of conditions such as a pain, inflammatory, immunol., bone, neurodegenerative or renal disorders, were prepared. E.g., a multi-step synthesis of II which showed a pKi of 7.0 or greater at EP4 receptors, was given.

IT 439295-40-69 439295-55-39 439295-57-59
439295-59-79 439295-60-09 439295-87-19
439295-90-69 439295-93-99 439295-95-19
439296-02-39 439296-03-49 439296-05-69
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzo[f]isoindoles which bind to the EP4 receptor)

RN 439295-40-6 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[[[4-(4,9-diethoxy-1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]- (CA INDEX NAME)



L19 ANSWER 31 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 439295-55-3 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-2,3-dimethoxy- (CA INDEX NAME)

RN 439295-57-5 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-2,5-dimethoxy- (CA INDEX NAME)



RN 439295-59-7 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-3,4-dimethoxy- (CA INDEX NAME)



RN 439295-60-0 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1-oxo-2H-

L19 ANSWER 31 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-2,5-dimethyl- (CA INDEX NAME)



RN 439295-07-1 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-3,4-dimethoxy- (CA INDEX NAME)



RN 439295-99-6 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-2,5-difluoro- (CA INDEX NAME)



L19 ANSWER 31 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 439296-03-4 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-3,5-dimethoxy- (CA INDEX NAME)



RN 439296-05-6 CAPLUS
CN 1,3-Benzodioxole-5-acetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-2,2-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 31 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 439295-93-9 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-2,6-dimethyl- (CA INDEX NAME)



RN 439297-95-1 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-3-fluoro-4-methyl- (CA INDEX NAME)



RN 439296-02-3 CAPLUS
CN Benzeneacetamide, N-[[[4-(4,9-diethoxy-1,3-dihydro-1-oxo-2H-benz[f]isoindol-2-yl)phenyl]methyl]sulfonyl]-3,4-diethoxy- (CA INDEX NAME)

L19 ANSWER 32 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2002:446202 CAPLUS
DOCUMENT NUMBER:	137:22367
TITLE:	Metal complex dye for a dye sensitized solar cell
INVENTOR(S):	Watanabe, Tetsuya
PATENT ASSIGNEE(S):	Fuji Photo Film Co., Ltd., Japan
SOURCE:	Eur. Pat. Appl., 35 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1213776	A2	20020612	EP 2001-129122	20011207
EP 1213776	A3	20040317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002176188	A	20020621	JP 2000-375146	20001208
JP 4162116	B2	20081008		
PRIORITY APPLN. INFO.:			JP 2000-375146	A 20001208

AB A photoelec. conversion device comprises a semiconductor fine particle sensitized by a dye having a proton dissociative imide group, and a photoelec. cell comprising the photoelec. conversion device is disclosed. A metal complex dye useful for the photoelec. conversion device is also provided.

IT 434339-64-7
RL: DEV (Device component use); USES (Uses)
(metal complex dye for dye sensitized solar cell)

RN 434339-64-7 CAPLUS
CN Cyclobutenediylium, 1,3-bis[(1,3-dihydro-9,3-dimethyl-1-(2-oxo-2-[[[trifluoromethyl)sulfonyl]amino]ethyl]-2H-indol-2-ylidene)methyl]-2,4-dihydroxy-, bis(inner salt) (9CI) (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 33 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:369929 CAPLUS
DOCUMENT NUMBER: 136:393179
TITLE: Silver halide color photographic film and paper comprising sensitizing methine dye
INVENTOR(S): Nakazyo, Tetsuoy; Hioki, Takaaki; Ohzeki, Katsuhisa; Hanaki, Tomoyuki
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl. Publ., 75 pp., Cont.-in-part of U.S. Ser. No. 338,679.
CODEN: EPXXDC
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020058216	A1	20020516	US 2001-931709	20010817
US 7291449	B2	20071106		
JP 2002023295	A	20020123	JP 2001-118281	20010417
PRIORITY APPLN. INFO.:			JP 1999-89424	A 19990330
			JP 2000-4868	A 20000113
			US 2000-536479	A2 20000328
			JP 2001-118281	A 20010417
			JP 2000-124612	A 20000425
			JP 2000-132357	A 20000501

OTHER SOURCE(S): MARPAT 136:393179
GI



AB Disclosed is a silver halide color photog. film and paper which comprise at least one methine dye represented by the following formula I (Y = furan ring, pyrrole ring, Y may be condensed with other 5- or 6-membered carbocyclic or heterocyclic ring; X = atomic group necessary to form a 5- or 6-membered nitrogen-containing heterocyclic ring, X may further be condensed

L19 ANSWER 33 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 391879-89-3 CAPLUS
CN Benzothiazolium, 2-[2-[[5-fluoro-3-[3-sulfopropyl]thieno[2,3-d]thiazol-2(3H)-ylidene]methyl]-1-buten-1-yl]-4,6-dimethyl-3-[2-[methylsulfonyl]amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

RN 423621-07-4 CAPLUS
CN Benzoxazolium, 5-chloro-3-[2-[[methylsulfonyl]amino]-2-oxoethyl]-2-[2-[[3-[sulfomethyl]furo[3,4-d]thiazol-2(3H)-ylidene]methyl]-1-buten-1-yl]-, inner salt (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 33 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
with other 5- or 6-membered carbocyclic or heterocyclic ring; R = alkyl, aryl, heterocyclic; D = group necessary to form a methine dye; L1, L2 = methine group; p = 0, 1; M = counter ion; m = no. necessary to neutralize the charge in the mol. High sensitivity and excellent residual color effect can be obtained by the constitution of the present invention

IT 391879-89-3 391879-88-2 391879-85-9
391879-89-3 423621-07-4
RL: PEP (Properties); TEM (Technical or engineered material use); USES (Uses)
(sensitizing dye; color photog. film and paper comprising sensitizing methine dye)

RN 391879-65-5 CAPLUS
CN Benzoselenazolium, 5-methyl-3-[2-[[methylsulfonyl]amino]-2-oxoethyl]-2-[[3-[4-sulfobutyl]thieno[2,3-d]thiazol-2(3H)-ylidene]methyl]-, inner salt (9CI) (CA INDEX NAME)

RN 391879-84-8 CAPLUS
CN Benzothiazolium, 2-[[5-bromo-3-(3-sulfopropyl)thieno[2,3-d]thiazol-2(3H)-ylidene]methyl]-5-methoxy-3-[2-[[methylsulfonyl]amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 391879-85-9 CAPLUS
CN Benzothiazolium, 2-[[5-bromo-3-(3-sulfopropyl)thieno[2,3-d]thiazol-2(3H)-ylidene]methyl]-5-chloro-3-[2-[[methylsulfonyl]amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 34 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:368842 CAPLUS
DOCUMENT NUMBER: 136:359669
TITLE: High-density lipoprotein-cholesterol level elevating agent
INVENTOR(S): Nishimoto, Tomoyuki; Tozawa, Syuichi; Kori, Masakuni; Amano, Yuichiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002037180	A1	20020516	WO 2001-JP9802	20011109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2428869	A1	20020516	CA 2001-2428869	20011109
AU 2002011741	A	20020521	AU 2002-11741	20011109
JP 2002205956	A	20020723	JP 2001-344074	20011109
JP 4138299	B2	20080827		
EP 1332743	A1	20030806	EP 2001-983043	20011109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040067750	A1	20040401	US 2003-416239	20030506
US 20080058210	A1	20080306	US 2007-910987	20070607
PRIORITY APPLN. INFO.:			JP 2000-342607	A 20001109
			WO 2001-JP9802	W 20011109
			US 2003-416239	A1 20030506

OTHER SOURCE(S): MARPAT 136:359669
AB Disclosed is a novel high-d. lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory effect. The HDL-cholesterol-elevating effect of N-[[3R,5S)-1-(7-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl]acetyl]piperidine-4-acetic acid (I) in common marmoset was examined Also, a tablet containing I 50, D-mannitol 50, corn starch 33.9, croscarmellose sodium 60, hydroxypropyl cellulose 5.5, and magnesium stearate 9.6 mg was prepared
IT 189059-84-5 189059-85-6 189060-07-9
189060-45-5 383652-09-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high-d. lipoprotein-cholesterol level elevating agents containing squalene

L19 ANSWER 34 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
synthase inhibitors)
RN 189059-84-5 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-(methylsulfonyl)-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 189059-85-6 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-N-(methylsulfonyl)-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 189060-07-9 CAPLUS

L19 ANSWER 34 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-3,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 189060-45-5 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383652-05-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-

L19 ANSWER 34 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-(propylsulfonyl)-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 35 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:19047 CAPLUS
DOCUMENT NUMBER: 136:158761
TITLE: Heat developable photographic films containing specific sensitizing dye
INVENTOR(S): Hioki, Takaeci; Kato, Takashi; Ozeki, Tomoyuki; Hanaki, Naoyuki
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 52 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002040591	A	20020206	JP 2000-219957	20000721
PRIORITY APPLN. INFO.:			JP 2000-219957	20000721

OTHER SOURCE(S): MARPAT 136:158761
AB The invention relates to a heat-developable film containing a light-sensitive silver halides, heat-insensitive organic silver salts, a reducing agent, and a binder on a support, wherein the film also contains sensitizing dye (dye1)-(R1)q M1m1 (dye1 = dye residue; M1 = counter ion; m1 = charge-neutralizing charge number; q, R1 integer; R1 = group containing -COOR2-, -SO2-NCO-, -COCO-, or -SO2NSO2-). The film provides the good image d. under various temperature and humidity.
IT 395662-15-4P 395662-30-3P
RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(sensitizing dye in heat-developable photog. films)
RN 395662-15-4 CAPLUS
CN Benzoxazolium, 3-[3-[(5,6-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene)methyl]-5,5-dimethyl-2-cyclohexen-1-ylidene]-1-propen-1-yl]-3-ethyl-5,6-dimethyl-, inner salt (CA INDEX NAME)



RN 395662-30-3 CAPLUS
CN Benzothiazolium, 2-[[3-ethyl-5-[2-[4-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-thiazolylidene]ethylidene]-4-oxo-2-thiazolidinylidene]methyl]-5,6-dimethoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 35 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 36 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2002:41857 CAPLUS
DOCUMENT NUMBER:	136:142540
TITLE:	Photographic films containing specific methine dye
INVENTOR(S):	Nakamura, Akiou; Hioki, Takanori; Ozeki, Katsuhisa; Nanaki, Naoyuki
PATENT ASSIGNEE(S):	Fuji Photo Film Co., Ltd., Japan
SOURCE:	Jpn. Kokai Tokkyo Koho, 109 pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002027295	A	20020123	JP 2001-118201	20010417
US 20020058216	A1	20020516	US 2001-837109	20010417
US 7291449	B2	20071106		
EP 1251395	A1	20021023	EP 2001-124750	20011017
	R: AT, BE, CH, DE, DK, ES, FI, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			JP 2000-124612 A	20000425
			JP 2000-132257 A	20000501
			JP 1999-89424 A	19990330
			JP 2000-4868 A	20000113
			US 2000-536679 A2	20000328
			JP 2001-118201 A	20010417

OTHER SOURCE(S): MARPAT 136:142540

GI



AB The invention relates to photog. films containing methine dye I (Y = 5-6 membered unsat. heterocyclic ring residue; Z = 5-6 membered unsat.

L19 ANSWER 36 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

heterocyclic ring residue, connecting group; R = alkyl, aryl, heterocyclic; D = dye functional group; L1-2 = methine; p = 0,1; M = counter ion; m = no. to neutralize charge in compd.). The photog. film provides the high sensitivity and little residual color after the process without detracting the pressure durability.

IT 391879-39-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(photog. film containing specific methine dye)

RN 391879-39-3 CAPLUS

CN 7Hsieno[2,3-d]thiazolium, 5-bromo-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



IT 391879-40-5P 391879-84-8P 391879-85-9P 391879-89-3P 393880-08-3P

RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(photog. film containing specific methine dye)

RN 391879-85-9 CAPLUS

CN Benzenemethanaminium, 5-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-[[3-(4-sulfobutyl)thieno[2,3-d]thiazol-2(3H)-ylidene]methyl]-, inner salt (SCI) (CA INDEX NAME)



RN 391879-84-8 CAPLUS

CN Benothiazolium, 2-[[5-fluoro-1-(3-sulfopropyl)thieno[3,2-d]thiazol-2(3H)-ylidene]methyl]-5-methoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 36 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 391879-85-9 CAPLUS

CN Benothiazolium, 2-[[5-bromo-3-(3-sulfopropyl)thieno[2,3-d]thiazol-2(3H)-ylidene]methyl]-5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 391879-89-3 CAPLUS

CN Benothiazolium, 2-[2-[[5-fluoro-3-(3-sulfopropyl)thieno[2,3-d]thiazol-2(3H)-ylidene]methyl]-1-buten-1-yl]-5,6-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

RN 391880-08-3 CAPLUS

CN Benzoxazolium, 5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-[2-[[3-(3-sulfopropyl)furo[3,4-d]thiazol-2(3H)-ylidene]methyl]-1-buten-1-yl]-, inner salt (CA INDEX NAME)

L19 ANSWER 36 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 37 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:335587 CAPLUS
DOCUMENT NUMBER: 136:498829
TITLE: Preparation of diallcoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents
INVENTOR(S): Mori, Masakazu; Mish., Takashi; Nishimoto, Tomoyuki; Tozawa, Kyuichi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 643 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095882	A1	20011227	WO 2001-JP5347	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2413429	A1	20011227	CA 2001-2413429	20010622
AU 2001074586	A	20020102	AU 2001-74586	20010622
JP 2002088048	A	20020319	JP 2001-189417	20010622
JP 2003064063	A	20030305	JP 2002-273086	20010622
EP 1292585	A1	20030319	EP 2001-941174	20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011835	A	20030429	BR 2001-11835	20010622
NO 2002901901	A2	20030828	NO 2002-1901	20020422
US 2003096825	A1	20030424	US 2002-207524	20020809
ZA 2002009655	A	20031107	ZA 2002-9655	20021127
MX 2002012481	A	20030606	MX 2002-12481	20021216
NO 2002904164	A	20021220	NO 2002-4164	20020902
PRIORITY APPLN. INFO.:			JP 2000-198253	A 20000623
			JP 2001-189417	A3 20010622
			WO 2001-JP5347	W 20010622
OTHER SOURCE(S):	MARPAT 136:498829			
GI				

AB Alkoxyphenyloxobenzoxazepineacetamides [I; R = (un)substituted 1-carboxyethyl; (un)substituted carboxyalkyl; sulfonylalkyl, (carboxycycloalkyl)alkyl, etc.; R1 = alkyl (un)substituted with alkanoyloxy or OH groups (if R = (un)substituted 1-carboxyethyl, alkyl), 4-carboxycyclohexylmethyl, or 4-carboxyphenylmethyl, then R1 must be substituted with a OH or alkanoyloxy group.; R2 = lower alkyl; W = halogen] are prepared as squalene synthase inhibitors for the treatment of hyperlipidemia and the decrease of serum triglycerides and lipids. (3R,4S)-2 [5 = Me(CH2)2OCH2; R1 = EtOCH(Me)CH2; R2 = Me; W = Cl] (II) was prepared in 3 steps from hydroxyazid (III) by acetylation of the hydroxyl group with acetic anhydride, treatment of the azid with thionyl chloride in THF to generate the azid chloride in situ, and addition of the mixture to a solution of PrSO2NHSi in THF to provide the acetylated methoxyphenyloxobenzoxazepineacetamide I (R = PrSO2; R1 = AcOCH2C(Me)2CH2; R2 = Me; W = Cl); hydrolysis of the acetoxy group with aqueous sodium hydroxide and ethanol provides II. Data for the inhibition of squalene synthase by I are given. Pharmaceutical compns. containing I (R = 5-(HO2CCH2CH2)C6H4; R1 = EtOCH2CMe2CH2; R2 = Me; W = Cl) are specified.

IT 383653-24-1P 383653-24-1P 383653-20-1P 383653-31-4P 383653-40-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(title compds.; preparation of dialkoxyphenyloxobenzoxazepineacetamide squalene synthase inhibitors as antihyperlipidemic and antihypercholesteremic agents)

RN 383653-04-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-(propylsulfonyl)- , (3S,5R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L19 ANSWER 37 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L19 ANSWER 37 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 383653-14-3 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, N-(butylsulfonyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2,2-dimethylpropyl]-2-oxo- , (3S,5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 383653-20-1 CAPLUS

CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-N-[[3-(acetyloxy)propyl]sulfonyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L19 ANSWER 37 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 383653-31-4 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[[3-(phenylthio)propyl]sulfonyl]-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 383653-40-3 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-[[3-(2-pyridinylthio)propyl]sulfonyl]-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L19 ANSWER 37 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

(butylsulfonyl)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo- , (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 383653-25-6 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2,2-dimethylpropyl)-N-[(3-hydroxypropyl)sulfonyl]- 2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 383653-35-8 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(phenylthio)propyl]sulfonyl]-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L19 ANSWER 37 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 383652-05-9P 383653-09-6P 383653-25-6P
383653-35-8P 383653-45-9P
RLA PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(title compds.; preparation of dialkoxyphenylbenzoxazepineacetamide squalene synthase inhibitors as antihypercholesterolemic and antihyperlipidemic and antihypercholesteremic agents)

RN 383652-05-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-N-(propylsulfonyl)-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 383653-09-6 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-N-

L19 ANSWER 37 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 383653-45-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-N-[[3-(2-pyridinylthio)propyl]sulfonyl]-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 38 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:935563 CAPLUS
DOCUMENT NUMBER: 136:54021
TITLE: Thyroid receptor ligands, namely 3,5-dichloro-4-(3-bromo-4-amidophenoxy)phenylacetic acids and analogs, pharmaceutical compositions comprising them, and their use in the treatment of disorders influenced by thyroid hormones
INVENTOR(S): Li, Yi-Lin; Malm, Johan; Litten, Chris; Garcia Collazo, Ana Maria; Garg, Neeraj
PATENT ASSIGNEE(S): Karo Bio AB, Swed.
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098256	A1	20011227	WO 2001-EP6815	20010615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412161	A1	20011227	CA 2001-2412161	20010615
EP 1296936	A1	20030402	EP 2001-951600	20010615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004501132	T	20040115	JP 2002-504212	20010615
AU 779880	B2	20050217	AU 2001-72484	20010615
US 20040097589	A1	20040520	US 2003-311524	20030422
US 7199265	B2	20070403		
PRIORITY APPLN. INFO.:			GB 2000-15205 A	20000621
			WO 2001-EP6815 W	20010615

OTHER SOURCE(S): MARPAT 136:54021
GI

L19 ANSWER 38 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB The invention relates to compds. I or pharmaceutically acceptable salts thereof [wherein: R1 = (un)substituted aryl, heteroaryl, alk(en/yn)yl, cycloalkyl; R2 = H, halo, NO2, CN, aryl, heteroaryl, alk(en/yn)yl, cycloalkyl; R1 can be linked to R2, thus forming an (un)substituted aza-containing C5-8 heterocyclic ring; Q = CO, SO, SO2, NHCS, or NHCO; R3, R4 = halo, (un)substituted alk(en/yn)yl, cycloalkyl, or bioisosteric equivalent; Z = (CH2)n, CH:CH, O(CH2)m, or NH(CH2)m; n = 0, 1, 2, or 3; m = 1 or 2; R5 = CO2H, PO(OH)2, PO(OH)NH2, SO2OH, CONHOH, NHCOCO2H, NHCOCH2CO2H, CONHSO2R', or CONR'R'' (R' and R'' not explicitly defined) where the amine portion is derived from an L- or D-amino acid or a mixture; or any other possible bioisosteric equivalent of all the groups above; including all stereoisomers, and prodrug esters]. Also disclosed are methods of preparing I, and methods for using them, such as in the regulation of metabolism I are thyroid receptor ligands, and are preferably selective for the thyroid hormone receptor β. Over 80 examples are given. For instance, 3,5-dichloro-4-(3-bromo-4-isobutyramidophenoxy)phenylacetic acid (II) was prepared in 9 steps as follows: (1) bromination of 2,6-dichlorophenol in the 4-position (85%), (2) etherification with 4-fluoronitrobenzene (45%), (3) coupling of the bromide with HC.tplbond.CSiMe3 (53%), (4) desilylation and oxidation to an acid, (5) conversion to the Me ester, (6) hydrogenation of the nitro group, (7) ring bromination adjacent to amino (57%), (8) amidation of the amino group with isobutyryl chloride (40%), and (9) alkaline

L19 ANSWER 38 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
hydrolysis of the ester (82%). Compds. I of the examples bound to thyroid receptor β with IC50 values of 0.2 nM to 10,000 nM.
IT 383180-96-9P, N-[[3,5-Dichloro-4-(3-bromo-4-isobutyramidophenoxy)phenyl]acetyl]benzenesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of dichloro(bromoamidophenoxy)phenylacetic acids and analogs as thyroid hormone receptor ligands)
RN 383180-96-9 CAPLUS
CN Benzeneacetamide, 4-[3-bromo-4-[(2-methyl-1-oxopropyl)amino]phenoxy]-3,5-dichloro-N-(phenylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 39 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:814242 CAPLUS
DOCUMENT NUMBER: 135:350442
TITLE: Silver halide photographic emulsions with high sensitivity and their photographic materials for fast development
INVENTOR(S): Nakamura, Akio; Hioki, Takanori
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001312023	A	20011109	JP 2000-132280	20000501
CN 1322965	A	20011121	CN 2001-115707	20010429
CN 1229688	C	20051130		
US 20020012891	A1	20020131	US 2001-845355	20010501
US 6762015	B2	20040713		
PRIORITY APPLN. INFO.:			JP 2000-132280 A	20000501

OTHER SOURCE(S): MARPAT 135:350442
AB The photog. emulsions preventing fog in fast development, contain ≥2 color sensitizing dyes Dye(ArQ)pMm [Dye = dye part (cyanine dye, etc.); A = linking group; Q = dissociable group, at least one of them is not SO3H; M = counter ion; r = 0, 1; q ≥1; m ≥0 (for neutralizing intramol. charges)]. The emulsions may be chemical sensitized by Se compds. and may contain tabular silver halide grains.
IT 364367-01-1
RL: DEV (Device component use); TEM (Technical or engineered material use); USES (Uses)
(photog. dye sensitizers for antifogging silver halide emulsions)
RN 364367-01-1 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-fluoro-3-(3-sulfopropyl)-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 40 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:729895 CAPLUS
DOCUMENT NUMBER: 135:296112
TITLE: Color photographic emulsion with improved solution storage stability and color photographic paper with high sensitivity and image graininess
INVENTOR(S): Ohsaki, Kotetsuka; Nakamura, Tetsuo; Hioki, Takaaki
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 91 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1139124	A1	20011004	EP 2001-107512	20010326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001343719	A	20011214	JP 2000-91825	20000329
JP 2001343724	A	20011214	JP 2000-238642	20000807
JP 4115076	B2	20080709		
JP 2001343721	A	20011214	JP 2000-270137	20000906
JP 2001343722	A	20011214	JP 2000-292446	20000926
JP 2001343723	A	20011214	JP 2001-85556	20010323
US 2002021974	A1	20020815	US 2001-816062	20010326
US 6566044	B2	20030520		
CN 1316674	A	20011010	CN 2001-117899	20010327
CN 1221851	C	20051005		
CN 1347006	A	20020501	CN 2001-142235	20010925
CN 1229684	C	20051123		
US 2002061819	A1	20020523	US 2001-960981	20010925
US 6649336	B2	20031118		

PRIORITY APPLN. INFO.: JP 2000-86489 A 20000327
JP 2000-91825 A 20000329
JP 2000-238642 A 20000807
JP 2000-292446 A 20000926

OTHER SOURCE(S): MARPAT 135:296112
GI

RE 364368-02-5 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[5-fluoro-3-(3-sulfopropyl)-2(3H)-benzothiazolylidene]methyl]-1-butenyl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 40 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB The purpose of the present invention is to provide silver halide photog. materials that are excellent in photog. speed as well as image graininess and exhibit low residual color even after rapid processing. A silver halide photog. material comprises a compound representated by formula I (Y = group necessary to form heterocyclic ring or a benzene ring; Z1, Z2 = group or a single bond necessary to form a nitrogen-containing heterocyclic ring; R = alkyl, aryl, heterocyclic ring; L1, L2 = methine; p = 0-1; M = counter ion; m = 0-1; D = group necessary to form a methine dye); and a compound represented by formula II (R31, R32 = alkyl, aryl, heterocyclic ring; L31- L37 = methine group; p31, p32 = 0-1; n3 = 0-4; M3 = counter ion; m3 = 0-1; Z31, Z32 = group necessary to form a nitrogen-containing heterocyclic ring).

IT 364368-98-3 364367-91-3
RLs TEM (Technical or engineered material use); USES (Uses)
(sensitizing dye; color photog. emulsion with improved solution storage stability and color photog. paper with high sensitivity and image graininess)

RN 364368-98-3 CAPLUS
CN Benzoxazolium, 5,6-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-[2-[[5-phenyl-3-(3-sulfopropyl)furo[2,3-d]oxazol-2(3H)-ylidene]methyl]-1-buten-1-yl]-, inner salt (CA INDEX NAME)

L19 ANSWER 41 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:359777 CAPLUS
DOCUMENT NUMBER: 134:371771
TITLE: Prevention of plaque rupture by ACAT inhibitors
INVENTOR(S): Bocan, Thomas Michael Andrew
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001034127	A1	20010517	WO 2000-US28705	20001017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2382676	A1	20010517	CA 2000-2382676	20001017
EP 1229907	A1	20020814	EP 2000-973408	20001017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200201264	T2	20020821	TR 2002-1264	20001017
HU 2002003160	A2	20030128	HU 2002-3160	20001017
HU 2002003160	A3	20040628		
JP 2003513909	T	20030415	JP 2001-536127	20001017
EA 2002001755	A	20030602	EA 2002-1755	20020501
PRIORITY APPLN. INFO.:			US 1999-163814P	P 19991105
			WO 2000-US28705	W 20001017

OTHER SOURCE(S): MARPAT 134:371771
GI



AB This invention is the administration of an ACAT inhibitor to prevent monocyte-macrophage accumulation and MMP expression in atherosclerotic lesions. Further, this invention relates to methods of inhibiting destabilization and/or rupture of atherosclerotic plaques and treatment of unstable angina. Tablets were prepared containing a ACAT inhibitor such as 1.

L19 ANSWER 41 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT 166518-64-5 176433-68-4
RL: TMU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prevention of plaque rupture by ACAT inhibitors)
RN 166518-64-5 CAPLUS
CN Benzeneacetamide, 2,6-bis[1-methylethyl]-N-[[[2,4,6-tris[1-methylethyl]phenyl]methyl]sulfonyl]- (CA INDEX NAME)



RN 176433-68-4 CAPLUS
CN Benzeneacetamide, 2,6-bis[1-methylethyl]-N-[[[2,4,6-tris[1-methylethyl]phenyl]methyl]sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 42 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1-pyrrolyl; the other W5 or W5 = H, F, Me, methylthio, ethoxy, ethoxycarbonyl, 2-pyridyl, 4-pyridyl; M1 = counter ion; n1 = no. required to neutralize intramol. charge; R3 = sulfo-substituted alkyl; Lf = methylene; k = 1-3, and III (E5, E6 = O, 5; A2 = H, alkyl; W6 = H, F, Me, methylthio, ethoxy, ethoxycarbonyl, 2-pyridyl, 4-pyridyl; W6 = Cl, Br, I, trifluoromethyl, Et, benzoyl, 1-pyrrolyl; M2 = counter ion; n2 = no. required to neutralize intramol. charge; R4 = sulfo-substituted alkyl; Xg = alkyl; Lg = methylene; k = 1-3) and also comrp. Ag halide grains with 3-100 av. aspect ratio. It shows high sensitivity and reduced dye stain.
IT 331229-77-7
RL: DEV (Device component use); USES (Uses)
(photog. sensitizer giving high sensitivity and reduced residual stain)
RN 331229-77-7 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-fluoro-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 43 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:120100 CAPLUS
DOCUMENT NUMBER: 134:259141
TITLE: Silver halide photographic material with reduced dye stain
INVENTOR(S): Nakamura, Akiyo; Morimura, Kimiyasu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 41 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001075224	A	20010323	JP 1999-246122	19990831
US 6458526	B1	20021001	US 2000-647717	20000927
PRIORITY APPLN. INFO.:			JP 1999-246122	A 19990831

OTHER SOURCE(S): MARPAT 134:259141
GI



AB The material contains X1 I (X1, X2 = O, S, Se, Te, NR; R = alkyl, aryl, heterocycle; L1-3 = methine; n1 = 0-3; V1-4, W1-4 = H, substituent; xv or ww ≥0.70 (xv and ww are sum of x values of V1-4 and W1-4 resp.); M = counter ion; m = number required to neutralize intramol. charge; R1 = alkyl, aryl, heterocycle; X2 = LaKaCONHSO2Rb, LbKbSO2NHCORb, LcKcCONHCORc, LdKdSO2NHSO2Rd, LeKeCOOH; Ra, Rb, Rc, Rd = alkyl, aryl, heterocyclyl, alkoxy, aryloxy, heterocyclyloxy, amino; La, Lb, Lc, Ld, Le = methylene; ka, kb, kc, kd, ke X1). The material comprises an emulsion layer containing ≥1 of I, II (E3, E4 = O, S; A1 = H, alkyl; either V5 or W5 = Cl, Br, I, trifluoromethyl, Et, benzoyl,

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:117202 CAPLUS
DOCUMENT NUMBER: 134:185877
TITLE: Silver halide photographic material
INVENTOR(S): Ito, Takanori
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 26 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001042467	A	20010216	JP 1999-213977	19990728
US 6348307	B1	20020219	US 2000-625324	20000725
PRIORITY APPLN. INFO.:			JP 1999-213977	A 19990728

AB The Ag halide photog. material comprises ≥1 methine dye represented by (dye1)(X1)q[X2]r M1m1 (dye1 = methine dye; M1 = charge-neutralizing counter ion; m1 = number needed for neutralization; q, r2≥1; X1 = alkyl derivative group) in ≥1 Ag halide emulsion layer which contains Ag halide grains ≥50% with an aspect ratio 3-100. The use of above sp. methine dyes in the Ag halide emulsion layer provided high sensitivity and little residual color.
IT 326494-02-4 326494-04-6 326494-06-8
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. emulsion layer containing)
RN 326494-02-4 CAPLUS
CN Benzothiazolium, 5-chloro-2-[[5-chloro-3-(2-hydroxy-3-sulfopropyl)-2(3H)-benzothiazolylidene]methyl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 326494-04-6 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-chloro-3-(2-hydroxy-3-sulfopropyl)-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 43 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 326494-06-8 CAPLUS
CN Benzothiazolium, 2-[[3-ethyl-5-[2-[4-methyl-3-(2-sulfoethyl)-2(3H)-thiazolylidene]ethylidene]-4-oxo-2-thiazolidinylidene]methyl]-5,6-dimethoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:93900 CAPLUS
DOCUMENT NUMBER: 134:164473
TITLE: Acylsulfonamido-substituted polymethine fluorescent dyes and their use as fluorescent coloring materials and/or markers for biomolecules
INVENTOR(S): Deroover, Geert; Missfeldt, Michael; Simon, Lydia
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 68 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 19937024	A1	20010208	DE 1999-19937024		19990805
CA 2381088	A1	20010215	CA 2000-2381088		20000724
WO 2001011370	A1	20010215	WO 2000-EP7070		20000724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
EP 1206703	A1	20020522	EP 2000-958289		20000724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
JP 2003506567	T	20030218	JP 2001-515974		20000724
US 6995262	B1	20060207	US 2002-48775		20020315
PRIORITY APPLN. INFO.:			DE 1999-19937024	A	19990805
			WO 2000-EP7070	W	20000724

OTHER SOURCE(S): MARPAT 134:164473
AB Polymethine dyes containing (1) at least one acylsulfonamido group of the formula (CH2)nYNHAR, where A and Y are electron-donating groups such as CO
or SO2, R = optionally substituted alkyl or aryl, and n = 1-9 and (2) and at least one other functional group are effective as fluorescent coloring materials or markers for biomols. The polymethine dyes have improved light stability compared to prior-art indole or squaric acid-based materials when used with RNA, DNA, or proteins. Examples of preparation of 2
dyes were given.
IT 324745-27-9 324745-29-1 324745-31-5
324745-33-7 324745-35-9 324745-37-1
325143-23-5 325143-24-6 325143-25-7
325143-26-8
RL: BUU (Biological use, unclassified); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(acylsulfonamido-substituted polymethine fluorescent dye markers for biomols.)
RN 324745-27-9 CAPLUS
CN 3H-Indolium,
2-[[3-[[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-2H-indol-2-ylidene]methyl]-2-hydroxy-4,5-dioxo-2-cyclopenten-1-ylidene]methyl]-1-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-3,3-dimethyl-5-sulfo-, inner salt, potassium salt (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

●2 K

RN 324745-29-1 CAPLUS
CN 3H-Indolium,
2-[[3-[[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-2H-indol-2-ylidene]methyl]-2-mercapto-4,5-dithioxo-2-cyclopenten-1-ylidene]methyl]-1-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-3,3-dimethyl-5-sulfo-, inner salt, potassium salt (1:2) (CA INDEX NAME)

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

●2 K

RN 324745-31-5 CAPLUS
CN 1H-Benz[e]indolium, 2-[[3-[[1,3-dihydro-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-7-sulfo-2H-benz[e]indol-2-
ylidene]methyl]-2-mercapto-4,5-dithioxo-2-cyclopenten-1-ylidene]methyl]-3-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-1,1-dimethyl-7-sulfo-, inner salt, dipotassium salt (9CI) (CA INDEX NAME)



●2 K

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 324745-33-7 CAPLUS
CN 1H-Benz[e]indolium, 2-[3-[[1,3-dihydro-1,1-dimethyl-3-[2-[[methylsulfonyl]amino]-2-oxoethyl]-7-sulfo-2H-benz[e]indol-2-ylidene]methyl]-2-hydroxy-4,5-dioxo-2-cyclopenten-1-ylidene]methyl]-3-[6-[[2,5-dioxo-1-pyrrolidinyl]oxy]-6-oxohexyl]-1,1-dimethyl-7-sulfo-, inner salt, dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

RN 324745-35-9 CAPLUS
CN 3H-Indolium,
2-[5-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-2H-indol-1-ylidene]-1,3-pentadien-1-yl]-1-[6-[[2,5-dioxo-1-pyrrolidinyl]oxy]-6-oxohexyl]-3,3-dimethyl-5-sulfo-, inner salt, potassium salt (1:1) (CA INDEX NAME)

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● K

RN 325143-23-3 CAPLUS
CN Cyclobutenediylium, 1-[[1,3-dihydro-1,1-dimethyl-3-[2-[methylsulfonyl]amino]-2-oxoethyl]-7-sulfo-2H-benz[e]indol-2-ylidene]methyl]-3-[[3-[6-[[2,5-dioxo-1-pyrrolidinyl]oxy]-6-oxohexyl]-1,3-dihydro-1,1-dimethyl-7-sulfo-2H-benz[e]indol-2-ylidene]methyl]-2,4-dihydroxy-, bis(inner salt), dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

RN 325143-24-4 CAPLUS
CN Cyclobutenediylium, 1-[[1,3-dihydro-3,3-dimethyl-1-[2-[methylsulfonyl]amino]-2-oxoethyl]-7-sulfo-2H-benz[e]indol-2-ylidene]methyl]-3-[[3-[6-[[2,5-dioxo-1-pyrrolidinyl]oxy]-6-oxohexyl]-1,3-dihydro-1,1-dimethyl-7-sulfo-2H-benz[e]indol-2-ylidene]methyl]-2,4-

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● K

RN 324745-37-1 CAPLUS
CN 1H-Benz[e]indolium, 2-[5-[1,3-dihydro-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-7-sulfo-2H-benz[e]indol-2-ylidene]-1,3-pentadienyl]-3-[6-[[2,5-dioxo-1-pyrrolidinyl]oxy]-6-oxohexyl]-1,1-dimethyl-7-sulfo-, inner salt, monopotassium salt (9CI) (CA INDEX NAME)

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
dimercapto-, bis(inner salt), dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

RN 325143-25-7 CAPLUS
CN Cyclobutenediylium, 1-[[1,3-dihydro-3,3-dimethyl-1-[2-[methylsulfonyl]amino]-2-oxoethyl]-5-sulfo-2H-indol-2-ylidene]methyl]-3-[[1-[6-[[2,5-dioxo-1-pyrrolidinyl]oxy]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]methyl]-2,4-dihydroxy-, bis(inner salt), dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 325143-26-8 CAPLUS
CN Cyclobutenediylium, 1-[[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-2H-indol-2-ylidene]methyl]-3-[[1-[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]methyl]-2,4-dimeraptor-, bis(inner salt), dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

IT 325143-27-9P 325143-28-0P
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(dye; production of acylsulfonamido-substituted polymethine fluorescent dye markers for biomols.)
RN 325143-27-9 CAPLUS
CN Cyclobutenediylium, 1-[[1-(5-carboxypentyl)-1,3-dihydro-3,3-dimethyl-2H-indol-2-ylidene]methyl]-3-[[1,3-dihydro-3,3-dimethyl-1-[2-

[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-2H-indol-2-ylidene]methyl]-2,4-dihydroxy-, bis(inner salt), monopotassium salt (9CI) (CA INDEX NAME)

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 324745-43-9 CAPLUS
CN 1-Butanaminium, N,N,N-tributyl-, 2,3-dihydro-2-[(2-hydroxy-3,4-dioxo-1-cyclobuten-1-yl)methylene]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-1H-indole-5-sulfonate (1:1) (CA INDEX NAME)

CM 3

CRN 324745-42-8
CMF C18 H17 N2 O9 S2

CM 2

CRN 10549-76-5
CMF C16 H36 N

n-Bu
|
n-Bu—N+—n-Bu
|
n-Bu

L19 ANSWER 44 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● 2

RN 325143-28-0 CAPLUS
CN Cyclobutenediylium, 1-[[1-(5-carboxypentyl)-1,3-dihydro-3,3-dimethyl-5-sulfo-2H-indol-2-ylidene]methyl]-3-[[1,3-dihydro-3,3-dimethyl-1-[2-

[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-2H-indol-2-ylidene]methyl]-2,4-dihydroxy-, bis(inner salt), disodium salt (9CI) (CA INDEX NAME)



● 2 Na

IT 324745-40-6P 324745-43-9P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; production of acylsulfonamido-substituted polymethine fluorescent dye markers for biomols.)
RN 324745-40-6 CAPLUS
CN 3H-Indolium, 2,3,3-trimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-, inner salt (CA INDEX NAME)

L19 ANSWER 45 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:83653 CAPLUS
DOCUMENT NUMBER: 134:311175
TITLE: Bioisosteres of 9-Carboxymethyl-4-oxo-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent In Vivo AMPA antagonists with longer durations of action
AUTHOR(S): Jimonet, P.; Bohme, G. A.; Bouguerel, J.; Boireau, A.; Damour, D.; Debono, M. W.; Genevois-Borella, A.; Hardy, J.-C.; Hubert, P.; Manfre, F.; Remeuck, P.; Pratt, J.; Randle, J. C. R.; Ribeill, Y.; Stutzmann, J.-M.; Vilbergre, M.; Wagnani, S.
CORPORATE SOURCE: Centre de Recherche de Vitry-Alfortville, Aventis Pharma S.A., Vitry-sur-Seine, F94403, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(2), 127-132
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:311175
GI

AB A novel series of 2- and 9-disubstituted heterocyclic-fused 4-oxo-indeno[1,2-e]pyrazin derivs. was synthesized. One of them, the 9-(1H-tetrazol-5-ylmethyl)-4-oxo-5,10-dihydroindeno[1,2-a]indeno[1,2-e]pyrazin-2-ylphosphonic acid (I) exhibited a strong and a selective binding affinity for the AMPA receptor (IC50=17 nM) and demonstrated potent antagonist activity (IC50=6 nM) at the ionotropic AMPA receptor. This compound also displayed good anticonvulsant properties against electr.-induced convulsions after i.p. and iv administration with ED50 values between 0.8 and 1 mg/kg. Furthermore, a strong increase in potency was observed when given iv 3 h before test (ED50=3.5 instead of 25 mg/kg for the corresponding 9-carboxymethyl-2-carboxylic acid analog). These data confirmed that there is an advantage in replacing the classical carboxy substituent by their bioisosteres such as tetrazole or phosphonic acid groups. The tetrazol-5-ylmethyl-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-yl phosphonic acid (I) exhibited potent and selective binding affinity for the AMPA receptor (IC50=17 nM). It also demonstrated a good anticonvulsant effect in MES test with ED50 values between 0.8 and 1 mg/kg

L19 ANSWER 45 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
i.p. or iv) and a long duration of action followed iv administration.
IT 193813-67-1P 333194-54-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of bioisosteres of 9-carboxymethyl-4-oxoimidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivs. as potent In Vivo AMPA
antagonists with longer durations of action)
RN 193813-67-1 CAPLUS
CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-4-oxo-9-[2-oxo-2-[(phenylsulfonyl)amino]ethyl]- (CA INDEX NAME)



RN 333194-54-2 CAPLUS
CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-9-[2-[(methylsulfonyl)amino]-2-oxoethyl]-4-oxo-, sodium salt (1:1) (CA INDEX NAME)



● Na

IT 193814-14-1P 193814-20-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bioisosteres of 9-carboxymethyl-4-oxoimidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivs. as potent In Vivo AMPA

L19 ANSWER 46 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:10474 CAPLUS
DOCUMENT NUMBER: 134:78685
TITLE: Heat-sensitive imaging element with cover layer for providing a lithographic printing plate
INVENTOR(S): Vermeersch, Joany Van Damme, Marc
PATENT ASSIGNEE(S): Agfa-Gevaert N.V., Belg.
SOURCE: Eur. Pat. Appl., 9 pp.
CODEN: EPXXLW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1045049	A1	20001018	EP 2000-201854	20000524
EP 1045049	B1	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6503894	B1	20030107	US 2000-584490	20000601
JP 2001239647	A	20010213	JP 2000-192384	20000627
PRIORITY APPLN. INFO.:			EP 1999-202108 A	19990629
			US 1999-1436649 P	19991714

AB The invention relates to heat-sensitive material for preparing lithog. plates. The invention provides a heat-sensitive material for making lithog. printing plates comprising on a lithog. support an image-forming layer comprising a hydrophilic binder a crosslinking agent for a hydrophilic binder and dispersed hydrophobic thermoplastic polymer particles, characterized in that the said image-forming layer is covered with a layer comprising at least one organic compound comprising cationic groups.
IT 251640-76-3
RL: DEV (Device component use); NUU (Other use, unclassified); TEM (Technical or engineered material use); USES (Uses)
(heat-sensitive imaging element with cover layer for providing lithog. printing plate coated with IR-sensitive layer containing)
RN 251640-76-3 CAPLUS
CN 3H-Indolium, 2-[2-[2-chloro-3-[2-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-2H-indol-2-ylidene]ethylidene]-1-cyclopenten-1-yl]ethenyl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-, inner salt, potassium salt (1:1) (CA INDEX NAME)

L19 ANSWER 45 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
antagonists with longer durations of action)
RN 193814-14-1 CAPLUS
CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-4-oxo-9-[2-oxo-2-[(phenylsulfonyl)amino]ethyl]-, ethyl ester (CA INDEX NAME)



RN 193814-20-9 CAPLUS
CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-9-[2-[(methylsulfonyl)amino]-2-oxoethyl]-4-oxo-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 46 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

● K

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 47 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:666600 CAPLUS
DOCUMENT NUMBER: 133:247292
TITLE: Amyotropic lateral sclerosis treatment with a combination of riluzole and an AMPA receptor antagonist
INVENTOR(S): Bohme, Andrees; Boireau, Alain; Canton, Thierry; Pratt, Jeremy; Stutzmann, Jean-Marie
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000054772	A1	20000921	WO 2000-FR590		20000310
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
FR 2790670	A1	20000915	FR 1999-3100		19990312
EP 1161238	A1	20011212	EP 2000-910920		20000310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002539162	T	20021119	JP 2000-604848		20000310
PRIORITY APPLN. INFO.:			FR 1999-3100	A	19990312
			US 1999-129318P	P	19990414
			WO 2000-FR590	W	20000310

OTHER SOURCE(S): MARPAT 133:247292
AB The invention discloses the prevention and/or treatment of amyotropic lateral sclerosis with a combination of riluzole and one or several AMPA receptor antagonists, as well as combinations of these compds. and pharmaceutical compns. containing them.
IT 193813-67-1 294841-73-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(riluzole-AMPA receptor antagonist combination for treatment of amyotropic lateral sclerosis)
RN 193813-67-1 CAPLUS
CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-4-oxo-9-[2-oxo-2-[(phenylsulfonyl)amino]ethyl]- (CA INDEX NAME)

L19 ANSWER 47 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 294841-73-9 CAPLUS
CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-9-[2-[(methylsulfonyl)amino]-2-oxoethyl]-4-oxo- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 48 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:457018 CAPLUS
DOCUMENT NUMBER: 133:89793
TITLE: Preparation of 4-(4-hydroxyphenoxy)phenylacetyl amino acids and related compounds as novel thyroid receptor ligands
INVENTOR(S): Hangeland, Jon; Zhang, Minsheng; Caringal, Yolanda; Ryono, Denis; Li, Yi-lin; Malm, Johan; Liu, Ye; Garg, Neeraj; Litten, Chris; Garcia Collazo, Ana Maria; Koehler, Konrad
PATENT ASSIGNEE(S): Karo Bio AB, Swed.; et al.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000039077	A2	20000706	WO 1999-IB2084		19991223
WO 2000039077	A3	20000921			
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2356319	A1	20000706	CA 1999-2356319		19991223
BR 9916851	A	20011016	BR 1999-16851		19991223
EP 1144370	A2	20011017	EP 1999-962486		19991223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
TR 200101834	T2	20011221	TR 2001-1834		19991223
HU 2001004666	A2	20020328	HU 2001-4666		19991223
HU 2001004666	A3	20030528			
JP 2002533432	T	20021008	JP 2000-590990		19991223
AU 758202	B2	20030320	AU 2000-18855		19991223
NZ 512422	A	20040227	NZ 1999-512422		19991223
CN 1186332	C	20050126	CN 1999-815057		19991223
NO 2001002931	A	20010821	NO 2001-2931		20010613
ZA 2001004932	A	20030115	ZA 2001-4932		20010615
MX 2001006482	A	20010910	MX 2001-6482		20010622
IN 2001KN00754	A	20050311	IN 2001-KN754		20010720
US 6989402	B1	20060124	US 2001-868889		20010914
US 20050282872	A1	20051222	US 2005-189654		20050726
US 7288571	B2	20071030			
PRIORITY APPLN. INFO.:			GB 1998-28442	A	19981224
			WO 1999-IB2084	W	19991223
			US 2001-868889	A3	20010914

OTHER SOURCE(S): MARPAT 133:89793
GI

L19 ANSWER 48 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I

AB Title compds. I [R1 = halo, trifluoromethyl, alkyl, cycloalkyl; R2, R3 = H, halo, alkyl, at least one of R2 and R3 being other than H; n = 0-4; R4 is an (un)substituted heteroarom. moiety linked to (CH2)n via a nitrogen or carbon atom; an amine, including those in which the amine is derived from an alpha amino acid of either L- or D-stereochem., an acylsulfonamide, or a carboxylic acid amide, with the proviso that when n = 0, then R4 can only be a carboxylic acid amide or an acylsulfonamide; R5 is H or an acyl or other group capable of bioconversion to generate the free phenol structure] were prepared for use in the treatment of diseases associated with metabolism dysfunction or which are dependent on the expression of a T3 regulated gene (such as obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer, glaucoma, cardiac arrhythmia, and congestive heart failure). Thus, coupling of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid with D-methionine Me ester hydrochloride followed by hydrolysis afforded N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]-D-methionine.
IT 280777-90-4P 280777-91-5P 280777-92-6P 280777-93-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hydroxyphenoxy)phenylacetyl amino acids and related compds. as novel thyroid receptor ligands)
RN 280777-90-4 CAPLUS
CN Benzeneacetamide, 3,5-dibromo-N-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-4-[4-hydroxy-3-(1-methylethyl)phenoxy]- (CA INDEX NAME)

L19 ANSWER 48 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 280777-91-5 CAPLUS
CN Benzeneacetamide, N-[[4-aminophenyl]sulfonyl]-3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]- (CA INDEX NAME)



L19 ANSWER 49 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:603173 CAPLUS
DOCUMENT NUMBER: 133:51111
TITLE: Silver halide color photographic material
INVENTOR(S): Morimoto, Kiyoshi; Hioki, Takanori; Yabuki, Yoshiharu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000162729	A	20000616	JP 1998-285898	19981008
PRIORITY APPLN. INFO.:			JP 1998-285898	A 19981008

OTHER SOURCE(S): MARPAT 133:51111
GI



AB The title photog. material possesses a hydrophilic colloid layer containing
R1 compound I [R1, R2 = alkyl, aralkyl, unsatd. hydrocarbon; L1-3 = methine; M1 = counter ion; m1 ≥ 0]. and a1 dye A-CHQ [A = azindic nucleus; Q = aryl or aromatic heterocycle]. The material shows low
residual sensitizing dye stain and high sensitivity.
IT 279370-88-3
RL: DEV (Device component use); USES (Uses)
(photog. paper containing cyanine dye sensitizer and dye)
RN 279370-88-3 CAPLUS
CN Benzoxazolium, 5-fluoro-2-[2-[[5-fluoro-2-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzoxazolylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 48 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 280777-92-6 CAPLUS
CN Benzeneacetamide, N-[[5-[(benzoylamino)methyl]-2-thienyl]sulfonyl]-3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]- (CA INDEX NAME)



RN 280777-93-7 CAPLUS
CN Benzeneacetamide, N-[[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl]-3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 49 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L19 ANSWER 50 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:198391 CAPLUS
DOCUMENT NUMBER: 132:207842
TITLE: Preparation of [[benzisoxazolyloxy]alkyl]thio- or -oxy]benzenealkanoates as antidiabetic agents
INVENTOR(S): Berger, Gregory D.; Santini, Conrad; Patchett, Arthur; Tsegaye, Richard B.; Fitch, Kenneth; Walsh, Thomas F.; Tolman, Richard L.; Sahoo, Soumya P.; Adams, Alan; Von Lagen, Dereki Jonas, Anthony R.; Graham, Donald W.; Leibowitz, Mark; Moller, David E.; Berger, David P.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U. African, 201 pp.
CODEN: SFXAAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 9709824	A	19981030	ZA 1997-824	19970131
PRIORITY APPLN. INFO.:			US 1996-112809P	P 19960202

OTHER SOURCE(S): MARPAT 132:207842
GI

AB Title compds. [I; R = R1X1Q?1; Q = (saturated) hydrocarbylene; R1 = H, (un)substituted alk(en)yl, -alkynyl; R2 = RSCHAR7, RSCHCR, RSCHAR7E2; R3R4 = atoms to complete an (un)substituted ring containing 2 heteroatoms; R5 = CO2R, alkoxycarbonyl, CONR2, tetrazolyl, etc.; R6,R7 = H or alkyl; Y = O, SOO-2, CR6, CO, NR, etc.; Y1 = O or C (sic); X2 = H, halo, alkyl, alkoxy, etc.; X1 = (un)substituted 1,3- or 1,4-phenylene; Z2 = CHR7, O, SOO-2, (alkyl)imino] were prepared Thus, 2,3-dihydroxy-3-propylpropiophenone was etherified by Br(CH2)3Br and the product thioetherified by MeOCOCH2COMe2 (X1 = 3-chloro-1,4-phenylene) to give, an 4 addnl. steps, title compound II. Data for biol. activity of I were given.

L19 ANSWER 51 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:137472 CAPLUS
DOCUMENT NUMBER: 132:187581
TITLE: New sensitizer and silver halide photographic material containing the sane
INVENTOR(S): Hioki, Takanori; Morimoto, Kiyoshi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000043389	A	20000229	JP 1998-240635	19980826
US 6365335	B1	20020402	US 1999-373584	19990813
PRIORITY APPLN. INFO.:			JP 1998-240635	A 19980826

OTHER SOURCE(S): MARPAT 132:187581
GI

AB The photog. material contains the new sensitizer represented by general formula I [X1 = O, S, Se, Te, C, N; Q = groups for forming methine dye; Mn = counter ion; Yp = F, Cl, etc.; p = 0-4; R1 = (La)1CONHSO2L1, (Lb)kSO2NHCOL1, (Lc)kSCONHCOL1, (Ld)kSO2NHSO2L4; R11-14 = alkyl, aryl, heterocycle, alkoxy, aryloxy, heterocyclyoxy, amino; La, Lb, Lc, Ld = methylene; k1, k2, k3, k4 = 1-10). The photog. material contains Ag halide grains with an average aspect ratio of 3-1,000. The photog. material shows excellent sensitivity and reduced color residue.
IT 259657-52-8
RL: DEV (Device component use); USES (Uses)
(new methine sensitizers for Ag halide photog. material with excellent sensitivity and reduced color residue)
RN 259657-52-8 CAPLUS
CN Benzothiazolium, 5-fluoro-2-[(5-fluoro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene)methyl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 50 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT 194990-61-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [[benzisoxazolyloxy]alkyl]thio- or -oxy]benzenealkanoates as antidiabetic agents)
RN 194990-61-1 CAPLUS
CN Benzeneacetamide, 3-chloro-4-[[3-[[3-ethyl-7-propyl-1,2-benzisoxazol-6-yl]oxy]propyl]thio]-N-(methylsulfonyl)- (CA INDEX NAME)



L19 ANSWER 51 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 259657-58-4P
RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(new methine sensitizer for Ag halide photog. material with excellent sensitivity and reduced color residue)
RN 259657-58-4 CAPLUS
CN Benzothiazolium, 5-fluoro-2-[2-[(5-fluoro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene)methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



IT 259657-66-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of new methine sensitizer for Ag halide photog. material with excellent sensitivity and reduced color residue)
RN 259657-66-4 CAPLUS
CN Benzothiazolium, 5-fluoro-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

L19 ANSWER 51 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L19 ANSWER 52 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000-117742 CAPLUS
DOCUMENT NUMBER: 132:187674
TITLE: Heat-mode lithographic original plate with improved storage stability
INVENTOR(S): Van Roogpy, Ludy; Meisters, August; Loenders, Luc
PATENT ASSIGNEE(S): AGFA Gevaert N.V., Belg.
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXLAP

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000061239	A	20000229	JP 1999-240226	19990714
PRIORITY APPLN. INFO.:			EP 1998-202382	A 19980716

AB A negative-working non-ablative image-forming material, suited for use in production of a lithog. printing master, comprises a metallic support coated with a layer or a stack of layers which contains a near IR ray-absorbing compound and other reactive compds. in an amount of ≥50 and ≤20 weight%, resp., to all the compds. present in the layer or stack and the near IR ray-absorbing compound is an organic compound or C-based compound. The image-forming material is imagewise exposed to near IR ray followed by wiping the layer with water, if necessary, to give a lithog. printing master. The material shows good storage stability is useful in production of a lithog. printing master by computer-to-plate, computer-to-press or on-press coating process.

IT 192220-92-1
RL: DEV (Device component use); USES (Uses)
(heat-mode lithog. plate containing IR absorbing compound)

RN 192220-92-1 CAPLUS
CN 1H-Benz[e]indolium, 2-[2-[2-chloro-3-[2-(1,3-dihydro-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benz[e]indol-2-ylidene)ethylidene]-1-cyclohexen-1-yl]ethenyl]-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 52 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 53 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:144624 CAPLUS
DOCUMENT NUMBER: 132:141951
TITLE: Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
INVENTOR(S): Bocan, Thomas Michael Andrew
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004892	A2	20000203	WO 1999-US13948	19990618
WO 2000004892	A3	20000518		
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UG, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335062	A1	20000203	CA 1999-2335062	19990618
AU 9947017	A	20000214	AU 1999-47017	19990618
BR 9912296	A	20010417	BR 1999-12296	19990618
EP 1096662	A2	20010516	EP 1999-930483	19990618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 2001000205	T2	20010521	TR 2001-205	19990618
EE 200100046	A	20020617	EE 2001-46	19990618
NO 2001002880	A2	20020629	NO 2001-2880	19990618
NO 2001002880	A3	20021128		
JP 2002521328	T	20020716	JP 2000-560885	19990618
IN 2001MN00019	A	20050401	IN 2001-MN19	20010104
ZA 2001000294	A	20020110	ZA 2001-294	20010110
BG 105162	A	20011231	BG 2001-105162	20010117
NO 2001000291	A	20010316	NO 2001-291	20010118
HR 2001000055	A1	20020430	HR 2001-55	20010119
MX 2001000760	A	20010521	MX 2001-760	20010122
IN 2001MN00455	A	20050318	IN 2001-MN455	20010424
PRIORITY APPLN. INFO.:			US 1998-93639P	P 19980721
			WO 1999-US13948	W 19990618

AB Acyl-CoA:cholesterol acyltransferase (ACAT) and matrix metalloproteinase (MMP) inhibitors are coadministered for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal. The direct antiatherosclerotic potential of the combination of ACAT inhibitor, [[2,4,6-tris-(1-methylphenyl)acetyl]-2,6-bis(1-methylethyl)phenyl sulfamic acid, and the HMG-CoA reductase inhibitor, simvastatin, in rabbits was studied. A tablet contained

L19 ANSWER 53 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
2-(4'-bromobiphenyl-4-sulfonylamino)-3-Me butyric acid 25 ACAT compd. lactose 50, corn starch 20, and magnesium stearate 5 mg.
IT 166518-64-5 176423-68-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing ACAT and MMP inhibitors for treatment of atherosclerotic lesions)
RN 166518-64-5 CAPLUS
CN Benzenemethanamine, 2,6-bis[1-methylethyl]-N-[[2,4,6-tris[1-methylethyl]phenyl]methyl]sulfonyl]- (CA INDEX NAME)



RN 176423-68-4 CAPLUS
CN Benzenemethanamine, 2,6-bis[1-methylethyl]-N-[[2,4,6-tris[1-methylethyl]phenyl]methyl]sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 54 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● K

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 54 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:767708 CAPLUS
DOCUMENT NUMBER: 132:17363
TITLE: Heat-sensitive imaging element for lithographic plate preparation
INVENTOR(S): Van Damme, Marc; Van Aert, Huub; Vermeersch, Joan
PATENT ASSIGNEE(S): Agfa-Gevaert N.V., Belg.
SOURCE: Eur. Pat. Appl., 15 pp.
CODEN: EPXLDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 960729	A1	19991201	EP 1999-200946	19990318
EP 960729	B1	20070523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6096471	A	20000801	US 1999-268656	19990729
JP 2000052649	A	20000222	JP 1999-137266	19990518
PRIORITY APPLN. INFO.:			EP 1998-201727	A 19980515
			US 1998-92557P	P 19980713

AB A heat-sensitive imaging element for lithog. plate preparation comprises a support and an image-forming layer comprising a hardened hydrophilic binder, a heat-switchable polymer, and a compound capable of converting light into heat, characterized in that the heat-switchable polymer is a polymer containing aryldiazosulfonate units.
IT 251640-76-3
RL: TEM (Technical or engineered material use); USES (Uses)
(heat-sensitive imaging elements for lithog. plate preparation containing aryldiazosulfonate group-containing polymers and)
RN 251640-76-3 CAPLUS
CN 3H-Indolium, 2-[2-[2-chloro-3-[2-[1,3-dihydro-3,3-dimethyl-1-[2-[[methylsulfonyl]amino]-2-oxoethyl]-5-sulfo-, inner salt, potassium salt (1:1) (CA INDEX NAME)

L19 ANSWER 55 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:487259 CAPLUS
DOCUMENT NUMBER: 131:130145
TITLE: Diterpene derivatives and anti-inflammatory analgesic agents comprising the same
INVENTOR(S): Suh, Young Ger; Choi, Young Hoon; Lee, Hye Kyung; Kim,
Young Ho; Park, Hyoung Sup
PATENT ASSIGNEE(S): Sam Han Pharm. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937620	A1	19990729	WO 1999-KR38	19990125
W: AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9921876	A	19990809	AU 1999-21876	19990125
EP 1056710	A1	20001206	EP 1999-901969	19990125
EP 1056710	B1	20031210		
R: CH, DE, ES, FR, GB, IT, LI				
JP 2002502271	T	20020122	JP 2000-528526	19990125
ES 2211030	T3	20040701	ES 1999-901969	19990125
CN 1171846	C	20041020	CN 1999-802428	19990125
US 6593362	B1	20030715	US 2000-600774	20000915
PRIORITY APPLN. INFO.:			KR 1998-2441	A 19980126
			WO 1999-KR38	W 19990125
OTHER SOURCE(S):	MARPAT 131:130145			
GI				



AB Title compds. I [R1, R2 = H, OH; or R1R2 = part of a ring; R3 = hydroxyethyl, methoxyethyl, acetoxyethyl, methoxymethoxyethyl,

L19 ANSWER 55 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
methoxyethoxymethoxyethyl, methoxyiminoethyl, isoxazolinyl; R4 = CH2OH, CH2COOH, carboxyvinyl, carboxyethyl, etc.] are prepd. as antiinflammatories. Thus, (-)-pimara-9(11),15-diene-4-carboxylic acid was
reduced with LiAlH4 to give 4-(hydroxymethyl)-(-)-pimara-9(11),15-diene. In an in vitro study, this had an IC50 of >2000 μM against PGE2 synthesis. Antiinflammatory compns. contg. I are described.

IT 233750-12-4P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antiinflammatory diterpene derivs.)

RN 233750-12-4 CAPLUS

CN 1-Phenanthreneacetamide, 7-ethenyl-1,2,3,4,4a,6,7,8,8a,9,10,10a-dodecahydro-N-[(4-iodophenyl)sulfonyl]-1,4a,7-trimethyl-, (1S,4aR,7S,8aS,10aR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L19 ANSWER 56 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:735409 CAPLUS
DOCUMENT NUMBER: 130:45211
TITLE: Silver halide photographic material containing benzoazolyl polymethine dye to improve storage stability
INVENTOR(S): Nakamura, Masaki; Kagawa, Nobuaki
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 50 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10301222	A	19981113	JP 1997-108894	19970425
JP 3557848	B2	20040825		
PRIORITY APPLN. INFO.:			JP 1997-108894	19970425

GI



I

AB The photog. material contains a benzoazolyl methine dye represented by the
formula I (Z = O, NR6, C:N, S, Se, Te; R1-4 = H, substituent; ≥1 of R1-4 = CR7mX(3-m); X = halo, cyano; R5-7 = H, alkyl, alkenyl, aryl; R7 ≠ aralkyl; D = nonmetallic atomic group to form methine dye; K = counter ion, n = the number for charge balance; m = 0-2) in ≥1 photog. emulsion layer. The dye I is a spectral sensitizer having antifogging property in addition to spectral sensitization. It also extends the storage
life of the photog. material, and is suitably used for both color and black-and-white materials.

IT 216866-21-6
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(silver halide photog. material containing benzoazolyl polymethine dye spectral sensitizer to improve storage stability)

RN 216866-21-6 CAPLUS

CN Benzoxazolium, 2-[3-[5-(chloromethyl)-6-[(methylamino)carbonyl]-3-[2-
[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]-1-butenyl]-

L19 ANSWER 56 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
3-(3-sulfopropyl)-6-(trifluoromethyl)-, inner salt, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216866-20-5
CMF C28 H28 Cl F3 N4 O8 S3



CM 2

CRN 121-44-8
CMF C6 H15 N

L19 ANSWER 57 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:627423 CAPLUS
DOCUMENT NUMBER: 129:323832
ORIGINAL REFERENCE NO.: 129:65901a,65904a
TITLE: Photographic film containing monomethine cyanine and providing low-fog image by rapid development
INVENTOR(S): Ooya, Toyotaka
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10254084	A	19980925	JP 1997-58150	19970312
PRIORITY APPLN. INFO.:			JP 1997-58150	19970312

OTHER SOURCE(S): MARPAT 129:323832
GI



AB The film contains ≥1 cyanine dye I (Z1 = naphthothiazole ring; Z2 = 5-membered heterocycle; V1 = CN; R1, R2 = alkyl; L1 = methine; X1 = counter ion; n1 = pos. number for electronic neutralization) and optional II
(Z11, Z12 = 5-membered heteroazacycle). The film provides clear images without color stains.

IT 214635-47-9
RL: MOA (Modifier or additive use); USES (Uses)
(sensitizer; photog. film containing monomethine cyanine and providing low-fog image even by rapid development)

RN 214635-47-9 CAPLUS

CN Naphtho[1,2-d]thiazolium, 2-[[6-chloro-5-cyano-3-[2-
[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]methyl]-1-(3-sulfopropyl)-, inner salt (CA INDEX NAME)

L19 ANSWER 57 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 58 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:251354 CAPLUS
DOCUMENT NUMBER: 129:10582
ORIGINAL REFERENCE NO.: 129:2207a,2210a
TITLE: Silver halide photographic materials using sensitizing dye
INVENTOR(S): Oya, Toyohisa
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10104775	A	19980424	JP 1996-259415	19960930
PRIORITY APPLN. INFO.:			JP 1996-259415	19960930

AB Title materials contain ≥1 compound B(X1A)2 (B) = atoms forming a methine dye structure; A = group released by nucleophilic attack) x1 = 1, 2; x2 = 1-4). The materials show high spectral sensitivity and high-quality images can be formed on it with low residual color stain.

IT 207574-15-0
RL: DEV (Device component use); USES (Uses)
(methine sensitizing dye for silver halide photog. material)

RN 207574-15-0 CAPLUS
CN Benzothiazolium, 5-[(1,4-dioxopentyl)oxy]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-[3-[3-[2-sulfoethyl]-2(3H)-benzothiazolylidene]-1-propen-1-yl]-, inner salt (CA INDEX NAME)



L19 ANSWER 59 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:176447 CAPLUS
DOCUMENT NUMBER: 128:302054
ORIGINAL REFERENCE NO.: 128:59779a,59720a
TITLE: Silver halide photographic material
INVENTOR(S): Suga, Yoichi; Taniguchi, Makoto
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 70 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10073898	A	19980317	JP 1996-246931	19960830
JP 3579385	B2	20041020		
US 6010842	A	20000104	US 1997-921359	19970829
PRIORITY APPLN. INFO.:			JP 1996-246931	A 19960830

GI

AB Title material comprises a support having ≥1 Ag halide emulsion layer containing an urea derivative R1R2NCONR3G1 (R1-3 = H, alkyl, aryl) and a sensitizing dye I [R = QarCOPBO2Ra, QarSO2NCORb, QarCONCORc, QarSO2NSO2Rd; Ra-Rd = alkyl, heterocyclyl, alkoxy, arylaxy, amino; Qa-Qd = methylene; e, s, t, u = 3-10; L1, L2 = methine; p1 = 0 or 1; Z1 = atoms required to form a 5 or 6-membered N-containing heterocycl; M1 = counter ion; m1 = 0-10;

Q = heterocyclic group- or aromatic group-substituted methine or polymethine]. The material shows high sensitivity and storage stability.

IT 148350-04-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(in preparation of sensitizing dye for high-d. and storage-stable silver halide photog. emulsion containing urea derivative)

RN 148350-04-3 CAPLUS
CN Benzothiazolium, 5-chloro-3-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

L19 ANSWER 59 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● Br⁻

IT 173307-54-5
RL: DEV (Device component use); USES (Uses)
(silver halide photog. emulsion containing urea derivative and sensitizing dye for high d. and storage stability)

RN 173307-54-5 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-(2-[(methylsulfonyl)amino]-2-oxoethyl)- (CA INDEX NAME)



L19 ANSWER 60 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:154920 CAPLUS
DOCUMENT NUMBER: 128:262877
ORIGINAL REFERENCE NO.: 128:52105a,52106a
TITLE: Silver halide photographic material using polymethine sensitizing dye
INVENTOR(S): Fujiwara, Nobuaki; Kita, Noriyasu; Nakamura, Masaki; Ishii, Fumio
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 62 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10061989	A	19980306	JP 1996-217245	19960819
JP 3470384	B2	20031028		
PRIORITY APPLN. INFO.:			JP 1996-217245	19960819

AB The title material contains a Ag halide emulsion layer spectrally sensitized with a polymethine dye in which the methine chains are replaced by ≥1 P and the aliphatic groups substituted on the N atom in the above rings are linked by ≥3 methine groups having ≥1 water-soluble group. The material shows good storage stability, low residual color stain, and improved photog. properties.
IT 205172-92-5 205172-99-2
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. emulsion sensitized with polymethine dye)
RN 205172-92-5 CAPLUS
CN Quinolinium,
4-[1-fluoro-3-methyl-5-[6-methyl-3-[2-[[methylsulfonyl]amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]-1,3-pentadien-1-yl]-6-methyl-1-[2-[[methylsulfonyl]amino]-2-oxoethyl]-, chloride (1:1) (CA INDEX NAME)



L19 ANSWER 60 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 205172-99-2 CAPLUS
CN Benzothiazolium, 2-[[3-[3-[6,6-dimethyl-2(3H)-benzothiazolylidene]-7-fluoro-1-propen-3-yl]-2-fluoro-5-methyl-2-cyclohexen-1-ylidene]fluoromethyl]-5-methoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, chloride (1:1) (CA INDEX NAME)



L19 ANSWER 61 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:167054 CAPLUS
DOCUMENT NUMBER: 128:161042
ORIGINAL REFERENCE NO.: 128:31579a,31580a
TITLE: Photothermographic recording material comprising sensitizing dye
INVENTOR(S): Deroover, Geert; Hoogmartens, Ivan; Strijckers, Hans
PATENT ASSIGNEE(S): Agfa-Gevaert N.V., Belg.
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXLDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 821266	A1	19980128	EP 1997-203906	19970623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 5876915	A	19990302	US 1997-889481	19970708
JP 10073900	A	19980317	JP 1997-211407	19970722
JP 3794793	B2	20060712		
PRIORITY APPLN. INFO.:			EP 1996-202108	A 19960724

OTHER SOURCE(S): MARPAT 128:161042
GI



AB A photothermog. recording material comprises a support and a photoadd.exasible thermally developable element comprising a substantially light-insensitive organic silver salt, a reducing agent therefor an thermal
working relationship therewith, a photosensitive silver halide spectrally sensitized with a dye and in catalytic association with the substantially light-insensitive organic silver salt, and a binder. The dye has the general
formula I where, X1, X2 = S, O, or Se; R1, R13 = alkylene; X1, X2 = (CO)R18, (SO2)R19, or (SO)R20 where R18, R19, and R20 = alkoxy, aryloxy, amino, or substituted amino; R2-5, R14-17 = H, Cl, Br, F, I, keto, sulfo, carboxy, ester, sulfonamido, amido, dialkylamino, nitro, cyano, alkyl, alkenyl, heteroarom., aryl, alkoxy, or aryloxy which may be substituted; R2 and R3, R3 and R4, R4 and R5, R14 and R15, R15 and R16, or R16 and R17 together may constitute the atoms necessary to complete a benzene ring which may be substituted; R6-12 = H, Cl, Br, F, I, alkyl, alkoxy, aryloxy, thioalkyl, or disubstituted amino, where the substituents may constitute the atoms necessary to complete a 5- or 6-membered heterocyclic ring; R6

L19 ANSWER 61 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
and R8, R8 and R10, R10 and R11, R7 and R9, or R9 and R11 together may constitute the atoms necessary to complete a 5- or 6-membered carbocyclic or heterocyclic ring which may be substituted; R1 and R6 or R13 and R12 may constitute the atoms necessary to complete a 5- or 6-membered heterocyclic ring which may be substituted.
IT 202658-86-4
RL: TEM (Technical or engineered material use); USES (Uses)
(sensitizer for photothermog. recording materials)
RN 202658-86-4 CAPLUS
CN Benzothiazolium, 2-[2-[5,5-bis(ethoxycarbonyl)-3-[[5-methoxy-3-[2-[[methylsulfonyl]amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]ethylidene]-1-cyclohexen-1-yl]ethenyl]-5-methoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 202658-85-3
CMF C38 H42 N4 O12 S4



CM 2

CRN 121-44-8
CMF C6 H15 N

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 62 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:752399 CAPLUS
DOCUMENT NUMBER: 128:68436
ORIGINAL REFERENCE NO.: 128:13255a,13258a
TITLE: Imidazole derivative and silver halide photographic material spectrally sensitized with the compound
INVENTOR(S): Kita, Noriyasu; Kapawa, Nobuaki
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 65 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09291220	A	19971111	JP 1996-106936	19960426
JP 3791245	B2	20060628	JP 1996-106936	19960426

PRIORITY APPLN. INFO.:

GI



AB The imidazole derivative is shown as I [R1 = aliphatic; A = group to form merocyanine dye via conjugated chain; V1, V2 = H, substituent; V1 and V2 may form condensed ring; or II [R1, A, V1, V2 = same as above; X = counter ion; l1 = number to neutralize intermol. charge). A Ag halide photog. material is spectrally sensitized with I and/or II. Fogging is minimized.

IT 200189-09-9 200189-22-6 200189-43-1
200189-46-2
RL: TEM (Technical or engineered material use); USES (Uses)
(imidazole derivative and Ag halide photog. material spectrally sensitized with the compound)

RN 200189-09-9 CAPLUS
CN Benzothiazolium, 2-[3-[1-ethenyl-1,3-dihydro-5-[4-(morpholinylsulfonyl)-3-[4-sulfobutyl]-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-(trifluoromethyl)-, inner salt (CA INDEX NAME)

L19 ANSWER 62 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● I⁻

RN 200189-46-2 CAPLUS
CN 2H-Benzimidazolium, 1-[carboxymethyl]-2-[[3-[carboxymethyl]-5-[2-[1-ethenyl-1,3-dihydro-5,6-dimethoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-2-methoxyethylidene]-4-oxo-2-thiazolidinylidene]methyl]-5-chloro-3-ethenyl-6-(trifluoromethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L19 ANSWER 62 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 200189-22-6 CAPLUS
CN Benzazolium, 2-[5-[5-chloro-3-ethenyl-1,3-dihydro-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-6-(trifluoromethyl)-2H-benzimidazol-2-ylidene]-1,3-pentadien-1-yl]-5-phenyl-3-(3-sulfopropyl)-, inner salt (CA INDEX NAME)

RN 200189-43-1 CAPLUS
CN Benzothiazolium, 2-[3-[3-[[5-chloro-6-cyano-1-ethenyl-1,3-dihydro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]methyl]-5,5-dimethyl-2-cyclohexen-1-ylidene]-1-propen-1-yl]-3-ethyl-6-methoxy-5-methyl-, iodide (1:1) (CA INDEX NAME)

L19 ANSWER 62 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● I⁻

RN 200189-46-2 CAPLUS
CN 2H-Benzimidazolium, 1-[carboxymethyl]-2-[[3-[carboxymethyl]-5-[2-[1-ethenyl-1,3-dihydro-5,6-dimethoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-2-methoxyethylidene]-4-oxo-2-thiazolidinylidene]methyl]-5-chloro-3-ethenyl-6-(trifluoromethyl)- (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L19 ANSWER 63 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:569195 CAPLUS
DOCUMENT NUMBER: 127:176439
ORIGINAL REFERENCE NO.: 127:34187a,34190a
TITLE: 5H,10H-Imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one derivatives, useful as AMPA and NMDA receptor antagonists, their preparation and intermediates, and drugs containing them
INVENTOR(S): Alcup, Jean-Claude; Bouquerel, Jean; Danoux, Dominique; Hardy, Jean-claude; Junonet, Patrick; Manfre, Marco; Mignani, Serge; Nemecek, Patrick
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Fr.; Alcup, Jean-Claude; Bouquerel, Jean; Danoux, Dominique; Hardy, Jean-Claude; Junonet, Patrick; Manfre, Marco; Mignani, Serge; Nemecek, Patrick
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725328	A1	19970717	WO 1997-FR19	19970106
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2743366	A1	19970711	FR 1996-192	19960110
FR 2743366	B1	19980206		
CA 2229254	A1	19970717	CA 1997-2229254	19970106
ZA 9700086	A	19970717	ZA 1997-86	19970106
AU 9713630	A	19970806	AU 1997-13630	19970106
EP 880522	A1	19981202	EP 1997-900236	19970106
EP 880522	B1	20001019		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1207102	A	19990203	CN 1997-191643	19970106
NO 9900566	A2	19991228	NO 1999-2566	19970106
JP 2000503673	T	20000411	JP 1997-524911	19970106
AT 205847	T	20011015	AT 1997-900236	19970106
ES 2164323	T3	20020216	ES 1997-900236	19970106
PT 880522	T	20020531	PT 1997-900236	19970106
US 5990106	A	19991123	US 1998-101428	19980709
US 6100264	A	20000808	US 1999-352216	19990713
PRIORITY APPLN. INFO.:			FR 1996-192	A 19960110
			WO 1997-FR19	W 19970106
			US 1998-101428	A3 19980709

OTHER SOURCE(S): MARPAT 127:176439
GI

L19 ANSWER 63 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB Title compds. I [R = H, CO2R, carboxyalkyl, PO3H2, CH2PO3H2, or CR4CR5CO2R, CR4CO2R; R1 = alk-CN, alk-CONR, alk-Het, alk-PO3H2, alk-CONHSO2R; R2 = alkyl or Ph; alk = alkyl; Het = saturated or unsatd. mono- or polycyclic heterocyclic ring containing 1-9 carbon atoms and one or more heteratoms selected from O, S and N, said heterocyclic ring optionally substituted by one or more alkyl, Ph, or phenylalkyl radicals; provided that when R = H or CO2R or PO3H2, then R1 ≠ alk-CO2R] and their isomers, racemic mixts., enantiomers, diastereoisomers, and salts are disclosed, as well as their preparation, intermediates, and drugs containing them. I have valuable pharmacol. properties, and are antagonists of the AMPA/quisqualate receptor. Furthermore, I are non-competitive antagonists of the NMDA receptor, and specifically ligands for NMDA receptor glycine modulator sites. For instance, cyclization of the (oxoindanyl)imidazolecarboxylate II (preparation given) in AcOH containing NH4OAc, and removal of the benzyl protective group with 47% HBr, gave title compound III. I inhibited binding to rat cortical AMPA receptors in vitro at concns. of ≤ 100 μM, and had LD50 values > 50 mg/kg i.p. in mice.

IT 193814-14-1P 193814-26-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of imidazoindenopyrazinones as AMPA and NMDA

L19 ANSWER 63 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 193813-68-2 CAPLUS

CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-9-[2-[(methylsulfonyl)amino]-2-oxoethyl]-4-oxo-, sodium salt (1:2) (CA INDEX NAME)

● 2 Na

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 63 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 193814-14-1 CAPLUS

CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-4-oxo-9-[2-oxo-2-[(phenylsulfonyl)amino]ethyl]-, ethyl ester (CA INDEX NAME)



RN 193814-26-9 CAPLUS

CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-9-[2-[(methylsulfonyl)amino]-2-oxoethyl]-4-oxo-, ethyl ester (CA INDEX NAME)



IT 193813-67-1P 193813-68-2P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSP (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazoindenopyrazinones as AMPA and NMDA receptor antagonists)

RN 193813-67-1 CAPLUS

CN 4H-Imidazo[1,2-a]indeno[1,2-e]pyrazine-2-carboxylic acid, 5,10-dihydro-4-oxo-9-[2-oxo-2-[(phenylsulfonyl)amino]ethyl]- (CA INDEX NAME)

L19 ANSWER 64 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:557723 CAPLUS

DOCUMENT NUMBER: 127:255256

ORIGINAL REFERENCE NO.: 127:49749a,49752a

TITLE: Silver halide photographic material and its photographing and processing methods

INVENTOR(S): Sokman, Ko; Kagawa, Nobuaki; Kita, Noriyasu

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09211772	A	19970815	JP 1996-22446	19960208
PRIORITY APPLN. INFO.:			JP 1996-22446	19960208

GI



AB The title material contains ≥1 spectral sensitizing dye I [R1, R2 = substituted lower alkyl, 1 of the alkyl groups is substituted for hydrophilic groups and the other is substituted for electron-attracting groups; R3 = (substituted) C≤2 alkyl; Z1-4 = H or substituent, the sum of the σp value of each group of Z1-4 is 20.9, ≥1 of Z1-4 is a group linking to the benzimidazole ring via sulfonyl group; X = ion required to neutralize the charge in the mol.; n = 1 or 2, when the dye forms an inner salt, n = 1]. The material is processed by using an automatic processor of which the total processing time is ≤30 s. The material is processed with a hydroxybenzene-free developing solution containing a developing agent Q1C(=T)CR15CR16Q2 [R15, R16 = OH, amino, arylamino, alkylsulfonylamino, arylsulfonylamino, alkoxycarbonylamino, mercapto, alkylthio; Q1-2 = OH, carboxy, alkoxy, hydroxyalkyl, carboxyalkyl, sulfo, sulfoalkyl, amino, aminoalkyl, mercapto, alkyl, aryl, Q1 and Q2 may link to form a 5 to 8-membered ring along with C atoms; T = O or NR17 (R17 = H, OH, alkyl, acyl, hydroxyalkyl, sulfoalkyl, carboxyalkyl)]. A photographing method is also claimed, in which the material sandwiched with high-sensitive intensifying screens is exposed to x-ray. The material, useful as a medical x-ray film, shows high sensitivity, low residual color stain, good storage stability and resistance to safelight

IT 195719-40-5

RL: DEV (Device component use); USES (Uses)

(benzimidazole derivative photog. spectral sensitizer)

L19 ANSWER 64 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 195713-40-5 CAPLUS
CN 1H-Benzimidazolium, 5,6-dichloro-2-[3-(1,3-dihydro-1-[2-methoxyethyl]-5-

[methylsulfonyl]-3-[2-[[methylsulfonyl]amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-2-propen-1-yl]-1-methyl-3-(3-sulfopropyl)-, inner salt (CA INDEX NAME)



OTHER SOURCE(S): MARPAT 127:220650
GI

AB Title compds. [I; R1 = H, (un)substituted alk(en)yl, etc.; R2 = R2112223134; R = CO2R3, CONR2, tetrazolyl, etc.; R3 = H, NHR1, alkyl, etc.;

R4R5 = atoms to completes an (un)substituted 5 to 6-membered (un)substituted heterocyclic ring; R8 = H, halo, alkyl, alkoxy, etc.; E = CR6R7CR6 or CR=CR; R6,R7 = H or alkyl; E1 = (un)substituted 1,3- or 1,4-phenylene; E2 = O, CO, NCO-2, CH2, etc.; E3 = alk(en)ylene; E4 = O or C (alc); E5 = bond, CH2R7, O, NR6, NCO-2] were prepared Thus, 2,4-dihydroxy-3-propylpropiophenone was etherified by Br(CH2)3Br and the product thioetherified by 3,4-Cl(Me2NCO)C6H3CH2COMe to give, in 4 additional steps, title compound II. Data for biol. activity of I were given.

IT 194985-41-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1[heterocyclyloxy]alkoxy- and -alkylthio]phenylalkanoates and analogs as peroxisome proliferator-activated receptor antagonists)

RN 194985-41-1 CAPLUS
CN Benzeneacetamide, 2-chloro-4-[[3-[(3-ethyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]thio]-N-[methylsulfonyl]- (CA INDEX NAME)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 65 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:523628 CAPLUS
DOCUMENT NUMBER: 127:220650
ORIGINAL REFERENCE NO.: 127:43005a,43006a
TITLE: Preparation of [[heterocyclyloxy]alkoxy- and -alkylthio]phenylalkanoates and analogs as peroxisome proliferator-activated receptor antagonists
INVENTOR(S): Adams, Alan D.; Berger, Joel P.; Berger, Gregory D.; Fitch, Kenneth J.; Graham, Donald W.; Jones, Anthony B.; Von Langen, Derek; et al.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA; Adams, Alan D ; Berger, Joel P.; Berger, Gregory D.; Fitch, Kenneth J.; Graham, Donald W.
SOURCE: PCT Int. Appl., 219 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9728137	A1	19970807	WO 1997-US1749	19970131
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2244836	A1	19970807	CA 1997-2244836	19970131
CA 2244836	C	20070501		
AU 9718563	A	19970822	AU 1997-18563	19970131
AU 709255	B2	19990729		
EP 882029	A1	19981209	EP 1997-904210	19970131
EP 882029	B1	20070402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6090836	A	20000718	US 1997-791211	19970131
JP 2002502003	T	20020122	JP 1997-527899	19970131
AT 256137	T	20040115	AT 1997-904210	19970131
ES 2194179	T3	20031116	ES 1997-904210	19970131
PRIORITY APPLN. INFO.:			US 1996-10098P	P 19960202
			GB 1996-4274	A 19960208
			US 1996-34474P	P 19961223
			WO 1997-US1749	W 19970131

L19 ANSWER 66 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:516288 CAPLUS
DOCUMENT NUMBER: 127:155246
ORIGINAL REFERENCE NO.: 127:29745a,29746a
TITLE: Silver halide photographic material with high sensitivity
INVENTOR(S): Matsumoto, Atsushi; Ikoki, Takanori; Nakamura, Tetsuo
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 64 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09203993	A	19970805	JP 1996-12755	19960129
US 6057089	A	20000502	US 1997-784919	19970116
PRIORITY APPLN. INFO.:			JP 1996-12755	A 19960129

GI

AB The title material comprises a support coated with 2l Ag halide emulsion layer containing reduction-sensitized Ag halide grains and contains

2l sensitizing dye I [R = QarCONSO2Ra, QbeSO2NCORb, QatCONSO2Re, QafSO2NSO2Rd (Ra-d = alkyl, aryl, heterocycle, alkoxy, aryloxy, amino; Qa-d = methylene group; z, x, t, v = 1-10; L1, L2 = methine group; p = 0,

1; E1 = atoms required to form 5 or 6-membered N-containing heterocycles; M1 = counter ion; m1 = 0-10; Q = methine or polymethine group substituted for heterocyclic or aromatic groups]. The material shows high sensitivity, low

fog, and improved storage stability. Thus, a photog. film was prepared by

using a Ag(Br,I) emulsion reduction-sensitized with Thiourea dioxide and containing II.

IT 169350-04-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyanine dye photog. sensitizer)

RN 169350-04-3 CAPLUS

L19 ANSWER 66 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Benzothiazolium, 5-chloro-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

L19 ANSWER 67 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:496774 CAPLUS
DOCUMENT NUMBER: 127:115221
ORIGINAL REFERENCE NO.: 127:22304a,22304a
TITLE: A novel class of non-sensitizing infra-red dyes for use in photosensitive elements
INVENTOR(S): Kuchta, Ki
PATENT ASSIGNEE(S): Agfa-Gevaert Naamloze Vennootschap, Belg.
SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXLDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 779540	A1	19970618	EP 1996-203355	19961128
R: BE, DE, FR, GB				
US 5741633	A	19980421	US 1996-762442	19961209
JP 09179236	A	19970711	JP 1996-351705	19961212
US 5936084	A	19990810	US 1996-28699	19980210
PRIORITY APPLN. INFO.:			EP 1995-203492	A 19951214
			US 1996-762442	A3 19961209

OTHER SOURCE(S): MARPAT 127:115221
AB A novel class of non-sensitizing infra-red dyes derived from heptamethine dyes with indolenine nuclei is disclosed. They are useful as filter, antiarea, or antihalation dyes for photog. elements based on silver halide
or for photothermog. elements.
IT 192220-83-0 192220-84-1 192220-86-3
192220-87-4 192220-89-6 192220-91-0
192220-92-1 192220-94-3 192220-95-4
192220-96-5 192220-97-6 192220-98-7
192220-99-8
RL: TEM (Technical or engineered material use); USES (Uses)
(non-sensitizing IR dye for photog. and photothermog. materials)
RN 192220-83-0 CAPLUS
CN 3H-Indolium,
2-[7-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-indol-2-ylidene]-2,4,5-heptatrien-1-yl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 67 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 192220-84-1 CAPLUS
CN 3H-Indolium, 2-[2-[2-chloro-3-[2-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-indol-2-ylidene]ethylidene]-1-cyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 192220-86-3 CAPLUS
CN 3H-Indolium, 2-[2-[3-[2-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-indol-2-ylidene]ethylidene]-5,5-bis(ethoxycarbonyl)-1-cyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 192220-87-4 CAPLUS
CN 1H-Indole-1-acetamide, 2,2'-[(2-hexahydro-1,3-dimethyl-2,4,6-trioxo-5-pyrimidinyl)-1,3-cyclopentanediylidene]di-2,1-ethanediylidene]bis[2,3-dihydro-3,3-dimethyl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L19 ANSWER 67 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 192220-89-6 CAPLUS
CN 3H-Indolium, 2-[2-[5-[2-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-indol-2-ylidene]ethylidene]-5,6-dihydro-2H-pyran-3-yl]ethenyl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 192220-91-0 CAPLUS
CN 1H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benz[e]indol-2-ylidene]-2,5-heptatrien-1-yl]-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 67 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 192220-92-2 CAPLUS
CN 1H-Benz[e]indolium, 2-[2-[2-chloro-3-[2-[1,3-dihydro-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benz[e]indol-2-ylidene]ethylidene]-1-cyclohexen-1-yl]ethenyl]-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 192220-94-7 CAPLUS
CN 3H-Benz[e]indole-3-acetamide, 2,2'-[[2-(hexahydro-1,3-dimethyl-2,4,6-trioxo-5-pyrimidinyl)-1,3-cyclopentanediylidene]di-2,1-ethanediylidene]bis[1,1-dihydro-1,1-dimethyl-N-[(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 192220-95-8 CAPLUS
CN 1H-Benz[e]indolium, 2-[2-[3-[2-[1,3-dihydro-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benz[e]indol-2-ylidene]ethylidene]-2,3-bis(ethoxycarbonyl)-1-cyclohexen-1-yl]ethenyl]-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 67 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 192220-98-7 CAPLUS
CN 1H-Benz[e]indolium, 2-[2-[5-[2-[1,3-dihydro-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benz[e]indol-2-ylidene]ethylidene]-5,6-dihydro-2H-thiopyran-3-yl]ethenyl]-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 192220-99-8 CAPLUS
CN 3H-Indolium, 2-[2-[5-[2-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-indol-2-ylidene]ethylidene]-5,6-dihydro-2H-thiopyran-3-yl]ethenyl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 67 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 192220-96-9 CAPLUS
CN 1H-Benz[e]indolium, 2-[2-[4-[2-[1,3-dihydro-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benz[e]indol-2-ylidene]ethylidene]-6,6-dimethylbicyclo[3.1.1]hept-2-en-3-yl]ethenyl]-1,1-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 192220-97-6 CAPLUS
CN 3H-Indolium, 2-[2-[4-[2-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-indol-2-ylidene]ethylidene]-6,6-dimethylbicyclo[3.1.1]hept-2-en-3-yl]ethenyl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 67 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 68 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:317798 CAPLUS
DOCUMENT NUMBER: 126:293368
ORIGINAL REFERENCE NO.: 126:56B161a,56B7a
TITLE: Benzoxazepine compounds, their production and use as lipid lowering agents
INVENTOR(S): Yokimasa, Hidefumi; Sugiyama, Yasuoy Tozawa, Ryuuchi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9719234	A1	19970530	WO 1996-JP3396	19961911
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2231052	AA	19970320	CA 1996-2231052	19961911
CA 2231052	C	20071113		
AU 9668442	A	19970401	AU 1996-68442	19961911
JP 09176088Q	A	19970327	JP 1996-242378	19961911
JP 3479796	B2	20031215		
EP 862562	A1	19960909	EP 1996-930365	19961911
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1196252	A	19981014	CN 1996-196892	19961911
CN 1072249	C	20011010		
EP 1297825	A1	20012509	EP 2000-126672	19961911
EP 1297923	B1	20080716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 202774	T	20010715	AT 1996-930365	19961911
ES 2158344	T3	20010901	ES 1996-930365	19961911
PT 862562	T	20011130	PT 1996-930365	19961911
AU 4023315	T	20030315	AT 2000-126672	19961911
RA 9702134	A	19990604	SA 1997-2134	19970312
US 6129929	A	20000929	US 1998-43265	19980312
US 6613763	B2	20030902	US 2000-587947	20000606
JP 2001297963	A	20010410	JP 2000-323310	20001018
JP 4021612	B2	20071212		
GR 3036707	T3	20011231	GR 2001-401564	20010926
JP 2004007819	A1	20040415	US 2003-606152	20030624
US 20070117797	A1	20070524	US 2006-639066	20061212
JP 2007351154	A	20071227	JP 2007-210920	20070910
US 20080153903	A1	20080626	US 2007-986290	20071119
PRIORITY APPLN. INFO.:			JP 1995-235457 A	19950913
			EP 1996-930365 A3	19961911

L19 ANSWER 68 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

		JP 1996-242378	A3 19961911
		WO 1996-JP3396	W 19961911
		ZA 1997-2134	A 19970312
		US 1998-43265	A3 19980312
		US 2000-587947	A1 20000606
		JP 2000-323310	A3 20001018
		US 2003-606152	B2 20030624
		US 2006-639066	B2 20061212

OTHER SOURCE(S): MARPAT 126:293368
GI

AB New benzoxazepines I [R = alkyl, hydroxyalkyl; R1 = alkyl; R2 = halogen; R3 = (un)substituted COMeR4, heterocyclic group having a deprotonatable hydrogen atom]were prepared for use as cholesterol and triglyceride lowering agent. Thus, I [R = CHClMe3, R1 = Me, R2 = Cl, R3 = COMe] was amidated, dehydrated to the nitrile, and cyclized with Me3SiN3 to give I [R = CHClMe3, R1 = Me, R2 = Cl, R3 = 5-tetrazolyl] which had a squalene synthetase inhibiting IC50 of 11X10-9 M.
IT 189059-84-5P 189059-85-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of arylbenzoxazepinones as hypolipemic agents)
RN 189059-84-5 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-(3-hydroxy-2,2-dimethylpropyl)-N-(methylsulfonyl)-2-oxo-,

L19 ANSWER 68 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.

RN 189059-85-6 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-[3-hydroxy-2-(hydroxymethyl)-2-methylpropyl]-N-(methylsulfonyl)-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.

IT 189059-79-9P 189059-80-1P 189059-81-2P 189059-82-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylbenzoxazepinones as hypolipemic agents)
RN 189059-79-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-

L19 ANSWER 68 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
dimethylpropyl)-1,2,3,5-tetrahydro-N-[(2-methylphenyl)sulfonyl]-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 189059-80-1 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-2-oxo-N-(phenylsulfonyl)-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 189059-81-2 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(1-methylethyl)sulfonyl]-2-oxo-, (3S,5S)- (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 68 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 189059-82-3 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-N-(methylsulfonyl)-1,2,3,5-tetrahydro-2-oxo-, (3R,5S)-(CA INDEX NAME)

Absolute stereochemistry.



IT 189059-76-9P 189059-78-1P 189060-07-9P
189060-45-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylbenzoxazepinones as hypolipaemic agents)
RN 189059-76-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]-2-oxo-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 68 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 189060-45-3 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 1-[3-[acetyloxy]-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-[methylsulfonyl]-2-oxo-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 68 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 189059-78-7 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 7-chloro-5-[2,3-dimethoxyphenyl)-1-[2,2-dimethylpropyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 189060-07-9 CAPLUS
CN 4,1-Benzoxazepine-3-acetamide, 1-[3-(acetyloxy)-2-[(acetyloxy)methyl]-2-methylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-N-(methylsulfonyl)-2-oxo-, (3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.

L19 ANSWER 69 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:715042 CAPLUS
DOCUMENT NUMBER: 126:293352
ORIGINAL REFERENCE NO.: 126:56809a,56812a
TITLE: Preparation of benzimidazoles for the prevention and/or the treatment of bone diseases
INVENTOR(S): Oku, Teruo; Kawai, Yoshio; Yatabe, Takumi; Sato, Shigeki; Yamazaki, Hitoshi; Kayakiri, Hatsuko; Yoshihara, Kousei
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9710219	A1	19970320	WO 1996-JP2530	19960905
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NC, NL, PT, SE				
EP 863881	A1	19980916	EP 1996-929540	19960905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 11513364	T	19991116	JP 1996-511824	19960905
PRIORITY APPLN. INFO.:			GB 1995-18552	A 19950911
			WO 1996-JP2530	W 19960905

OTHER SOURCE(S): MARPAT 126:293352
GI



AB The title compds. [I; R1 = acyl, (un)substituted lower alkanyl, lower alkyl; R2 = H, lower alkyl, lower alkoxy, etc.; R123 = lower alkylene, lower alkenylene (may include O, S, NH, N-alkyl); R3 = H, halo; R4 = (un)substituted heterocyclyl, aryl; A = CONR5, N(R10)CO; wherein R5, R10 = H, (un)substituted lower alkyl)], and their pharmaceutically acceptable salts, inhibitors of bone resorption and bone metabolism, were prepared Thus, hydrogenation of 1,2-dimethyl-4-nitro-1H-benzimidazole over 10% Pd/C in MeOH followed by reaction of the resulting 4-amino-1,2-dimethyl-1H-benzimidazole with 2,6-dichlorobenzoyl chloride in

L19 ANSWER 69 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
the presence of Et3N in ethylene chloride afforded I [R1, R2 = Me; R3 = H;
R4 = 2,6-Cl2C6H3; A = NHCO]. Compds. I are effective at 0.1-1000 mg/body/day.

IT 189043-28-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazoles for the prevention and/or the treatment of bone diseases)

RN 189043-28-5 CAPLUS

CN 1H-Benzimidazole-1-acetamide, 4-[(2,6-dichlorobenzoyl)amino]-N-(phenylsulfonyl)-2-(trifluoromethyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 70 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:281083 CAPLUS
DOCUMENT NUMBER: 126:314002
ORIGINAL REFERENCE NO.: 126:60824h,60825a
TITLE: Design and Synthesis of Transition State Analogs for Induction of Hydride Transfer Catalytic Antibodies
AUTHOR(S): Schroeer, Josef; Sanner, Michel; Reymond, Jean-Louis; Lerner, Richard A.
CORPORATE SOURCE: Departments of Molecular Biology and Chemistry, Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Journal of Organic Chemistry (1997), 62(10), 3220-3229
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 126:314002

AB Alc. dehydrogenases and related aldehyde reductase enzymes catalyze the oxidation of alcs. to aldehydes and the simultaneous reduction of a nicotinamide derivative (NAD+ or NADP+) to the corresponding 1,4-dihydronicotinamide. Herein we report the design and synthesis of a stable transition state analog for this hydride transfer process. Compound 1 is a rigid [3.2.2] bicyclic structure containing 3-piperidone oxime as a mimic for 1,4-dihydronicotinamide. The piperidone is held in the boat conformation corresponding to the transition state by a three-atom lactam bridge between N(1) and C(4). The oxime function mimics the carboxamide group in nicotinamide. The lactam nitrogen serves as an attachment point for the alkyl group of the alc. substrate, and the amide oxygen atom mimics its hydroxyl group. Compound 1 was prepared in 10 steps from N-benzylpiperidone, functionalized with substrate and cofactor recognition elements into transition state analogs 2 and 3 and conjugated to carrier proteins for immunization. These novel analogs open the way for the exploration of the dehydrogenase reaction using catalytic antibodies.

IT 189361-65-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(design, synthesis and crystal structure of transition state analogs for induction of hydride transfer catalytic antibodies)

RN 189361-65-7 CAPLUS

CN Pyridinium, 1-[[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]methyl]-1,2,3,6-tetrahydro-3-(hydroxyamino)-1-[2-oxo-2-[(propylsulfonyl)amino]ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 189361-64-6
CMF C21 H31 N4 O7 S

L19 ANSWER 70 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



CM 2

CRN 14477-72-6
CMF C2 F3 O2

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 71 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:226940 CAPLUS
DOCUMENT NUMBER: 126:207527
ORIGINAL REFERENCE NO.: 126:39997a,40000a
TITLE: Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
INVENTOR(S): Krause, Brian Robert
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Krause, Brian Robert
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705868	A1	19970220	WO 1996-US11366	19960708
W: AU, BG, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2221729	A1	19970220	CA 1996-2221729	19960708
AU 9664541	A	19970305	AU 1996-64541	19960708
AU 716255	B2	20000224		
EP 841913	A1	19980520	EP 1996-923687	19960708
EP 841913	B1	20030205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1192140	A	19980902	CN 1996-196033	19960708
HU 9900668	A2	19990628	HU 1999-668	19960708
HU 9900668	A3	20000828		
JP 11510184	T	19990907	JP 1997-508427	19960708
NZ 312571	A	20000728	NZ 1996-312571	19960708
AT 232097	T	20030215	AT 1996-923687	19960708
ES 2191762	T3	20030916	ES 1996-923687	19960708
PL 185943	B1	20030930	PL 1996-324908	19960708
ZA 9606617	A	19970218	ZA 1996-6617	19960802
US 6117909	A	20000912	US 1998-296	19980126
BG 63863	B1	20030430	BG 1998-102222	19980130
NO 9800466	A	19980203	NO 1998-466	19980203
PRIORITY APPLN. INFO.:			US 1995-3031P P	19950804
			WO 1996-US11366 W	19960708

OTHER SOURCE(S): MARPAT 126:207527

AB The invention provides new therapeutic uses of compds. R1XS(:O)2N(R)C(:O)YR2 [X, Y = O, S, (CR'R'')n; n = 1-4; R', R'' = H, alkyl, alkoxy, halo, OH, etc.; R = H, alkyl, benzyl; R1, R2 = (substituted) Ph, (substituted) naphthyl, aralkyl, alkyl, adamantyl, cycloalkyl]. The compds., e.g. sulfamic acid (phenylacetyl)-2,6-bis(1-methylethyl)phenyl ester, may be used for treatment of cerebrovascular disease, peripheral vascular diseases, and restenosis. Cholesterol-lowering and Lp(a)-lowering activity are reported for one of the compds.

L19 ANSWER 71 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
IT 166518-64-5 176433-68-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfanic acid derivs., acyl sulfonamides, and sulfonyl carbamates for lowering lipoprotein levels and treating cardiovascular disorders)
RN 166518-64-5 CAPLUS
CN Benzeneacetamide, 2,6-bis[1-methylethyl)-N-[[2,4,6-tris(1-methylethyl)phenyl]methyl]sulfonyl]- (CA INDEX NAME)



RN 176433-68-4 CAPLUS
CN Benzeneacetamide, 2,6-bis[1-methylethyl)-N-[[2,4,6-tris(1-methylethyl)phenyl]methyl]sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 72 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:90192 CAPLUS
DOCUMENT NUMBER: 126:124704
ORIGINAL REFERENCE NO.: 126:23978a,23978a
TITLE: Silver halide photographic material containing hydrazine derivative and method of developing
INVENTOR(S): Tanabe, Junichi; Ito, Hirohide
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Kohyo, 51 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08272030	A	19961018	JP 1995-78835	19950404
JP 3416838	B2	20030616		
			JP 1995-78835	19950404

PRIORITY APPLN. INFO.:

GI



AB In a Ag halide photog. material having ≥1 layer containing a hydrazine derivative on an emulsion layer side of a support, (1) the Ag halide photog. material is spectrally sensitized by a compound I (V1,2 = H, electron-attracting group; V3,4 = electron-attracting group; X1-4 = CS10 alkyl, alkenyl; X1- = counter ion neutralizing charge; n = 0, 1; n = 0 for intramol. salt) and (2) ≥1 layer on the emulsion layer side of the support contains solid dye microparticle dispersion. The process comprises a development using a developer which contains a compound RICH(OH)C(=O)(X)NR2 [R1,2 = alkyl, amino, alkoxy, alkylthio; R1 and r2 may form a ring; k = 0,1; when k = 1, X represents CO or CS) but is free of dihydroxybenzene compds. The Ag halide photog. material is suitable for a film for printing, and provided super-high contrast image.
IT 161911-20-2 161911-21-3
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. material containing hydrazine derivative and method of developing)
RN 161911-20-2 CAPLUS
CN 1H-Benzimidazolium, 5,6-dichloro-2-[3-[3,6-dichloro-1,3-dihydro-1,3-bis[2-

L19 ANSWER 72 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-1-methyl-3-[3-sulfopropyl]-, inner salt (CA INDEX NAME)

OTHER OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 161911-21-3 CAPLUS
CN 1H-Benzimidazolium, 5,6-dichloro-2-[3-[5,6-dichloro-1,3-dihydro-1-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-3-[3-[(methylsulfonyl)amino]-2-oxoethyl]-1-[3-sulfopropyl]-, inner salt (CA INDEX NAME)



OTHER OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L19 ANSWER 73 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:466522 CAPLUS
DOCUMENT NUMBER: 125:288709
ORIGINAL REFERENCE NO.: 125:53768a,53766a
TITLE: Silver halide photographic material spectrally sensitized by trinuclear cyanine having improved red sensitivity and low dye stain
INVENTOR(S): Kagawa, Nobuaki; Kita, Haruyasu
PATENT ASSIGNEE(S): Konishiroku Photo Ind., Japan
SOURCE: Jpn. Kokai Tokkyo Kohyo, 30 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08201954	A	19960809	JP 1995-11332	19950127

PRIORITY APPLN. INFO.: JP 1995-11332 19950127

GI For diagram(s), see printed CA Issue.
AB The claimed photog. material is characterized by (1) that ≥1 of the emulsion layer is spectrally sensitized by a cyanine dye I (X1, X2 = S, or 6-membered heterocyclic ring; Z3 = NR, O, S, Se, Te; R, R2 = aliphatic, aryl, heterocyclic group; R1, R3 = C 1-10 aliphatic; at least one of R and R1-3 has a water-solubilizing group; L1 = substituted methine; L2, L3 = methine; M1 and n = counter ion for stoichiometric balance; l, k, z = 0, 1). A sensitizing dye II [Y11-13 = NR10, O, S, Se, Te; R10-13, L11-13 have the same meaning as R, R2-3, L2-3 in I; Y0-4 = H, alkyl, aryl, alkoxy; Z1 R10-13 has a water-solubilizing group; M11 and n = counter ion for stoichiometric balance; m = 0, 1] The spectral sensitizer provides high sensitivity at red spectral region, and also provides the material with good shelf life and low residual dye stain at the processing.
IT 162746-33-4
RL: DEV (Device component use); USES (Uses)
(Ag halide photog. material spectrally sensitized by trinuclear cyanine having improved red sensitivity and low dye stain)
RN 162746-33-4 CAPLUS
CN Benzothiazolium, 2-[[3-(carboxymethyl)-5-[2-[5-methoxy-3-(3-sulfopropyl)-1,3-benzothiazolin-2(3H)-ylidene]propylidene]-4-oxo-2-thiazolidinylidene]methyl]-5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 73 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 74 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 74 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:520842 CAPLUS
DOCUMENT NUMBER: 125:181329
ORIGINAL REFERENCE NO.: 125:3769a,3769b
TITLE: Silver halide photographic materials with high sensitivity and low fog
INVENTOR(S): Ootani, Hiroshi
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 71 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08146548	A	19960607	JP 1994-286502	19941121
PRIORITY APPLN. INFO.:			JP 1994-286502	19941121

GI

AB The title materials have a photosensitive Ag halide emulsion layer, in which Ag halide particles (e.g., planar particles with aspect ratio ≥3 and ≥70% projection area) are chemical sensitized by a Te compound or a Te compound and a Se compound and spectrally sensitized by the dye
I (Z1-2 = nonmetal atomic group for 5- or 6-membered N-containing heterocycle; L1 = methine; R1 = JSO2NR2, JCONHCOR3, JCONHSO2R3, JSO2NHCOR3, JSO2NHSO2R3, JCOOR3, JSCOR3, JOCOR3, JSCOOR3; J = alkylene; R2 = R1, unsubstituted alkyl, alkyl substituted with sulfoalkyl, carboxyalkyl, hydroxyalkyl; m1-2 = 0, 1; n = odd integer).
IT 172415-58-6
RL: NUU (Other use, unclassified); USES (Uses)
(sensitizing dye; silver halide photog. materials with high sensitivity and low fog)
RN 172415-58-6 CAPLUS
CN Benzoxazolium, 5-chloro-2-[2-[[6-methoxy-5-methyl-3-[2-[[methylsulfonyl]amino]-2-oxoethyl]-2[3H]-benzothiazolylidene]methyl]-1-buten-1-yl]-3-(2-sulfoethyl)-, inner salt (CA INDEX NAME)

L19 ANSWER 75 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:514078 CAPLUS
DOCUMENT NUMBER: 125:168038
ORIGINAL REFERENCE NO.: 125:31497a,31500a
TITLE: Preparation of naphthylbenzoazepines or -benzothiazepines as squalene synthetase inhibitors
INVENTOR(S): Hanasaka, Ernest S.; Hawkins, Joel M.; Hayward, Cheryl
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9620184	A1	19960704	WO 1995-IB424	19950602
W: CA, FI, JP, KG, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2207772	A1	19960704	CA 1995-2207772	19950602
JP 10500702	T	19980120	JP 1995-520314	19950602
IN 1995DB02260	A	20050311	IN 1995-DI2260	19951207
LV 11325	B	19970220	LV 1995-379	19951221
BR 9505995	A	19971223	BR 1995-5995	19951221
NO 9505298	A	19960624	NO 1995-5298	19951222
AU 9540677	A	19960704	AU 1995-40677	19951222
CN 1133297	A	19961016	CN 1995-120143	19951222
HU 74672	A2	19970128	HU 1995-3783	19951222
US 5770599	A	19980623	US 1997-860155	19970617
FI 9702696	A	19970623	FI 1997-2696	19970623
PRIORITY APPLN. INFO.:			US 1994-362713	A 19941223
			WO 1995-IB424	W 19950602

OTHER SOURCE(S): MARPAT 125:168038
GI



L19 ANSWER 75 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB Title compds. [I; R = CO2R, alkoxycarbonyl, CONR2, etc.; R1,R2 = H, halo, alkyl,alkoxy, etc.; R3 = (un)substituted naphthyl; R4 = alkyl, cycloalkylmethyl, etc.; X1 = S, NCO-2; X2 = CO or CH2] were prepared as squalene synthetase inhibitors (no data). Thus, 4-ClC6H4NHCH2CMe3 [preparation

given] was hydroxyalkylated by 1-naphthaldehyde and the product N-acylated

by (E)-ClCOCH:CHCO2Me to give, after cyclization, title compds. II.

IT 192746-09-3P 192746-10-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naphthylbenzoazepines or benzothiazepines as squalene

synthetase inhibitors)

RN 192746-09-3 CAPLUS

CN 4,1-Benzothiazepine-3-acetamide, 7-chloro-1-[2,2-dimethylpropyl]-1,2,3,5-tetrahydro-5-methylsulfonyl-5-(1-naphthalenyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 192746-10-5 CAPLUS

CN 4,1-Benzoazepine-3-acetamide, 7-chloro-1-[2,2-dimethylpropyl]-1,2,3,5-tetrahydro-5-methylsulfonyl-5-(1-naphthalenyl)-2-oxo-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L19 ANSWER 76 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:497787 CAPLUS

DOCUMENT NUMBER: 125:161007

ORIGINAL REFERENCE NO.: 125:29987a,29990a

TITLE: A new binding model for structurally diverse acetolactate synthase (ALS) inhibitors

AUTHOR(S): Akagi, Toshio

CORPORATE SOURCE: Central Research Inst., Ishihara Sangyo Kaisha Ltd., Kusatsu, 525, Japan

SOURCE: Pesticide Science (1994), 47(4), 309-318

CODEN: PSSCBG; ISSN: 0031-613X

PUBLISHER: Wiley

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study, the common structural features within a subset of ALS inhibitors were investigated by mol. graphics and quantum chemical calcns.

Satisfactory results were obtained with model calcns. based on the presumption that the relative location of the inhibitor aline moiety and some receptor cationic group remained fixed. The cationic group was assumed to interact with an acidic group in each of the inhibitors. This model explains many aspects of ALS inhibitors (sulfonylureas, triazolopyrimidines, pyrimidyl ethers and other classes) such as: (1) the common structural feature among the different classes of ALS inhibitors, (2) the substituent effects in the hydrophobic moiety of each class and (3) the structure-activity relationships of the acidic moiety of each class. These are significant achievements for a model based on in-vivo herbicidal activity and gas-phase calcns., but the model also has its limitations: (1) only compds. with acidic groups and aline moieties can be

addressed, (2) the structure-activity relationships of the hydrophobic moiety are not yet fully understood and (3) only a qual. prediction of activity levels is possible.

IT 192229-14-7

RL: AGR (Agricultural use); PRP (Properties); BIOL (Biological study); USES (Uses)

(binding model for structurally diverse herbicidal acetolactate synthase inhibitors)

RN 192229-14-7 CAPLUS

CN 2-Pyrimidineacetamide, 4,6-dimethoxy-N-[[3-(trifluoromethyl)-2-pyridinyl]sulfonyl]- (CA INDEX NAME)



L19 ANSWER 75 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 77 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:353185 CAPLUS

DOCUMENT NUMBER: 125:33473

ORIGINAL REFERENCE NO.: 125:6533a,6536a

TITLE: Preparation of heterocyclic compounds useful as allosteric effectors at muscarinic receptors

INVENTOR(S): Birdsall, Nigel; Lazareno, Sebastian; Naruto, Syun; Koyama, Yasuo; Sugimoto, Masahiko; Marumoto, Shinji

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 353 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603377	A1	19960208	WO 1995-JP1494	19950727
W: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2196046	A1	19960208	CA 1995-2196046	19950727
AU 9530866	A	19960222	AU 1995-30866	19950727
AU 686426	B2	19980205		
EP 804416	A1	19971105	EP 1995-926509	19950727
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
CN 1166169	A	19971126	CN 1995-195262	19950727
HU 76923	A2	19980128	HU 1997-248	19950727
JP 10503488	T	19980331	JP 1995-505655	19950727
NZ 292385	C1	20000710	NZ 1997-302695	19950727
NO 9700308	A	19970325	NO 1997-308	19970124
FI 9700328	A	19970327	FI 1997-328	19970127
US 5877199	A	19990302	US 1997-793499	19970127
PRIORITY APPLN. INFO.:			GB 1994-15175	A 19940727
			GB 1994-23948	A 19941125
			WO 1995-JP1494	W 19950727

OTHER SOURCE(S): MARPAT 125:33473

GI

AB Title compds. [I; 1 of X1,X2 = N, alkyl, alkanoyl, aryl, etc. and the other = N, alkyl, arylalkyl); X3 = N, amino-protective group; 1 of Y1-Y4 = CO2R, SO2NR2, carboxyalkyl(oxy), etc. and the others = H, halo, alkyl, alkoxy, etc.; W = CH2, CH, NCO-2, S = CH2,CH, NH, N; dashed line =

L19 ANSWER 77 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
qn ional bond] were prepd. Data for effect of prepd. 1 on acetylcholine binding were given.
IT 177550-07-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SYN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. useful as allosteric effectors at muscarinic receptors)
RN 177550-07-1 CAPLUS
CN 9H-Carbazole-3-acetamide, 4-methyl-N-(methylsulfonyl)-1-(methylthio)-9-[phenylmethyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 78 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:107615 CAPLUS
DOCUMENT NUMBER: 125:14959
ORIGINAL REFERENCE NO.: 125:2645a,2646a
TITLE: Silver halide photographic material spectrally sensitized by low-stain cyanine dye having substituent with conjugated double bond
INVENTOR(S): Inagaki, Toshio
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 71 pp
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08043981	A	19960216	JP 1994-193029	19940727
PRIORITY APPLN. INFO.:			JP 1994-193029	19940727

GI For diagram(s), see printed CA Issue.
AB The claimed photog. material contains a cyanine dye I (G1 = 5- or 6-membered heterocyclic group; R1 = alkyl; G = TIGINBAG; G1 = carbonyl, sulfonyl, sulfonyl; G2 = CO2, SO2, SO2I2, CN, T2 = monovalent group T1 = bivalent linkage). The dye is a spectral sensitizer having little stain derived from the residual dye and has good spectrally sensitizing characteristics and storage stability. It is suitably applied to multilayer color photog. films and papers and medical x-ray films.
IT 177837-42-2
RL: DEV (Device component use); USES (Uses)
(silver halide photog. material spectrally sensitized by low stain cyanine dye having substituent with conjugated double bond)
RN 177837-42-2 CAPLUS
CN Benzothiazolium, 2-[[5,5-dimethyl-3-[[6-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]methyl]-2-cyclohexen-1-yl]ethenyl]methyl]-6-[2-[(methylsulfonyl)amino]-2-oxoethyl]-3-(4-sulfobutyl)-, inner salt, sodium salt (1:1) (CA INDEX NAME)

L19 ANSWER 78 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

● Na

L19 ANSWER 79 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:169243 CAPLUS
DOCUMENT NUMBER: 124:316749
ORIGINAL REFERENCE NO.: 124:5737a,5740a
TITLE: N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
INVENTOR(S): Lee, Helen T.; Picard, Joseph A.; Silakovic, Drago R.
Wierenga, Wendell
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 17 pp. Cont.-in-part of U.S. Ser. No. 62,515, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5491372	A	19960213	US 1994-223932	19940413
IL 109431	A	20010111	IL 1994-109431	19940426
CA 2158268	A1	19941124	CA 1994-2158268	19940511
CA 2158268	C	20061107		
WO 9426702	A1	19941124	WO 1994-US5233	19940511
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9468311	A	19941212	AU 1994-68311	19940511
AU 681152	B2	19970821		
EP 698010	A1	19960228	EP 1994-916734	19940511
EP 698010	B1	19990414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
NO 72653	A2	19960528	NO 1995-2811	19940511
NO 303044	B1	20040301		
JP 08510256	T	19961029	JP 1994-525674	19940511
JP 3704149	B2	20051005		
AT 178895	T	19990415	AT 1994-916734	19940511
ES 2133169	T3	19990901	ES 1994-916734	19940511
RU 2137756	C1	19990920	RU 1995-122768	19940511
CZ 290683	B6	20020911	CZ 1995-2966	19940511
SK 282796	B6	20021203	SK 1995-1596	19940511
ZA 9403313	A	19951110	ZA 1994-3313	19940513
US 5633387	A	19970527	US 1995-504967	19951023
FI 9505438	A	19951110	FI 1995-5438	19951110
NO 9504564	A	19960111	NO 1995-4564	19951113
NO 305861	B1	19990809		
PRIORITY APPLN. INFO.:			US 1993-62515	B2 19930514
			US 1994-223932	A 19940413
			WO 1994-US5233	W 19940511

OTHER SOURCE(S): CASREACT 124:316749; MARPAT 124:316749
AB The present invention is directed to title ACAT-inhibiting compds. HISSOSNHCOYR2 useful for the regulation of cholesterol, methods for using them and pharmaceutical compns. thereof, wherein: X and Y are oxygen, sulfur, or (CR'R'')n wherein n is 1 to 4 and R' and R'' are each

L19 ANSWER 79 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
independently, e.g., H, alkyl, alkoxy or R' and R'' together form a spirocycloalkyl or a carbonyl; R is hydrogen, alkyl, or benzyl; R1 and R2 are Ph, substituted Ph, naphthyl, substituted naphthyl, an aralkyl group, an alkyl chain, adamantyl, or a cycloalkyl group. Thus, e.g., hydroxyethylation of 2,6-diisopropylbromobenzene with Li/ethylene oxide afforded 2-(2,6-diisopropylphenyl)ethanol; Jones oxidn. of the latter afforded the (2,6-diisopropylphenyl)acetic acid; conversion to the acid chloride followed by amidation with 2,6-diisopropylphenyl sulfamate afforded ArCH2CONHSO2OAr (Ar = 2,6-diisopropylphenyl) which exhibited
IC50
= 9.7 μM for inhibition of ACAT in vitro and -63% change in mean cholesterol levels in vivo.

IT 166518-64-5P 176433-68-4P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(N-acyl sulfamic acid esters, N-acyl sulfonamides, and N-sulfonyl carbamic acid esters as hypercholesterolemic agents)

RN 166518-64-5 CAPLUS
CN Benzeneacetamide, 2,6-bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]methyl]sulfonyl]- (CA INDEX NAME)



RN 176433-68-4 CAPLUS
CN Benzeneacetamide, 2,6-bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]methyl]sulfonyl]-, sodium salt (1:1) (CA INDEX NAME)



L19 ANSWER 80 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:155517 CAPLUS
DOCUMENT NUMBER: 124:202010
ORIGINAL REFERENCE NO.: 124:37341a,37344a
TITLE: Preparation of N-sulfonylpyrrolizineacetamides and analogs as cyclooxygenase and lipoxygenase inhibitors
INVENTOR(S): Laufer, Stefan; Striegel, Hans Guenther; Dannhardt, Gerd
PATENT ASSIGNEE(S): Merckle GmbH, Germany
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 4419247	A1	19951207	DE 1994-4419247		19940601
CA 2191746	A1	19951207	CA 1995-2191746		19950531
CA 2191746	C	20070410			
WO 9532972	A1	19951207	WO 1995-EP2079		19950531

W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ, VN
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
AU 9526730	A	19951221	AU 1995-26730		19950531
EP 763037	A1	19970319	EP 1995-921801		19950531
EP 763037	B1	20011114			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,
SE

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 10506370	T	19980623	JP 1996-500334		19950531
JP 3671303	B2	20050713			
AT 208777	T	20011115	AT 1995-921801		19950531
ES 2166823	T3	20020501	ES 1995-921801		19950531
PT 763037	T	20020531	PT 1995-921801		19950531
NO 9605095	A	19961129	NO 1996-5095		19961129
NO 310076	B1	20010514			
FI 9604773	A	19970127	FI 1996-4773		19961129
FI 114099	B1	20040813			
US 5942535	A	19990824	US 1997-737921		19970328
PRIORITY APPLN. INFO.:			DE 1994-4419247	A	19940601
			WO 1995-EP2079	W	19950531

OTHER SOURCE(S): MARPAT 124:202010
GI

L19 ANSWER 80 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB Title compds. [I; 2 of R1-R3 = H or (hetero)aryl and the other = COCO2H, alkoxycarbonyl, sulfonylcarbamoylalkyl, etc.; R4-R7 = H or alkyl; 2 vicinal R4-R7 = bond; X = CH2, O, S, (alkyl)imino, etc] were prepared
Thus,
title compound II had IC50 of 2.3x10-7 and 1.5x10-7 (units not given) against lipoxygenase and cyclooxygenase, resp.

IT 174347-96-7P 174347-97-8P 174347-98-9P
174347-99-0P 174348-07-3P 174348-08-4P
174348-09-5P 174348-10-8P 174348-11-9P
174348-12-0P 174348-14-2P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-sulfonylpyrrolizineacetamides and analogs as cyclooxygenase and lipoxygenase inhibitors)

RN 174347-96-7 CAPLUS
CN 1H-Pyrrolizine-5-acetamide,
6-(5-chloro-2-thienyl)-2,2-diethyl-2,3-dihydro-
N-(methylsulfonyl)-7-phenyl- (CA INDEX NAME)



RN 174347-97-8 CAPLUS
CN 1H-Pyrrolizine-5-acetamide,
6-(5-chloro-2-thienyl)-2,2-diethyl-2,3-dihydro-
N-[(4-methylphenyl)sulfonyl]-7-phenyl- (CA INDEX NAME)

L19 ANSWER 80 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 174347-98-9 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(5-chloro-2-thienyl)-2,3-dihydro-2,2-dimethyl-N-(methylsulfonyl)-7-phenyl- (CA INDEX NAME)



RN 174347-99-0 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(5-chloro-2-thienyl)-2,3-dihydro-2,2-dimethyl-N-[(4-methylphenyl)sulfonyl]-7-phenyl- (CA INDEX NAME)



RN 174348-07-3 CAPLUS
CN 1H-Pyrrolizine-5-acetamide,
6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-
phenyl-N-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)

L19 ANSWER 86 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 174348-08-4 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-N-[(4-methylphenyl)sulfonyl]-7-phenyl- (CA INDEX NAME)



RN 174348-09-5 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl-N-[(phenylsulfonyl)- (CA INDEX NAME)



RN 174348-10-8 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-N-

L19 ANSWER 86 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 174348-14-2 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 2,3-dihydro-2,2-dimethyl-N-(methylsulfonyl)-7-phenyl-6-[4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L19 ANSWER 86 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
[(4-methylphenyl)sulfonyl]-7-phenyl- (CA INDEX NAME)



RN 174348-11-9 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(4-chlorophenyl)-2,2-diethyl-2,3-dihydro-N-(methylsulfonyl)-7-phenyl- (CA INDEX NAME)



RN 174348-12-0 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(4-chlorophenyl)-2,2-diethyl-2,3-dihydro-N-[(4-methylphenyl)sulfonyl]-7-phenyl- (CA INDEX NAME)

L19 ANSWER 87 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1996:155516 CAPLUS
DOCUMENT NUMBER: 124:202009
ORIGINAL REFERENCE NO.: 124:37741a,37744a
TITLE: Preparation of heteroarylpyrrolizineacetates and analogs as cyclooxygenase and lipoxygenase inhibitors
INVENTOR(S): Lasser, Stefan; Striegel, Hans Guenther; Dannhardt, Gerd
PATENT ASSIGNEE(S): Merckle GmbH, Germany
SOURCE: Ger. Offen., 25 pp.
CODEN: GWXXEX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4419246	A1	19951207	DE 1994-4419246	19940601
CA 2191747	A1	19951207	CA 1995-2191747	19950531
CA 2191747	C	20070123		
WO 9532979	A1	19951207	WO 1995-EP2077	19950531
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9526728	A	19951221	AU 1995-26728	19950531
EP 763036	A1	19970319	EP 1995-921799	19950531
EP 763036	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10504769	T	19980623	JP 1996-500332	19950531
JP 3671302	B2	20050713		
AU 223917	T	20020915	AT 1995-921799	19950531
PT 763036	T	20021231	PT 1995-921799	19950531
ES 2182963	T3	20030316	ES 1995-921799	19950531
US 5958943	A	19990928	US 1996-737919	19960328
NO 9605093	A	19961129	NO 1996-5093	19961129
NO 310491	B1	20010618		
FI 9604771	A	19970127	FI 1996-4771	19961129
FI 113964	B1	20040715		
PRIORITY APPLN. INFO.:			DE 1994-4419246	A 19940601
			WO 1995-EP2077	W 19950531
OTHER SOURCE(S):			MARPAT 124:202009	
GI				



L19 ANSWER 81 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB Title compds. [I; 1 of R1-R3 = heteroaryl, 1 of the remaining = H or (hetero)aryl, and the remaining = H, CHO, carboxy(alkyl), alkoxycarbonyl, etc.; R4-R7 = H or alkyl; 2 of vicinal R4-R7 = bond; X = CH2, CO, O, S, etc.] were prepared Thus, title compound II had IC50 of 4x10-7 and 2x10-7 (units not given) against lipoxygenase and cycloxygenase, resp.
IT 174347-96-7P 174347-97-8P 174347-98-9P
174347-99-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylpyrrolizineacetates and analogs as cyclooxygenase and lipoxygenase inhibitors)
RN 174347-96-7 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(5-chloro-2-thienyl)-2,2-diethyl-2,3-dihydro-N-(methylsulfonyl)-7-phenyl- (CA INDEX NAME)



RN 174347-97-8 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(5-chloro-2-thienyl)-2,2-diethyl-2,3-dihydro-N-[(4-methylphenyl)sulfonyl]-7-phenyl- (CA INDEX NAME)



L19 ANSWER 81 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 174347-98-9 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(5-chloro-2-thienyl)-2,3-dihydro-2,2-dimethyl-N-(methylsulfonyl)-7-phenyl- (CA INDEX NAME)



RN 174347-99-0 CAPLUS
CN 1H-Pyrrolizine-5-acetamide, 6-(5-chloro-2-thienyl)-2,3-dihydro-2,2-dimethyl-N-[(4-methylphenyl)sulfonyl]-7-phenyl- (CA INDEX NAME)



L19 ANSWER 82 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:148174 CAPLUS
DOCUMENT NUMBER: 124:274366
ORIGINAL REFERENCE NO.: 124:50511a,50514a
TITLE: Silver halide photographic material containing dye with lens residual color
INVENTOR(S): Harada, Tooru; Arai, Naoki
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07333784	A	19951222	JP 1994-122666	19940603
PRIORITY APPLN. INFO.:			JP 1994-122666	19940603

GI



I

AB The material has a hydrophilic colloidal layer containing ≥1 dye I [Z1-2 = nonmetal atoms to form benzo or naphtho condensed ring; L4-5 = C1-4 alkylene, R1-2 = CONHA, SO2NHA; A = COR7, SO2R7; R7 = alkyl; R3-6 = alkyl, R3 and R4 or R5 and R6 may form a ring; L1-3 = methine (which may link to form 5- or 6-membered ring); M1-2 = alkali metal salt, ammonium salt, neg. charge; X = anion; n = 1-2, when inner salt is formed, n = 1]. The material shows good storage stability and less residual color after processing.
IT 175220-19-6 175220-22-1
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(photog. film containing dye in surface protective layer)
RN 175220-19-6 CAPLUS
CN 3H-Indolium, 2-[7-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-2H-indol-2-ylidene]-1,3,5-heptatrien-1-yl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-, inner salt, potassium salt (1:1) (CA INDEX NAME)

L19 ANSWER 82 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—Me

RN 175220-22-1 CAPLUS
CN 3H-Indolium, 2-[2-[2-[(2-carboxyphenyl)thio]-3-[2-[1,3-dihydro-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-2H-indol-2-ylidene]ethylidene]-1-cyclohexen-1-yl]ethenyl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-sulfo-, inner salt, potassium salt (1:1) (CA INDEX NAME)



L19 ANSWER 83 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:34578 CAPLUS
DOCUMENT NUMBER: 124:73507
ORIGINAL REFERENCE NO.: 124:13117a,13120a
TITLE: Direct positive silver halide color photographic material and image formation with improved background whiteness and processing stability
INVENTOR(S): Sasagawa, Masayuki; Ookawachi, Susumu
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 56 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07257631	A	19951023	JP 1994-45937	19940316
PRIORITY APPLN. INFO.:			JP 1994-45937	19940316

GI

AB In the title photog. material having a photosensitive layer containing pevaniformed inner latent image type Ag halide grains and a nonphotosensitive layer, a) photosensitive emulsion layer contains compound I [E1, E2 = non-metallic atoms required to form 5- or 6-membered ring; L1 = methine; R1 = -J2SO2NR2, -J3CONHCOA2, -J4CONHSO2A3, -J5SO2NHCOA4, NHSO2NHSO2A5; J1-4, R2-5 = alkylene; l1, l2 = 0, 1; n = odd integer), and the total swelling degree of the emulsion layer-containing side comparing to the support ranges from 80-200%.
IT 172415-58-6
RL: DEV (Device component use); USES (Uses)
(sensitizing dye contained in direct pos. photog. material)
RN 172415-58-6 CAPLUS
CN Benzoxazolium, 5-chloro-2-[2-[[6-methoxy-5-methyl-3-(2-[methylsulfonyl]amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-(2-sulfoethyl)-, inner salt (CA INDEX NAME)

L19 ANSWER 84 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:990799 CAPLUS
DOCUMENT NUMBER: 124:131426
ORIGINAL REFERENCE NO.: 124:24178a,24179a
TITLE: Supersensitizing bisbenzothiazolocyanine dye combination for red-sensitive silver halide emulsion
INVENTOR(S): Preddy, Carl R.; Holtzclaw, John V.
PATENT ASSIGNEE(S): Eastman Kodak Co., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5464735	A	19951107	US 1993-163969	19931207
PRIORITY APPLN. INFO.:			US 1993-163969	19931207

OTHER SOURCE(S): MARPAT 124:131426
GI

AB There is disclosed a photog. material comprising a layer of a silver halide emulsion containing a sensitizing combination of a first dye represented by the formula I (R1, R2 = halogen; R3 = H; R4, R5 = RSCONHSO2R8- or -RSCONHSO2R8 where R8 = alkyl; R9 = alkylene; R6, R7 = H, alkyl, or alkoxy; X+ = monovalent cation) and a second dye represented by the formula I (R1, R2 = H, halogen, alkyl, or alkoxy; R3 = alkyl; R4, R5 = sulfoalkyl, carboxyalkyl, sulfoalkylcarbamoylalkyl, sulfoalkylcarbamoylalkyl, sulfo(hydroxy)alkyl, RSCONHSO2R9- or -RSCONHSO2R8 where R8 = alkylene; R6, R7 = H or alkoxy; X+ = a monovalent cation).
IT 173307-54-5 173307-55-6 173307-56-7
173307-57-8 173307-58-9
RL: TEM (Technical or engineered material use); USES (Uses)
(red-sensitive silver halide emulsion supersensitization using bisbenzothiazolocyanine dye combinations containing)
RN 173307-54-5 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]- (CA INDEX NAME)



L19 ANSWER 83 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 84 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

RN 173307-55-6 CAPLUS
CN Benzothiazolium, 5-chloro-2-[3-[5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]- (CA INDEX NAME)

RN 173307-56-7 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-chloro-3-[2-[(ethylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[(ethylsulfonyl)amino]-2-oxoethyl]- (CA INDEX NAME)



RN 173307-57-8 CAPLUS
CN Benzothiazolium, 5-chloro-2-[3-[5-chloro-3-[2-[(ethylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]-1-propen-1-yl]-3-[2-[(ethylsulfonyl)amino]-2-oxoethyl]- (CA INDEX NAME)

L19 ANSWER 84 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 173307-58-9 CAPLUS
CN Benzothiazolium, 3-chloro-2-[3-[5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]- (CA INDEX NAME)



L19 ANSWER 85 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:853720 CAPLUS
DOCUMENT NUMBER: 124:101746
ORIGINAL REFERENCE NO.: 124:18768a,18752a
TITLE: Silver halide photographic material spectrally sensitized by cyanine dye
INVENTOR(S): Kita, Noriyasu; Kozawa, Nobuaki
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 51 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07209792	A	19950811	JP 1994-2731	19940114
PRIORITY APPLN. INFO.:			JP 1994-2731	19940114

GI



AB The claimed photog. material has at least one Ag halide emulsion layer spectrally sensitized by a merocyanine dye I (R1 = C1-10 aliphatic group with water-solubilizing substituent; A = group forming a merocyanine dye and linked through conjugated bonds with the oxazole moiety) or cyanine dye II (R2 = C1-10 aliphatic group with water-solubilizing substituent; D = group forming a cyanine dye and linked through conjugated bonds with the oxazole moiety; X- = counter ion). The spectral sensitizers increase both photosp. speed and wash off property resulting in low residual dye stain. They are suited for color papers and medical x-ray films of rapid processing types.
IT 172356-56-8 172356-99-9
RL: DEV (Device component use); USES (Uses)
(silver halide photog. material spectrally sensitized by cyanine dye)
RN 172356-56-8 CAPLUS
CN Benzoxazolium, 2-[2-[[5-chloro-3-(3-sulfopropyl)-2(3H)-benzoxazolylidene]methyl]-1-buten-1-yl]-5,6-dimethoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 83 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 172356-99-9 CAPLUS
CN Benzoxazolium, 2-[2-[3-[carboxymethyl)-2-[(2,3-dihydro-3-methyl-2-benzothiazolyl)methylene]-1-methyl-5-oxo-4-imidazolidinyl]-1-propen-1-yl]-5,6-dimethoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br-

L19 ANSWER 86 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:896138 CAPLUS
DOCUMENT NUMBER: 123:286058
ORIGINAL REFERENCE NO.: 123:51267a,51270a
TITLE: Preparation of imidazopyridazine angiotensin II antagonists
INVENTOR(S): Dorsch, Dieter; Medereski, Werner; Oswald, Mathias; Schelling, Pierre; Seiss, Norbert; Lues, Ingo; Nunch, Klaus-Otto
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4339868	A1	19950524	DE 1993-4339868	19931123
EP 657454	A1	19950614	EP 1994-117936	19941114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2136288	A1	19950524	CA 1994-2136288	19941121
AU 9478950	A	19950601	AU 1994-78950	19941121
NO 9404469	A	19950524	NO 1994-4469	19941122
ZA 9408260	A	19950803	ZA 1994-8260	19941122
CN 1109057	A	19950927	CN 1994-118958	19941122
JP 07267959	A	19951017	JP 1994-288411	19941122
HU 71113	A2	19951128	HU 1994-3364	19941123
PRIORITY APPLN. INFO.:			DE 1993-4339868	A 19931123

OTHER SOURCE(S): CASREACT 123:286058; MARPAT 123:286058
GI

AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, (un)substituted OCOR, CN, NO2, (un)substituted NH2, etc.; R3 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl; X = NHCO, CONH, OCH(CO2H), NHCH(CO2H), etc.; Y = O, S], useful as angiotensin II antagonists (no data), are prepared and I-containing formulations presented.
IT 169752-16-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

L19 ANSWER 86 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
study); PAEP (Preparation); USES (Uses)
(prepn. of imidazopyridazine angiotensin II antagonists)
RN 169752-34-5 CAPLUS
CN 5H-Imidazo[4,5-d]pyridazine-5-acetamide, 2-butyl-3-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3,4-dihydro-4-oxo-N-[phenylsulfonyl]- (CA INDEX NAME)



L19 ANSWER 87 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:773837 CAPLUS
DOCUMENT NUMBER: 123:270636
ORIGINAL REFERENCE NO.: 123:48163a,48164a
TITLE: Silver halide photographic material spectrally sensitized by trimethine cyanine and containing hydrazine for enhanced contrast
INVENTOR(S): Toshida, Tetsuo
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07120863	A	19950512	JP 1993-286148	19931022
JP 3030462	B2	20000508		
PRIORITY APPLN. INFO.:			JP 1993-286148	19931022

GI For diagram(s), see printed CA Issue.
AB The photog. material contains (1) a hydrazine derivative
RIR(A1)NA2)G1R2 (R1 = aliphatic or aromatic substituent; R2, R3 = H, alkyl, aryl, unsatd. heterocyclic ring, alkoxy, aryloxy, amino, hydrazino, etc.; G1 = CO, SO2, SO, POR3, COCO, thiocarbonyl, iminomethylene; A1, A2 = H, alkylsulfonyl, arylsulfonyl, acyl) and (2) a spectral sensitizer I [Z1, Z2, Z3 = 5- or 6-membered N-containing heterocyclic ring; R1, R2, R3 = H, alkyl, aryl, heterocyclic ring; at least 2 of R1, R2, and R3 are organic groups with water-solubilizing groups; L1-L7 = methine; n, m = 0, 1; X1 = counter ion]. The material has high contrast and is suitable for scanners and laser image recording. It is little affected by exhaustion of a developer solution
IT 169409-33-4
RL: TEM (Technical or engineered material use); USES (Uses)
(Ag halide photog. material spectrally sensitized by trimolear cyanine and containing hydrazine for enhanced contrast)
RN 169409-33-4 CAPLUS
CN Benzothiazolium, 2-[[3-ethyl-5-[2-[4-methyl-3-(4-sulfobutyl)-2(3H)-thiazolylidene]ethylidene]-4-oxo-2-thiazolidinylidene]methyl]-5,6-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt, potassium salt (1:1) (CA INDEX NAME)

L19 ANSWER 87 OF 138 CAPLUS (Continued)

L19 ANSWER 88 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:753716 CAPLUS
DOCUMENT NUMBER: 123:301415
ORIGINAL REFERENCE NO.: 123:53775a,53778a
TITLE: Silver halide photographic materials providing low residual color
INVENTOR(S): Kuno, Koichi; Suga, Shuzo
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07128779	A	19950519	JP 1993-293825	19931101
US 5589325	A	19961231	US 1996-589210	19960122
PRIORITY APPLN. INFO.:			JP 1993-293825	A 19931101
			US 1994-331193	B1 19941028

GI

AB The materials comprise supports coated with Ag halide emulsions that are spectrally sensitized by DYE-Gn or DYE-G-n [DYE = methyne dye; n = 1, 3; G, G- = substituent TIG1NHG2 or TIG1N-G2 (T1 = linking group; G1 = CO, SO, SO2; G2 = CO2, SO2, SO2T2, CH; T2 = monovalent group)] and contains a phenony alc. I [R = alkylene, A = halo, NO2, alkyl, (substituted) amino, CO2R, SO3M (R2 = H, OM, alkyl, alkoxy, (substituted) amino; M, alkali metal, monovalent cation); n = 0-5]. The materials show high sensitivity and low residual color.
IT 165594-05-8
RL: TEM (Technical or engineered material use); USES (Uses)
(Ag halide photog. material containing spectral sensitizing dye and phenony alc. for low residual color stain)
RN 165594-05-8 CAPLUS
CN Benzothiazolium, 6-methoxy-2-[3-[6-methoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]-2-methyl-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 88 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 89 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:746412 CAPLUS
DOCUMENT NUMBER: 124:41266
ORIGINAL REFERENCE NO.: 124:7609a,7612a
TITLE: Image forming method by hydrazine-containing silver halide photographic material spectrally sensitized by trimerkein cyanine
INVENTOR(S): Yoshida, Tetsuo
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 59 pp.
CODEN: JKXLAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07122893	A	19950512	JP 1993-287316	19931025
PRIORITY APPLN. INFO.:			JP 1993-287316	19931025

AB The photog. material, having ≥1 Ag halide emulsion layer (≥50 mol% AgCl) and containing hydrazine compound I(HAL)NA(R1)NR2 [R1 = aliphatic, aromatic; R2 = H, alkyl, aryl, unsatd. heterocyclic, etc.; Gl = CO, SO2, SO, CCCO, CS, iminoethylene; A1, A2 = H, (substituted) alkyl, aryl, etc.] and a spectral sensitizer I (L1-7 = methyne), is developed by a dihydroxybenzene-free developer containing PC(=Y)C(R3)=C(R2)Q [R1, R2 = OH, (substituted) amine, SH, alkylthio; P, Q = OH, carboxyl, alkoxy, (substituted) alkylsulfo, amine, aryl; Y = O, NR3; R3 = H, OH, (substituted) alkyl, acyl]. The photog. material may contain a nucleating accelerator of amines, disulfides, oniums, and/or hydroxymethyl compds. The material gives an image with high contrast suitable for graphic arts.

IT 160891-51-8
RL: DEV (Device component use); USES (Uses)
(sensitizer; development of hydrazine-containing Ag halide photog. material)
spectrally sensitized by trimerkein cyanine by hydroxybenzene-free developer)

RN 160891-51-8 CAPLUS
CN Benzothiazolium, 2-[[3-ethyl-5-[2-[4-methyl-3-(4-sulfobutyl)-2(3H)-thiazolylidene]ethylidene]-4-oxo-2-thiazolidinylidene]methyl]-5,6-dimethoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, sodium salt (1:1) (CA INDEX NAME)

L19 ANSWER 89 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L19 ANSWER 90 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:742595 CAPLUS
DOCUMENT NUMBER: 123:143436
ORIGINAL REFERENCE NO.: 123:25537a,25540a
TITLE: N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
INVENTOR(S): Lee, Helen Tsenzhen; Floyd, Joseph Armand; Slikkovic, Drago Robert; Wierenga, Wendell
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9426702	A1	19941124	WO 1994-US5233	19940511
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5481172	A	19960102	US 1994-223932	19940413
CA 2158268	A1	19941124	CA 1994-2158268	19940511
CA 2158268	C	20061107		
AU 9468311	A	19941212	AU 1994-68311	19940511
AU 681152	B2	19970821		
EP 698010	A1	19960228	EP 1994-916734	19940511
EP 698010	B1	19990414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 72653	A2	19960528	HU 1995-2811	19940511
HU 223044	B1	20040201		
JP 08510256	T	19961029	JP 1994-525674	19940511
JP 3704149	B2	20051005		
RU 2137756	C1	19990920	RU 1995-122768	19940511
NZ 262790	B6	20021203	NZ 1995-262790	19940511
FI 9505438	A	19951110	FI 1995-5438	19951110
NO 9504544	A	19960111	NO 1995-4544	19951113
NO 305961	B1	19990609		
PRIORITY APPLN. INFO.:			US 1993-62515	A 19930514
			US 1994-223932	A 19940413
			WO 1994-US5233	W 19940511

OTHER SOURCE(S): CASREACT 123:143436; MARPAT 123:143436
AB Compds. of formula R1SO(O)NHCOYR2 (R = H, C1-8 alkyl, benzyl; R1, R2 = Ph, phenoxy, naphthyl, arylalkyl, C1-20 alkyl, etc.; X, Y = O, S, alkyl), or their salts, are useful for the regulation of plasma cholesterol Compds. may be used for treatment of hypercholesterolemia and atherosclerosis. Preparation of 68 compds. is presented.

IT 166518-64-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acyl sulfamic acid esters (or thioesters), acyl sulfonamides, and sulfonyl carbamic acid esters (or thioesters) as antihypercholesterolemic agents)

L19 ANSWER 90 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 166518-64-5 CAPLUS
CN Benzeneacetamide, 2,6-bis[1-methylethyl)-N-[[2,4,6-tris[1-methylethyl]phenyl]methyl]sulfonyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L19 ANSWER 91 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:712005 CAPLUS
DOCUMENT NUMBER: 123:97735
ORIGINAL REFERENCE NO.: 123:17178a,17182a
TITLE: Methine compounds and silver halide photographic materials containing the compound.
INVENTOR(S): Inagaki, Yoshiyo; Suga, Shuso
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 57 pp.
CODEN: EPXLDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 638841	A2	19950215	EP 1994-106493	19940607
EP 638841	A3	19950913		
EP 638841	B1	20000419		
R: DE, FR, GB				
JP 07056265	A	19950303	JP 1994-125318	19940607
JP 3480949	B2	20040106		
US 5464734	A	19951107	US 1994-257851	19940608
PRIORITY APPLN. INFO.:			JP 1993-137412	A 19930608

OTHER SOURCE(S): MARPAT 123:97735
AB A Ag halide photog. material contains a compound of formula; (DYE)-(G)n or (DYE)-(G)n-L [DYE = a methine dye residue; G and G- each = a substituent for the methine dye residue, and are represented by formula: -T1-G1NEG2 and -T1-G1N-G2 resp.; T1 = a divalent linking group; G1 = a carboxyl group, a sulfinyl group, or a sulfonyl group; G2 = -CO-T2, -SO-T2, -SO2-T2, or a cyano group; and T2 = a monovalent group; n = an integer of from 1 to 4]. The spectral sensitivity of the material is high, and the material has few residual color after processed.
IT 165594-05-8
RL: MOA (Modifier or additive use); USES (Uses)
(photog. sensitizer)
RN 165594-05-8 CAPLUS
CN Benzothiazolium,
6-methoxy-2-[3-[6-methoxy-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]-2-methyl-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 91 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L19 ANSWER 92 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:497795 CAPLUS
DOCUMENT NUMBER: 123:183362
ORIGINAL REFERENCE NO.: 123:32564b,32565a
TITLE: Silver halide photographic materials and methine compounds
INVENTOR(S): Inagaki, Yoshio
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07128782	A	19950519	JP 1993-276653	19931105
PRIORITY APPLN. INFO.:			JP 1993-276653	19931105

GI



AB The photog. materials contain the compound I or II (Q = benzoxazole, thiazoline; L1-4 = methine; T1 = divalent residue; G1 = CO, SO, SO2; G2 = COT2, SOT2, SO2T2; CN; T2 = monovalent residue; R1-3 = alkyl, alkylene forming heterocycle; X- = anion). The methine compds. I and II are claimed. The materials prevent residual color stains.
IT 167697-00-5
RL: NEV (Novel component use); USES (Uses)
(hemicyanine spectral sensitizing dyes for silver halide photog. materials)
RN 167697-00-5 CAPLUS
CN Benzoxazolium, 2-[4-[(carboxymethyl)ethylamino]-1,3-butadien-1-yl]-5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 92 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 93 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:641173 CAPLUS
DOCUMENT NUMBER: 124:8801
ORIGINAL REFERENCE NO.: 124:1561a,1564a
TITLE: Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazolealkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
INVENTOR(S): Musser, John H.; Kreft, Anthony F., III; Failli, Amedeo A.; Demerson, Christopher A.; Shah, Utesh S.; Nelson, James A.
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: U.S., 35 pp. Cont.-in-part of U.S. 5,229,516.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5420289	A	19950530	US 1993-29199	19930310
CA 2090042	A1	19910828	CA 1990-2090042	19901017
US 5229516	A	19930720	US 1992-911434	19920710
PRIORITY APPLN. INFO.:			US 1989-428640	B2 19891027
			US 1990-596134	B2 19901011
			US 1992-911434	A2 19920710
			CA 1990-2090422	A3 19901027

OTHER SOURCE(S): CASREACT 124:8801; MARPAT 124:8801
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention relates to substituted indole derivs. A(CE2)nOB wherein A =

I or II wherein R1 is hydrogen, lower alkyl, Ph or Ph substituted with trifluoromethyl; R2 is hydrogen or lower alkyl; or R1 and R2 taken together form a benzene ring; R3 is hydrogen or lower alkyl; n is 1-2; B is III-VII wherein R4 is, e.g., CO2R2, m is 0-3; R5 is A(CH2)nOC6H4 or Ph or Ph substituted by halo, lower alkylthio, lower alkylsulfinyl or lower alkylsulfonyl; R6 is A(CH2)nO or halo; R7 is lower alkyl; Y is CH2 or O; R8 is lower alkyl or (CH2)mCO2R3 ; R9 is CO3l0 or (CH2)s3l0, o is 1-4;
R10
is lower alkyl, Ph, Ph substituted with carboxy, halo, lower alkyl, loweralkylthio or loweralkylsulfinyl; naphthyl, pyridyl, furanyl, quinolinyl, or 2-R14-thiazolyl; R11 is lower alkyl or phenyl; R12 is hydrogen or loweralkylcarbonyl R13 is hydrogen, hydroxy, lower alkyl or lower alkoxy; R14 is Ph or halophenyl; Z2 is hydrogen, lower alkyl or N(CH3)OH; and the pharmacol. acceptable salts thereof possessing

L19 ANSWER 94 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:641018 CAPLUS
DOCUMENT NUMBER: 123:286097
ORIGINAL REFERENCE NO.: 123:5127Sa,5127Sa
TITLE: Pyrimidinyl alkanoic acid amide derivatives, salts, and herbicidal compositions
INVENTOR(S): Yoshinura, Takumi; Toriyabe, Keiji; Maruda, Katsumi; Banal, Ryo
PATENT ASSIGNEE(S): Kumiai chemical industry co., ltd., Japan; Ihara chemical industry co., ltd.
SOURCE: U.S., 30 pp. Cont.-in-part of U.S. Ser. No. 916,127.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5418212	A	19950523	US 1993-53908	19930427
US 5411934	A	19950502	US 1992-916127	19920730
PRIORITY APPLN. INFO.:			JP 1990-330168	A 19921130
			US 1992-916127	A2 19920730
			WO 1991-JP1649	W 19911129

OTHER SOURCE(S): CASREACT 123:286097; MARPAT 123:286097
GI

AB The present invention provides a novel alkanoic acid amide derivative of the
formula I [wherein X1 is a hydrogen aten, an alkyl group or an alkoxyalkoxy group, X2 is a group of NO2R (R = e.g., alkyl or a hydroxyl group, X5 is an alkyl group, X3 is an alkyl group, a cycloalkyl group, a cycloalkenyl group or a Ph group, Y4 is a hydrogen aton or an alkyl group,
X and Y may be the same or different and are an alkoxy group, an alkylamino group or a dialkylamino group, and Z is a nitrogen aton] and its salt, a process for preparing the same and a herbicidal composition containing the
same as an effective ingredient. This compound kills annual and perennial
weeds grown in paddy fields and upland fields at a small dose, and is safe
to a useful crop plant. Thus, e.g., 2-(4,6-dimethoxypyrimidin-2-yl)-3-methylbutyric acid (preparation given) was



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 95 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
lipoxygenase inhibitory, phospholipase A2 inhibitory and leukotriene antagonist activity, which are useful as anti-inflamatory, antiallergic and cytoprotective agents. Thus, e.g., condensation of 2-methyl-5-[2-quinolinylmethoxy]indene-3-acetic acid Et ester (prepn. given, mixt. of endo and exo isomers) with p-chlorobenzaldehyde afforded

3-[(4-chlorophenyl)methylene]-2-methyl-6-(2-quinolinylmethoxy)-3H-indene-1-acetic acid (VIII, Q = 2-quinolinylmethyl, mixt. of S (major) and R (minor) isomers). The specificity of action of PLA2 inhibitors can be detd. by the activity of test compds. to inhibit the synthesis of LTB4 by rat glycogen-elicited polymorphonuclear leukocytes (PMN) in the presence of exogenous substrates VIII demonstrated 96% inhibition at 10 mM. VIII also inhibited the synthesis of the arachidonic acid cyclooxygenase oxidn.
product PGH2 with 81% inhibition at 10 mM. VIII inhibited the release of arachidonic acid from an arachidonic acid-contg. substrate by the action of phospholipase A2 enzyme from human synovial fluid with IC50 = 9.7 nM. Further assays demonstrated that the compds. of the invention exerted an inhibitory effect on both the lipoxygenase pathway and the cyclooxygenase pathway and have significant leukotriene (LTD4) antagonist activity. The compds. of the invention inhibited the acute inflammatory response and inhibited 5-lipoxygenase in human whole blood.
IT 135872-84-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PUSP (Preparation) (THER (Ther.)
(substituted indole-, indene-, pyranoindole- and tetrahydrocarbazolealkanoic acid derivs. as inhibitors of PLA2 and lipoxygenase)
RN 135872-84-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)-5-[(2-quinolinylmethoxy)- (CA INDEX NAME)



L19 ANSWER 94 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
treated with carboxylidinindazole in THF to afford 2-(4,6-dimethoxypyrimidin-2-yl)-3-methylbutyrylimidazole (86.7% yield); amidation of the latter with methanesulfonamide afforded 2-(4,6-dimethoxypyrimidin-2-yl)-3-methyl-N-methylsulfonylbutyric acid amide (76.8% yield) which demonstrated an herbicidal effect of at least 50% against barnyardgrass, monochoria, and bulrush.
IT 140764-78-5P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrimidinsyl alkanoic acid amide derivs., salts, and herbicidal compns.)
RN 140764-78-5 CAPLUS
CN 2-Pyrimidineacetamide, 4,6-dimethoxy-N-(methylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 95 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:459462 CAPLUS
DOCUMENT NUMBER: 122:201055
ORIGINAL REFERENCE NO.: 122:36503a,36504a
TITLE: Silver halide photographic material for super high-contrast images
INVENTOR(S): Yamasaki, Kazuki; Okazaki, Masaki; Fujiwara, Toshinori
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXLAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06250322	A	19940909	JP 1993-33722	19930223
US 5480994	A	19960102	US 1994-334042	19941103
PRIORITY APPLN. INFO.:			JP 1992-353136	A 19921207
			JP 1992-352393	A 19921211
			JP 1992-354748	A 19921217
			JP 1993-356502	A 19921222
			JP 1993-33722	A 19930223
			JP 1993-75004	A 19930310
			JP 1993-96449	A 19930401
			US 1993-161500	B1 19931206

GI

L19 ANSWER 95 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB In the title photog. material, the Ag halide emulsion layer is made of a chemical-sensitized Ag halide particle containing 50% of AgCl containing Rh compound 1a10-8-5a10-6 mol/mol(Ag) and Ir compound 1a10-8-1a10-6 mol/mol(Ag) and ≥1 spectrally sensitized by a dye selected from I or II (each R and V is a specified organic group), and a hydrazine compound is contained.
IT 161911-20-2 161911-21-3
RL: DEV (Device component use); USES (Uses)
(sensitizing dye contained in photog. film)
RN 161911-20-2 CAPLUS
CN 1H-Benzimidazolium, 5,6-dichloro-2-[3-[3,6-dichloro-3-(3-hydro-1,3-bis[2-

[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-1-methyl-3-[3-sulfopropyl]-, inner salt (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 161911-21-3 CAPLUS
CN 1H-Benzimidazolium, 5,6-dichloro-2-[3-[5,6-dichloro-1,3-dihydro-1-methyl-3-

[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-1-[3-sulfopropyl]-, inner

L19 ANSWER 95 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
salt (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L19 ANSWER 96 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:339378 CAPLUS
DOCUMENT NUMBER: 122:118768
ORIGINAL REFERENCE NO.: 122:22027a,22030a
TITLE: silver halide color photographic material
INVENTOR(S): Kuroishi, Masayuki; Ikegawa, Akihiko
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 51 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06138574	A	19940520	JP 1992-309751	19921026
PRIORITY APPLN. INFO.:			JP 1992-309751	19921026

GI



I

AB A silver halide color photog. material showing improved photosensitivity and granularity without causing increased residual color formation after development comprises ≥1 photosensitive silver halide emulsion layer and ≥1 nonphotosensitive layer, wherein the silver halide grains in the photosensitive silver halide emulsion layer contain ≥4 mol% of AgI and ≥1 of the photog. layers contains ≥1 methine compound represented by the formula I [R1 = (CH2)rCONHSO2R3, (CH2)sSO2NHCOR4, (CH2)tCONHCOR5, or (CH2)uSO2NHSO2R6 where R3-6 = alkyl, alkoxy, or amino; r, s, t, u = an integer of 1-5; R2 = alkyl or R1; Z1, Z2 = a nonmetallic atomic group necessary for forming a 5-6-membered heterocyclic ring; p, q = 0 or 1; L1-3 = a methine group; m = 0, 1, or 2; X = an anion; k = a number necessary to adjust the charge of the compound to 0].
IT 148364-36-7P
RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(preparation and use of, in silver halide color photog. material)
RN 148364-36-7 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-(methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 96 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 97 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:680647 CAPLUS
DOCUMENT NUMBER: 121:280647
ORIGINAL REFERENCE NO.: 121:51239a,51242a
TITLE: Preparation of [(tetrazolylbiphenylyl)methyl]imidazo[4,5-c]pyridines and related compounds as angiotensin II antagonistes
INVENTOR(S): Mederski, Werner; Dorsch, Dieter; Osswald, Mathias; Beier, Norbert; Schelling, Pierre; Lues, Ingeborg; Minck, Klaus Otto
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 574846	A2	19931222	EP 1993-109410	19930611
EP 574846	A3	19940706		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4305602	A1	19931223	DE 1993-4305602	19930224
AU 9341238	A	19931223	AU 1993-41238	19930611
AU 669895	B2	19960627		
CZ 283081	B6	19971217	CZ 1993-1145	19930611
CA 2098473	A1	19931218	CA 1993-2098473	19930615
NO 9302218	A	19931220	NO 1993-2218	19930616
ZA 9304289	A	19940117	ZA 1993-4289	19930616
CN 1082545	A	19940223	CN 1993-107194	19930617
CN 1038511	C	19980527		
HU 64761	A2	19940228	HU 1993-1766	19930617
JP 06056832	A	19940301	JP 1993-146312	19930617
US 5476857	A	19951219	US 1993-77592	19930617
PL 173777	B1	19980430	PL 1993-299368	19930617
PRIORITY APPLN. INFO.:			DE 1992-4219818 A	19920617
			DE 1993-4305602 A	19930224

OTHER SOURCE(S): MARPAT 121:280647
GI



I

L19 ANSWER 97 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB Title compds. [I; R1 = alkyl, alkenyl, alkynyl, cycloalkylalkyl, etc.; R2 = H, CO2H, alkoxycarbonyl, cyano, NO2, acylamino, 1H-tetrazol-5-yl; R3 = substituted alkenyl, etc.; R4 = H, halo; X = null, NHCO, OCH(CO2H), NHCH(CO2H), CH:C(CO2H), CH:C(CN), etc.; Y = O, S], were prepared as angiotensin II antagonists (no data). Thus, valeric acid and 4-amino-1,2-dihydro-2-oxo-3-[2'-(1H-5-tetrazolyl)biphenylyl-4-methylamino]-1-(N,N-dimethylcarbamoylmethyl)pyridine (preparation given) were heated 5 h in polyphosphoric acid at 140° to give 2-butyl-4,5-dihydro-5-(N,N-dimethylcarbamoylmethyl)-4-oxo-3-[2'-(1H-5-tetrazolyl)biphenylyl-4-methyl]-3H-imidazo[4,5-c]pyridine. Generic I drug formulations are given.
IT 158938-68-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)
RN 158938-68-2 CAPLUS
CN 5H-Imidazo[4,5-c]pyridine-5-acetamide, 2-butyl-3-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-3,4-dihydro-4-oxo-N-(phenylsulfonyl)- (CA INDEX NAME)



L19 ANSWER 98 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:641569 CAPLUS
DOCUMENT NUMBER: 121:241569
ORIGINAL REFERENCE NO.: 121:43961a,43964a
TITLE: Silver halide photographic material
INVENTOR(S): Ikegawa, Akihiko; Furunitsu, Masayuki; Okazaki, Masaki
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 96 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06061123	A	19931015	JP 1992-94872	19920323
US 5329748	A	19940503	US 1993-35697	19930323
PRIORITY APPLN. INFO.:			JP 1992-94872	A 19920323

GI

AB The title photog. material contains I, and II and/or III [X1 = -(CH2)-CONHSO2R3, -(CH2)-SO2NHCOR4, -(CH2)-CONHCOR5, -(CH2)-SO2NHSO2R6; R3-6 = alkyl, alkoxy, amino; r, s, t, u = 1-5; Z1,2 = non-metallic atoms required to complete a 5- or 6-membered heterocyclic ring; L1-3 = methine; n = 0-2; X = anion; k = number to neutralize charge in mol., p, q = 0, 1] in

L19 ANSWER 98 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

PAGE 1-A

PAGE 2-A



CN 2

CAN 16732-51-3
CMF C7 H7 O3 S



L19 ANSWER 98 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
.ts Ag halide photog. emulsion layers. This material shows reduced residual color and high sensitivity.
IT 157158-16-2 157158-18-4
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. sensitizer)
RN 157158-16-2 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-(2-[(methylsulfonyl)amino]-2-oxoethyl)-, bromide (1:1) (CA INDEX NAME)



● Br⁻

RN 157158-18-4 CAPLUS
CN Benzothiazolium, 5-chloro-2-[3-[5-chloro-3-[2-[[(2-hydroxyethyl)sulfonyl]amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]-2-methyl-1-propen-1-yl]-3-[2-[[(2-hydroxyethyl)sulfonyl]amino]-2-oxoethyl]-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 157158-17-3
CMF C26 H27 Cl2 N4 O8 S4

L19 ANSWER 99 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:617485 CAPLUS
DOCUMENT NUMBER: 121:217485
ORIGINAL REFERENCE NO.: 121:39375a,39378a
TITLE: Silver halide photographic photosensitive material
INVENTOR(S): Aida, Shunichi; Ikegawa, Akihiko
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 48 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05297498	A	19931112	JP 1992-125467	19920420
PRIORITY APPLN. INFO.:			JP 1992-125467	19920420

OTHER SOURCE(S): MARPAT 121:217485
GI

AB In the title material, X1 of the Ag halide emulsion layers contains a Ag halide emulsion having a Ag halide grain size <0.3 μm and X1 kind(s) of methine compds. I [X1 = -(CH2)r-CONHSO2-R3, -(CH2)s-SO2NHCO-R4, -(CH2)t-CONHCO-R5, -(CH2)u-SO2NHSO2-R6; R3-6 = alkyl, alkoxy, amino; r, s, t, u = 1-5; R2 = R1, alkyl; Z1-2 = atoms for forming a 5- or 6-membered heterocyclic ring; p, q = 0, 1; L1-3 = methine; n = 0, 1, 2; X1 = anion; k = a number for adjusting mol. charge to 0]. The material shows high spectral sensitivity, little residual color after development, and improved graininess.
IT 140350-04-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, for spectral photog. sensitizing dye)
RN 140350-04-3 CAPLUS
CN Benzothiazolium, 5-chloro-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

L19 ANSWER 99 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● Br⁻

IT 148764-36-7
RL: USES (Uses)
(spectral photog. sensitizing dye)
RN 148764-36-7 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-(methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 100 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:61476 CAPLUS
DOCUMENT NUMBER: 121:217476
ORIGINAL REFERENCE NO.: 121:39774a,39774a
TITLE: Silver halide color photographic material
INVENTOR(S): Sakuragawa, Mamoru; Ikegawa, Akihiko
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 81 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06065157	A	19931015	JP 1992-92356	19920219
PRIORITY APPLN. INFO.:			JP 1992-92356	19920219

GI

AB The title full color photog. material contains ≥ 1 [R1 = -(CH2)rCONHSO2R3, -(CH2)rCONHSO2R4, -(CH2)rCONHSO2R5, -(CH2)rCONHSO2R6; R3-6 = alkyl, alkoxy, amino; r, s, t, u = 1-5; R2 = same as R1 or alkyl; Z1,2 = non-metallic atoms required to complete a 5- or 6-membered heterocyclic ring; L1-7 = methine; n = 0-2; X = anion; k = number to neutralize charge in mol.; p, q = 0, 1], and a magenta coupler II [R1 = H, substituent; Z = non-metallic atoms required to complete a 5-membered azole ring containing 2-4 N's; X = H, group releasable on coupling reaction with oxidized developing agent]. This material shows reduced residual color.
IT 149702-97-6
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. sensitizer)
RN 149702-97-6 CAPLUS

L19 ANSWER 100 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Benzothiazolium, 5-chloro-2-[3-[5-(methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]-2-methyl-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



IT 148350-04-3P, 5-Chloro-3-methanesulfonylaminocarbonylmethyl-2-methylbenzothiazolium bromide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, photog. sensitizer from)
RN 148350-04-3 CAPLUS
CN Benzothiazolium, 5-chloro-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

L19 ANSWER 101 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:191093 CAPLUS
DOCUMENT NUMBER: 121:191093
ORIGINAL REFERENCE NO.: 121:34458a,34458a
TITLE: methine compound and silver halide photographic material using same
INVENTOR(S): Hioki, Takanori; Ikegawa, Akihiko
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05273684	A	19931022	JP 1992-98503	19920326
PRIORITY APPLN. INFO.:			JP 1992-98503	19920326

OTHER SOURCE(S): MARPAT 121:191093
GI

AB Claimed are a methine compound I [Z1-3 = atoms required to complete a 5- or 6-membered N-containing heterocyclic ring; L1-9 = methine group; l, o = 0, 1; n, n > 0; W = counter ion; m1 ≥ 0; R1,3 = alkyl; R2 = alkyl, aryl, heterocyclyl]. The title Ag halide photog. material contains ≥1 methine compound claimed above. This material shows high sensitivity and reduced residual color.
IT 157939-94-1 157939-95-2 157939-96-3
RL: USES (Uses)
(photog. sensitizing dye)
RN 157939-94-1 CAPLUS
CN Benzothiazolium, 5-chloro-2-[3-ethyl-5-(3-ethyl-2(3H)-benzothiazolylidene)-4-oxo-2-thiazolidinylidene]methyl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, sodide (1:1) (CA INDEX NAME)

L19 ANSWER 101 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● I⁻

RN 157939-95-2 CAPLUS
CN Benzothiazolium, 5-chloro-3-[[5-(3-ethyl-2(3H)-benzothiazolylidene)-3-[2-[methylsulfonyl]amino]-2-oxoethyl]-4-oxo-2-thiazolidinylidene]methyl]-3-[2-[(methylsulfonyl]amino]-2-oxoethyl]-, iodide (1:1) (CA INDEX NAME)



● I⁻

RN 157939-96-3 CAPLUS
CN Benzothiazolium, 5-chloro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-[[3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-[3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2(3H)-benzothiazolylidene]-4-oxo-2-thiazolidinylidene]methyl]-, iodide (1:1) (CA INDEX NAME)

L19 ANSWER 101 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

● I⁻

IT 140370-04-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, photog. sensitizing dye Ircn)
RN 140370-04-3 CAPLUS
CN Benzothiazolium, 5-chloro-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

IT 157940-11-9P
RL: PREP (Preparation)
(preparation of, as photog. sensitizing dye)
RN 157940-11-9 CAPLUS
CN Benzothiazolium, 5-chloro-2-[[3-ethyl-5-[2-[3-ethyl-4-methyl-2(3H)-thiazolylidene)ethylidene]-4-oxo-2-thiazolidinylidene]methyl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 101 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 102 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:521597 CAPLUS
DOCUMENT NUMBER: 121:121597
ORIGINAL REFERENCE NO.: 121:21725a,21728a
TITLE: Processing method for high-sensitivity silver halide color photographic photosensitive material
INVENTOR(S): Kuroiahi, Masayuki; Ikegawa, Akihiko
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 42 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05297543	A	19931112	JP 1992-125464	19920420
PRIORITY APPLN. INFO.:			JP 1992-125464	19920420

OTHER SOURCE(S): MARPAT 121:121597
GI



AB The title method processes a Ag halide color photog. photosensitive material containing ≥1 kind(s) of methine compds. I [R1 = (-CH2-)r-CONHSO2-R3, (-CH2-)s-SO2NHCOR4, (-CH2-)t-COHNSO-R5, (-CH2-)u-SO2NHSO2-R6; R3-R6 = alkyl, alkoxy, amino; r, s, t, u = 1-5; R2 = R1, alkyl; Z1, Z2 = nonmetallic atoms for forming 5- or 6-membered heterocyclic ring; p, q = 0, 1; L1-L3 = methine group; m = 0-2; X1 = anion; k = numbers necessary for adjusting charge on the mol. to zero] and the processing method comprises color development with a color developer having a pH >11. The invention provides color images without residual color after developing-processing a high-sensitivity color photog. photosensitive material.
IT 140364-36-7
RL: USES (Uses)
(photog. sensitizing dye, for high-sensitivity photosensitive material)
RN 140364-36-7 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-(methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-3-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 102 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 148750-04-7P, 5-Chloro-3-methanesulfonylaninoxobornylmethyl-2-methylbenzothiazolium bromide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, for photog. sensitizing methine dye)
RN 148750-04-7 CAPLUS
CN Benzothiazolium, 5-chloro-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



L19 ANSWER 103 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:699050 CAPLUS
DOCUMENT NUMBER: 121:299050
ORIGINAL REFERENCE NO.: 121:57358a,57358a
TITLE: Synthesis and excitatory amino acid pharmacology of some novel quisqualic diodioses
AUTHOR(S): Epperson, James R.; Newcaaan, Fayaena; Mearwell, Nicholas A.; Boissard, Christopher G.; Gribbofd, Valentin R.; Post-Munson, Debra
CORPORATE SOURCE: Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, 06492, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1993), 3(12), 2801-4
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

AB The synthesis and amino acid pharmacol. of 12 N-substituted quisqualinediioses is reported. In particular, (I, R = Me, or Cl) show significant antagonism at both the AMPA and glycine-site NMDA receptors. The functional antagonism of I (R = Me) was demonstrated.
IT 156452-61-9P 156452-62-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and AMPA and NMDA receptor antagonist activities of, structure in relation to)
RN 156452-61-8 CAPLUS
CN 1(2H)-Quinoxalineacetamide, 3,4-dihydro-6,7-dimethyl-N-(methylsulfonyl)-2,3-dioxo- (CA INDEX NAME)



RN 156452-62-9 CAPLUS
CN 1(2H)-Quinoxalineacetamide, 3,4-dihydro-6,7-dimethyl-N-[(4-

L19 ANSWER 103 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 104 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:495797 CAPLUS
DOCUMENT NUMBER: 121:95797
ORIGINAL REFERENCE NO.: 121:16985a,16986a
TITLE: Silver halide photographic material
INVENTOR(S): Ikeda, Midoru; Ikegawa, Akihiko
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05204082	A	19930813	JP 1992-36928	19920129
JP 2779725	B2	19980723		
PRIORITY APPLN. INFO.:			JP 1992-36928	19920129

OTHER SOURCE(S): MARPAT 121:95797
GI

AB In the title material having ≥1 Ag halide emulsion layer(s), the emulsion contains ≥3 mol% of Ag1 and the layer(s) contains Z1 methine compd(s). I R1 = (CH2)2COMBSO2R3, (CH2)2SO2NHCOR4, (CH2)2CONHCOR5, (CH2)2SO2NHSO2R6; R3-6 = alkyl, alkoxy, NH2; r, s, t, u = 1-3; R2 = H, alkyl; Z1, Z2 = non-metallic atoms forming 5- or 6-membered heterocycle; p, q = 0,1; L1-3 = methine; m = 0-2; X1 = anion; k = number to neutralize charge of I). The above material also contains ≥1 mercapto compd(s). II (M1 = H, group protecting mercapto group cleavable by cation or alkali; X2 = atoms forming 5- or 6-membered heterocycle which may be substituted or fused). The material containing I and II has improved shelf life and forms less residual color.
IT 168364-36-7P
RL: PREP (Preparation)
(preparation of, photog. emulsion from)
RN 168364-36-7 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[5-(methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 104 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 105 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:495788 CAPLUS
DOCUMENT NUMBER: 121:95788
ORIGINAL REFERENCE NO.: 121:16982h,16983a
TITLE: Silver halide color photographic material
INVENTOR(S): Hara, Takeshi; Ikegawa, Akihiko
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 69 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05100373	A	19930423	JP 1991-289544	19911009
PRIORITY APPLN. INFO.:			JP 1991-289544	19911009

GI


I

AB In the title photog. material possessing at least each one blue-, green-, and red-sensitive silver halide emulsion layer on a support, at least one constituent layer of said photog. material contains at least one development inhibitor-releasing coupler ALnGm(Time)tX {A = oxidation-reduction parent nucleus or its precursor, which is a group of atoms capable of releasing (Time)tX only when oxidized during photog. development; Time = group capable of releasing a development inhibitor X after it leaves from the oxidized form of a; L = bivalent linkage group; G = acidic group; n, m, t = 0, 1], and at least one of silver halide emulsion layers contains at least one methine sensitizing dye [I; R1 = (CH2)rCONHSO2R3, (CH2)sSO2NHCOR4; R3, R4 = alkyl; r, s = 1-5; R5 = sulfoalkyl; Z1, Z2 = a group of nonmetal atoms required to form a 5- or 6-membered heterocyclic ring; P, q = 0, 1; L1-L3 = methine; m = 0, 1, 2]. This photog. material provides large interimage effect and excellent desilverization during photog. development.

IT 148364-36-7
RL: USES (Uses)
(photog. sensitizing dye, color photog. film containing)

RN 148364-36-7 CAPLUS

CN Benzothiazolium, 5-chloro-2-[2-[[5-(methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 105 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 106 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:446483 CAPLUS
DOCUMENT NUMBER: 121:46483
ORIGINAL REFERENCE NO.: 121:8223a,8226a
TITLE: Silver halide color photographic material
INVENTOR(S): Nagaoka, Satoshi; Yamakawa, Kazuyoshi; Yamamoto, Mitsuru; Suzuki, Makoto; Shimada, Yasuhiro; Nagaoka, Katsuro; Ikeda, Hideo; Hara, Takefumi; Shuto, Sadanobu
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 181 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 566115	A1	19931020	EP 1993-106136	19930415
R: BE, DE, FR, GB, NL				
JP 05289270	A	19931105	JP 1992-119862	19920415
US 5460929	A	19951024	US 1993-45776	19930414
US 5578441	A	19961126	US 1994-315573	19940930
PRIORITY APPLN. INFO.:			JP 1992-119862	A 19920415
			US 1993-45776	A3 19930414

OTHER SOURCE(S): MARPAT 121:46483

GI


I

AB There is disclosed a silver halide color photog. material having ≥1 red-sensitive silver halide emulsion layer, ≥1 green-sensitive silver halide emulsion layer, and ≥1 blue-sensitive silver halide emulsion layer, wherein ≥1 of the emulsion layers contains ≥1 cyan dye-forming coupler represented by the formula I wherein Za represents NH or CHR3, Zb and Zc represent CR4 or N, R1-3 represent an electron-attracting group wherein the Hammett substituent constant σp value is 0.20 or more, provided that the sum of the σp value of R1 and the σp value of R2 is 0.65 or more, R4 represents a hydrogen atom or a substituent, if there are two groups R4 in the formula, they may be the same or different, and X represents a hydrogen atom or a group capable of being released upon a coupling reaction with the oxidized product of an aromatic primary amine color-developing agent, provided that R1-4 or X may be a divalent group to form a homopolymer or a copolymer by bonding with a dimer or higher polymer or polymer chain and ≥1

L19 ANSWER 106 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
sensitizing dye contg. a sulfonamido group.
IT 143564-36-7
RL: USES (Uses)
(silver halide color photog. materials containing pyrrolopyrazole cyan photog couplers and)
RN 143564-36-7 CAPLUS
CN Benothiazolium, 5-chloro-2-[2-[[5-(methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[methylsulfonyl]amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 107 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:437623 CAPLUS
DOCUMENT NUMBER: 121:35621
ORIGINAL REFERENCE NO.: 121:6587a,6590a
TITLE: Preparation of triazinyl- and pyrimidinylalkanoic acid amide derivatives as herbicides
INVENTOR(S): Maseda, Katsumi; Toyabe, Keiji; Yoshimura, Takumi; Yoshida, Ryo
PATENT ASSIGNEE(S): Kumiai Chemical Industry Co, Japan; Ihara Chemical Ind Co
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06041096	A	19940215	JP 1991-337875	19911128
PRIORITY APPLN. INFO.:			JP 1991-337875	19911128

OTHER SOURCE(S): MARPAT 121:35621
GI

AB Triazinyl- and pyrimidinylalkanamides [I; R1 = H, OH, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, benzyloxy, alkenyloxy, alkynyloxy; R2 = SO2R5, OH, alkoxy, benzyloxy, alkenyloxy, cyano, (un)substituted Ph, NR6R7, alkylsulfonylamino; R5 = (un)substituted alkyl, alkenyl, cycloalkyl, (di)alkylamino, 1-pyrrolidinyl, anilino; R3 = H, (un)substituted alkyl, (halo)alkenyl, alkynyl, (alkyl)cycloalkyl, cycloalkenyl, (un)substituted Ph, tetrahydrothienyl, tetrahydrofuryl; R4 = H, alkyl; X, Y = CH, halo, (halo)alkyl, alkoxy(alkyl), alkoxy, (alkyl)phenoxy, haloalkoxy, alkenyloxy, alkynyloxy, alkylthio, PhS, NH2, (di)alkylamino, pyrrolidino; Z = CH, N], useful as herbicides for a rice paddy, a plowed field, and nonagricultural land are prepared Thus, di-Et 2-isopropylmalonate was treated with NaH in DMF at 60° for 30 min and condensed with 4,6-dimethoxy-2-fluoropyrimidine to give di-Et 2-(4,6-dimethoxypyrimidin-2-yl)-2-isopropylmalonate which was refluxed with NaOH in aqueous MeOH for 6 h and acidified with dilute HCl to give 2-(4,6-dimethoxypyrimidin-2-yl)-3-methylbutyric acid. The latter compound

L19 ANSWER 107 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
was condensed with carbonyl diimidazole in THF to give 96.7% N-[2-(4,6-dimethoxypyrimidin-2-yl)-3-methylbutyryl]imidazole which was amidated with MeSO2NH2 in DMF contg. NaH to give 76.8% title compd. (II). II and other 21 I at 25 g/10 are in preemergence soil-application controlled 2904 or 70-894 7 weeds including Echinochloa crus-galli, Amaranthus retroflexus, and Chenopodium album. A total of I were prepd.
IT 140704-78-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SYN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 140704-78-9 CAPLUS
CN 2-Pyrimidineacetamide, 4,6-dimethoxy-N-(methylsulfonyl)- (CA INDEX NAME)

L19 ANSWER 108 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:334737 CAPLUS
DOCUMENT NUMBER: 120:334737
ORIGINAL REFERENCE NO.: 120:6566a,6565a
TITLE: Direct positive silver halide photographic material containing sensitizing dyes
INVENTOR(S): Kato, Seiichi; Ikegawa, Akihiko; Kuramitz, Masayuki
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05127292	A	19930525	JP 1991-313066	19911101
PRIORITY APPLN. INFO.:			JP 1991-313066	19911101

GI



AB In the title photog. material having on its support 1l photosensitive emulsion layer(s) containing unpreflogged internal latent image-type Ag halide grains, at1 of sensitizing dye I [R1 = (CH2)rCONHSO2R3, (CH2)rSO2NHCOR4 (R3, R4 = alkyl; r, s = 1-5); R2 = sulfoalkyl; Z1, Z2 = non-metallic atoms required to form 5-6-membered heterocycle; p, q = 0, 1; L1-3 = methine; n = 0-2] is contained. The photog. material shows high-stability and superior whiteness without color residue after processing.
IT 143564-36-7
RL: USES (Uses)
(sensitizing dye, direct pos. photog. material using)
RN 143564-36-7 CAPLUS
CN Benothiazolium, 5-chloro-2-[2-[[5-(methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-1-buten-1-yl]-3-[2-[methylsulfonyl]amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 108 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 109 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:298483 CAPLUS
DOCUMENT NUMBER: 120:298483
ORIGINAL REFERENCE NO.: 120:52605a,52608a
TITLE: Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of phospholipase A2 and lipoxygenase
INVENTOR(S): Musser, John H.; Kreft, Anthony F., III; Failli, Amedeo A.; Demerson, Christopher A.; Shah, Uresh S.; Nelson, James A.
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 32 pp. Cont.-in-part of U.S. Ser. No. 596,134, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5229516	A	19930720	US 1992-911434	19920710
CA 2070422	A1	19910428	CA 1990-2070422	19901027
CA 2090042	A1	19910428	CA 1990-2090042	19901027
HU 63407	A2	19930830	HU 1992-1383	19901027
US 5420289	A	19950530	US 1993-29199	19930310
WO 9401407	A2	19940120	WO 1993-US6441	19930707
WO 9401407	A3	19940303		
W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9346694	A	19940131	AU 1993-46694	19930707
PRIORITY APPLN. INFO.:			US 1989-428260	B2 19891027
			US 1990-596134	B2 19901011
			CA 1990-2070422	A3 19901027
			US 1992-911434	A2 19920710
			WO 1993-US6441	A 19930707

OTHER SOURCE(S): MARPAT 120:298483
GI



L19 ANSWER 109 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

AB The title compds. A(CH2)nOB [A = Q; B = (un)substituted indenonyl, (un)substituted indolyl, etc.; n = 1-2], useful as antiinflammatory agents which possess leukotriene antagonistic activity, are prepared. Thus, 3-[(4-chlorophenyl)methylene]-[2-methyl-6-(2-quinolinylmethyoxy)]-3H-indene-1-acetic acid (Z configuration), prepared from 4-methoxybenzaldehyde in 7 steps, demonstrated 81% inhibition of PGE2 at 10 μM.

IT 135872-84-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and lipoxygenase and phospholipase A2 inhibitory activity of)

RN 135872-84-3 CAPLUS

CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)-5-(2-quinolinylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 110 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:244710 CAPLUS
DOCUMENT NUMBER: 120:244710
ORIGINAL REFERENCE NO.: 120:43373a,43376a
TITLE: 2-Substituted (quinolylmethoxy)phenylacetic acid derivatives, process for their preparation, and their pharmaceutical use
INVENTOR(S): Matzke, Michael; Mohrs, Klaus Helmut; Raddatz, Siegfried; Fruchmann, Romanis; Mueller-Peddinghaus, Rainer; Hatzelmann, Armin
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 582908	A1	19940216	EP 1993-112154	19930729
EP 582908	B1	19980527		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4226519	A1	19940217	DE 1992-4226519	19920811
NO 9302709	A	19940214	NO 1993-2709	19930727
NO 179513	B	19960715		
NO 179513	C	19961023		
AU 9344253	A	19940217	AU 1993-44253	19930728
AU 668574	B2	19960509		
AT 166645	T	19980615	AT 1993-112154	19930729
ES 2117070	T3	19980801	ES 1993-112154	19930729
US 5597833	A	19970128	US 1993-102453	19930804
CA 2103521	A1	19940212	CA 1993-2103521	19930806
JP 06157463	A	19940603	JP 1993-213596	19930806
IL 106622	A	19970218	IL 1993-106622	19930809
ZA 9305795	A	19940307	ZA 1993-5795	19930810
HU 70041	A2	19950928	HU 1993-2313	19930810
CN 1087337	A	19940601	CN 1993-108822	19930811
PRIORITY APPLN. INFO.:			DE 1992-4226519	A 19920811

OTHER SOURCE(S): MARPAT 120:244710
GI

L19 ANSWER 110 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I

II

AB Title compds. I [A, B, D, E, G, L = N, CH, halo, cyano, CO2R, NO2, CF3, CF3O, alkyl, alkoxy, (un)substituted aryl; R1 = halo, cyano, NO2, NJ, CH, CO2R, CF3, CF3O, CF3S, (cycloalkyl)alkyl, -alkenyl, -alkynyl, alkoxy, alkoxycarbonyl; R2 = H, (cycloalkyl) R3 = CH, alkoxy, Ph, NR4SO2R3, NR6R7; R4, R6, R7 = H, alkyl, Ph, PhCH2; R5 = CF3, (un)substituted Ph or alkyl] and salts are claimed. I are inhibitors of enzymes in the metabolism of arachidonic acid, especially 5-lipoxygenase (no data), and are useful for treating a wide variety of conditions. For example, etherification of 2-(chloromethyl)quinoline-HCl with 2-bromo-4-hydroxyphenylacetic acid Me ester (K2CO3, 2NF, 102°, 63.9%) and a-alkylation of the resultant ester with cyclopentyl bromide (KOBu-t-tert, DMF, 80.4%) gave title compound II (R2 = Br), which was converted to II (R2 = allyl, cyclopropyl, Pr, vinyl, Et, C(tpl)ene.CPh) as well as corresponding acids and sulfonylated amide deriva. Synthetic examples are given for 38 I and 10 precursors.

IT 154353-27-0P 154353-27-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as 12lipoxygenase inhibitor)

RN 154353-28-0 CAPLUS

CN Benzeneacetamide, N-(methylsulfonyl)-2-propyl-4-(2-quinolinylmethoxy)-

L19 ANSWER 110 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(CA INDEX NAME)



RN 154353-27-2 CAPLUS

CN Benzeneacetamide, 2-(2-methylpropyl)-N-(methylsulfonyl)-4-(2-quinolinylmethoxy)- (CA INDEX NAME)



L19 ANSWER 111 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:233835 CAPLUS

DOCUMENT NUMBER: 120:233835

ORIGINAL REFERENCE NO.: 120:40837a,40840a

TITLE: Silver halide color photographic material

INVENTOR(S): Hara, Takeshi; Tavakawa, Naoyoshi; Ehoto, Sadanobu; Yamanoto, Mitsuru; Suzuki, Makoto; Shimada, Yasuhiro; Nagaoka, Tatsuru; Nagaoka, Satoshi; Shimahara, Yoshihiko; Ikeda, Hideo

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 234 pp.
CODEN: EPXLDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 563985	A1	19931006	EP 1993-105497	19930402
R: BE, DE, FR, GB, NL				
JP 05281681	A	19931029	JP 1992-109131	19920403
JP 2777949	B2	19980723		
US 5378436	A	19951106	US 1995-453398	19950530
US 5691125	A	19971125	US 1996-645897	19960419
			JP 1992-109131	A 19920403
			US 1993-43027	B2 19930405
			US 1995-453398	A3 19950530

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 120:233835

GI

I

AB A multicolor photog. material comprises a cyan dye-forming coupler I [R1 = H, substituent; R2 = substituent; X = H, a group capable of being released upon a coupling reaction with the oxidized product of a color-developing agent; Z1 = group of nonmetallic atoms required for forming a N-containing 6-membered heterocyclic ring, which contains at least one group capable of being dissociated], and (a) a monodisperse Ag halide emulsion, (b) non-photosensitive Ag halide emulsion wherein the inside or the surface of grains is fogged, (c) a colloidal Ag, (d) req.-type internal latent image-type Ag halide grains chemical sensitized to a defined depth from the

L19 ANSWER 111 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
surface, (e) a sensitizing dye contg. a sulfonamide group, (f) three segd. layers of high, medium, and low sensitivities, (g) two sepd. layers each having different content of I, (h) grains each having a defined spectral sensitivity distribution and a DIR-hydroquinone, or (i) a DIR-hydroquinone. The novel cyan dye-forming coupler-contg. photog. material is excellent in sensitivity/grainness ratio and color reprodn.

IT 148364-36-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. sensitizer)

RN 148364-36-7 CAPLUS

CN Benzothiazolium, 5-chloro-2-[[5-[methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-3-(sulfo-3-yl)-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 112 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:164795 CAPLUS
DOCUMENT NUMBER: 120:164795
ORIGINAL REFERENCE NO.: 120:29977a,29980a
TITLE: Silver halide photographic material
INVENTOR(S): Ohno, Shigeru
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: U.S., 30 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5223382	A	19930629	US 1992-983701	19921201
JP 06150401	A	19940518	JP 1991-318201	19911202
JP 3046992	B2	19970602		
PRIORITY APPLN. INFO.:			JP 1991-318201	A 19911202

GI



AB The title material comprises 2) hydrophilic colloidal layer containing a dye I [X = atoms necessary to form 5- or 6-membered N-containing heterocyclyl; ring; R1-R3 = H, monovalent group; R3-R4 and/or R4-R5 may combine to form ring; R6 = alkyl; aryl; alkenyl; L1-L4 = methine group; X- = anion; n = 1-2; n = 0, 1; p = 0, 0.5, 1;]. The dye can be quickly decolored during development and can provide images with excellent sharpness and less residual color.
IT 153411-13-3 153411-15-5
RL: USES (Uses)
(photog. films containing)
RN 153411-13-3 CAPLUS
CN 3H-Indolium, 5-carboxy-2-[2-[7-(dimethylamino)-2-oxo-2H-1-benzopyran-3-yl]ethenyl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, hexafluorophosphate(1-) (1:1) (CA INDEX NAME)

CM 1

CM 2

CRN 37181-39-8
CMF C F3 O3 S

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 112 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

CM 2

CRN 37181-39-8
CMF C F3 O3 S

L19 ANSWER 112 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



CM 2

CRN 16919-18-9
CMF F6 P
CCI CCS

RN 153411-15-5 CAPLUS
CN 3H-Indolium, 2-[2-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]ethenyl]-3,3-dimethyl-1-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, 1,1,1-trifluoromethanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 153411-14-4
CMF C28 H32 N3 O5 S

L19 ANSWER 113 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:65779 CAPLUS
DOCUMENT NUMBER: 120:65779
ORIGINAL REFERENCE NO.: 120:11701a,11704a
TITLE: Green sensitizing dyes for variable contrast photographic elements
INVENTOR(S): Price, Harry J.; Gilman, Paul B.; Dobles, Thomas R.; Knapp, Linda J.
PATENT ASSIGNEE(S): Eastman Kodak Co., USA
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 536771	A1	19930414	EP 1992-117281	19921009
EP 536771	B1	19980213		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5219723	A	19930615	US 1991-774440	19911010
JP 05216153	A	19930827	JP 1992-271882	19921009
PRIORITY APPLN. INFO.:			US 1991-774440	A 19911010

OTHER SOURCE(S): MARPAT 120:65779
GI

AB A variable-contrast photog. material, with reduced photosensitivity at wavelengths longer than 570 nm, thereby enhancing safe light tolerance, while still maintaining good spectral sensitivity at wavelengths in the green region, comprises a photosensitive Ag halide emulsion layer sensitized with a green-sensitivity benzimidazolooxacarbocyanine dye of the general formula I (R1,R2,R4,R7 = H, halogen, OH, alkyl, alkenyl, alkoxy, alkylamino, aryl, alkylthio, aryloxy, arylamino, or arylthioy R3, R6 = alkyl; R5 = a substituent containing an electron-withdrawing group; X- = counterion as needed to balance the charge of the dye mol.).
IT 152085-93-7
RL: USES (Uses)
(green, benzimidazoloxacarbocyanide dyes as, for variable-contrast photog. materials with good safe light property)
RN 152085-93-7 CAPLUS
CN Benzoxazolium, 2-[3-[1-ethyl-1,3-dihydro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-(trifluoromethyl)-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-5-phenyl-3-(3,3,2-trifluoroethyl)-, inner salt (CA INDEX NAME)

L19 ANSWER 113 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 114 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:568 CAPLUS
DOCUMENT NUMBER: 120:568
ORIGINAL REFERENCE NO.: 120:125a,128a
TITLE: Rhodacyanine compounds as neoplasm inhibitors
INVENTOR(S): Shishido, Tadaoy Chem, Lan Bo
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan; Dana-Farber Cancer Institute
SOURCE: Jpn. Kokai Tokkyo Koho, 174 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05117148	A	19930514	JP 1992-104724	19920423
US 5561424	A	19960219	US 1995-470582	19950607
PRIORITY APPLN. INFO.:			US 1991-692347	A 19910426
			US 1992-974400	B1 19921112

OTHER SOURCE(S): MARPAT 120:568
GI



AB Rhodacyanine compds. [I] [X2, X3, Y1 = O, S or Se; Z1 = atom for forming ring; Z2 = atom for forming (un)substituted naphthalene, anthracene, phenanthrene; R1,R3 = (un)substituted alkyl; R2 = (un)substituted alkyl, aryl, or heterocyclic; L1-3 = (un)substituted methylene; Q- = pharmaceutically acceptable anion; n = 0 or 1; l = 1 or 2] are neoplasm inhibitors. II was prepared by treating

5-[(1-ethyl-2(1H)-1,2-dihydroquinolinylidene)ethylidene]-2-methylmercapto-

L19 ANSWER 114 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
4-thiazolone ethp-p-toluenesulfonate with 1-ethyl-4-methylquinolinium p-toluenesulfonate. II inhibited the growth of human colon cancer cell line CX-1 in cultures. The IC50 value was 0.1 μg/mL.
IT 149258-43-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor activity of)
RN 149258-43-5 CAPLUS
CN Benzothiazolium, 5-chloro-2-[[3-ethyl-5-[2-[3-ethyl-2-thiazolidinylidene]ethylidene]-4-oxo-2-thiazolidinylidene]methyl]-3-[2-[methylsulfonyl]amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

L19 ANSWER 115 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:591854 CAPLUS
DOCUMENT NUMBER: 119:191854
ORIGINAL REFERENCE NO.: 119:34027a,34040a
TITLE: Silver halide photographic light-sensitive material
INVENTOR(S): Nagaoki, Katsuroy Ikegawa, Akihiro; Furanito, Masayuki
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 137 pp.
CODEN: EPXLDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 534283	A2	19930331	EP 1992-115755	19920915
EP 534283	A3	19930630		
EP 534283	B1	19971217		
R: DE, FR, GB				
JP 05080447	A	19930402	JP 1991-243128	19910924
JP 2794232	B2	19980903		
JP 05173276	A	19930713	JP 1991-210220	19911030
JP 05127291	A	19930525	JP 1991-311382	19911031
JP 05127293	A	19930525	JP 1991-318507	19911106
US 5290676	A	19940301	US 1992-944314	A 19920914
PRIORITY APPLN. INFO.:			JP 1991-243128	A 19910924
			JP 1991-310220	A 19911030
			JP 1991-311382	A 19911031
			JP 1991-318507	A 19911106

OTHER SOURCE(S): MARPAT 119:191854
GI

AB The title material contains Zl Ag halide emulsion spectrally sensitized with the methine dye I [R = (CH)nCOMBSOR or (CH)nSO3M1COR where R and R are alkyl and r and s = 1-5; R = sulfoalkyl; Z, Z = nonmetal atoms required to form ring; p, q = 0, 1; L-L =methine; n = 1-2] 1 of which is added at 50 at any step from the step of preparing the emulsion to the step of coating. The material has excellent sensitivity/graininess ratio, storage stability, and color stability after development.
IT 149350-04-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, photog. sensitizer from)

L19 ANSWER 115 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 148350-04-3 CAPLUS
CN Benzothiazolium, 5-chloro-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

IT 148364-76-7P 149702-97-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and use of, as photog. sensitizer)
RN 148364-76-7 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-[methoxycarbonyl]-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-2-buten-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 149702-97-6 CAPLUS
CN Benzothiazolium,
5-chloro-2-[3-[5-(methoxycarbonyl)-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]-2-methyl-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 115 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 116 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:492794 CAPLUS
DOCUMENT NUMBER: 119:92794
ORIGINAL REFERENCE NO.: 119:16467a,16470a
TITLE: Silver halide color photographic material
INVENTOR(S): Ikegawa, Akihiko; Furenitsu, Masayuki; Okazaki, Masaki
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 130 pp.
CODEN: EPXLDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 530511	A1	19930310	EP 1992-113135	19920731
EP 530511	B1	19980603		
R: DE, GB, NL				
JP 05093978	A	19930416	JP 1992-23524	19920114
JP 2829452	B2	19981125		
JP 05188516	A	19930730	JP 1992-23422	19920114
JP 2779722	B2	19980723		
US 5422239	A	19950606	US 1993-165140	19931213
PRIORITY APPLN. INFO.:			JP 1991-21472	A 19910202
			JP 1992-23524	A 19920114
			JP 1992-23422	A 19920114
			US 1992-922221	B1 19920731

OTHER SOURCE(S): MARPAT 119:92794
GI

AB A Ag halide color photog. material showing improved sensitivity and reduced residual color formation during development contains a merocyanine compound represented by the formula I [R1 = (CH2)nCONHSO2R3, (CH2)nSO2NHCOR4, (CH2)nCOMeCOR3, or (CH2)nSO2NHSO2R6 where R3-6 = alkyl, alkoxy, or amino; n, m = 0, 1, 2, 3; p = an integer of 1-3; R2 = same as R1 or alkyl; Z1, Z2 = a nonmetallic atomic group required to form a 5- or 6-membered heterocyclic group; p,q = 0 or 1; L1-L2 = a methine group; n = 0, 1, or 2; X = an anion; k = an integer required to adjust the charge in the mol. to 0].
IT 148364-76-7
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. sensitizer)
RN 148364-76-7 CAPLUS
CN Benzothiazolium, 5-chloro-2-[2-[[5-[methoxycarbonyl]-3-(4-sulfobutyl)-2(3H)-benzothiazolylidene]methyl]-2-buten-1-yl]-3-[2-

L19 ANSWER 116 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

IT 148350-04-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparing photog. sensitizer)
RN 148350-04-3 CAPLUS
CN Benzothiazolium, 5-chloro-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

● Br⁻

L19 ANSWER 117 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:112880 CAPLUS
DOCUMENT NUMBER: 118:112880
ORIGINAL REFERENCE NO.: 118:19509a,19512a
TITLE: Benzimidazolocarbocyanine photographic sensitivity dye
INVENTOR(S): Anderson, Richard B.; Dickerson, Robert E.; Link, Steven G.; Macon, Fred M.; Weber, Wayne W. II
PATENT ASSIGNEE(S): Eastman Kodak Co., USA
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 506077	A1	19920930	EP 1992-105300		19920327
EP 506077	B1	19970604			
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE					
US 5210014	A	19930511	US 1991-676913		19910328
CA 2062570	A1	19920929	CA 1992-2062570		19920310
JP 05088293	A	19930409	JP 1992-70815		19920327
AT 154142	T	19970615	AT 1992-105300		19920327
PRIORITY APPLN. INFO.:			US 1991-676913	A	19910328

OTHER SOURCE(S): MARPAT 118:112880
GI



I

AB A benzimidazolocarbocyanine photog. sensitizing dye that aggregates and sensitizes efficiently in the 540-555-nm spectral region and leaves a very low level of residual dye stains in photog. materials after processing is represented by the general formula I [R1, R3 = Me or Et, with ≥1 of R1 and R3 being Me; R2, R4 = (substituted) C1-6 alkyl, with R2 and R4 being not both Me; R5-8 H, Me, methylthio, or F-substituted Me or methylthio, with ≥1 of R5 and R6 and ≥1 of R7 and R8 being not H; X- = anion as needed to balance the charge of the dye mol.].
IT 145300-28-3
RL: USES (Uses)
(mid-green photog. spectral sensitizer)
RN 145300-28-3 CAPLUS
CN 1H-Benzimidazolium, 2-[3-[1,3-dihydro-1-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-(trifluoromethyl)-2H-benzimidazol-2-

L19 ANSWER 117 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
ylidene]-1-propen-1-yl]-1-methyl-3-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)- (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L19 ANSWER 118 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1993:38772 CAPLUS
DOCUMENT NUMBER: 118:38772
ORIGINAL REFERENCE NO.: 118:7063a,7066a
TITLE: Preparation of 2-cycloalkyl-2-[(quinolylmethoxy)phenyl] acetates as lipoxygenase inhibitors
INVENTOR(S): Raddatz, Siegfried; Mohrs, Klaus Helmut; Matzke, Michael; Fruchtmann, Romanis; Hatzelmann, Armin; Kohlsdorfer, Christian; Mueller-Peddinghaus, Reiner; Theisen-Popp, Pia
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 52 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 499926	A1	19920826	EP 1992-102156		19920210
EP 499926	B1	19960911			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE					
DE 4105551	A1	19920827	DE 1991-4105551		19910222
AU 9210542	A	19920827	AU 1992-10542		19920129
AU 641585	B2	19930923			
AT 142623	T	19960915	AT 1992-102156		19920210
ES 2091958	T3	19961116	ES 1992-102156		19920210
JP 05092957	A	19930416	JP 1992-69073		19920218
IL 101009	A	19960804	IL 1992-101009		19920219
PL 170726	B1	19970131	PL 1992-293534		19920219
PL 171026	B1	19970228	PL 1992-314698		19920219
FI 9200732	A	19920823	FI 1992-732		19920220
ZA 9201268	A	19921125	ZA 1992-1268		19920221
RU 2077532	C1	19970420	RU 1992-5010907		19920221
CZ 282723	B6	19970917	CZ 1992-514		19920221
PRIORITY APPLN. INFO.:			DE 1991-4105551	A	19910222

OTHER SOURCE(S): MARPAT 118:38772
GI



1

AB Title compds. (I; R = H, OH, halo, alkyl, aryl, etc.; R1 = halo, OH, alkyl, aryl, etc.; R2 = cycloalkyl, -alkenyl; R3 = OH, alkoxy, OPh, arylsulfonylamino, etc.; n = 1-6) were prepared. Thus, 3,4-F(HO)C6H3CH2CO2H was esterified and the product condensed with 2-chloromethylquinoline to give, after alkylation with cyclopentyl bromide, 3,4-R1(R4O)C6H3CHR2CO2Me

L19 ANSWER 118 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(R2 = cyclopentyl, R4 = 2-quinolylmethyl)(II; R1 = F). II (R1 = CH:CH2) had IC50 of 0.56 μM for inhibition of 5-lipoxygenase in vitro.
IT 145043-26-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of lipoxygenase inhibitors)
RN 145043-26-1 CAPLUS
CN Benzeneacetamide, 3-ethyl-N-(methylsulfonyl)-4-(2-quinolinylmethoxy)- (CA INDEX NAME)



IT 145042-99-5P 145043-00-1P 145043-05-6P 145043-10-3P 145043-19-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of lipoxygenase inhibitors)
RN 145042-99-5 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-(methylsulfonyl)-4-(2-quinolinylmethoxy)- (CA INDEX NAME)



RN 145043-00-1 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[(phenylmethyl)sulfonyl]-4-(2-quinolinylmethoxy)- (CA INDEX NAME)



L19 ANSWER 118 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 145043-08-6 CAPLUS
CN Benzeneacetamide, 3-bromo-N-(methylsulfonyl)-4-(2-quinolinylmethoxy)- (CA INDEX NAME)



RN 145043-19-3 CAPLUS
CN Benzeneacetamide, N-(methylsulfonyl)-4-(2-quinolinylmethoxy)-3-[(trifluoromethyl)thio]- (CA INDEX NAME)



RN 145043-19-2 CAPLUS
CN Benzeneacetamide, N-(methylsulfonyl)-3-propyl-4-(2-quinolinylmethoxy)- (CA INDEX NAME)



L19 ANSWER 119 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1992:402825 CAPLUS
DOCUMENT NUMBER: 117:2825
ORIGINAL REFERENCE NO.: 117:581a,584a
TITLE: Preparation of N-sulfonamides as herbicides
INVENTOR(S): Togame, Kenji; Yoshimura, Takumi; Nasuda, Katsumi; Yoshioka, Ryo
PATENT ASSIGNEE(S): Sumitomo Kagaku Kogyo K. K., Japan; Ihara Chemical Kogyo
K. K.
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04054148	A	19920221	JP 1990-164271	19900625
PRIORITY APPLN. INFO.:			JP 1990-164271	19900625

OTHER SOURCE(S): MARPAT 117:2825
GI

I

AB Herbicides contain N-sulfonamides I [R = (halo)alkyl, (un)substituted Ph; R1 = H, alkyl, (halo)alkenyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, (un)substituted Ph; X, Y = alkyl, (halo)alkoxy, halo] or their salts as active ingredients. MeSO2NH2 was treated with NaH in DMF at room temperature
for 1 h, followed by treatment with
2-(4,6-dimethoxy-2-pyrimidinyl)-3-methylbutyrylimidazole (preparation given) at
room temperature for 1 h to give 76.8% I (R = Me, R1 = MeCH, X = Y = OMe),
which, at 100 g/10 are, showed almost complete control of Echinochloa crus-galli oryzicola, Monochoria vaginalis, and Scirpus juncoides. Formulation examples are given.
IT 140704-78-5P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)
RN 140704-78-5 CAPLUS

L19 ANSWER 119 OF 138 CAPLUS (Continued)
CN 2-Pyrimidineacetamide, 4,6-dimethoxy-N-(methylsulfonyl)- (CA INDEX NAME)

L19 ANSWER 120 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1992:255642 CAPLUS
DOCUMENT NUMBER: 116:255642
ORIGINAL REFERENCE NO.: 116:43554h,43355a
TITLE: Preparation of
2-(4,6-dimethoxypyrimidin-2-yl)-N-(methylsulfonyl)alkanamides and related triazinyl compounds as herbicides
INVENTOR(S): Jones, Graham Peter
PATENT ASSIGNEE(S): Schering Agrochemicals Ltd., UK
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9201677	A1	19920206	WO 1991-GB1152	19910712
W: AU, BB, CA, CS, FI, HU, JP, KR, PL, RO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 8180996	A	19920218	AU 1991-80996	19910712
EP 539427	A1	19930505	EP 1991-912994	19910712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5317005	A	19940531	US 1993-966169	19930119
PRIORITY APPLN. INFO.:			GB 1990-15916	A 19900719
			WO 1991-GB1152	A 19910712

OTHER SOURCE(S): MARPAT 116:255642
GI

Q

AB ACR1R2CONHSO2R [I; A = pyrimidinyl or triazinyl residue Q; R = anhe, (un)substituted alkyl; R1 = (un)substituted (cycloalkyl, -CH2-heterocyclyl; R2 = H, halo, alkyl; R3, R4 = H, alkyl, alkoxy, NR5, (di)alkylamino, halo; X = CH, N] and their salts, were prepared, e.g., by condensation reaction of pyrimidines or triazines Q8 (Z = leaving group) with acetamides R1R2CHCONHSO2R. Thus, 20 mL of 2.5 N n-BuLi in hexane was
added at -70° under N to a stirred solution of 4.67 g
N-(methylsulfonyl)-2-(2-thienyl)acetamide in THF, the mixture was stirred 2
h at room temperature, treated by 5.45 g
4,6-dimethoxy-2-methylsulfonylpyrimidine, and stirred overnight at room temperature to give 1.8 g title compound [I; A = 4,6-dimethoxypyrimidin-2-yl, X = Me,
R1 = 2-thienyl, R2 = H]. The latter at 0.25 kg/ha preemergence gave 90-100% control of Veronica persica and 70-89% control of Stellaria media.

L19 ANSWER 120 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
Galium sparine, and Polygonum lapathifolium. Approx. 32 l were prepd.
IT 140704-78-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and alkylation of, in preparation of herbicide)
RN 140704-78-5 CAPLUS
CN 2-Pyrimidinecarboxamide, 4,6-dimethoxy-N-(methylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 121 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:535835 CAPLUS
DOCUMENT NUMBER: 115:135935
ORIGINAL REFERENCE NO.: 115:23308a,23310a
TITLE: Preparation of indole-, indene-, pyrazeindole- and tetrahydrocarbazolealkanoic acid derivatives as inhibitors of phospholipase A2 and lipoxygenase
INVENTOR(S): Musser, John Henry; Kreft, Anthony Frank, III; Failli, Amedeo Arturo; Demerson, Christopher Alexander; Shah, Dinah Shantilal; Nelson, James Albert
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: PCT Int. Appl., 85 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9106537	A2	19910516	WO 1990-US6251	19901027
WO 9106537	A3	19911017		
W: AU, BB, CA, FI, HU, JP, KR, NO, SU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2070422	A1	19910428	CA 1990-2070422	19901027
CA 2090042	A1	19910428	CA 1990-2090042	19901027
AU 9177404	A	19910531	AU 1991-77404	19901027
AU 643996	B2	19931202		
EP 502106	A1	19920909	EP 1991-900147	19901027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HR 9007790	A	19920915	HR 1990-7790	19901027
JP 05502222	T	19930422	JP 1991-500787	19901027
HU 63407	A	19930830	HU 1992-1383	19901027
FI 9201865	A	19920424	FI 1992-1865	19920424
			US 1989-428260	A 19891027
			US 1990-596134	A 19901011
			CA 1990-2070422	A3 19901027
			WO 1990-US6251	A 19901027

PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 115:135935
GI

L19 ANSWER 121 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB A[CR2]nOB [I; A = C4-9 alkyl, PhOCH2CH2, PhOCH2S4, Q, Q1; R1 = H, alkyl, Ph, CH2CF3; R2 = H, alkyl; R1R2 = benzene; X = N, NR7, R3 = H, alkyl; Z =
R3C:CR3, R3C:N, N:CR3, NR3, O, S; n = 1, 2; B = substituted indanyl, substituted carbazolyl, substituted pyranoindolyl, etc.] and a salt thereof, are prepared I are useful as antiinflammatory agents and possess
leukotriene antagonistic activity. To a stirred suspension of NaH in DMF at 0° was added 5-hydroxy-2-methyl-1H-indole-3-acetic acid followed after 1 h by 2-(chloromethyl)quinoline. The reaction mixture allowed to warm at room temperature with stirring overnight and the pH adjusted to 5 with
HCl to give the indoleacetic acid (II) which at 10 μM in vitro gave 47% inhibition of phospholipase A2 (PLA2) from semi-purified human platelet extract, and 90% of PLA2 from purified human synovialfluid.
IT 135872-84-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as lipoxygenase and phospholipase A2 inhibitor)
RN 135872-84-3 CAPLUS
CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)-5-[(2-quinolinylmethoxy)- (CA INDEX NAME)



L19 ANSWER 121 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 122 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1990:459231 CAPLUS
DOCUMENT NUMBER: 113:59231
ORIGINAL REFERENCE NO.: 113:10030h,10031a
TITLE: Azinylacylsulfonamides as herbicides and plant growth regulators
INVENTOR(S): Ort, Oswald; Willms, Lothar; Bauer, Klaus; Bieringer, Hermann; Schulz, Arno
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Ger. Offen., 121 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 3826230	A1	19900208	DE 1988-3826230		19880802
EP 353640	A2	19900207	EP 1989-113916		19890728
EP 353640	A3	19910508			
EP 353640	B1	19950412			
EP 353640	B2	20031015			
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE					
ES 2070870	T3	19950616	ES 1989-113916		19890728
DD 283915	A5	19901031	DD 1989-331307		19890731
US 5053072	A	19911001	US 1989-387531		19890731
IL 91164	A	19941128	IL 1989-91164		19890731
DK 8903773	A	19900203	DK 1989-3773		19890801
AU 8939144	A	19900208	AU 1989-39144		19890801
AU 636299	B2	19930429			
ZA 8905852	A	19900425	ZA 1989-5852		19890801
JP 02282371	A	19901119	JP 1989-198114		19890801
JP 3117137	B2	20001211			
HU 55001	A2	19910429	HU 1989-3924		19890801
BR 8903885	A	19900320	BR 1989-3885		19890802
US 5186736	A	19930216	US 1991-728632		19910711
PRIORITY APPLN. INFO.:			DE 1988-3826230	A	19880802
			US 1989-387531	A3	19890731

OTHER SOURCE(S): CASREACT 113:59231; MARPAT 113:59231
GI


II

L19 ANSWER 122 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
AB L(X)mSO2NR1C(W)(CR2R3)nA [I; R1 = H, alkyl, alkenyl, alkynyl; R2, R3 = H, alkyl, Ph; R4 = H, alkyl, haloalkyl, Ph; X = CHR2, O, NR4; W = O, S, NR4, NOR4; L = (substituted) Ph, naphthalinyl, furyl, thienyl, pyrazolyl, pyridyl; A = (substituted) triazinyl, cyclopentapyrimidinyl, furylpyrimidinyl, triazolyl triazinyl, etc.], were prepared. Thus, a mixture of DCC, 4-dimethylaminopyridine, and 4,6-dimethoxypyrimidine-2-carboxylic acid (preparation given) in CH2Cl2 at 0-2° was treated with 2-MeO2CC6H4SO2NH2 to give pyrimidinylcarbonylsulfonamide II. II at 0.3 kg/ha preemergent gave complete control of Sinapsis alba and Chrysanthenum segetum.
IT 128276-45-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as herbcide and plant growth regulator)
RN 128276-45-9 CAPLUS
CN Benzoic acid, 2-[[[[2-(4,6-dimethoxy-2-pyrimidinyl)acetyl]amino]sulfonyl]methyl]-, methyl ester (CA INDEX NAME)



IT 128276-42-6P 128276-43-7P 128276-44-8P
128276-45-9P 128276-46-0P 128276-47-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide and plant growth regulator)
RN 128276-42-6 CAPLUS
CN 2-Pyrimidineacetamide, N-[(2-chlorophenyl)sulfonyl]-4,6-dimethoxy- (CA INDEX NAME)



RN 128276-43-7 CAPLUS
CN 2-Pyrimidineacetamide, 4,6-dimethoxy-N-[(2-nitrophenyl)sulfonyl]- (CA INDEX NAME)

L19 ANSWER 122 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 128276-44-8 CAPLUS
CN 2-Pyrimidineacetamide, 4,6-dimethoxy-N-[(2-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 128276-45-9 CAPLUS
CN Benzoic acid, 2-[[[[2-(4,6-dimethoxy-2-pyrimidinyl)acetyl]amino]sulfonyl]methyl]-, methyl ester (CA INDEX NAME)



RN 128276-46-0 CAPLUS
CN 2-Pyrimidineacetamide, N-[[(2-ethoxyphenyl)methyl]sulfonyl]-4,6-dimethoxy- (CA INDEX NAME)



RN 128276-47-1 CAPLUS
CN 2-Pyrimidineacetamide, N-[(3-chloro-2-thienyl)sulfonyl]-4,6-dimethoxy- (CA INDEX NAME)

L19 ANSWER 122 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 123 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1990:178357 CAPLUS
DOCUMENT NUMBER: 112:178357
ORIGINAL REFERENCE NO.: 112:29148a,29152a
TITLE: Preparation of [(halophenoxy)phenyl]alkanoates and analogs as herbicides
INVENTOR(S): Kirsten, Rolf; Braun, Ulrich; Santel, Hans Joachim; Schmidt, Robert R.; Strang, Harry
PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 43 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3812769	A1	19891026	DE 1988-3812769	19880416
EP 338706	A2	19891025	EP 1989-105791	19890403
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
DK 8901911	A	19891017	DK 1989-1911	19890414
BR 8901796	A	19891128	BR 1989-1796	19890414
DA 8902776	A	19891227	DA 1989-2776	19890414
JP 02004423	A	19900110	JP 1989-93503	19890414
HU 51101	A2	19900428	HU 1989-1864	19890414
AU 8935079	A	19891019	AU 1989-35079	19890417
PRIORITY APPLN. INFO.:			DE 1988-3812769	A 19880416

OTHER SOURCE(S): MARPAT 112:178357
GI



AB The title compds. [I; R1 = H, halo, cyano, CF3; R2, R4, R5 = H, halo; R3 = halo, cyano, CF3, CF3O, CF3SO2; X = halo; Y = halo, cyano, alkoxycarbonyl, etc.] were prepared as herbicides (no data). Thus, phenoxybenzyl bromide II (R = Br) was refluxed 12 h with NaCN in aqueous EtOH and the product stirred 12 h in Br2O-MeOH containing HCl to give II (R = CO2Me).
IT 126745-64-8P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic

L19 ANSWER 123 OF 138 CAPLUS (Continued)
preparation); RCOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide)
RN 126745-64-8 CAPLUS
CN Benzeneacetamide, 2-chloro-5-[2,6-dichloro-4-(trifluoromethyl)phenoxy]-N-(methylsulfonyl)- (CA INDEX NAME)



L19 ANSWER 124 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1982:64127 CAPLUS
DOCUMENT NUMBER: 97:64127
ORIGINAL REFERENCE NO.: 97:10599a,10602a
TITLE: Photographic recording material with variable contrast
INVENTOR(S): Gernert, Herbert; Borges, Theo
PATENT ASSIGNEE(S): Agfa-Gevaert A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 35 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3028167	A1	19820401	DE 1980-3028167	19800725
PRIORITY APPLN. INFO.:			DE 1980-3028167	19800725

AB A variable contrast photog. material is described which possesses high sensitivity for scanner exposure and shows a sufficiently steep gradation in the blue spectral region for use as a scan film along with a 50-100% flatter gradation in the green spectral region in comparison to the blue exposure. The material consists of a support with 2 emulsion layers, one of which is sensitive to blue and green light and the other which is sensitive to blue light. The exposure factor of the gradation curve for the blue sensitive layer lies in the region of its green sensitivity upon exposure of the material with light from 500 to 620 nm at a d. of 1.0-2.0 of the gradation for the green sensitivity. The material is especially useful in the production of color separ. by exposure with a scanner and exposure in a copy apparatus for a γ-1-variable material.
IT 53132-00-6
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. sensitizer, for variable contrast films for scanner exposure)
RN 53132-00-6 CAPLUS
CN 1H-Benzimidazolium, 5,6-dichloro-2-[3-(5,6-dichloro-1,3-diethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)-2-propen-1-yl]-1-ethyl-3-[2-[methyl(sulfo)]amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L19 ANSWER 125 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1981:606959 CAPLUS
DOCUMENT NUMBER: 95:6959
ORIGINAL REFERENCE NO.: 95:1314h,1315a
TITLE: Chemical structure and antiinflammatory activity in the group of substituted indole-3-acetic acids
AUTHOR(S): Bolte, K. H.; Brendler, O.; Jacobs, H.; Opitz, W.; Raddatz, S.; Seidel, F. R.; Wolfarth, D.
CORPORATE SOURCE: Abt. Chem. Forsch., Troponwerke G.m.b.H. and Co. K.-G., Cologne, 5000/80, Fed. Rep. Ger.
SOURCE: Arzneimittel-Forschung (1980), 30(8A), 1214-25
CODEN: ARZMAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 95:6959
GI



AB About 110 potential antiinflammatory compds. were prepared by systematically modifying indometacin (I; R = H) by modifying the α-methylene group, derivatizing the CO2H group, substituting the 4-ClC6H4CO moiety by ether aryl groups, introducing other substituents into the indole ring, and fusing other heterocycles to the indole ring. Of all these compds., acemetacin (I; R = CH2CO2H) showed appr. 2 times the activity of I (R = H) an the kaolin-induced rat paw edema test. Further modification of acemetacin did not improve its activity. Apparently substitution of the indole moiety and the acetoxyacetic acid side chain are responsible for the high activity.
IT 76912-29-9P 76912-30-2P 76912-31-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 76912-29-9 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-(methylsulfonyl)- (CA INDEX NAME)

L19 ANSWER 125 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 76812-30-1 CAPLUS
CN 1H-Indole-3-acetamide, 1-[(4-chlorobenzoyl)-5-methoxy-2-methyl-N-[(trifluoromethyl)sulfonyl]- (CA INDEX NAME)



RN 76812-31-2 CAPLUS
CN 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)

L19 ANSWER 125 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 126 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1977:133107 CAPLUS
DOCUMENT NUMBER: 86:133107
ORIGINAL REFERENCE NO.: 86:20559a,20562a
TITLE: Electrophotographic recording material
INVENTOR(S): Vechalle, Karel E.; Noe, Robert J.; Voet, Lucian F.; Depooter, Henri
PATENT ASSIGNEE(S): Agfa-Gevaert A.-G., Fed. Rep. Ger.
SOURCE: Ger., 6 pp.
CODEN: GWXXAW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1772318	A	19710128	DE 1967-1772318	19680427
DE 1772318	B2	19760722		
DE 1772318	C3	19770310		
PRIORITY APPLN. INFO.:			DE 1967-1772318	19680427

GI



I



II

AB Dispersions of a photoconductive ZnO yield electrophotog. recording materials of improved light sensitivity when containing a dye having the general structure of I (R3, R4, R5, R6 = H, halo, alkyl, arylalkyl, or R3R4 or R5R6 together may form a ring; R1, R2 = sulfatoalkyl, phosphatoalkyl, or a group containing NR2, substituted NR2, SO2, or CO; R7 = H, alkyl, or substituted alkyl; n = 1, 2; X = anion). Thus, a photoconductive ZnO 20

g

was dispersed in a solution containing a maleic anhydride-N-vinylpyrrolidone
polymer 2:1, a vinyl acetate-crotonic acid polymer 2, a melamine-HCHO resin 1, the dye II 0.01, and a concentrated NH4OH solution 38.5g, coated on a
paper support, dried, and compared with a II-free control to show a photosensitivity increase of 56%.

IT 27746-86-7
RL: USES (Uses)

L19 ANSWER 126 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(electrophotog. sensitizer, for zinc oxide photoconductive compns.)

RN 27746-86-7 CAPLUS
CN Benzoxazolium, 5-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-[3-[3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-(phenylmethyl)-2(3H)-benzoxazolylidene]-1-propen-1-yl]-5-(phenylmethyl)-, inner salt (CA INDEX NAME)



L18 ANSWER 127 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1976:464904 CAPLUS
DOCUMENT NUMBER: 85:64904
GIVEN REFERENCE NO.: 85:10427a,10429a
TITLE: Methine dyes
INVENTOR(S): Libert, Marcel J.; Depoorter, Henri; Van Mierlo, Serfi G.J.; Lenahien, Raymond G.
PATENT ASSIGNEE(S): Agfa-Gevaert N. V., Belg.
SOURCE: U.S., 46 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3931154	A	19760106	US 1973-355770	19730430
PRIORITY APPLN. INFO.:			GB 1961-19269	A 19610529
			US 1962-197925	A3 19620528
			US 1966-547140	A1 19660202

GI



AB One hundered thirty-four cyanine dyes containing the pyrrolobenzimidazole,

L19 ANSWER 127 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
benzimidazoloquinoline, and dipyridinebenzoimidazole nuclei were prepd. and their photosensitizing properties detd. in Ag halide emulsions. The syntheses of the heterocyclic nuclei and the cyanine dyes derived from them were given. Representative dye structure are: I [59506-84-2], II [59506-85-3], and III [59506-86-4].
IT 59504-64-4P 59504-92-6P 59504-99-3P 59505-22-5P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation and cyanine dye manufacture from)
RN 59504-64-4 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 6,7-dichloro-2,3-dihydro-4-[2-[[methylsulfonyl]amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

RN 59504-92-6 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 7-ethoxy-6-[ethoxycarbonyl]-2,3-dihydro-4-[2-[[methylsulfonyl]amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

RN 59504-99-3 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 7-bromo-6-[ethoxycarbonyl]-2,3-dihydro-4-

L19 ANSWER 127 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
[2-[[methylsulfonyl]amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

RN 59505-22-5 CAPLUS
CN Pyrido[1,2-a]benzimidazolium, 7,8-dichloro-1,2,3,4-tetrahydro-5-[2-[[methylsulfonyl]amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

IT 59505-68-0P 59505-76-8P 59505-84-9P
59506-52-4P 59596-71-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and photosensitizing properties of)
RN 59505-68-0 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 7-chloro-6-(ethoxycarbonyl)-3-[2-[3-ethyl-2-thiazolidinylidene]ethylidene]-2,3-dihydro-4-[2-[[methylsulfonyl]amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 127 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 59505-76-8 CAPLUS
CN Pyrido[1,2-a]benzimidazolium, 7,8-dichloro-4-[2-[3-ethyl-2-thiazolidinylidene]ethylidene]-1,2,3,4-tetrahydro-5-[2-[[methylsulfonyl]amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 59505-84-9 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 7-bromo-6-[ethoxycarbonyl]-3-[2-[3-ethyl-2-thiazolidinylidene]ethylidene]-2,3-dihydro-4-[2-[[methylsulfonyl]amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 59506-52-4 CAPLUS

L19 ANSWER 127 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN Pyrido[1,2-a]benzimidazolium, 7,8-dichloro-4-[2-[3-ethyl-5-phenyl-2(3H)-benzoxazolylidene]ethylidene]-1,2,3,4-tetrahydro-5-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 59506-71-7 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 6,7-dichloro-3-[2-(3-ethyl-2-selenazolidinylidene)ethylidene]-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 128 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1974:444048 CAPLUS
DOCUMENT NUMBER: 81:44048
ORIGINAL REFERENCE NO.: 81:6997a,7000a
TITLE: Influence of the habit of silver halide crystals on the absorption spectra of adsorbed sensitizing dyes. II. Silver chloride emulsions
AUTHOR(S): Vanassche, W.; Claes, F. E.; Borginon, H.; Libeer, J.
CORPORATE SOURCE: Res. Lab., Agfa-Gevaert N. V., Mortsel, Belg.
SOURCE: Photogr. Sensitivity, Proc. Symp. (1973), Meeting Date 1972, 265-81. Editor(s): Cox, R. J. Academic: London, Engl.
CODEN: 28MDAQ
DOCUMENT TYPE: Conference
LANGUAGE: English
AB A new crystallog. form, the {100} habit, of AgCl was prepared. The absorption spectra of sensitizing dyes adsorbed on AgCl crystals with different crystallog. habits in photog. emulsions are affected by the crystal shape. Unlike AgBr, the cubic habit of AgCl induces J-aggregation. The J-band is weakened or disappears when the dye is adsorbed on octahedral or dodecahedral crystals. An explanation for this J-aggregation was previously proposed for the absorption spectrum of dyes adsorbed on AgBr crystals. There are effects other than surface structure; AgCl and AgBr differ in the ireasity of hydration of the halide ion, and the signs of the space charge layers are opposed. The {110} and {111} crystals of AgCl induce M-or D-absorption maxima
IT 53132-00-6
RL: USES (Uses)
(absorption spectra of sorbed photog. sensitizer, silver halide crystal habit effect on)
RN 53132-00-6 CAPLUS
CN 1H-Benzimidazolium, 5,6-dichloro-2-[3-(5,6-dichloro-1,3-diethyl-1,3-dihydro-2H-benzimidazol-2-ylidene)-1-propen-1-yl]-1-ethyl-3-[6-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L19 ANSWER 129 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1971:510057 CAPLUS
DOCUMENT NUMBER: 75:110957
ORIGINAL REFERENCE NO.: 75:19749a,19752a
TITLE: Photosensitive copying materials containing diazo dyes
INVENTOR(S): Poot, Albert L.; Deporter, Henri
PATENT ASSIGNEE(S): Agfa-Gevaert A.-G.
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXKBW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2059192	A	19710609	DE 1970-2059192	19701202
CA 968211	A1	19750527	CA 1970-98246	19701116
FR 2072695	A5	19710924	FR 1970-43073	19701130
JP 48043202	B	19731205	JP 1970-105761	19701130
CH 569996	A5	19751128	CH 1970-17563	19701130
US 3676138	A	19720711	US 1970-94574	19701202
NL 7017685	A	19710607	NL 1970-17685	19701203
PRIORITY APPLN. INFO.:			GB 1969-59093	A 19691203

GI For diagram(s), see printed CA Issue.
AB Photosensitive copying materials were prepared in which an image was formed by coupling, in alkaline medium, a diazonium compound and a quaternary salt of structure I or II, where R is a substituted or unsubstituted aliphatic or cycloaliphatic group, n = 1 or 2, and X- is an anion. For example, a mixture of 2-(diethylamino)benzenediazonium tetrafluoroborate 6, 2-methyl-3-[2-(methylsulfonyl)carbamoylmethyl]-5,6-dimethoxy-benzothiazolium bromide (I; R = CH2CONHSO2Me, X = Br) 8, citric acid 40, tri-Na naphthalenetrisulfonate (III) 8, urea 20, silica 1, and saponin 0.1 g, and 56 ml 25% aqueous III was diluted with H2O to 400 ml, coated on a paper support, and dried. A black image with colorless background was formed when the coated paper was exposed through a diapos. and developed with NH3.
IT 34238-93-4
RL: USES (Uses)
(diazo process coupler)
RN 34238-93-4 CAPLUS
CN Benzothiazolium, 5,6-dimethoxy-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

L19 ANSWER 129 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

L19 ANSWER 130 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:498443 CAPLUS
DOCUMENT NUMBER: 75:98443
ORIGINAL REFERENCE NO.: 75:15561a,15564a
TITLE: Indole-3-acetic acid derivatives as muscle stimulants
INVENTOR(S): Rooney, Clarence S.; Gleason, Clarence H.
PATENT ASSIGNEE(S): Merck Sharp and Dohme (I.A.) Corp.
SOURCE: Ger. Offen., 59 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 2062017	A	19710812	DE 1970-2062017		19701216
CA 903210	A	19720620	CA 1970-73875		19700203
US 3758500	A	19730911	US 1970-92210		19701123
ZA 7007949	A	19720726	ZA 1970-7949		19701124
NL 7017488	A	19710805	NL 1970-17488		19701130
FR 2081481	A5	19711203	FR 1970-43350		19701202
FR 2081481	B1	19740322			
GB 1291657	A	19721004	GB 1970-1291657		19701202
SE 372266	B	19741216	SE 1970-16301		19701202
IL 35771	A	19741231	IL 1970-35771		19701202
DK 129993	B	19741209	DK 1970-6190		19701204
HU 162286	B	19730129	HU 1970-ME1302		19701210
JP 48029224	B	19730908	JP 1970-121852		19701229
US 3833608	A	19740903	US 1972-289511		19720915
PRIORITY APPLN. INFO.:			CA 1970-73875	A	19700203
			US 1970-92210	A3	19701123

GI For diagram(s), see printed CA Issue.
AB The title compds. (I, R = Pr, Bu, or CH2CH2Cl; R1 = CO2H, CONHSO2NMe2, CONHSO2Me, CONHSO2C6H4Me-p, SO2NHMe, SO2NHCONMe2, SO(:NH)Me, or CONHAc; R2 = H or Me), useful as muscle stimulants and for treatment of myasthenia gravis, were prepared Thus, reaction of BuCOCl with 2,4-Me2C6H3NH2 gave the amide, which on reaction with NaNH2 gave 2-butyl-3-methylindole (II). Reaction of II with HCHO/Me2NH gave I (R = Bu, R1 = NMe2, R2 = Me), the MeI salt of which reacted with KCN to give I (R = Bu, R1 = CN, R2 = Me) (III). Reaction of III with KOH in H2O-EtOH gave I (R = Bu, R1 = CO2H, R2 = Me). Also prepared were 9 other I.
IT 33414-10-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33414-10-7 CAPLUS
CN 1H-Indole-3-acetamide, 5-methyl-N-(methylsulfonyl)-2-propyl- (CA INDEX NAME)

L19 ANSWER 130 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 131 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1970:95344 CAPLUS
DOCUMENT NUMBER: 72:95344
ORIGINAL REFERENCE NO.: 72:17325a,17328a
TITLE: Sensitized zinc oxide photoconductor compositions
INVENTOR(S): Verhille, Karel E.; Noe, Robert J.; Voet, Luciaan F.; Depoorter, Henri
PATENT ASSIGNEE(S): Gevaert-Agfa N. V.
SOURCE: Fr., 28 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1560976		19690321	FR	19680424
GB 1199062			GB	
US 3617269		19711102	US	19680426
PRIORITY APPLN. INFO.:			GB	19670426

GI For diagram(s), see printed CA Issue.
AB Carbocyanines I, where n is 0 and 1 (X is Br and I), are added to dispersions of ZnO in vinyl copolymer solution andthe compns. are coated on parchment paper to give layers 3-10 μ thick. The ZnO-binder weight ratio is 1:0.1-1:0.6, the amount of I added is 0.0-1mg/g ZnO, and the coating compns.contain 95-60 weight% ZnO. Thus, a dispersion prepared from 20 g ZnO, 25 ml H2O, and 1 ml 10% maleic anhydride-1-vinylpyrrolidone copolymer (1:9 NH3-water) is added to a solution of 2 g vinyl acetate-crotoric acid copolymer and 1.25 ml melamine-formaldehyde resin in 25 ml water and 1 ml 25% NH3,, and a 0.1% solution of I [R =r1 = O,R2 =CH2CONHSO2Me,, R3 = Et, R5 = R7 = PhCH2, R4 = R6 =R8 = H, n = 1 (X= I] is added at 0.5mg/g ZnO. The composition is coated on a baryta paper to give 25 g ZnO/m2, charged (-7000 V), irradiated for 15 sec (2240 lux, 2750°K), and developed. The sensitivity is more than double that of a standard photoconductor material.
Also used are sM40 addn1. tA, where R and R1,R2 and R3, and R5 and R7 are the same or different, R and R1 are O, S, Se, and NEt, R2 and R3 are Et, (CH2)nSO2NHAc and (CHnSO2N-Ac, CH2CONHSO2Me,CH2CON-SO2Me, and (CH2)3-OSO3-, R4 and R6 are H and Me, R5 and R7 are PHCH2, PH, Me, and OMe, and R8 is H or a C1-3 alkyl group.
IT 27746-86-7
RL: USES (Uses)
(zinc oxide photoconductor sensitized by, for electrophotography)
RN 27746-86-7 CAPLUS
CN Benzoxazolium, 3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-[3-[3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-5-(phenylmethyl)-2(3H)-benzoxazolylidene]-1-propen-1-yl]-5-(phenylmethyl)-, inner salt (CA INDEX NAME)

L19 ANSWER 131 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



IT 27276-62-6 27570-44-1
RL: TEM (Technical or engineered material use); USES (Uses)
(zinc oxide photoconductor sensitized by, for electrophotography)
RN 27276-62-6 CAPLUS
CN Benzothiazolium, 2-[3-(3-ethyl-6-methyl-2(3H)-benzothiazolylidene)-2-methyl-1-propen-1-yl]-6-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 27570-44-1 CAPLUS
CN Benzoxazolium, 2-[3-[5-(ethoxycarbonyl)-1-ethyl-1,3-dihydro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-3-ethyl-5,6-dimethyl-, inner salt (CA INDEX NAME)



L19 ANSWER 132 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1969:464036 CAPLUS
DOCUMENT NUMBER: 71:64036
ORIGINAL REFERENCE NO.: 71:12197a,12200a
TITLE: Red sensitive silver halide films
INVENTOR(S): Goetze, Johannes; Kiester, Oskar; Philippaerts, Herman
A.; Ghys, Theofiel H.; Hase, Marley Kueffner, Karl
PATENT ASSIGNEE(S): Gevaert-Agfa N. V.
SOURCE: Belg., 29 pp.
CODEN: BEXKAN
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 717449		19681031	BE	
DE 1547641			DE	
DE 1597474			DE	
FR 1559558			FR	
GB 1123191			GB	
US 3616674		19711026	US	19690402
PRIORITY APPLN. INFO.:			DE	19670410
			DE	19670824

GI For diagram(s), see printed CA Issue.
AB A Ag(Br, I) emulsion containing 6.7 mole % AgI and 0.3 mole AgX/-kg. emulsion is sensitized with 20 mg. of a 3-type dye and coated on cellulose acetate base. The film has no sensitivity in the blue and a Amaximum at 710 nm.
IT 24687-43-0
RL: USES (Uses)
(photographic sensitizer)
RN 24687-43-0 CAPLUS
CN Benzothiazolium, 2-[2-[(3-ethyl-5-methyl-2(3H)-benzothiazolylidene)methyl]-1-buten-3-yl]-5-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 133 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1966:68695 CAPLUS
DOCUMENT NUMBER: 64:68695
ORIGINAL REFERENCE NO.: 64:12857e-h,12858a-e
TITLE: Photographic methine dye sensitizers
INVENTOR(S): Gevaert-Agfa N. V.
SOURCE: 30 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6511027		19651025	NL 1965-11027	19650824
PRIORITY APPLN. INFO.:			GB	19640825

GI For diagram(s), see printed CA Issue.
AB 2,3-Diethyl-4-sulfanylbenzothiazolium p-toluenesulfonate (4.15 g.) and 3.25 g. 2-(2-acetanilidovinyl)-3-ethylthiazolidinium bromide (I) in 25 cc. EtOH refluxed 5 min. with 2.8 cc. Et3N yielded II (X = H, X1 = SO2NH2 R = Me, R1 = Et, A = Br), m. >260° (PhOH), Amaximum 508 mu (log e 5.12) (the absorption maximum and log e values are given throughout this abstract in brackets and parentheses, resp.) Similarly were prepared II (X = H, X1 = AsMeSO2, R = Me, R1 = Et, A = Br), m. >260° [508 (5.20)], and III (X = SO2N-Me, R = Et), m. >270° [504 (5.16)]. 2-Methyl-3-[N-(methylsulfonyl)carbamoylmethyl]-7-sulfanylbenzothiazolium bromide (6.2 g.) and 5 g. I in 75 cc. aqueous MeOCH2CH2OH, treated, with cooling, with 4 cc. Et3N and diluted with 300 cc. EtOH gave IV (X = SO2NH2, R = MeSO2N-CO2H2, R1 = Et), m. 220° (PhOH-EtOH), [552]. Similarly was prepared IV (X = SO2NH2, X1 = H, R = R1 = Et, A = Br) [552 (5.07)]. 2,3-Dimethyl-7-[methyl(sulfonamido)benzothiazolium Me sulfate (IV) (3.7 g.), 3.65 g. I, 25 cc. EtOH, and 2.8 cc. Et3N shaken 0.5 hr. at room temperature gave IV (X = MeSO2N-, R = Me, R1 = Et), m. 276-8° (1:1 EtOH-H2O) [506 (4.96)]. Similarly was prepared V (X = MeSO2N-, R1 = R4 = R3= Me, R3 = H, Z = O, R2 = Et), m. 282-2° (320(5.16)). IV (7.6 g.), 7.6 g. MC(OEt)3, and 50 cc. AcOH refluxed 20 min. gave VI (X = XI = MeSO2)N, R1 = R2 = Me, R3 = R4 = R5 = H, Z = N, A = MeSO4), m. 278-81° (diacetone alc.-EtOH-H2O) [546 (4.96)]. 3-Ethyl-2-methyl-7-sulfanylbenzothiazolium p-toluenesulfonate (4.3 g.) and 3.6 g. 2-(2-methyl-2-ethylthiovinyl)-3-ethylbenzothiazolium sulfate in 60 cc. CH3NO refluxed 0.5 hr. with 1.4 cc. Et3N gave VI (X = SO2NH2, X1 = R4 = R5 = H, X1 = R2 = Et, R3 = Me, Z = S, A = MeSO4), m. 260° (PhOH) [547 (5.11)]. Similarly were prepared VI (X = SO2NH2, X1 = R4 = H, R1 = R2 = R3 = Et, R5 = Ph, Z = S, A = MeSO4), m. >260° [553 (4.98)], V (X = AcN-SO2, R1 = R2 = Et, R3 = Me, R4 = R5 = H, Z = S), m. >270° [545 (4.74)], VII (X = MeSO2NH, A = MeSO4), m. 249-50° [508 (4.80)], VIII, m. 265-7° [582 (5.14)], VII (X = MeJNSO2NH, A = iodine), m. 180° [568 (5.06)], V (X = AcN-SO2, R1 = R2 = Me, R3 = Et, R4 = H,

L19 ANSWER 132 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

R5 = Ph, Z = S), m. >270° [553 (4.80)]. 2,3-Dimethyl-7-(methylsulfonamido)benzothiazolium Me sulfate (3.68 g.), 4.0 g. 2-(2-acetanilidovinyl)-3-ethylbenzothiazolium iodide, 2.8 cc. Et3N, and 50 cc. EtOH refluxed 0.5 hrs. gave VI (X = MeSO2NH, X1 = R3 = R4 = R5 = H, R1 = Me, R2 = Et, Z = S, A = iodine), m. 207-9° (2:1 diacetone alc.-H2O) [559 (5.12)].

2-(2-Anilidovinyl)-3-methyl-7-(methylsulfonamido)-benzothiazolium methylsulfate (4.7 g.), 1.6 g. 3-ethylthiazolidine-2-thion-4-one, 2.4 cc. Et3N, and 25 cc. Ac2O refluxed 15 min. gave IX (Z = S), m. 265° (diacetone alc.) [516 (4.53)]. Similarly were prepd. IX (Z = PhN), m. 275-8° [506 (4.39)], and X, m. 265° [4.92 (4.77)]. The sensitization max. of the various methine dyes in AgCl emulsions were detd. and are tabulated.

IT 5045-26-1P, Benzothiazolium, 2-methyl-3-[(methylsulfonyl)carbamoyl]methyl]-7-sulfamoyl-, bromide 5045-44-3P, Benzothiazolium, 2-[3-(3-ethyl-2-thiazolidinylidene)propenyl]-3-[[(methylsulfonyl)carbamoyl]methyl]-7-sulfamoyl-, hydroxide, inner salt RL: PREP (Preparation) (preparation of)

RN 5045-26-1 CAPLUS
CN Benzothiazolium, 7-(aminosulfonyl)-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

● Br⁻

RN 5045-44-3 CAPLUS
CN Benzothiazolium, 7-(aminosulfonyl)-2-[3-(3-ethyl-2-thiazolidinylidene)-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 133 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



L19 ANSWER 134 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1963:442230 CAPLUS
DOCUMENT NUMBER: 59:42230
ORIGINAL REFERENCE NO.: 59:7692c-g
TITLE: Benzimidazole methine dyes
PATENT ASSIGNEE(S): Gevaert Photo-Producten N.V.
SOURCE: 19 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 619851		19621031	BE	
GB 980234			GB	
PRIORITY APPLN. INFO.:			GB	19610706

GI For diagram(s), see printed CA Issue.

AB Benzimidazole methine dyes of the general formula I, where n = 0, 1, or 2, and Z is a selenazoline or benzimidazole ring system were prepared for use as photographic sensitizers. 1-Ethyl-2-methyl-5,6-dibromobenzimidazole (II) (6.5 g.) and 2.2 cc. EtI heated 15 hrs. in a sealed tube at 120°, powdered, and washed with Et2O yielded 8.5 g. 1,3-diethyl-2-methyl-5,6-dibromobenzimidazolium iodide (III), m. 294-6°. II (6.5 g.) and 10.8 g. BrCH2CONHSO2Me heated 48 hrs. at 105° gave 1-ethyl-2-methyl-3-[(methylsulfonylcarbamoyl)methyl]-5,6-dibromobenzimidazolium bromide (IV), m. 194°. 1,3,4-C6H3Br3 treated with HNO3 yielded 2,4,5-Br3C6H2NO2 (V), m. 95° (EtOH); V with EtNH2 gave orange 4,5,2-Br2(O2N)C6H2NHEt, m. 127°, which was reduced to EtNHBr2C6H2NH2, m. 62-4°, and heated with HCl and HOAc to give light brown II, m. 118-19°. 2-(2-Acetanilidovinyl)-3-ethylselenazolinium iodide (6.73 g.) and 7.11 g. III in C5H5N heated 20 min. at 140-50° with 6 cc. Et3N, cooled, and diluted with Et2O precipitated I (Z = 3-ethylselenazolin-2-ylidene, n = 1), m. 268°, λmaximum 472 mμ (log ε 5.049); it sensitizes a AgClAgBr emulsion with a maximum at 515 mμ. III (9.58 g.) and 7 cc. EtOCH:CHCH(OEt)2 refluxed 5 min., cooled, and filtered gave I (Z = 1,3-diethyl-5,6-dibromobenzimidazolin-2-ylidene, n = 2); m. 148-51° (MeOH and MeOCH2CH2OH), λmaximum 615 mμ (log ε 5.224), sensitization maximum (AgCl) 650 mμ. 1,3-Dimethyl-2-(methylthio)-5,6-dichlorobenzimidazolium methosulfate (3.70 g.) and 4.70 g. III in 25 cc. PhNO2 refluxed 45 min. with 2.8 cc. Et3N and diluted with Et2O yielded I (Z = 1,3-dimethyl-5,6-dichlorobenzimidazolin-2-ylidene, n = 0), m. 260-1° (EtOH) λmaximum 412 mμ (log ε 4.059), sensitization maximum (AgCl) 435 mμ. III (8.5 g.) in 70 cc. PhNO2 refluxed 40 min. with 9 cc. HC(OEt)3, cooled, and diluted with Et2O precipitated I (Z = 1,3-diethyl-5,6-dibromobenzimidazolin-2-ylidene, n = 1), red needles, m. 264-6° (MeOCH2CH2OH-PhOH-EtOH), λmax 518

L19 ANSWER 134 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

mμ (log ε 5.30), sensitization max. (AgCl) 580 mμ. IV (5.34 g.), 3.5 g. 2-(2-acetanilidovinyl)thiazolinium bromide, 30 cc. C5H5N, and 1.7 cc. piperidine boiled 0.5 hr. and filtered gave VI, m. >250° (diacetone alc.), λmax. 417 mμ (log ε 4.88), sensitization max. (AgClAgBr) 510 mμ

IT 96473-31-3P, 5,6-Dibromo-1-ethyl-2-methyl-3-[[(methylsulfonyl)carbamoyl]methyl]benzimidazolium bromide
100171-06-0P, 5,6-Dibromo-1-ethyl-2-[3-(3-ethyl-2-thiazolidinylidene)propenyl]-3-[[(methylsulfonyl)carbamoyl]methyl]benzimidazolium hydroxide, inner salt
RL: PREP (Preparation)
(preparation of)

RN 96473-31-3 CAPLUS

CN 1H-Benzimidazolium, 5,6-dibromo-1-ethyl-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 100171-06-0 CAPLUS

CN 1H-Benzimidazolium, 5,6-dibromo-1-ethyl-2-[3-(3-ethyl-2-thiazolidinylidene)-1-propen-1-yl]-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L19 ANSWER 135 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1963:82273 CAPLUS
DOCUMENT NUMBER: 58:82273
ORIGINAL REFERENCE NO.: 58:14169h,14170a-h,14171a-g,14172a-c
TITLE: Sensitizers containing an imidazole nucleus substituted by a fluorine atom or a cyano radical
INVENTOR(S): Depoorter, Henri; Libeer, Marcel J.; Van Mierlo, Gerrit G.; Nys, Jean M.
PATENT ASSIGNEE(S): Gevaert Photo-Producten N. V.
SOURCE: 51 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 595980		19610413	BE	
DE 1180241			DE	
GB 955962			GB	
GB 955964			GB	
US 3264110		19660802	US 1964-341445	19640130
US 3268334		19660823	US 1964-341446	19640130
PRIORITY APPLN. INFO.:			GB	19511013

AB The title compds. are obtained by known methods. The following new products were prepared: 1,3-diethyl-2-methyl-5-cyanobenzimidazolium iodide, m. 260°; 1-ethyl-2-methyl-3-(β-hydroxyethyl)-5-cyanobenzimidazolium bromide, m. >250°; 1-ethyl-2-methyl-3-[[(methylsulfonyl)carbamoyl]methyl]-5-cyanobenzimidazolium bromide; 1-ethyl-2-methyl-3-(γ-sulfatopropyl)-5-cyanobenzimidazolium betaine; 1-ethyl-2-methyl-3-[ω-(acetylsulfamoyl)propyl]-5-cyanobenzimidazolium bromide; 1-ethyl-2-methyl-3- [ω-(acetylsulfamoyl)butyl]-5-cyanobenzimidazolium bromide; 1-(β-acetoxyethyl)-2-methyl-3-(β-hydroxyethyl)- 5-cyanobenzimidazolium bromide, m. 202°; 1,3-bis(β-acetoxyethyl)-2-methyl-5-cyanobenzimidazolium bromide, m. 250°; 1-ethyl-2-methyl-3-(β-acetoxyethyl)-5-cyanobenzimidazolium bromide; 1,3-diethyl-2-(β-anilinovinyl)-5-cyanobenzimidazolium iodide, m. 265°; I,3-diethy-2-[β-(phenylimino)ethylidene]-5-cyanobenzimidazoline, m. 175° (C6H6-C6H14); 1,3-diethyl-2-[β-(p-toluenesulfonanilido)-vinyl]-5-cyanobenzimidazolium chloride, m. 185°; 1,3-diethyl-2-methyl-5-chloro-6-cyanobenzimidazolium iodide; 1,3-diethyl-2-methyl-5-fluoro-6-cyanobenzimidazolium iodide, m. >250°; 1-ethyl-2-methyl-3-(β-hydroxyethyl)-5-fluorobenzimidazolium bromide, m. 248°; 1-ethyl-2-methyl-3-[ω (acetylsulfamoyl)-butyl]-5-fluorobenzimidazolium bromide, m. 198°; 1,3-diethyl-2-methyl-5-fluorobenzimidazolium iodide, m 218°; 1,3-diethyl-2-(β-anilinovinyl)-5-chlorobenzimidazolium bromide, m. 228° (EtOH); 1,3-diethyl-2-[β-(phenylimino)ethylidene]-5-chlorobenzimidazoline, m. 157°; 1,3-diethyl-2-[β-(p-toluenesulfonanilido)vinyl]-5-chlorobenzimidazolium chloride, m. 187°; 1,3-diethyl-2-methyl-5-chloro-6-fluorobenzimidazolium iodide, m. 268-70°; 1,3-diethyl-2-(β-anilinovinyl)-5,6-dichlorobenzimidazolium, iodide, m. 265°; 1,3-diethyl-2-[β-(phenylimino)ethylidene]-5,6-dichlorobenzimidazoline, m. 148° (C6H6-C6H14);

L19 ANSWER 135 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1,3-diethyl-2-[β-(p-toluenesulfonanilido)vinyl]-5,6-dichlorobenzimidazolium chloride, m. 228°. From these intermediates the following new dyes were prepd. (m.p., λmax. in mμ, log ε, Ag halide, sensitizing limit, sensitization max., and sensitivity to light above 510 mμ in terms which correspond to a sensitivity of 100 for the non-sensitized emulsions given):

1,3-diethyl-2-[3-(1,3-di-ethyl-5-cyano-2-benzimidazolinytidene)propenyl]-5-cyanobenzimidazolium iodide, 267° (EtOH), 514, 5.32, Ag(Br, I), 595, 585, 305; 1,3-diethyl-2-[13-(3-ethyl-5-phenyl]-2-benzoxazolinylidene)propenyl]-5-cyanobenzimidazolium iodide, 178° (EtOH), 493, 4.61, AgCl, 555, 535, 265 and Ag (Cl, Br), 580, 560, 250;

1,3-diethyl-2-[3-(3-ethyl-5,6-dimethyl-2-benzoxazolinylidene)-propenyl]-5-cyanobenzimidazolium iodide, 248° (EtOH), 497, 5.07, AgCl, 570, 540, 255; 1,3-diethyl-2-[3-(3-ethyl-2-thiazolidinylidene)propenyl]-5-cyanobenzimidazolium iodide, 250° (EtOH), 472, 5.12, AgBr, 555, 525, 265; 1-ethyl-2-[3-(3-ethyl-2-[thiazolidinylidene)propenyl]-3-(β-acetoxyethyl)-5-cyanobenzimidazolium bromide, 162° (EtOH), 470, 5.11, AgBr, 540, 520, 200; 1-ethyl-2[3-(3-ethyl-5-methyl-2-benzoxazolinylidene)-propenyl]-3-(β-acetoxyethyl)-5-cyanobenzimidazolium bromide, 140° (EtOH), 491, 5.15, Ag(Br, I), 575, 555, 230; 1-ethyl-2-[3-(3-ethyl-5,6-dimethyl-2-benzoxazolinylidene)propenyl] - 3-[[(methylsulfonyl)carbamoyl]methyl] - 5 - cyanobenzimidazolium betaine, >250° (MeOCH2CH2OH-EtOH), 498, 5.22, Ag(Cl, I), 580, 545, 215; 1-ethyl-2-[3-(3-ethyl-5,6-dimethyl-2-benzoxazolinylidene)propenyl]-3-(γ-sulfatopropyl)-5-cyanobenzimidazolium betaine, >250° (MeOCH2CHOH), 500, 5.16, Ag(Br, I), 590, 570, 230 and AgBr, 580, 545, 255; 1-ethyl-2-[3-(3-ethyl-5,6-dimethyl-2-benzoxazolinylidene)propenyl]-3-[ω-(acetylsulfamoyl)-propyl]-5-cyanobenzimidazolium bromide, 162° (EtOH), 500, 5.17, Ag(Br, I), 590, 570, 255 and AgBr, 580, 545, 275; 1-ethyl-2-[3-(3-ethyl-2-benzoselenazolinylidene)propenyl]-3-(γ-sulfatopropyl)-5-cyanobenzimidazolium betaine, >260° (EtOH-Me2CO), 531, 5.03, Ag(Br, I), 630, 600, 325; 1-ethyl-2-[3-(3-ethyl-2-benzothiazolinylidene)propenyl]-3-[[(methylsulfonyl)-carbamoyl]methyl] - 5 - cyanobenzimidazolium betaine, >260° (EtCH), 524, 5.18, Ag (Br, I), 605, 585,305; 1-(β-acetoxyethyl)-2-[3-(1,3-diethyl-5,6-dichloro-2-benzimidazolinylidene)propenyl]-3-(β-hydroxyethyl)-5-cyanobenzimidazolium iodide, 214° (EtOH), 515, 5.32, AgBr, 600, 680, 275; 1,3-bis(β-acetoxyethyl)-2-[3-(1,3-diethyl-5,6-dichloro-2-benzimidazolinylidene)propenyl]-5-cyanobenzimidazolium bromide, 163° (EtOH), 513, 5.29, AgBr, 595, 575, 255; 1-ethyl-2-[3-(1,3-diethyl-5,6-dichloro-2-benzimidazolinylidene)propenyl]
-

3 - [ω-(acetylsulfamoyl)butyl]-5-cyanobenzimidazolium bromide, >250° (EtOH), 514, 5.38, AgBr, 605, 590, 270; 1-ethyl-2-[3-[1-ethyl-3-(β-hydroxyethyl)-5-cyano-2-benzimidazolinylidene]propenyl]-3-(β-hydroxyethyl)-5-cyanobenzimidazolium iodide, 180° (EtOH), 517, 5.31; 1-ethyl-2-[3-[1-ethyl-3-(β-acetoxyethyl)-5-cyano-2-benzimidazolinylidene]propenyl] -3-(β-acetoxyethyl)-5-cyanobenzimidazolium bromide, >250° (EtOH), 514, 5.34, Ag(Cl, Br),

L19 ANSWER 135 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
605, 585, 295; 1-(β-acetoxyethyl)-2-[3-(1,3-diethyl-5-cyano-2-benzimidazolinylidene)propenyl] -3-(β - hydroxyethyl) - 5-cyanobenzimidazolium bromide, 188° (EtOH), 514, 5 32, Ag (Br, I), 605, 585, 305; 1,3-bis(β-acetoxyethyl)-2-[3-(1,3-diethyl-5-cyano-2-benzimidazolinylidene)propenyl] -5-cyanobenzimidazolium iodide, 201° (EtOH), 512, 5.28, --, --, --, --; 1,3-dethyl-2-[3-(3-ethyl-2-thiazolidinylidene)propenyl] -5-chloro-6-cyanobenzimidazolium iodide, >250° (EtOH-C5H5N and MeOCH2CH2OH), 479, 5.18, AgBr, 560, 540, 270; 1,3-diethyl-2-[3-(3-ethyl-2-thiazolidinylidene)propenyl] -5-fluoro-6-cyanobenzimidazolium iodide, 269° (EtOH), 472, 5.112, AgCl, 475, 440, 195 (total sensitivity); 1,3-diethyl-2-[3-(1,3-diethyl-5-chloro-2-benzimidazolinylidene)propenyl]-5-cyanobenzimidazolium iodide, >250° (EtOH), 507, 5.33, AgBr, 605, 580,340;
1-ethyl-2-[3-(3-ethyl-5-chloro-2-benzoxazolinylidene)propenyl]-3-(γ-sulfatopropyl)-5-cyanobenzimidazolium betaine, >260° (EtOH/Me2SO), 488, 5.06, AgCl, 555,530,210 and Ag(Cl, Br), 585, 565, 325; 1,3-diethyl-2-[(3-ethyl-2-benzoxazolinylidene)methyll-5-cyanobenzimidazolium iodide, --, 385 (EtOH), --, --, --, -- ,--; 1-ethyl-2-[3-(3-ethyl-2-thiazolidinylidene)propenyl]-3-(β-acetoxyethyl)-5-fluorobenzimidazolium perchlorate, 234° (EtOH) 459, 4.89, AgCl, 520,490,255; 1-ethyl-2-[3-(3-ethyl-5,6-dimethyl-2-benzoxazolinylidene)propenyl]-3-[ω(acetylsulfamoyl)butyl]-5-fluorobenzimidazolium bromide, 210°. (EtOH), 482, 5.07, Ag(Br, I), 565, 550, 230; 1,3-diethyl-2-[3-(1,3-diethyl-5-chloro-2-benzimidazolinylidene) propenyl]-5-fluorobenzimidazolium iodide, >250° (EtOH), 502, 5.28, AgCl, 585, 570, 385; 1-ethyl-2-[3-(1,3-diethyl-5,6-dichloro-2-benzimidazol-inylidene)propenyl]-3-(β-hydroxyethyl)-5-fluorobenzimidazolium bromide, >250° (EtOH) 514, 5.32, AgCl, 600, 580,385; 1,3-diethyl-2-

[3-(1,3-diethyl-5,6-dichloro-2-benzimidazolinylidene)propenyl]-5-chloro-6-fluorobenzimidazolium iodide, >250° (EtOH-C5H5N), 508, 5.82,--, --, --, --; 1,3-diethyl-2-[3-(3ethyl-5-phenyl-2-benzoxazolinylidene)propenyl]-5-fluorobenzimidazolium iodide, 250° (EtOH), 470, 4.88, AgBr, 555, 525, 145; 1,3-diethyl-2-[3-(3-ethyl-2-thiazolidinylidene)propenyl]-5fluorobenzimidazolium iodide, 232° (EtOH), 460, 4.87, AgBr, 540, 520, 165; 1,3-diethyl-2-[3-(1,3-diethyl-5-fluoro-2-benzimidazolinylidene)propenyl]-5-fluorobenzimidazolium iodide, 267° (EtOH), 504, 5.17, Ag(Br, I), 595, 570, 280; 1,3-diethyl-2-[3-(3-ethyl-5,6-dimethyl-2-benzoxazolinylidene)propenyl]-5-fluorobenzimidazolium iodide, 260° (EtOH), 480, 4.97, Ag(Cl, Br), 555, 520, 200;
1,3-diethyl-2-[3-(3-ethyl-2-benzothiazolinylidene)propenyl]-5-fluorobenzimidazolium iodide, 245° (EtOH), 507, 5.00, AgCl, 580, 555, 235 and Ag (Br, I), 605, 590, 270; 1,3-diethyl-2-[3-(3-ethyl-2-benzoxazolinylidene)propenyl]-5-fluorobenzimidazolium iodide, 255° (EtOH), 472, 5.00, AgCl, 540, 515, 110; 1,3-diethyl-2-[3-(3-ethyl-5-methyl-2-benzoxazolinylidene)propenyl]-5-fluorobenzimidazolium iodide, 247° (EtOH), 476, 5.02, AgCl, 545, 525, 130; 1,3-diethyl-2-[3-(1,3-diethyl-5,6-dichloro-2-

L19 ANSWER 135 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
benzimidazolinylidene)propenyll-5-fluorobenzimidazolium iodide, 260° (EtOH), 510, 5.31, Ag(Br, I), 600, 575, 330; 2-thio-3-ethyl-5-[(1,3-diethyl-5-cyano-2-benzimidazolinylidene)-ethylidene]-2,4-thiazolidinedione, >250° (EtOH-C5H5N), 518, 5.08, Ag (Br, I), 625, 590, 296;
1-methyl-2-thio-3-ethyl-5-[(1,3diethyl-5cyano-2-benzimidazolinylidene)ethylidene]-2,4-imidazolidinedione, 224-6° (EtOH), 526, --, AgCl, 600, 550, 415, (total sensitivity); 4-(1,3-diethyl-5-fluoro-2-benzimidazolinylidene)-2-cyanobutyronitrile, 208° (EtOH), 419, 4.91, AgCl, 465, 450, 215 (total sensitivity); 2-thio-3-ethyl-5-[(1,3-diethyl-5-fluoro-2-benzimidazolinylidene)ethylidene]-2,4-thiazolidinedione, 196° (EtOH), 514, 5.14, AgCl, 610, 550,470 (total sensitivity). Belg.
615,550,
July 16, 1962, Brit. Appl. Mar. 24, 1961 and Apr. 12, 1961; 18 pp. Addn. to Belg. 595,980. The following intermediate products were prepd.: 2,3-Br(O2N)C6H3CO2Et (I), m. 38-9° (EtOH), yield: 126 g. from 130 g. 2,3-Br(O2N)C6H3CO2H; 2,3-MeNH(O2N)C6H3CO2Et (II), m. 50° (MeOH), yield: 5 g. from 12.5 g. I; 3,2-H2N(MeNH)C6H3CO2Et (not sepd.); 1-methyl-2-mercapto-7-carbethoxybenzimidazole (III), m. 161° (C6H6), yield: 4.6 g. from 11.2 g. II; 1-methyl-2-(methylmercapto)-7-carbethoxybenzimidazole, b2 186-90°, yield: 0.85 g. from 2.36 g. III; 4,3-MeNH(O2N)C6H3CN (IV), m. 167° (MeOCH2CH2OH), yield: 45 g. from 67 g. 4,3-Br(O2N)C6H3CN; 3,4-H2N(MeNH)C6H3CN (V), m. 140-1° (C6H6-C6H14), yield: 6.2 g. from 11.1 g. IV; 1-methyl-2-mercapto-5-cyanobenzimidazole (VI), yield: 3.8 g. from 3 g. V; 1-methyl-2-(methylmercapto)-5cyanobenzimidazole (VII), m. 124° (petr. ether b. 90-120°), yield: 1.8 g. from 1.9 g. VI; 4,2-F(O2N)C6H3NHMe (VIII), m. 76° (C6H14), yield: 8.2 g. from 14.8 g. 4,2-F(O2N)C6H3NHAc and MeI; 1-methyl-2-mercapto-5-fluorobenzimidazole (IX), m. 230°, yield: 47.5 g. from 51.4 g. VIII; 1-methyl-2-(methylmercapto)-5-fluorobenzimidazole (X), m. 91° (Me2CO-H2O), yield: 43 g. from 49.2 g. IX; 4,3-MeNH(O2N)C6H3SO2NHMe (XI), m. 181°, yield: 89 g. from 102.5 g. 4,3-Cl(O2N)C6H3SO2Cl; 3,4-H2N(MeNH)C5H3SO2NHMe (XII), m. 103°, yield: 53.4 g. from 63.5 g. XI; 1-methyl-2-mercapto-5-(N-methylsulfamoyl)benzimidazole (XIII), m. 268°, yield: 42.1 g. from 36.9 g. XII; 1-methyl-2-(methylmercapto)-5-(N-methylsulfamoyl)benzimidazole, m. 191° (EtOH), yield: 3.7 g. from 5.14 g. XIII; 1-methyl-2-(methylmercapto)-5-(N-dimethylsulfamoyl)benzimidazole, m. 118° (AcOEt-C6H14), yield: 3.8 g. from 5.14 g. XIII. 1,3-dimethyl-2-(methyimercapto)-5-cyanobenzimidazolium Me sulfate, m. 160° yield: 16 g. from VII; 1,3-dimethyl-2-(methylmercapto)-5fluorobenzimidazolium Me sulfate, oil. The following dyes are prepd. (m.p., λmax. in mμ, log ε, type of emulsion, sensitization max., and sensitivity given): 1,3-diethyl-2-[5-(1,3-diethyl-5-cyano-2-benzimidazolinylidene)-1,3-pentadienyl]-5-cyanobenzimidazolium, iodide, 255° (MeOH and EtOH), 610, 5.212, Ag(Br, I), 645, 410 (minus blue);

1,3-dimethyl-2-[(1,3-diethyl-5-carbethoxy-2-benzimidazolinylidene)methyl]-5-fluorobenzimidazolium, perchlorate, 208° (EtOH), 402, 4.351, AgCl, 435, 475 (total); 1,3-dimethyl-2-[(1,3-diethyl-5-cyano-2-benzimidazolinylidene)methy]-5-cyanobenzimidazolium iodide, >250° (EtOH), 404, 4 340, AgCl, 440, 795;

1,3-dimethyl-2-[(1,3-diethyl-5,6-dichloro-2-benzimidazolinylidene)methyl]-5-cyanobenzimidazolium. iodide, >250°, (EtOH), 409, 4.459, AgCl,

L19 ANSWER 135 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
440, 825;
2-thio-3-allyl-5-(1,3-dimethyl-5-fluoro-2-benzimidazolinylidene)-2,4-thiazolidinedione, 246° (PrOH), 414, 4.618, AgCl, 460,845; 2-thio-3-ethyl-5-(1,3-dimethyl-5-cyano-2-benzimidazolinylidene)-2,4-thiazolidinedione, >250° (PrOH) 424, 4.880, AgCl, 470, 880.

IT 96775-39-2P, 5-Cyano-1-ethyl-2-methyl-3-[[(methylsulfonyl)carbamoyl]methyl]benzimidazolium bromide
101201-38-1P, 5-Cyano-1-ethyl-2-[3-(3-ethyl-2-benzothiazolinylidene)propenyl]-3-[[(methylsulfonyl)carbamoyl]methyl]benzimidazolium hydroxide, inner salt
103534-82-3P, 5-Cyano-1-ethyl-2-[3-(3-ethyl-5,6-dimethyl-2-benzoxazolinylidene)propenyl]-3-[[(methylsulfonyl)carbamoyl]methyl]benzimidazolium hydroxide, inner salt
106503-15-5P, 6,7-Dichloro-3-[2-(3-ethyl-2-thiazolidinylidene)ethylidene]-2,3-dihydro-4-[[(methylsulfonyl)carbamoyl]methyl]-1H-pyrrolo[1,2-a]benzimidazolium hydroxide, inner salt
RL: PREP (Preparation)
(preparation of)

RN 96775-39-2 CAPLUS

CN 1H-Benzimidazolium,
5-cyano-1-ethyl-2-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, hydrobromide (1:1) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 101201-38-1 CAPLUS

CN Benzothiazolium, 2-[3-[5-cyano-1-ethyl-1,3-dihydro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-3-ethyl-, inner salt (CA INDEX NAME)

L19 ANSWER 135 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 103534-82-3 CAPLUS
CN Benzoxazolium, 2-[3-[5-cyano-1-ethyl-1,3-dihydro-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-3-ethyl-5,6-dimethyl-, inner salt (CA INDEX NAME)



RN 106503-15-5 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 6,7-dichloro-3-[2-(3-ethyl-2-thiazolidinylidene)ethylidene]-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



L19 ANSWER 136 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1963:82272 CAPLUS
DOCUMENT NUMBER: 58:82272
ORIGINAL REFERENCE NO.: 58:14164f-h,14165a-h,14166a-h,14167a-h,14168a-h,14169a-h
TITLE: Methine dyes
PATENT ASSIGNEE(S): Gevaert Photo-Producten N.V.
SOURCE: 129 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 618235		19620917	BE	
GB 1001061			GB	
US 3243298		19660329	US 1962-197925	19620528
PRIORITY APPLN. INFO.:			GB	19610529

GI For diagram(s), see printed CA Issue.

AB New sym. and unsym. methine dyes for sensitizing photographic Ag halide emulsions are described. The new dyes are formed when benzimidazole derivs. of the general formulas I and II, where the aromatic nucleus may be substituted by Br, Cl, F, CO2Et, CO2H, AcNH, and CN, or by a sequence of atoms necessary to complete another aromatic ring, and where X = CH2, CH2CH2, or O, are quaternized with MeI, EtI, HOCH2CH2Br (III), AcNHSO2(CH2)4Br (IV), MeSO2NHCOCH2Br (V), HO2C(CH2)2Br (VI), or 1,3-propanediol sulfate (VII) and subsequently condensed with 2-(2-acetanilidovinyl)-3-ethyl-thiazolinium bromide (VIII), the 2-(2-anilinovinyl) analog (IX) of VIII, the selenazolium iodide analog (X) of VIII, 2-(2-phenyliminoethylidene)-3-ethyl-2,3-dihydrobenzoxazole (XI), the 5-Me derivative (XII) of XI, the 5-Ph derivative (XIII) of XI, 1,3-diethyl-2-[2-(p-toluenesulfonylanilino)vinyl]-5,6-dichlorobenzimidazolium chloride (XIV), 3-ethyl-5-(2-acetanilidovinylmethylene)-2-thio-2-2,4-thiazolidinedione (XV), or the 5-(3-acetanilidopropenylidene analog (XVI) of XV to yield unsym. methine dyes, or subsequently condensed with HC(OEt)3 or EtOCH:CHCH(OEt)2 (XVII) to yield sym. methine dyes. 2,5-Cl2C6H3NO2 (96 g.) added at 50° to 71 g. pyrrolidine (XVIII), kept 15 min. at 50°, diluted with H2O, and filtered gave 102 g. N-(2-nitro-4-chlorophenyl)pyrrolidine (XIX), m. 73° (iso-PrOH). 2,5-F2C6H3NO2 (76.4 g.) added at 90° to 89 cc. XVIII, poured into H2O, and extracted with C6H6 yielded the 4-fluoro analog of XIX, m. 48° (iso-PrOH). XVIII (15.6 g.) added dropwise to 23 g. 4,3-Cl(O2N)C6H3CO2Et in 60 cc. refluxing absolute EtOH, refluxed 1 hr., poured into H2O, and filtered yielded the 4-CO2Et analog of XIX, m. 78°. 2,4,5-Cl(O2N)2C6H2CO2H (143 g.) and 140 cc. SOCl2 heated 3 hrs. on the water bath and evaporated, and the residue treated slowly with 220 cc. EtOH, poured into 2 l. H2O, and filtered yielded 2,4,5-Cl(O2N)2C6H2CO2Et (XX), m. 78° (EtOH). XX (55 g.) in 250 cc. MeOH added dropwise to 28.4 g XVIII, heated 10 min. on the water bath, and filtered gave the N-[5,4,2-Cl(EtO2C)(O2N)C6H2] derivative of XVIII, m. 105°. 4,3-Cl(O2N)C6H3SO2Cl (102.4 g.) added dropwise at 50° to 148 cc. XVIII, heated 15 min. on the water bath, poured into H2O, and filtered yielded 2-pyrrolidino-5-(pyrrolidinosulfonyl)-1-nitrobenzene, m. 133° (iso-PrOH). 2,5-Br(F)C6H3NO2 (115 g.) and 109 cc. piperidine

(XXI) heated 1.5 hrs. with stirring at 95°, dild. with H2O, and filtered gave the 2,4-F(O2N)C6H3 deriv. of XXI, m. 53° (iso-PrOH). 1-[4,2-Cl(H2N)C6H3] deriv. (82.4 g.) of XVIII (obtained by hydrogenation of XIX) in 625 cc. 2N HCl diazotized with 29.4 g. NaNO2 in 70 cc. H2O, poured into 35.3 g. NaN3 in 168 g. NaOAc in 650 cc. H2O, and filtered, the residue dissolved in 500 cc. PhNO2, added dropwise at. 170° to 500 cc. PhNO2, concd. in vacuo to about 100 cc., cooled, and filtered yielded 6-chloro-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazole (XXII), m. 137° (C6H6-hexane). By the method employed for the prepn. of XIX were prepd. the following N-aryl-substituted derivs. (XXIII) of XVIII and converted further by the method described for the prepn. of XXII to the following substituted derivs. of 2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazole (XXIV)[N-aryl substituent of the XXIII used, m.p. or b.p./mm. of the XXIII, substituent(s) of the resulting deriv. of XXIV, and its m.p. given]: 6,2-Cl(O2N)C6H3, 134-6°/3, 8-Cl (XXV), 122°; 4,5,2-Cl2(O2N)C6H2, 80°, 6,7-di-Cl (XXVI), 215°; 4,2-F(O2N)C6H3, 48°, 6-F (XXVII), 128°; 4,2-Br(O2N)C6H3, 76°, 6-Br (XXVIII), 150°; 4,2-EtO2C(O2N)C6H3, 78°, 6-CO2Et, 134°; 6,2-EtO2C(O2N)C6H3, 53°, 8-CO2Et, 96°; 5,4,2-Cl(EtO2C)(O2N)C6H3, 105° (2-NH2 analog, m. 90°), 6-carbethoxy-7-chloro (XXIX), 138°; 4-pyrrolidinosulfonyl-2-nitrophenyl, 133° (2-NH2 analog, m. 174°), 6-pyrrolidinosulfonyl (XXX), 239°; 4,2-Me(O2N)C6H3, 60°, 6-Me (XXXI), 146°; 5,4,2-Br(EtO2C)(O2N)C6H2, 105° (2-NH2 analog, m. 95°), 6-carbethoxy-7-bromo (XXXIA), 114°. By the same methods were prepd. the following substituted derivs. of 1,2,3,4-tetrahydropyrido [1,2-a]benzimidazole (XXXII) via the corresponding N-aryl-substituted derivs. (XXXIII) of XXI [N-aryl substituent of the XXXIII used, m.p. of the XXXIII, substituent(s) of the resulting XXXII, and m.p. of the XXXII given]: 4,2-Cl(O2N)C6H3, --, 7-Cl (XXXIV), 151-3°; 4,2-F(O2N)C6H3, 53°, 7-F (XXXV), 110°; 4,5,2-Cl2(O2N)C6H3, --, 7,8-di-Cl (XXXVI), 184°; 4,2-Br(O2N)C6H3, --, 7-Br (XXXVII), 163°; 4,2-NC(O2N)C6H3, 112°, 7-CN (XXXVIII), 176°; 4-piperidinosulfonyl-2-nitrophenyl, 106° (2-NH2 analog, m. 139°), 7-piperidinosulfonyl (XXXIX), 229°; 4,2-F3C(O2N)C6H3, 55 (2-NH2 analog, m. 52°), 7-CF3 (XL), 140-1°; 5,2-Cl(O2N)C6H3, --, 8-Cl (XLI), --. By the method of Saunders (CA 50, 7797c) were prepd. the following substituted 3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzimidazoles (XLII) from 3,4-dihydro-1H-1,4-oxazine via the appropriate N-aryl-substituted derivs. (XLIII) of XLII [N-aryl substituent of XLIII, m.p. of XLIII, substituent(s) of XLII, and m.p. of XLII given]: 4,2-Cl-(O2N)C6H3, --, 8-Cl (XLIV), --; 4,2-NC(O2N)C6H3, 130° (2-NH2 analog, m. 177°), 8-CN (XLV), 186°; 4,5,2-Cl2(O2N)C6H2, 75° (2-NH analog, m. 146°), 7,8-di-Cl (XLVI), 192°. XXVIII (19.1 g.) in 60 cc. concd. H2SO4 treated at 0-5° with 7.7 cc HNO3 (d. 1.42) in 25 cc. concd. H2SO4, poured into H2O, basified with NH4OH, and filtered gave the 6-bromo-7-nitro (XLVII) deriv. of XXIV, m. 201° (EtOH). XLVII (15.2 g.) in MeOCH2CH2OH hydrogenated over Raney Ni yielded the 7-NH2 analog (XLVIII) of XLVII, m. 264° (EtOH). XLVIII (9.2 g.) in 30 cc. H2O and 9 cc. HCl diazotized with 2.5 g. NaNO2 in 15 cc. H2O, neutralized with Na2CO3, treated with stirring with 6.89 g. CuCN and 12.3 g. KCN in 100 cc. H2O, kept 0.5 hr. at room temp. and 15 min. at 50-60°, cooled, and filtered, and the residue sublimed at 200°/2 mm. yielded 6-bromo-7-cyano deriv. (XLIX) of XXIV, m. 224° (C6H6-hexane). 7-NH2 deriv. (L) (17.3 g.) of XXIV in

200 cc. 5N HCl diazotized with 7.2 g. NaNO2 in 30 cc. H2O, treated with 8 g. CuCl in 35 cc. concd. HCl at 50-60°, cooled, and filtered, and the residue in H2O treated with 25% NH4OH yielded the 7-Cl deriv. (LI) of XXIV, m. 136° (C6H6). L(43.6 g.) in 31% aq. HBF4 diazotized with 18.5 g NaNO2 in ,50 cc. H2O, and neutralized with cooling with Na2CO3 yielded the diazonium fluoroborate analog (LII) of L, m. 170-80° (decompn.). LII added to refluxing 250 cc. Tetralin until the BF3 evolution ceased and evapd., the residue extd. with warm 2N HCl, the ext. basified with Na2CO3 and extd. with CHCl3, and the CHCl3 ext. distd. gave the 7-F deriv. (LIII) of XXIV, m. 124°, b3 166°. Similarly were prepd. by these methods the following substituted derivs. of XXIV from the corresponding 7-NO2 (LIV) via the 7-NH2 derivs. (LV) [substituent of LIV and LV, m. ps. of LIV and LV, and substituent(s) and m.p. of the resulting deriv. of XXIV given]: 6-Cl, 203°, 264°, 6-chloro-7-cyano (LVI), 215°; 6-F, 236°, 230°, 6-fluoro-7-cyano (LVII), 210°; none, --, --, 7-CN (LVIII), 155°. In the same manner were prepd. the following substituted XXXII [substituent and m.ps. of the 7-NO2 and 7-NH2 analogs of the resulting XXXII, and substituent(s) and m.p. of the XXXII given]: 6-Br, 184°, 217°, 7-bromo-8-cyano (LVIIIA), 210°; 6-Cl, 194°, 210°, 7-chloro-8-cyano (LIX), 212°; 6-F, 264°, 199°, 7-fluoro-8-cyano (LX), 253°; none, --, --, 8-CN (LXI), 194°. In the same manner was prepd. 7-cyano-8-chloro-3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole (LXII), m. 300°, from the 7-NO2 analog, m. 220°, via the 7-NH2 analog, m. 264°. 6-CO2Et deriv. (LXIII) (5 g.) of XXIV in 15 cc. EtOH and 25 cc. 2.5N NaOH refluxed 5 min., cooled, acidified with AcOH, and filtered yielded the 6-CO2H deriv. (LXIV) of XXIV, m. 300°. Similarly were obtained the following derivs. of XXIV [substituent(s) and m.p. given]: 8-CO2H (LXIVA) 310-12°, 6-carboxy-7-chloro (LXV), >270°. L(8.65 g.) in 50 cc. C6H6 treated dropwise with Ac2O, refluxed 15 min., cooled, and filtered yielded 7.3 g.7-AcNH deriv. (LXVI) of XXIV, m. 260-2° (EtOH). CuCl (18.6 g.) added to 40.3 g. 6-Br deriv. of XXIV in 200 cc. PhNO2, refluxed 1.5 hrs., cooled to 100°, treated with shaking with 34 g. NaCN in 100 cc. H2O, and dild. with 40 cc. H2O and 40 cc. CHCl3, and the org. phase worked up yielded 6-CN deriv. of XXIV, m. 190° (EtOH). 3,6-Dihydro-4,5-benzo-2-pyrone (24.8 g.) and 18.1 g. o-C6H4(NH2)2 heated 15 hrs. at 250° under pressure and distd. yielded 6,11-dihydrobenzimidazolo[1,2-b]isoquinoline (LXVII), m. 202° (EtOAc). XXIV (6.3 g.) and 5.7 g. MeI in 15 cc. Me2CO refluxed 0.5 hr., cooled, and filtered gave XXIV.MeI, m. 220°. XXIV (16 g.) and 23.5 g. EtI heated 15 hrs. at 110° under pressure gave XXIV.EtI, m. 198°. XXX (3.4 g.) and 1.2 cc. MeI heated 16 hrs. under pressure at 95° gave XXX.MeI, m. >270°. XXXIV (6.2 g.) and 6.2 g. EtI heated 1.5 hrs. at 110° yielded XXXIV.EtI, m. >250°. XLIV (10.4 g.) and 10 g. Etl heated 16 hrs. at 110° yielded XLIV EtI, m. 186°. 8-Aminopyrido[1,2-a]benzimidazole (LXVIII) (8.8 g.) in 80 cc. 5N HCl diazotized with 3.7 g. NaNO2 in 10 cc. H2O, poured into a CuCl soln., filtered, basified with NH4OH, and filtered yielded the 8-Cl analog (LXIX) of LXVIII, m. 207°. LXIX (2 g.) and 1.7 g. EtI heated 15 hrs. at

110° gave LXIX.EtI,m. >250°. LXIX.EtI (3 g.) in MeOCH2CH2OH hydrogenated at 80° over Raney Ni gave XLI.EtI, m. 250°. L (8.6 g.) in 50 cc. MeOH treated dropwise with 4 cc. MeI and refluxed 15 min. gave L.MeI, m. 282°. 4-Hydroxy-6-cyano deriv. (4 g.) of XXIV in 40 cc. Ac2O refluxed 10 min. and dild. with Et2O pptd. the 4-acetoxy-6-cyano deriv. of XXIV, m. 208°. The following quaternary salts were prepd. in Me2CO (except where another solvent is indicated in parentheses) (starting tertiary base and alkyl halide used, reaction time in hrs., reaction temp., and m.p. of the resulting quaternary ammonium salt given): XXIV, III, 6, 105°, 180°; 2,3-dihydro-1H-pyrrolo [1,2-a]naphtho[2,3-d]imidazole (LXIXA), EtI, 24, 110°, 250; XXII, EtI, 15, 110°, 242°; XXV, EtI, 3.5, 105-10°, 238°; XXVI, EtI, 16, 110°, >250°; XXVI, III, 4, 110°, >250°; XXVI, IV, 4, 140°, 252°; XXVI, V, 4, 140°, >260°; XXVII, EtI, 16, 110°, 237°; XXVIII, EtI, 15, 110°, 250°; LXIII, MeI, 3, 90°, 238°; 8-CO2Et deriv. (LXX) of XXIV, MeI, 3.5, 90°, 190°; XXIX, MeI, 2, 95°, 250°; XXIX, VI, 3, 125°, 192°; XXIX, VII, 2, 120°, 140-5°; XXIX, IV, 4 (in MeNO2), 120°, --; XXIX, V, 2, 120°, 120-5°; XXX, MeI, 6, 95°, >270°; XXX, EtI, 16, 105°, 220°; XXXI, EtI, 8 (in MeNO2), 100°, 202°; XXXIA, III, 2, --; XXXIA, VII, 2, 120°, --; XXXIA, IV, 2, 120°, 100°; XXXIA, V, 1, 120°, >250°; L, MeI, 0.25, -- (at reflux)(in MeOH), 282°; XLIX, EtI, 16, 110°, > 250°; LVI, EtI, 16, 110°, >250°; LVII, EtI, 16, 110°, 280°; LVIII, III, 3, 105°, 246°; LI, EtI, 5.5, 110°, 238°; LIII, EtI, 15, 110°, 210°; LXIV, MeI, 15, 100°, 304°; LXIVA, MeI, 16, 125°, 265°; LXV, MeI, 17, 125°, 270-2°; LXVI, EtI, 16, 110°, 230°; 6-CN deriv. (LXXI) of XXIV, EtI, 16, 105°, >250°; LXXI, III, 15 (in MeNO2), 125°, 207-9°; LXXI, V, 3 (in MeNO2), 125°, 200°; XXXII, MeI, 0.5, -- (at reflux), 210°; XXXII, EtI, 15, 110°, 246°; XXXII, VII, 3, -- (at reflux), 260°; XXXII, AcNHSO2(CH2)3. Br, 3, -- (at reflux), >260°; XXXII, IV, 4, -- (at reflux), 206-8°; XXXII, V, 5, -- (at reflux), 238°; XXXIV, EtI, 15, 110°, >250°; XXXIV, III, 16, 120°, 228°; XXXIV, VII, 2, 120°, >260°; XXXV, EtI, 15, 110°, >250°; XXXVI, III, 4, 110°, >250°; XXXVI, V, 3, -- (at reflux). >260°; XXXVII, EtI, 15, 110°, >250°; XXXVIII, EtI, 15, 100°, 306°; XXXIX, EtI, 15, 110°, >250°; XL, EtI, 3 (in MeNO2), 100°, 260°; XL, MeI, 1.5, -- (at reflux), 270°; XLI, EtI, 15, 110°, 250°; LVIIIA, EtI, 16, 110°, >300°; LIX, EtI, 15, 110°, >250°; LX, EtI, 15, 110°, >250°; LXI, EtI, 15, 110°, >260°; LXVII, MeI, 4, 95, 260°; 1,2,3,4,8,9,10,11-octa-hydrodipyrido[1,2-a:1',2'-a']benzo[1,2-d:5,4-d']diimidazole (LXXII), 2EtI, 16, 110°, >260°; XLIV, EtI, 16, 110°, 186°; XLV, EtI, 15, 100, 200-10°; XLVI, 16, 110°, 202-5°; LXII, MeI, 4, 110°, 170°; LXII, EtI, 16, 110°, --. XXIV.EtI (6.3 g.), 7 cc. XVII, and 20 cc. PhNO2 refluxed 5 min., cooled, and filtered gave LXXIII (R, R' = Et, A = CHCH:CH, X = H), m. 197° (596, --, 640 AgCl); the

nos. given in parentheses after the m.p. throughout this abstr. are the absorption max. and the log ε value of the resp. compd. and the absorption max. of an AgCl, AgCl-AgBr, or AgBr-AgI photographic emulsion sensitized with the compd.). XXX.MeI (4.9 g.) in 25 cc. PhNO2 refluxed 2 hrs. with 3.5 cc. HC(OEt)3, cooled, and filtered yielded LXXIII (R and R' = Me, A = CH, X = pyrrolidinosulfonyl), m. above 320° (530, 5.32, 575 AgCl). Similarly were prepd. by treatment with HC(OEt)3 dyes from the following quaternary salts (m.p. and, in parentheses, absorption data of the resulting dye given): XLIV.EtI, 238° (528, --, 590 AgCl): LXIII.MeI, 260° (532, --, 575 AgCl); LXXI.III, 220-4° (537, 4.97, 590 AgCl); IX (3.1 g.) and 3.1 g. LVIII.III in 20 cc. Ac2O treated with 2.8 cc. Et3N, refluxed 15-min., cooled, dild. with Et2O, and filtered and the residue treated with NaClO4 gave LXXIV (R = Et, R' = CH2CH2OAc, X and X'' = H, X' = CN, Z = S, An = ClO4), m. 175° (476, 5.12, 520 AgCl-AgBr). XLIX.EtI (2.1 g.), 1.6 g. IX, and 25 cc. Ac2O refluxed 2 hrs. with 1.4 cc. Et3N, cooled, and filtered gave LXXIV (R and R' = Et, X = Br, X' = CN, X'' = H, Z = S, An = I), m. >260°, (MeOH)(480, 5.135, 540 AgBr-AgI). Similarly were prepd. dyes from the following quaternary salts (same data given): XXIV.EtI, >250° (462, 5.03, 500 AgCl-AgBr); XLIX.EtI, 302° (474, 5.09, 520 AgCl-AgBr); XXXVIII.EtI, 270° (474, 5,034, 520 AgCl-AgBr); XXXI.EtI, >260° (472, 5.01, 525 AgCl-AgBr); LIX.EtI, >250° (480, 5.18, 540 AgCl-AgI); LX.EtI, >250° (480, 5.10, 540 AgBr-AgI); XLIV.EtI, 240° (483, 4.95, 520 AgCl-AgBr); XLV.EtI, >250° (500, 5.058, 540 AgCl); XXIV.EtI, >250° (454, 4.95, 490 AgCl-AgBr); LI.EtI, >250° (465, 5.03, 510 AgCl); XXV.EtI, 291-2° (462, 4.962, 515 AgCl); XXVI.EtI, >260° (468, 5.206, 519 AgCl); XXXII.EtI, >260° (458, 4.991, 500 AgCl-AgBr); LXIII.EtI, >260° (466, 5.088, 520 AgCl-AgBr); LI.MeI, >270° (468, 5.030, 505 AgCl); LXIVA.MeI, >270° (470, 5.006, 500 AgCl); XXXIX.IV, >260° (474, 5.025, 520 AgCl-AgBr); XXIX.V, >260° (480, 5.075, 520 AgCl-AgBr); XXIX.VII, >260° (477, 4.917, 520 AgCl-AgBr); XXX.MeI, <250° (468, 5.009, 510 AgCl-AgBr); LXIXA.EtI, >250° (478, 5.14, 525 AgCl-AgBr); XXVII.EtI, >250° (458, 4.95, 500 AgCl-AgBr); XXXIV.EtI, 240° (466, 4.91, 510 AgCl-AgBr); XXXVI.EtI, >260° (570, 5.241, 520 AgCl-AgBr); XXXVI.V, >260° (461, --, 515 AgCl-AgBr); XXXVII.EtI, >260° (468, 4.982, 500 AgCl-AgBr); XXXIX.EtI, >250° (472, 5.155, 520 AgCl); XXXI.EtI, >260° (458, 4.93, 490 (AgCl-AgBr); LXXI.EtI, 281° (474, 5.068, 520 AgCl-AgBr); LXV.MeI, >250° (470, 5.104, 505 AgCl); LVIII.EtI, 292° (480, 5.111, 5.15 AgCl); XXXIA.IV, >250° (474, 5.070, 520 AgCl); XXXIA.V, >260° (479, 5.006, 520 AgCl-AgBr); XXXIA.VII, > 260° (479, 4.985, 520 AgCl-AgBr); XL MeI, 256° (466, 5.014, 500 AgCl-AgBr); XL.EtI, 260° (467, 5.84, 500 AgCl-AgBr); XLIX.EtI, >260° (478, 5.13, 525 AgCl). XXV EtI (4.35 g.) and 5.60 g. X in 30 cc. Ac2O refluxed 5 min. with 3.2 cc. Et3N and cooled gave LXXIV (R and R' = Et, X and X' = H, X'' = Cl, Z = Se, An = I), m. 285° (EtOH) (462, 5.13, 500 AgCl-AgBr). XII (2.8 g.) and 3.15 g. XXIV.EtI in 30 cc. Ac2O refluxed 45 min. with 2.8 cc. Et3N, cooled, and dild. with Et2O, and the ppt. treated with NaClO4 yielded LXXV (R and R' = Et, X = Me, X', Y, and Y' = H,Z = O, An = ClO4), m. >250° (470, 4.99, 510 AgCl-AgBr). Similarly were prepd. dyes from the following quaternary salts with the 5,6-di-Me deriv. of XI (same

data given): XXIX.MeI, >310° (490, 5.22, 540 AgCl); XXX.MeI (with XII), 295° (486, 5.205, 520 AgCl-AgBr); LXIV.MeI, >270° (486, 5.194, 520 AgCl); LXIVA.MeI, >270° (492, 5.153, 535 AgCl); XLV.EtI, 302-4° (520, 5.158, 560 AgCl-AgBr); LXXI.EtI, 285° (496, 5.218, 540 AgCl-AgBr); LXV.MeI, >270° (492, 5.273, 530 AgCl). XII (5.6 g.) and 5.6 g. XXIV.III in 50 cc. Ac2O treated with stirring with 5.6 cc. Et3N, stirred 2 hrs. at room temp. and 15 min. at reflux, cooled, and dild. with Et2O, and the ppt. treated with NaClO4 yielded LXXV (R = Et, R' = CH2CH2OAc, X = Me, X', Y, and Y' = H, Z = O, An = ClO4), m. >250° (474, 5.07, 540 AgBr-AgI). LVIII.III gave similarly a dye, m. 220° (4.92, 5.12, 520 AgCl-AgBr). 5,6-Di-Me deriv. (LXXVI)(2.9 g.) of XI and 3.15 g. XXIV.EtI in 30 cc. Ac2O treated with stirring with 2.8 cc. Et3N, stirred 1 hr. at room temp. and 15 min. at reflu, and dild. with Et2O pptd. LXXV (R and R' = Et, X and X' = Me, Y and Y' = H, Z = O, An = I), m. 169° (EtOH) (476, 5.08, 510 AgCl-AgBr). Similarly were prepd. dyes from the following quaternary salts (same data given): XLIX.EtI, >260° (498, 5.281, 540 AgCl-AgBr); LXX.MeI, >270° (492, 5.125, 540 AgCl); LXIXA.EtI, >250° (498, 5.37, 545 AgCl); XXXIV.EtI (with XII), >250° (480, 5.10, 525 AgCl); XXXVI.EtI, >250° (492, 5.14, 540 AgCl); LI.EtI (with XII), >250° (478, 5.18, 520 AgCl-AgBr); XXII.EtI with XII, >250° (478, --, 520 AgCl-AgBr); XXVI.EtI, >260° (494, 5.163, 520 AgCl-AgBr); XXVII.EtI, >260° (484, 5.156, 520 AgCl-AgBr); LIII.EtI (with XII), >250° (472, 5.08, 520 AgCl-AgBr); LXIII.MeI, >270° (488, 5.207, 540 AgCl); XXV.EtI (with XII), >250° (494, 5.25, 540 AgCl); XXXV.EtI, >260° (480, 4.926, 520 AgCl-AgBr); XXXVI.EtI, >250° (492, 5.14, 545 AgCl-AgBr); XLV.EtI, >260° (506, 4.976, 520 AgCl-AgBr); LXVII.MeI, 275° (477, 4.925, 540 AgCl); LXXI.III, >260° (501, 5.184, 555 AgCl); XLVI.EtI, >260° (516, 5.157, 580 AgCl-AgBr); XXXVII.EtI (with XII), >250° (480 --, --, --). XIV (6.8 g.), 3.9 g. XXIV.EtI, 30 cc. C5H5N, and 3.5 cc. Et3N refluxed 2 hrs. and dild. with Et2O gave LXXV (R and R' = Et, X, and X' = Cl, Y and Y' = H, Z = NEt, An = I), m. >250° (aq. MeOCH2CH2OH) (504, 5.20, 560 AgCl). Similarly were prepd. dyes from the following quaternary salts (same data given): XXII.EtI [with 1,3-diethyl-5-chloro analog (XIVA) of XIV], 240° (502, 5.30, 580 AgCl-AgBr); XXVII.EtI (with XIVA), >260° (500, 5.24, 535 AgCl); LIII.EtI [with 1,3-diethyl-5-cyano analog (XIVB) of XIV], >250° (500, 5.15, 540 AgCl); LVIII (with XIVB), >250° (512, 5.32, 560 AgCl); XXXIV.EtI, 200° (508, 4.91, 570 AgCl); XXXV.EtI (with XIVA), 230° (500, --, 570 AgCl); XXXIX.EtI, 286° (514, 5.41, 580 AgCl); XXXVI.III, >260° (528, 5.16, 614 AgCl); LXX.EtI (with XIVA), >260° (508, 5.16, 580 AgCl); XLIV.EtI, >260° (533, 5.29, 615 AgCl); LXXI.V (with XIVB), >250° (515, 5.331, 560 AgCl). XIV (2.5 g.), 1.5 g. LI.EtI, 10 cc. PhNO2, and 1.2 cc. Et3N refluxed 15 min., cooled, and dild. with Et2O pptd. LXXV (R and R' = Et, X, X', and Y = Cl, Y' = H, Z = NEt, An = I), m. 250° (EtOH)(506, 5.24, 575 AgCl). Similarly were prepd. dyes from the following quaternary salts (same data given): XXVI.III, 260° (516, 4.85, 580 AgCl); XXVI.EtI, >260° (510, 5.481, 580 AgCl); LVIII.III, >250° (512, 5.39, 560 AgCl); LXVI.EtI, 260° (506, --, 540 AgCl); LI.EtI, >250° (504, 5.38, 570-80 AgCl); LIII.EtI [with XIVA], >250° (504, 5.22, 570 AgCl); LVIII.EtI, >250° (510, 5.35, 600 AgCl); XLIXA.EtI, >250° (517, 5.48, 595 AgCl); XXXVI.IV, >260° (516, 5.298, 590 AgCl); XXXIV.EtI (with XIVA), >250° (507, 5.15, 540-575 AgCl); XXXVI.EtI, >250° (515, 5.37, 580 AgCl); XXXVI.EtI (with XIVA), >250° (512, 5.13, 580 AgCl); XXXII.VII, >260° (515, 4.937, 580 AgCl);

L19 ANSWER 136 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
L.MeI, -- (--, --, 580). XL.EtI (3.8 g.), 3.3 g. benzoselenazole analog of XI, 25 cc. Ac2O, and 1.4 cc. Et3N heated 5 min. at 60°, cooled, and filtered gave LXXVII (R = Et,R' = Me, X,X',and Y' = H, Y = CF3, Z = Se, An = I), m. 268° (MeOCH2CH2OH) (512, 5.024, 560 AgBr-AgCl). XXIX.MeI (4.06 g.) and 3.55 g. VIII in 60 cc. abs. refluxing EtOH treated dropwise with 1.4 cc Et3N, refluxed 20 min., cooled, and filtered gave LXXV (R = Et,R' = Me,X = CO2Et, X' = Cl,X'' = H,S = S, An = I), m. >270° (MeOH)(470, 5.145, 520 (AgCl-AgBr). Similarly were prepd. dyes from the following quaternary salts (same data given): XLVI.EtI, >260° (495, 5.048, 540 AgCl-AgBr); LXII.MeI, >260° (500, 4.793, 550 AgCl-AgBr). LXVII.MeI (3.62 g.), 3.55 g. VIII, 25 cc. HCCNMe2, and 1.4 cc. Et3N refluxed 5 min., cooled, filtered, dild. with EtO2, and filtered again yielded LXXVII, m. 275° (EtOH) (456, 4.796, 520 AgCl-AgBr). XXV.EtI (4.9 g.) and 4.9 g. XI in 30 cc. Ac2O refluxed 3 min. with 3.2 cc. Ec3N, cooled, and filtered gave LXXV (R and R' = Et, X, X', and Y = H, Y' = Cl, Z = Se, An = I), m. 290° (HCONMe2) (506, 5.01, 555 AgBr-AgI). XXXVI.V (4.56 g.), 3.4 g. XIII, 40 cc. HCONMe2, and 1.4 cc. Et3N refluxed 10 sec., treated with 5 cc. Ac2O, refluxed 4 min., cooled, and filtered yielded LXXVII (R = Et, R' = MeSO2N-COCH2, X = Ph, X' = H, Y' and Y' = Cl, Z = O, no An (R' is charged), m. >260° (PhOH-EtOH)(495, 4.950, 555 AgCl-AgBr). LXVII.MeI (2.75 g.), 1.81 g. XIV, 75 cc. MeOH, and 3.4 cc. Et2N refluxed 5 min., cooled, and filtered yielded LXXVII (R = Et, R' = Me, X and X' = Cl, Y and Y' = H, Z = NEt, An = I), m. >270° (MeOCH2CH2OH) (502, 4.960, 570 AgCl). LXXII.2EtI (1.73 g.), 1.9 g. IX, 20 cc. Ac2O, and 1.7 cc. Et3N refluxed 45 min., cooled, and dild. with Et2O pptd. LXXIX, m. >320° (EtOH) (548, 5.30, 595 AgCl-AgBr). XXII.EtI (3.5 g.), 3.1 g. XV, 25 cc. Ac2O, and 2.8 cc. Et3N, cooled, and dild. with H2O pptd. LXXX (R and R' = Et, X = Cl, Z = S, A = CH), m. 294° (MeOCH2CH2OH)(524, 4.95, 590 AgCl). Similarly were prepd. dyes from the following quaternary salts (same data given): XXIV.MeI, 265-7° (516-488, 4.57-4.49, 570 AgCl); XXVII.EtI, 276-8° (520, 4.98, 570 (AgCl); XXVIII.EtI, 260° (524, 5.01, 575 AgCl); XXVI.MeI, 262-3° (521, 5.02,570 AgCl); XXXVI.EtI, 280° (528, 5.16, 585 AgCl); XXXV.EtI, 164-5° (522, --, 580 AgCl); XXXIX.EtI, 278° (528, 1.154,580 AgCl); XLIV.EtI, 305° (548, 4.92, 600 AgCl); LXIII.MeI, >270° (536, 5.231, 590 AgCl); LXVII.MeI, 260° (518, 4.832, 570 AgCl); XLVI.EtI, >260°, (552, 4.745, 605 AgCl); XXXIV.EtI, 244° (526, 4.96, 580 AgCl). XXIV.EtI (3,14 g.), 2.9 g. XV, 25 cc. Me Carbitol, and 2.8 cc. Et3N refluxed 20 min., cooled, and dild. with H2O pptd. LXXX (R and R' = Et, X = H, Z = O, A = CH), m. 160° (1:1: EtOH-Me Carbitol) (498, 4.332, 550 AgCl). XXXIV.EtI gave similarly a dye, m. 192° (522, --, 575 AgCl).
2-Thio-3-ethyl-5-[4-(5-ethyl-7-chloro-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazolyl)-methylene]-2,4-thiazolidinedione (1.8 g.) in 150 cc. dry C6H6 refluxed 4 hrs. with 0.58 cc. Me2SO4, cooled, and filtered, the resulting LXXXII (R = MeS) (1.7 g.), 0.6 g. 3-ethyl-2-thio-2,4-thiazolidinedione, 20 cc. C5H5N, and 0.5 cc. Et3N refluxed 2-3 min., dild. with 15 cc. C5H5N, cooled, and filtered, and the

L19 ANSWER 136 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
residue recrystd. successively from C5H5N, HCONMe2-PrOH, and MeOCH2CH2OH gave LXXXIII, m. >260° (592, 5.124, 650 AgCl-Ag-Br). LXXXII (R = MeS) (0.53 g.), 0.6 g. LXXXIII, 0.31 g. 2,5-dimethyl-3-ethylbenzothiazolium methosulfate, 15 cc. C5H5N, and 0.14 cc. Et3N refluxed 2.3 min., cooled, and filtered gave LXXXII (R = 5-methyl-3-ethyl-2-benzothiazolylidenemethyl), m. >260° (MeOCH2CH2OH)(605, 4.943, 640 AgCl-AgBr). XVI (3.32 g.) and 3.625 g. XXXIV.EtI in 70 cc. refluxing Me2SO treated with 1.4 cc. Et3N, heated 2 hrs. at 90°, cooled, dild. with 210 cc. H2O, refrigerated overnight, and filtered gave LXXX (R and R' = Et, X = Cl, Z = S, A = CHCH:CH), decomp. on heating (EtOH) (615 , --, 670 (AgCl-AgBr). LXXXII.2EtI (2.89 g.) in refluxing 80 cc. Me2SO treated with 3.06 g. XV and 2.8 cc. Et3N, heated 3 hrs. at 95° while being treated with an addnl. 1.4 cc. Et3N during 2 hrs., dild. with 100 cc. MeOH, and filtered gave LXXXIV, m. >260° (PhOH-MeOH)(620, 5.460, 645 AgCl). p-Me2NC6H4CHO (1.5 g.) and 3.14 g. XXIV.EtI in Ac2O treated with 2.8 cc. Et3N, refluxed 15 min., cooled, and filtered gave the 3-(p-dimethylaminobenzylidene) deriv. of XXIV.EtI, m. 270° (EtOH) (429, 4.13, 430-485 AgCl). XXVI.IV (4.85 g.) in 125 cc. Me Carbitol treated with 4.49 g. X and 2.8 cc. Et3N, heated 10 min. at 100% cooled, dild. with 200 cc. Et2O. and decanted, and the residue recrystd. from HCONMe2 gave LXXIV (R = Et, R' = AcNHSO2(CH2)4, X and X' = Cl, X'' = H, Z = Se, An = I). XXVI.V gave similarly a dye, m. >260° (477, --, 525 AgCl-AgBr). XXVI.V treated similarly with VIII yielded a dye, m. >260° (472, --, 560 AgCl-AgBr). XXVI.IV treated in the same manner with VIII gave a dye, m. >240° (470, -- 520 AgCl-AgBr).
IT 59504-84-6P, 1H-Pyrrolo[1,2-a]benzimidazolium, 6,7-dichloro-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide 59504-92-6P, 1H-Pyrrolo[1,2-a]benzimidazolium, 7-chloro-6-(ethoxycarbonyl)-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide 59504-99-3P, 1H-Pyrrolo[1,2-a]benzimidazolium, 7-bromo-6-(ethoxycarbonyl)-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide 59505-22-5P, Pyrido[1,2-a]benzimidazolium, 7,8-dichloro-1,2,3,4-tetrahydro-5-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide 59505-69-0P, 1H-Pyrrolo[1,2-a]benzimidazolium, 7-chloro-6-(ethoxycarbonyl)-3-[(3-ethyl-2-thiazolidinylidene)ethylidene]-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt 59505-84-9P, 1H-Pyrrolo[1,2-a]benzimidazolium, 7-bromo-6-(ethoxycarbonyl)-3-[(3-ethyl-2-thiazolidinylidene)ethylidene]-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt 59506-52-4P, Pyrido[1,2-a]benzimidazolium, 7,8-dichloro-4-[(3-ethyl-5-phenyl-2(3H)-benzoxazolylidene)ethylidene]-1,2,3,4-tetrahydro-5-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt 100260-61-5P, 6,7-Dichloro-4-[2-(3-ethyl-2-thiazolidinylidene)ethylidene]-1,2,3,4-tetrahydro-5-[[(methylsulfonyl)carbamoyl]methyl]pyrido[1,2-a]benzimidazolium hydroxide, inner salt 106884-83-7P,

6,7-Dichloro-3-[2-(3-ethyl-2-selenazolinylidene)ethylidene]-2,3-dihydro-4-

L19 ANSWER 136 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
[[(methylsulfonyl)carbamoyl]methyl]-1H-pyrrolo[1,2-a]benzimidazolium hydroxide, inner salt
RL: PREP (Preparation)
(prepn. of)
RN 59504-84-6 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 6,7-dichloro-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



RN 59504-92-6 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 7-chloro-6-(ethoxycarbonyl)-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



RN 59504-99-3 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 7-bromo-6-(ethoxycarbonyl)-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

L19 ANSWER 136 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 59505-22-5 CAPLUS
CN Pyrido[1,2-a]benzimidazolium, 7,8-dichloro-1,2,3,4-tetrahydro-5-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



RN 59505-69-0 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 7-chloro-6-(ethoxycarbonyl)-3-[2-(3-ethyl-2-thiazolidinylidene)ethylidene]-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 59505-84-9 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium,
7-bromo-6-(ethoxycarbonyl)-3-[2-(3-ethyl-

L19 ANSWER 136 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
2-thiazolidinylidene)ethylidene]-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 59506-52-4 CAPLUS
CN Pyrido[1,2-a]benzimidazolium, 7,8-dichloro-4-[2-(3-ethyl-5-phenyl-2(3H)-benzoxazolylidene)ethylidene]-1,2,3,4-tetrahydro-5-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)



RN 100260-61-5 CAPLUS
CN Pyrido[1,2-a]benzimidazolium, 6,7-dichloro-4-[2-(3-ethyl-2-thiazolidinylidene)ethylidene]-1,2,3,4-tetrahydro-5-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, inner salt (CA INDEX NAME)

L19 ANSWER 136 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 106884-83-7 CAPLUS
CN 1H-Pyrrolo[1,2-a]benzimidazolium, 6,7-dichloro-3-[2-(3-ethyl-2(3H)-selenazolylidene)ethylidene]-2,3-dihydro-4-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, hydroxide (1:1) (CA INDEX NAME)



L19 ANSWER 137 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1962:401934 CAPLUS
DOCUMENT NUMBER: 57:1934
ORIGINAL REFERENCE NO.: 57:328g-i,329a-i,330a-i,331a-f
TITLE: Sensitization of photographic silver halide emulsions
INVENTOR(S): Nys, Jean; Depoorter, Henri
PATENT ASSIGNEE(S): Gevaert Photo-Producten N.V.
SOURCE: 17 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1081311		19600505	DE 1958-G24862	19580704
GB 904332			GB	
US 3282933		19661101	US 1960-76525	19601219
PRIORITY APPLN. INFO.:			GB	19570705

AB The preparation is described of polymethine photog. sensitizers which contain at least 1 heterocyclic N atom and an organic group of the type AWNHXY or AWNXY, where A is a hydrocarbon radical, W and X are SO2 or CO or single bonds, at least 1 W or X is SO2, and Y is a hydrocarbon radical, a substituted amino group, or (if X is not CO or SO2) a 14 atom. The absorption maximum of a dye, the upper limit of sensitization by the dye of a photog. emulsion layer, and the absorption maximum of the sensitized Ag halide emulsion are given in mμ in parentheses together with the dye throughout this abstract Powdered Br(CH2)3SO3Na (275 g.) added with cooling and stirring slowly to 276 g. PCl5, kept 1 h. at room temperature, heated 2 h. at 70 80°, cooled, poured with stirring onto 700 g. ice, stirred some time, and extracted with Et2O yielded Br(CH2)3SO2Cl (I), b2 98°. 1 (25 g.) in 250 cc. dry Et2O treated with stirring at 0° with dry NH3 gave Br(CH2)3SO2NH2 (II), m. 60° (C6H6-petr. ether). II (7 g.) and 5.2 cc. Ac2O heated 1 h. on a water bath, cooled, and filtered gave Br(CH2)3SO2NHAc, m. 93°. EtNH2 (4 g.) in 10 cc. dry Et2O added dropwise with stirring to 9.5 g. Br(CH2)4SO2Cl (III) in 100 cc. dry Et2O at 0°, filtered, and worked up gave Br(CH2)4SO2NHEt, m. 33-5° (C6H6-petr. ether). MeSO2NH2 (IV) (4 g.) in 20 cc. H2O treated dropwise at 5° with stirring with 16.8 cc. 5N NaOH and 9 g. I during 3 h. at pH 8, stirred 20 min., acidified with 4.2 cc. concentrated HCl, and evaporated, and the residue extracted with Me2CO gave from the extract Br(CH2)3SO2NHSO2Me, m. 72°. IV (72 g.) and 208 g. BrCH2COCl heated 1 h. at 100° gave BrCH2CONHSO2Me, m. 110° (C6H6). EtSO2NH2 (4.8 g.), 12 g. BrCH2COCl, and 25 cc. dry C6H6 refluxed 3 h., cooled, and diluted with petr. ether gave BrCH2CONHSO2Et, m. 104° (C6H6). BrCH2CH2NH2.HBr (51 g.) in 100 cc. C5H5N treated at 5-10o dropwise with MeSO2Cl, cooled, filtered, and evaporated, and the residual oil extracted with Me2CO gave MeSO2NHCH2CH2Br, m. 49°. III (23.,5 g.) in 100 cc. dry dioxane treated with stirring at 0° with 6.4 cc. N2H4, stirred 1 h. at 0° filtered, and evaporated yielded oily Br(CH2)4SO2NHNH2 (V). V (31.7 g.) treated gradually with 31.7 cc. Ac2O, kept several days, heated

L19 ANSWER 137 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
1 h. on the water bath, and cooled gave Br(CH2)4SO2NHNAc2 m. 116° (C6H6-hexane). Me2 NSO2NH2 (186 g.), 409 g. BrCH2COCl, and 2 l. dry C6H6 refluxed 10-15 h., filtered, cooled, and dild. with 3 I. hexane gave BrCH2CONHSO2Me2, m. 84°. 2-(2-Acetylanilinovinyl)-3-ethylbenzoxazolium iodide (Va) (1.45 g.), 1 g. 2,4-dimethyl-3-(3-sulfamoylpropyl)thiazolium bromide, 15 co. C5H5N, and 1 cc. Et3N heated 10 min. on a water bath and poured into Et2O pptd. [2-(3-ethylbenzoxazole)][2-[3(3 - sulfamoylpropyl) - 4 - methylthiazole]] trimethinecyanine iodide (VI) (517, 600, 550). 1-(2-Methylsulfonylaminoethyl)quinolinium bromide (2.6 g.) and 2.3 g. 2-methylthio3-methylbenzothiazolium toluenesulfonate gave similarly [2-[1-(2-methylsulfonylaminoethyl)quinoline]] [2-(3-methylbenzothiazole)]monomethinecyanine bromide (486, 560, 540), and 4.07 g. 2,6-dimethyl-3-(3-acetylsulfamoylpropyl)benzothiazolium bromide and 2.6 g. 1-phenyl-3-methyl-4(α-ethylthioethylidene)-5-pyrazolone yielded [2-[3-(3-acetylsulfamoylpropyl)-6 - methylbenzothiazole]] [4 - (1-Ph - 3-methyl-5-pyrazolone)]-α-dimethinemerocyanine (492, 620, 540). 2-Methylthio-3- methylnaphtho [1',2',4,5] thiazolium methosulfate (VII) (1.8 g.) and 1.8 g. 2-methyl-3-(4acetylsulfamoylbutyl)benzothiazolium bromide (VIIa) in 20 cc. EtOH treated at 0° with 1.4 cc. Et3N, shaken 2 h. at 0° and filtered gave [2-(3-methylnaphtho[1',2',4,5]thiazole)] [2 - [3 - (4 - acetylsulfamoylbutyl)benzothiazole]] - monomethinecyanine bromide (VIII) (444, 500,480). Similarly, were prepd, the following dyes (starting materials and g. amts. used are given): [2-[3-[3-(N-methylsulfonylsulfamoyl)propyl]benzothiazole]-2-(3 - ethylthiazoline)]trimethinecyanine bromide (504, 590, 540), 2-methyl-3-[3-(N-methylsulfonylsulfamoyl)propyl] benzothiazolium bromide, 4.29, 2-(2-acetylanilinovinyl)-3-ethylthiazolium bromide, 3.55; [2-(3-methylnaphtho[1',2',4,5]thiazole)] [3-(N-methylsulfonylcarbamoylmethyl)benozhiazolel]monomethinecyanine bromide (444, 500, 480), VII, 3.6, 2-Me - 3 - (N-methylsulfonylcarbamoylmethyl)benzothiazolium bromide, 3.6; [2-[3-(N-methylsulfonylcarbamoyhnethyl)benzoselenazole]] [2 - (3 - ethylbenzothiazole)] mesomethyltrimethinecyanine bromide (550, 670, 605), 2-methyl-3-(N-methylsulfonylcarbamoyhnethyl)benzoselenazolium bromide, 4.12, 2-(2-methyl-2-methylthiovinyl)-3-ethylbenzothiazolium methosulfate, 3.61; (2,3-[2-(N-methylsulfonylcarbamoyl)ethyl] benzothiazole) [2 - (3 - ethylbenzoxazole)]trimethinecyanine iodide (522, 600, 560), 2-methyl-3-[2-(N-methylsulfonylcarbamyl)ethyl] benzothiazolium bromide, 3.79, Va, 4.34; 2-[3-(2-methylsulfonylandnoethyl)benzothiazole] [2-(3-ethylthiazoline)]trimethinecyanine bromide (501, 580, 540), 2-methyl-3-(2-methylsulfonylaminoethyl)benzothiazolium bromide (VIIIa), 5.3, 2-(2-acetylanilinovinyl)-3ethylthiazolinium bromide, 5.3. 2-Methyl-3-(3-acetylsulfamoylpropyl)-5-phenylbenzoxazolium bromide (4 53 g.) and 4.50 g. 2-(2-acetylanilinovinyl)-3-ethylbenzothiazolium iodide (VIIIb) in 20 cc. EtOH treated at 0° with 2.8 cc. Et3N, kept 2 h , and dild. with Et2O, and the ppt. dissolved in warm EtOH, treated with aq. KI, and filtered gave [2- [3 - (3 - acetylsulfamoylpropyl) - 5-phenylbenzoxazole]] [2(3-ethylbenzothiazole)]trimethinecyanine iodide (526, 615, 560). [2-[3-(4-Ethylsulfamoylbutyl)benzoselenazole]] [2-(3ethylbenzoselenazole)] mesomethyltrimethinecyanine iodide (IX) (560, 660, 605-10) was prepd, by heating 5.8 g. 2-methyl-3 - (4 - ethylsulfamoylbutyl)benzoselenazolium bromide, 2 g.

L19 ANSWER 137 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
2-(2-methylthio-2-methylvinyl)-3-ethylbenzoselenazolium methosulfate, 30 cc. C5H5X, and 2 cc. Et3N 5 min., and pouring into Et2O, dissolving the ppt, in EtOH, and treating the soln. with aq. KI.
2-Methyt-3-(4-acetylsulfamoylbutyl)benzothiazolium bromide (IXa) (4.07 g.), 2.96 g. HC(OEt)3 (X), and 10 cc. Ac2O refluxed 15 min. and cooled gave bis[2- [3- (4-acetylsulfamoylbutyl)benzothiazole]]trimethinecyanine bromide (560, 665, 595). 2-Methyl-3 - [2 - (N-methylsulfonylcarbamoyl)ethyl] benzoselenazolium bromide (4.26 g.), 2.96 g. X, and 25 cc. Ac2O gave similarly

bis[2-[3-(2-(N-methylsulfonylcarbamoyl)ethyiz)benzoselenazole]]trimethinec
yanine bromide (576, 670, 605-10), and 4.9 g.
1-ethyl-2-methyl-3-(4-acetylsulfamoylbutyl)-5,6-dichlorobenzimidazolium bromide with 4.4 g. Va gave [2-(3-ethylbenzoxazole)]2-[1-ethyl-3-(4-acetylsulfamoylbutyl) - 5,6 - dichlorobenzimidazole] trimethinecyanine iodide (490, 600, 547). 2-Methyl-3-(N-ethylsulfonylcarbamoylmethyl)benzothiazolium bromide (3.79 g.), 3.24 g. MeC(OEt)3, and 25 cc. C5H5N refluxed 10 min., cooled, and dild. with Et2O pptd. bis[2-[3-(N-ethylsulfonylcarbamoyhnethyl)benzothiazole]] mesomethyltrimethinecyanine bromide (546, 660, 600).
2-Methyl-3-(dimethylaminosulfonylcarbamoylmethyl)benzothiazolium bromide (5.9 g.) and 5.9 cc. MeC(OMe)3 gave similarly
bis[2-[3-(dimethylaminosulfonylcarbamoylmethyl)benzothiazole]] mesomethlyltrimethinecyanine iodide (549, 650, 595). 2,5,6-Tri-Me - 3 -
(N
- methylsulfonylcarbamoylmethyl)benzothiazolium bromide (3.93 g.), 4.5 g. VIIIb, 50 cc. EtOH, and 2.8 cc. Et3N refluxed 15 min. and cooled gave [2-[3-(N-methylsulfonylcarbamoylmethyl) - 5,6 - dimethylbenzothiazole]] [2(3-ethylbenzothiazole)]trimethinecyanine iodide (568, 670, 605-10). Similarly, were prepd. (same data given): [2-(3 ethylbenzoxazole)] [2 -
[3
-dimethylaminosulfonylcarbamoylmethyl)benzothiazole]]trimethinecyanine iodide (526, 600, 560), 2-methyl-3-(dimethylaminosulfonylcarbamoylmethyl)benzothiazolium bromide, 2, Va, 2.17; 2-[3-(2-methylsulfonylcarbamoylethyl) - 5 - methylbenzothiazole] [5 - (3 - allyl- rhodanine)]dimethinemerocyanine (530, 640, 605), 2,5-dimethyl-3-(2-methylsulfonylcarbamoylethyl)benzothiazolium bromide, 3.9, 3-allyl-5-acetylanilinomethylidenerhodanine (XI), 3.2; [2-[3-(3-acetylsulfamoylpropyl)benzothiazole]][5-(3-allylrhodanine)]dimethinemerocyanine (524, 640, 605), 2-methyl-3-(3-acetylsulfamoylpropyl)benzothiazolium bromide, 4, XI, 3.2; [2-[3-(2-methylsulfonylaminoethyl)benzothiazole]] [5- (3 -allylrhodanine)] dimethinemerocyanine (XII) (522, 650, 600), Villa,
15.8,
XI, 14.3; [2-[3-ethyl-4(3-ethyl-2-benzothiazolinylidenethylidene)-5-thiazolinone]][2 - [3 - (2 - methylsulfonylaminoethyl)ben zothiazole]] monomethinecvanine bromide (611, 710, 660), [2-(3-ethylbenzothiazole)][4-(2-methylthio-3-Et - 5 - thiazolinone)] dimethinemerocyanine methosulfate, 4.75, Villa, 3.5. 2-Methyl- 3 - (N - methylsulfonylcarbamoylmethyl)- 5 - phenylbenzoxazolium bromide (4.25
g.),
4.5 g. VIIIb, 25 cc. Ac2O, and 2.8 cc. Et3N refluxed 10 min. and cooled gave [2-[3-(N-methylsulfonylcarbamoylmethyl) - 5 - phenylbenzoxazole]]
[2-

L19 ANSWER 137 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
(3ethylbenzothiazole)]trimethinecyanine iodide (526, 620, 560).
Similarly
were prepd (same data given) [2-[3-(4-acetylsulfamoylbutyl) - 5,6 - dimethylbenzoxazole]] [2 - [3 - (N methylsulfonylcarbamoylmethyl)-5,6-dimethylbenzoxazole] trimethinecyanine bromide (501, 555, 520), 2,5,6-trimethyl-3-(N)-methylsulfonylcarbamoylmethyl)benzoxazolium bromide, 2.4, 2-(2-anilinoyinyl)-3-(4-acetylsulfamoylbutyl)5,6-dimethylbenzoxazolium bromide (XIII), 2.6; anhydro[2- [3 - (4- acetylsulfamoylbutyl) - 5,6-dimethylbenzoxazole]][2-[3 - (sulfocarbomethoxymethyl)benzothiazole]] trimethinecyanine hydroxide (526, 600, 560), XIII, 2.6, 2-methyl-3(sulfocarbomethoxymethyl)benzothiazolium bromide Na salt, 2.0; bis[2-[3-(4-(acetylsulfamoylbutyl)benzothiazole]]pentamethinecyanine bromide (654, 760, 700), IXa, 8.14, 1- anilino-3-phenyliminopropene-HCl, 2.6; 2-(3,3-dicyanopropenylidene)- 3 - (4 - acetylsulfmoylbutyl)benzothiazoline (450, 540, 485), Xa, 4, anilinomethylidenemalononitrile 1.7. VIlla (7 g.) in 30 cc. C5H5N
refluxed
0.5 h. with 7 cc. X and dild. with aq. KBr gave bis[2-[3-(2-methylsulfonylaminoethyl)benzothiazole]]trimethinecyanine bromide (563, 665, 595). 2-Methyl-3-(N-methylsulfonylcarbamoylethyl)5-chlorobenzothiazolium bromide (4.1 g.) with 2.96 g. X gave similarly [2-[3-(N-methylsulfonylcarbamoylethyl)-5-chlorobenzothiazole]]trimethinecyanine bromide (570, 675, 610), and 1 g. 2-methyt-3-(3-acetylsulfamoylpropyl)-5-phenylbenzoxazolium bromide
with
1 cc. PrC(OEt)3 yielded bis[2- [3-(3 - acetylsulfonylpropyl)-5-phenylbenzoxazole]] mesopropyltrimethinecyanine iodide (506, 580,
555).
2,4-Di- Me - 3 - (N - methylsulfonylcarbamoylmethyl)thiazolium bromide (1.64 g.) and 2 g. 2-(2-anilinovinyl)-3-benzylbenzoxazolium bromide in 15 cc. C5H5N, 2 cc. Ac2O, and 1.4 cc. Et3N heated 10 min., poured into Et2O, and the ppt. treated with aq. NaI yielded [2-(3-benzylbenzoxazole)][2-[3-(N- methylsulfonylcarbamoylmethyl) - 4 - methylthiazole]]trimethinecyanine iodide (514, 600, 555).
2-Methyl-3-(N-methylsulfonylcarbamoylmethyl)-5- methylbenzothiazolium bromide (3.8 g.) and 5.2 g. 2-(2-acetylanilinovinyl)-3propylthiazolinium bromide in 25 cc. MeOH treated at 0° with 2.8 cc. Et3N, kept 1.5 h. at 0° and dild. with Et2O gave [2-[3-(N-methylsulfonylcarbamoylmethyl)-5-methylbenzothiazole]] - [2 - (3-propylthiazoline)]trimethinecyanine bromide (509, 585, 545).
2,6-Dimethyl-3-(3-acetylsulfamoylpropyl)benzothiazolium bromide (4.1 g.) and 4.5 g. 2-(2- acetylanilinovinyl)selenazolium-EtI in 30 cc. MeOH treated at 0° with 2.8 cc. Et3N gave 2-[3-(3-acetytsulfamoylpropyl)6-methylbenzothiazole] - 2 - (3-ethylselenazoline)trimethinecyanine iodide (510, 570, 545).
2-Methyl-3-(4-diacetylhydrazinosulfonylbutyl)benzothiazolium bromide (3.5 g.) and 2.7 g. 2-(2-acetylanilinovinyl)-3-ethylthiazolinium bromide gave similarly [2-[3-(4-diacetylhydrazinosulfonylbutyl)benzothiazole]] [2 -
(3
- ethylthiazoline)] trimethinecyanine bromide (504, 570, 540). VIIIa (3.5 g.) and 3.2 g. XI in 50 cc. EtOH heated 15 min. with 2.8 cc. Et3N and cooled gave [2 - [3 - (2 - methylsulfonylaminoethyl)benzothiazole]] [
5

L19 ANSWER 137 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
- (3-allylrhodanine]dimethinemerocyanine (535, 675, 590). XII (4.53 g.) and 2.52 g. Me2SO4 heated 10 min. at 120-30o, 2.9 g. of the resulting
dye
salt (XV), 2.1 g. 2,6-dimethyl-3(sulfocarbomethoxymethyl)benzothiazolium bromide Na salt, 20 cc. C5H5N, and 1.4 ccq. Et2N heated 0.5 h. on the water bath and cooled gave anhydro[2-[3-allyl-5-[3-(2-methylsulfonylaminoethyl) - 2 - benzothiazolinylideneethylidene]-4-thiazolinone]] [2-(3-sulfocarbomethoxymethyl) - 6 - methylbenzothiazole]monomethinecyanine hydroxide (595, 700, 640). XV (2.9 g.), 2 g. 2-methyl-3-ethyl-4,5-diphenylthiazolium iodide, 100 cc. EtOH, and 1.4 cc. Et2N heated 15 min. on a water bath yielded [2-[3-allyl-5-[3-(2-methylsulfonylaminoethyl) - 2 - benzothiazolinylideneethylidene] - 4 - thiazolinone]] [2 - (3 - ethyl-4,5-diphenyl)thiazole] monomethinecyanine iodide (XVI) (591, 700, 640). XII (2.9 g.), 1.75 g. 2-(2-methoxypropylidene)-3-ethylbenzothiazolium methosulfate, 25 cc. C5H5N, and 1.4 cc. Et3N refluxed 15 min. gave the [2-(N-ethylbenzothiazole)]mesomethoxytrimethinecyanine methosulfate
analog
of XVI (618, - 690). XV (2.9 g.), 0.95 g. 3-allylrhodanine, 30 cc. EtOH, and 1.4 cc. Et3N yielded similarly [2-[3-(2-methylsulfonylaminoethyl)benzothiazole]] [5- [2-(5,3-allyl-2-thio-2,4-dioxothiazolidinylidene)-3-allyl-4-thiazolidinone]] dimethinemerocyanine (568, 700, 640). XV (2.9 g.) with 1.31 g. 3-ethyl-5-(1-phenylethylidene)rhodanine gave similarly [2-[3-(2-methylsulfonylaminoethyl)benzothiazole]] [5- [2-[2-(3-ethyl-2-thio-2,4-di- oxo - 5- thiazolidinylidene) - 2 - phenylethylidene] -3 - allyl - 4-thiazolidinone]]dimethinemerocyanine (630,-, 730). VIIa (4 g.), 1.5 g. p-Me2NC6H4CHO, and 25 cc. Ac2O refluxed 0.5 h., cooled, and dild. with Et2O gave [2-[2-(p-dimethylaminophenyl)vinyl]]-3-(4-acetylsulfamoylbutyl)benzothiazolium bromide (544, 680, 600).

IT 99996-52-8P, Benzothiazolium, 5-methyl-3-[[(methylsulfonyl)carbamoyl]methyl]-2-[3-(3-propyl-2-thiazolidinylidene)propenyl]-, bromide 101983-48-6P, Benzothiazolium, 2-[3-(3-ethyl-2-benzothiazolinylidene)propenyl]-5,6-dimethyl-3-[[(methylsulfonyl)carbamoyl]methyl]-, iodide
RL: PREP (Preparation)
(preparation of)

RN 99996-52-8 CAPLUS

CN Benzothiazolium,
5-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-[3-(3-propyl-2-thiazolidinylidene)-1-propen-1-yl]-, bromide (1:1) (CA INDEX NAME)

L19 ANSWER 137 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 101983-48-6 CAPLUS

CN Benzothiazolium, 2-[3-(3-ethyl-2(3H)-benzothiazolylidene)-1-propen-1-yl]-5,6-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, iodide (1:1) (CA INDEX NAME)



L19 ANSWER 138 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1962:71146 CAPLUS
DOCUMENT NUMBER: 56:71146
ORIGINAL REFERENCE NO.: 56:13705g-i,13706a-i,13707a-g
TITLE: Polymethine dyes
INVENTOR(S): Nys, Jean; Depoorter, Henri
PATENT ASSIGNEE(S): Gevaert Photo-Producten N.V.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 569130		19581102	BE	
PRIORITY APPLN. INFO.:			GB	19570705

AB Substitution at a polymethine dye heterocyclic N atom of an electroneg. hydrophilic group containing at least one SO2 group and consisting of a hydrocarbon radical linked by a CO or SO2 group to NH which in one of the same ways is linked to another hydrocarbon radical, OH, or amino, prevents these dyes from permanently coloring photog. material without destroying their sensitizing power. These new dyes can also have the betaine structure. The following compds. were prepared: Br(CH2)4SO2Cl, b2 98° (new method); Br(CH2)3SO2NH2, m. 60° (from C6H6-petr. ether); Br(CH2)3SO2NHAc, m. 93° (idem); Br(CH2)4SO2Cl, b2.5 128°; Br(CH2)4SO2NH2, m. 68° (idem); Br(CH2)4SO2NHAc, m. 88° (idem); Br(CH2)4SO2NHEt, m. 33-35° (idem); Br(CH2)3SO2NHSO2Me, m. 72° (Me2CO); BrCH2CONHSO2Me, m. 110° (C6H6); BrCH2CONHSO2Et, m. 104° (C6H6); BrCH2CH2CONHSO2Me, m. 130° (C6H6); MeSO2NH(CH2)2Br, m. 49° (Me2CO); Br(CH2)4SO2NHNH2, a white oil; Br(CH2)4SO2NHN(Ac)2, m. 116° (C6H6-C6H14); BrCH2CONHSO2NMe2, m. 84° (C6H6); 2,4-dimethyl-3-(ωsulfamoylpropyl)thiazolium bromide, m. 224° (EtOHEt2O-H2O); 2 - Me -3 - [ω - (acetylsulfamoyl)propyl] - 5-phenylbenzoxazolium bromide, m. 270°; 2 methyl-3-(ω-sulfamoylbutyl)benzothiazolium bromide, m. 243°; 2-methyl- 3- [ω-(acetylsulfamoyl)butyl] benzothiazolium bromide, m. 234-5°; 2-methyl-3-[ω-(methylsulfonylsulfamoyl)propyl]benzothiazolium bromide, m. 180°; 2-methyl-3-[(methylsulfonylcarbamoyl)methyl] benzothiazolium bromide, m. 188°; 2-methyl-3-[(methylsulfonylcarbamoyl)-methyl]benzoselenazolium bromide, m. 104°; 2-methyl-3[(ethylsulfonylcarbamoyl)methyl] benzothiazolium bromide, m. 170°; 2-methyl-3-[β-(methylsulfonylcarbamoyl)ethyl]benzothiazolium bromide, m. 248°; 2-methyl-3-[β-(methylsulfonylcarbamoyl)ethyl]benzoselenazolium bromide, m. 102°; 2,5,6-trimethyl-3-[(methylsulfonylcarbamoyl)methyl]benzothiazolium bromide, m. 114°; 2-methyl-3-[(methylsulfonylcarbamoyl)methyl] - 5- phenylbenzoxazolium bromide, m. 124°; 2-methyl-3-[β-(methylsulfonamido)ethyl]-benzothiazolium bromide, m. 150°; 2,6-dimethyl-3-[ω(acetylsulfamoyl)propyl]benzothiazolium bromide, m. 218° (EtOH-Et2O); 1 ethyl-2-methyl-3-[w-(acetylsulfamoyl)butyl]-5,6-

L19 ANSWER 138 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

dichlorobenzimidazolium bromide, m. 225°; 2,4 - di-Me - 3 - [(methylsulfonylcarbamoyl)methyl] thiazolium bromide, m. 228°; 2 methyl-3-[β-(methylsulfonylcarbamoyl)ethyl]-5-chlorobenzothiazolium bromide, m. 115°; 1- [β- (methylsulfonamido)ethyl] - 2-methylquinolinium bromide, m. 226°; 2-methyl-3-[[(dimethylsulfamoyl)carbamoyl] methyl] benzothiazolium bromide, m. 160°; 2-methyl-3-[ω-(acetylsulfamoyl)propyl]benzothiazolium bromide, m. 260°; 2,5-dimethyl-3- [β-(methylsulfonylcarbamoyl)ethyl]benzothiazolium bromide, m. 204°; 2,5,6-trimethyl-3-[ω(acetylsulfamoyl)butyl] benzoxazolium bromide, m. 213-14°; 2 (β-anilinovinyl)-3[ω-(acetylsulfamoyl)butyl]-5,6-dimethylbenzoxazolium bromide, m. 187°; 2,5,6-trimethyl-3-[(methylsulfonylcarbamoyl)methyl] benzoxazolium bromide, m. 174-6° (tetrahydrofuran-Et2O). From these intermediates the following polymethine dyes were prepd. (dye, absorption max. (mμ), Ag halide, sensitizing limit, and sensitization max. given): 2[[3-(ω-sulfamoylpropyl)-4methyl-2- thiazolinylidene]propenyl] -3-ethylbenzoxazolium iodide, 517, Ag bromoiodide (I), 600, 550; 1 methyl-2-[[3[ω - (acetylsulfamoyl)butyl] - 2 - benzothiazolinylidene] methyl]naphtho[1,2-d]thiazolium bromide, 444, AgCl, 500, 480; 2-[(3-ethyl-2-benzothiazolinylidene)propenyl]- 3- [ω-(acetylsulfamoyl)propyl]-5-phenylbenzoxazolium iodide, 526, Ag chlorobromide (II), 615, 560; 2-[(3-ethyl-2-benzoselenazolinylidene)-2-methylpropenyl]-3- [ω- (ethylsulfamoyl)butyl]benzoselenazolium iodide, 560, I, 660, 605-10; 2-[[3-[ω(acetylsulfamoyl)butyl]-2-benzothiazolinylidene]-propenyl]-3-[ω-(acetylsulfamoyl)butyl]benzothiazolium bromide, 560, I, 665, 595; 2-[(3-ethyl-2-thiazolidinylidene)propenyl]-3[ω-(methylsulfonylsulfamoyl)propyl], 504, AgBr, 590, 540; 1-methyl-2- [[3-[(methylsulfonylcarbamoyl)methyl] -2-benzothiazolinylidene] methyl] naphtho [1,2-d] thiazolium bromide, 444, AgCl, 500,480; 2-[[3-[(ethylsulfonylcarbamoyl)-methyl] - 2 - benzothiazolinylidene] - 2 - methylpropenyl] - 3-[(ethylsulfonylcarbamoyl)methyl] benzothiazolium bromide, 546, I, 660, 600; 2-[(3-ethyl-2-benzothiazolinylidene)-2-methylpropenyl] - 3 - [(methylsulfonylcarbamoyl) Me] benzoselenazolium bromide, 550, I 670, 605; 2-[(3-[ωmethylsulfonylcarbamoyl)ethyl] -2-benzoselenazolinylidene]propenyl] - 3 - [ω - (methylsulfonylcarbamoyl)ethyl]benzoselenazolium bromide, 576, I, 670, 605-10; 2-[(3-ethyl-2benzoxazolinylidene)propenyl] - 3-[β-(methylsulfonylcarbamoyl)ethyl]benzothiazolium iodide, 522, AgBr, 600, 560; 2-[(3- ethyl- 2- benzothiazolinylidene)propenyl] -3-[(methylsulfonylcarbamoyl)methyl] - 5,6 - dimethylbenzothiazolium iodide, 568, I, 670, 605-10; 2-[(3-ethyl-2-benzothiazolinylidene)propenyl] - 3 - [(methylsulfonylcarbamoyl)methyl] - 5-phenylbenzoxazolium iodide, 526, AgBr, 620, 560; 2-[[3-[β[(methylsulfonamido)ethyl] - 2 - benzothiazofinylidene]propenyl]-3- [β-(methylsulfonamido)ethyl] benzothiazolium bromide, 563, I, 665, 595; 2-[(3-ethyl-2-thiazolidinylidene)propenyl]-3-[β(methylsulfonamido)ethyl] benzothiazolium bromide, 501, AgCl, 580, 540; 2 [[3-[(methylsulfonylcarbamoyl)methyl] -4- Me - 2 -

L19 ANSWER 138 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

thiazolinylidene] propenyl] - 3 - benzylbenzoxazolium iodide, 514, I, 600, 555; 2-[(3-propyl-2thiazolidinylidene)propenyl]-3-[(methylsulfonylcarbamoyl)methyl] 5 methylbenzothiazolium bromide, 509, AgBr, 585, 545; 1-ethyl-2- [(3-ethyl-2-benzoxazolinylidene)propenyl] -3-[ω-(acetylsulfamoyl)butyl] - 5,6 - dichlorobenzimidazolium iodide, 490, AgBr, 600, 547; 2-[[3-[β-(methylsulfonylcarbamoyl)ethyl]-5-chloro-2- benzothiazolinylidene] propenyl] -3 - [β - (methylsulfonylcarbamoyl)ethyl] - 5 - chlorobenzothiazolium bromide, 570, I, 675, 610; 2-[(3-ethyl-2-selenazolidinylidene)propenyl] -3 - [ω - (acetylsulfamoyl)propyl]-6-methylbenzothiazolium iodide, 510, AgCl, 570, 545; 2-thio-3-allyl-5-[[3- [β-(methylsulfonamido)ethyl] -2-benzo-thiazolinylidene]ethylidenel-2,4-thiazolidinedione, 535, I, 675, 590; 2-[[3- [ω- (acetylsulfamoyl)propyl] -5-phenyl-2-benzoxazolinylidenel-2-propylpropenyl]-3-[ω-(acetylsulfamoyl)propyl] - 5 - phenylbenzoxazolium iodide, 506, AgBr, 580, 555; 2-[(3-ethyl-2-thiazolidinylidene)propenyl]-3-[ω - [(β - diacetylhydrazino)sulfonyl]butyl]benzothiazolium bromide, 504, AgCl, 570, 540; 2-[[3-[(methylsulfonylcarbamoyl)methyl] - 5,6 - dimethyl-2 - benzoxazolinylidene[propenyl] - 3 - [ω- (acetylsulfamoyl)butyl] - 5,6 - dimethylbenzoxazolium bromide, 501, AgBr, 555, 520; 2-[[3-(sulfometh-oxycarbonylmethyl) - 2 - benzothiazolinylidene] propenyl] - 3[ω- (acetylsulfamoyl)butyl] - 5,6 - dimethylbenzoxazolium betaine, 526, I, 600, 560; 2-[[3-[ω-(acetylsulfamoyl)butyl]-2 - benzothiazolinylidene] - 1,3 - pentadienyl] - 3 - [ω - (acetyl-sulfamoyl)butyl]benzothiazolium bromide, 654, AgCl, 760, 700 (in the presence of 10 g. of 1 hydroxy-2-stearoylaminonaphthalenesulfonic acid (III)); 4-[3-[ω-(acetylsulfamoyl)butyl] - 2 - benzothiazolinylidene] -2-cyano-2 - butyronitrile, 450, II, 540, 485; 1-[β-(methylsulfonamido)ethyl]-2-[(3- Me - 2 - benzothiazolinylidene)methyl] quinolinium bromide, 486, I, 560, 540; 2-[[3-[[(dimethylsulfamoyl)carbamoyl]methyl]-2-benzothiazolinylidene] propenyl] -3- ethylbenzoxazolium iodide, 526, I, 600, 560; 1-phenyl-3-methyl-4 - [[3- [ω - (acetylsulfamoyl)propyl]-6- Me -2 - benzothiazolinylidene]-1-methylethylidene]-5-pyrazolone, 492, AgBr, 620, 540; 2-thio-3-allyl-5-[[3-[β-(methylsulfonylcarbamoyl)ethyl] - 5 - Me - 2 - benzothiazolinylidene] ethylidene]-2,4-thiazolidinedione, 530, II, 640, 605; 2-[[3-[[(di- methylsulfamoyl)carbamoyl]methyl] - 2 - benzothiazolinylidene] - 2 - methylpropenyl] - 3 - [[(dimethylsulfamoyl)carbamoyl]methyl]benzothiazolium iodide, 549, I, 650, 595; 2-thio-3-allyl-5- [[3- [ω-(acetylsulfamoyl)propyl] -2-benzothiazolinylidene] ethylidene]-2,4-thiazolidinedione. 524, AgCl, 640, 605; 2-thio-3-allyl-5-[[3-[β-(methylsulfonamido)ethyl] -2-benzothiazolinylidene] ethylidene] -2,4 - thiazolidinedione, 522, II, 650, 600; 2-[[3-(sulfomethoxycarbonylmethyl)-6-methyl-2-benzothiazolinylidene] methyl]-3-allyl-4 oxo- 5 - [[3 - [β - (methylsulfonamido)ethyl) - 2 - benzothiazolinylidene]ethylidene]thiazolinium betaine, 595, I, 700, 640; 2-[(3 - Et - 4,5 - diphenyl-2 - thiazolinylidene)methyl] - 3-allyl-4-oxo-5- [[3- [β- (methylsulfonamido)ethyl] -2-benzothiazolinylidene]ethylidene]thiazolinium iodide, 591, I, 700, 640; 2-[(3-ethyl-2-benzothiazolinylidene)-2-methoxypropenyl]-3-allyl-4-oxo-5-[[3-[β- (methylsulfonamido)ethyl]-2 - benzothiazolinylidene]ethylidene]thiazolinium methosulfate, 618, AgCl, -, 690 (in the presence of 10 g. III); 2 - [[3 - [β - (methylsulfonamido)ethyl] - 2 - benzothiazolinylidene]

L19 ANSWER 138 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

methyl]-3-ethyl-4-[(3-Et - 2 - benzothiazolinylidene)ethylidene]-5-oxothiazolinium bromide, 611, I, 710, 660; 2-(2-thio-3 allyl-4- oxo- 5-thiazolidinylidene) - 3 - allyl - 5- [[3[β - (methylsulfonamido)ethyl] - 2 - benzothiazolinylidene]-ethylidene]-4-thiazolidinone, 568, I, 700, 640; 2-[(2-thio-3-Et - 4 - oxo - 5 - thiazolidinylidene) - 2- phenylethylidene] - 3-allyl-5-[[3-[β-(methylsulfonamido)ethyl]-2-benzothiazolinylidene]ethylidene]-4-thiazolidinone, 630, I, -, 730; and 2(p-dimethylaminostyryl)-3-[ω-(acetylsulfamoyl)butyl]benzothiazolium bromide, 544, AgCl, 680, 600.

IT 92504-82-0P, Thiazolium, 2,4-dimethyl-3-[[(methylsulfonyl)carbamoyl]methyl]-, bromide 96435-22-2P, Benzothiazolium, 2,5,6-trimethyl-3-[[(methylsulfonyl)carbamoyl]methyl]-, bromide 96435-23-3P, Benzoxazolium, 2,5,6-trimethyl-3-[[(methylsulfonyl)carbamoyl]methyl]-, bromide 99996-52-8P, Benzothiazolium, 5-methyl-3-[[(methylsulfonyl)carbamoyl]methyl]-2-[3-(3-propyl-2-thiazolidinylidene)propenyl]-, bromide 101983-48-6P, Benzothiazolium, 2-[3-(3-ethyl-2-benzothiazolinylidene)propenyl]-5,6-dimethyl-3-[[(methylsulfonyl)carbamoyl]methyl]-, iodide 106599-46-6P, Benzoxazolium, 3-[4-(acetylsulfamoyl)butyl]-2-[3-[5,6-dimethyl-3-[[(methylsulfonyl)carbamoyl]methyl]-2-benzoxazolinylidene]propenyl]-5,6-dimethyl-, bromide
RL: PREP (Preparation)
(preparation of)

RN 92504-82-0 CAPLUS
CN Thiazolium, 2,4-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



RN 96435-22-2 CAPLUS
CN Benzothiazolium, 2,5,6-trimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

L19 ANSWER 138 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● Br⁻

RN 96475-23-3 CAPLUS
CN Benzoxazolium, 3,3,6-trimethyl-3-[2-[[methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)



● Br⁻

RN 99996-52-8 CAPLUS
CN Benzothiazolium, 5-methyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-2-[3-(3-propyl-2-thiazolidinylidene)-1-propen-1-yl]-, bromide (1:1) (CA INDEX NAME)

L19 ANSWER 138 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● Br⁻

RN 101993-48-6 CAPLUS
CN Benzothiazolium, 2-[3-(3-ethyl-2(3H)-benzothiazolylidene)-1-propen-1-yl]-5,6-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, iodide (1:1) (CA INDEX NAME)



● I⁻

RN 106599-46-6 CAPLUS
CN Benzoxazolium, 2-[3-[3-[4-[(acetylamino)sulfonyl]butyl]-5,6-dimethyl-2(3H)-benzoxazolylidene]-1-propen-1-yl]-5,6-dimethyl-3-[2-[(methylsulfonyl)amino]-2-oxoethyl]-, bromide (1:1) (CA INDEX NAME)

L19 ANSWER 138 OF 138 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



● Br⁻